

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |           |  |
|--|--|-----------|--|
| (51) International Patent Classification <sup>6</sup> :<br><b>C12N 15/11, 15/00, 15/63, C07H 21/02, 21/04</b>  |  | <b>A1</b> | (11) International Publication Number: <b>WO 00/04140</b>  |
|  |  |           | (43) International Publication Date: 27 January 2000 (27.01.00)  |
| (21) International Application Number: PCT/US99/15849<br>(22) International Filing Date: 14 July 1999 (14.07.99)<br>(30) Priority Data:<br>60/092,921           15 July 1998 (15.07.98)           US<br>60/092,922           15 July 1998 (15.07.98)           US<br>60/092,956           15 July 1998 (15.07.98)           US<br>(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).<br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). KOMATSOUKIS, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). DUAN, Roxanne, D. [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). MOORE, Paul, A. [US/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yang-gu [CN/US]; Apartment 102, 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne |  |           | Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; Apartment 115, 410 Van Dyke Street, St. Paul, MN 55119-4321 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). MUCENSKI, Michael [US/US]; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US).<br>(74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).<br>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br>Published<br>With international search report. |
| (54) Title: 71 HUMAN SECRETED PROTEINS   |  |           |  |
| (57) Abstract  |  |           |  |
| The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.  |  |           |  |

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |



## 71 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human

growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent  
5 medical disorders by using secreted proteins or the genes that encode them.

### *Summary of the Invention*

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells,  
10 antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

15

### *Detailed Description*

#### Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

20 In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of  
25 matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released  
30 into the extracellular space, the secreted protein can undergo extracellular processing

to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of the coding sequence, but do not comprise all or a portion of any intron. In another embodiment, the nucleic acid comprising the coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an

overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

- 5           Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or
- 10   temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent
- 15   hybridization can be done at higher salt concentrations (e.g. 5X SSC).

- Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and
- 20   commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

- Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a
- 25   complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

- The polynucleotide of the present invention can be composed of any
- 30   polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of

single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation,

gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

5 (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

10 "SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

#### Polynucleotides and Polypeptides of the Invention

#### 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 1

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

30 PFCSGFFPSLWIYLPFIFNVSDLWMGSLSGCALPFCLXVFFLTVSPSAVGLLXF  
AGGPLQTLFAWVSPVEAAEQRLLPVLSSGSFVSEGTCQMPARALLYEVS VG

PYWEIPPSQDTRRSGLTYLRRQSDP (SEQ ID NO: 195) . Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in pancreas islet cell tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as  
5 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the pancreas, including cancer and diabetes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
10 a number of disorders of the above tissues or cells, particularly of the pancreas, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., endocrine, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the  
15 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of pancreatic islet cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment and intervention of such tumors, in addition to other endocrine or  
20 gastrointestinal tumors where expression has been indicated. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1099 of SEQ ID NO:11, b is an integer of 15 to 1113, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 2

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the

10 following amino acid sequence:

HEGSCRAPGFSAHKGRGCPSPRMTLPSRALASLGVGWGMRLRNQVTVSCG  
GSRWSSRVALGAFSWVCGVALVLQPSGGGLGLTSPSEGCWEGELALAVLRA  
PGGSPS (SEQ ID NO: 196) . Polynucleotides encoding these polypeptides are also provided.

15 This gene is expressed equally in in .

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic disorders, particularly leukemia. Similarly,

20 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hemolymphoid,

25 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 104 as residues: Gly-29 to Ser-35, Ser-63 to Cys-68. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in hemangiopericytoma, breast lymph node, and bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in  
10 Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency  
15 etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions,  
20 in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
30 formula of a-b, where a is any integer between 1 to 969 of SEQ ID NO:12, b is an

integer of 15 to 983, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 3

5           The translation product of this gene shares sequence homology with the *Drosophila melanogaster* slit protein, a secreted protein that contains both an EGF domain and Leucine Rich Repeat domains. It is thought to be important in the development of midline glia and commissural axon pathways (See e.g., Rothberg et al. *Genes Dev.* 4:2169-87 (1990); which is hereby incorporated by reference herein).

10           This gene is expressed primarily in human hippocampus.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, and developmental disorders. Similarly, polypeptides and  
15   antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neurological, cancerous, or wounded tissues) or  
20   bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          The tissue distribution within human hippocampus combined with the  
25   homology to the *Drosophila* slit protein, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and  
30   elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,

Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 959 of SEQ ID NO:13, b is an integer of 15 to 973, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 4

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by

the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

IPLTLPGIFLLIRLFWRLGQSICGPGKLVLPQFCCGCAVISGHCVPRGMPSSW  
LPGCFVLLCLVAVGCQLREWGVGGVSAVGLLALPHLQVLGMRGRGLISGG

5 (SEQ ID NO: 197) . Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed in KMH2 cells, osteoblasts, fetal spleen, Jurkat  
10 membrane bound polysomes, breast, and cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, immune, and skeletal disorders. Similarly, polypeptides and  
15 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, skeletal, cancerous, or wounded tissues) or bodily  
20 fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in KMH2 cells, osteoblasts, and fetal spleen indicates  
25 that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Expression of this gene product in fetal spleen and T-cells indicates a role in the regulation of the  
30 proliferation: survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved

in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene  
5 product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
10 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity  
15 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that  
20 recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify  
25 agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
30 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1444 of SEQ ID NO:14, b is an

integer of 15 to 1458, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 5

- 5       The translation product of this gene shares sequence homology with phospholipase A2 which cleaves fatty acids from carbon 2 of glycerol (ref. Prosite pattern documentation for PS2\_HIS). Many snake venoms contain phospholipase A2, which prevents transmission of nerve impulses to muscles by blocking the release of acetylcholine from the neuron. Therefore, included in this invention as preferred
- 10       domains are Phospholipase A2 histidine active site domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Phospholipase A2 is an enzyme which releases fatty acids from the second carbon group of glycerol. Structurally, PA2's are small and rigid proteins of 120 amino-acid residues that have four to seven disulfide bonds. PA2 binds a calcium ion which is required for activity.
- 15       The side chains of two conserved residues, a histidine and an aspartic acid, participate in a 'catalytic network'. Two different signature patterns for PA2's were developed. The first is centered on the active site histidine and contains three cysteines involved in disulfide bonds. The consensus pattern is as follows: C-C-x(2)-H-x(2)-C [H is the active site residue].
- 20       Preferred polypeptides of the invention comprise a Phospholipase A2 histidine active site domain selected from the following amino acid sequences: CCNQHDRC (SEQ ID NO: 199), SLTKCCNQHDRCYET (SEQ ID NO: 200) , and/or LTKCCNQHDRCYETCG (SEQ ID NO: 201) . Polynucleotides encoding these polypeptides are also provided. Further preferred are polypeptides comprising the
- 25       Phospholipase A2 histidine active site domain of the sequence listed in Table 1 for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues is N-terminal or C- terminal to the Phospholipase A2 histidine active site domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and
- 30       C-terminal to the Phospholipase A2 histidine active site domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The

above preferred polypeptide domain is characteristic of a signature specific to Phospholipase A2 proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Phospholipase A2 proteins. Such activities are known in the art, some of which are described elsewhere herein, or see, for example, McIntosh, et al. J. Biol. Chem. 270 (8), 3518-3526 (1995), incorporated herein by reference.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

GPAGKEAWIWSWLLPSPGPAPLPSASWGLCGDAPR  
AAARGPVEPGAARMALLSRPALTLALLMAAVVRCQEQAQTTDWRATLKTI  
RNGVHKIDTYLNAALDLLGGEDGLCQYKCSDBGSKPFPRYGYKPSPPNGCGSP  
LFGXHLNIGIPSLTKCCNQHDRCYETCGKSKNDCDEEFQYCLSKICRDVQKTL  
GLTQHVQACETTVELLFDSEVIHLGCKPYLDSQRAACRCHYEEKTDL (SEQ ID  
NO: 198) . Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

This gene is expressed in a variety of cell types with no single type predominating.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological disorders, or metabolism disorders, specifically phospholipase A2 deficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neuromuscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pancreas, cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph,

serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 5 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 107 as residues: Gln-23 to Asp-30, Lys-66 to Cys-87. Polynucleotides encoding said polypeptides are also provided.
- The ubiquitous tissue distribution and homology to phospholipase A2 indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neuromuscular disorders. Alternatively, considering the activity of phospholipase A2 as a block for neuro- transmission may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the homology to Phospholipase A2 proteins may indicate a potential use for the protein product of this gene in diagnosis, treatment and/or prevention of metabolism disorders, specifically deficiencies in Phospholipase A2. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of



the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
 5 formula of a-b, where a is any integer between 1 to 1991 of SEQ ID NO:15, b is an integer of 15 to 2005, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 6

10 In a specific embodiment polypeptides of the invention comprise the following amino acid sequence:

GTSSARPRGALPGGSAPSAPHGQLPGRAQPAPVSGPPPTSGLCHFDPAAPWPL  
 WPGPWQLPPHPQDWPAPHPDIPQDWVSFLRSFGQLTLCPRNGTVTGKWRGSH  
 VVGLLTTLNFGDGPDRNKTRTFQATVLGSQMGLKGSSAGQLVLITARVTTER  
 15 TAGTCLYFSAVPILPSSQPPISCSEEGAGNATLSPRMGEECVSVWSHEGLVLT  
 KLLTSEELALCGSRLLVLGSFLLFCGLLCCVTAMCFHPRRESHWSRTRL  
 (SEQ ID NO: 202). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by  
 20 the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

ARAPPGPEGLSPEAQPLLPMGNCQAGHNLHLCLAHHPPLVCATLILLGLS  
 GLGLGSFLLTHRTGLRT LTSPRTGSLF (SEQ ID NO: 203). Polynucleotides  
 encoding these polypeptides are also provided.

25 This gene is expressed in a wide variety of tissue types including testes, cerebellum, dendritic cells, breast cancer, umbilical vein endothelial cells, epididymus, corpus colosum, chronic synovitis, liver hepatome, normal breast, osteoblasts, melanocytes, B cell lymphomas, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, cancer, particularly of endothelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system,

5 expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., endothelial, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in

10 healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 108 as residues: Thr-52 to Gly-57. Polynucleotides encoding said polypeptides are also provided.

Expression within embryonic tissue and other cellular sources marked by

15 proliferating cells indicates that the protein product of this gene may play a role in the regulation of cellular division and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Additionally, the expression

20 in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic

25 development also relies on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain

30 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have

applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 929 of SEQ ID NO:16, b is an integer of 15 to 943, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 7

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

RFLSVXPQXEVPFLLHPCVCFXGGHPSLLPDPCRAVGGGWEAPRCCLHEALC  
QSLGCKAEEIVSVSESSAQRCWYLLRGRKAGGRGPASPVLFALMRLES LCH  
LCLACLFFRLPATRTVYCMNEAEIVDVALGILIESRKQXKACEQPALAGADNP  
EHSPPCSVSPHTSSGSSSEEEEDSGKQALXPGLSPSQRPGGSSSACSRSPEEEE

- 5 EEDVLKYVREIFFS (SEQ ID NO: 204) . Polynucleotides encoding these polypeptides are also provided. Polynucleotides of the invention do not consist of the nucleic acid sequences shown as GeneSeq Accession Nos: V59595 and V59744, which are hereby incorporated herein by reference.

- 10 This gene is expressed primarily in a variety of immune cell types, including stromal cells, dendritic cells, leukocytes, activated T-cells, macrophages, monocytes, neutrophils and to a lesser extent in a variety of other adult and fetal tissues.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 25 The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Expression of this gene product in fetal tissue and various hematopoietic cancers indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all
- 30

hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses).

5           Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
10    such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted  
15    factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity,  
20    raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

          Many polynucleotide sequences, such as EST sequences, are publicly  
25    available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
30    more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1489 of SEQ ID NO:17, b is an

integer of 15 to 1503, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 8

- 5           When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the NF-kB (Nuclear Factor kB) pathway. Thus, it is likely that this gene activates T-cells through the NF-kB signal transduction pathway. NF-kB is a transcription factor activated by a wide variety of agents, leading to cell activation, differentiation, or apoptosis. Reporter constructs utilizing the NF-kB promoter element are used to screen supernatants for such activity. Preferred polypeptides of the invention comprise the following amino acid sequence: VPGWPRACSPCQADSPRAHPPKLRGILRWAPVPLXCAALCPPLDSG MSMAACPEAPEPSFLREVPSSTQWHRPCNFRQVEANPRKEPKNLVWRD VSLGQXSRTPRGSGLELVRVCGGGMQRDKTVVEERVGEERERERERESLGG
- 10           AGKHGEMRCVYVRESVGAPGRAGGGGNGVNSVGCVRTVHSGSXPPPSAGV S (SEQ ID NO: 205). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in parts of the brain such as cerebellum and frontal lobe.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.
- 20
- 25
- 30

The tissue distribution in cerebellum and frontal lobe indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, prevention and/or treatment of neurodegenerative disease states and behavioural disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1498 of SEQ ID NO:18, b is an

integer of 15 to 1512, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 9

5 In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:  
TRPGKELNLVFGLQLSMARIGSTVNMNLMGWLYSKIEALLGSAGHTTLGITL  
10 MIGGITCILSLICALALAYLDQRAERILHKEQGKTGEVIKLTVDKDFSLPLWLIF  
IICVCYYVAVFPFIGLGKVFFTEKFGFSSQAASAINSVVYVISAPMSPVFGLLV  
DKTGKNIIWVLCA (SEQ ID NO: 206) . Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
15 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in fetal tissue, and to a lesser extent in a variety of adult human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as  
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fetal abnormalities, particularly developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
25 a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developing, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having  
30 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 111 as residues: Lys-30 to Thr-35. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal tissue indicates that polynucleotides and  
5 polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

10 Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Expression within embryonic tissue and other cellular sources marked by proliferating cells  
15 indicates that this protein may play a role in the regulation of cellular division. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,  
20 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in  
25 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders,  
30 and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Furthermore, the protein

may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
5 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1641 of SEQ ID NO:19, b is an integer of 15 to 1655, where both a and b correspond to the positions of nucleotide  
15 residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The translation product of this gene shares sequence homology with human histiocyte-secreted factor (HSF) which is a novel cytokine that shows in vivo  
20 antitumour activity without the cytotoxicity associated with tumour necrosis factor. Furthermore, The translation product of this gene also shares sequence homology with the human endogenous virus S71 gag polyprotein, the sequence of which is believed to represent a transformation locus for several cancers (See Genebank Accession No. pir|A46312|A46312; all references available through this accession are  
25 hereby incorporated by reference herein). Similarly, The translation product of this gene also shares homology with B219, a sequence that is expressed in at least four isoforms in very primitive hematopoietic cell populations which may represent a novel hemopoietin receptor (See, e.g., Cioffi, et al. Nat. Med. 2:585-589 (1996), which is hereby incorporated by reference herein). In a preferred embodiment  
30 polypeptides of the invention comprise the following amino acid sequence:

CKDLCSRVLTLSPLLSYDPATSHSPRNTQ (SEQ ID NO: 207) . Also preferred are the polynucleotides encoding these polypeptides.

This gene is expressed primarily in tonsil, and colon, and to a lesser extent in a wide variety of human tissues.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and gastrointestinal disorders, particularly tumors of the colon and tonsil. Similarly, polypeptides and antibodies directed to  
10 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, digestive and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, gastrointestinal, or  
15 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 112 as residues: Met-1 to Cys-6. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in tonsil and colon, combined with the homology to human histiocyte growth factor, the human endogenous viral protein, and B219  
25 strongly indicate that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment and/or prevention, of a variety of hematopoietic and immune system disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,  
30 20, and 27, and elsewhere herein. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation

of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses).

5           Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, 10 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted 15 factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, 20 raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

          Many polynucleotide sequences, such as EST sequences, are publicly 25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or 30 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2511 of SEQ ID NO:20, b is an

integer of 15 to 2525, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 11

5           The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

10           In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

IIECWEEECQSCRLKITQPREICRMDFLVLFLFYLASVLMGLVLICVCSKTHS  
LKGLARGGAQIFSCIPECLQRAXHGLLHYLFHTRNHTFIVLHLVLQGMVYTE  
YTWEVFGYCQELELSLHYLLPYLLGVNLFFFTLTCGTNPGIITKANELLFLH  
15   VYEFDEVMFPKNVRCSTCDLRKPARSKHCSVCNWCVHRFDHHCVVVNNCI  
GAWNIRYFLIYVLTLTASAATVAIVSTTFLVHLVVMSDLYQETYIDDLGHLHV  
MDTVFLIQYLFLTFPRIVFMLGFVVVLSFLLGGYLLFVLYLAATNQTNEWYR  
GDWAWCQRCPLVAWPPSAEPQVHRNIHSHGLRSNLQEIFLPAFPCHERKKQE  
(SEQ ID NO: 208) . Polynucleotides encoding these polypeptides are also provided.

20           This gene is expressed primarily in colon and brain and to some extent in all tissues.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25   not limited to, neurological and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and digestive system, expression of this gene at significantly higher or lower levels is  
30   routinely detected in certain tissues or cell types (e.g., neurological, gastrointestinal, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,

synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,  
10   the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive  
15   compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,  
20   neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Alternatively, expression of this gene in colon may indicate a role in the detection, prevention and/or treatment of colon disorders such as colon cancer, Crohn's Disease, ulcers, and digestive tract disorders in general. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to  
25   isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
30   available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 1382 of SEQ ID NO:21, b is an integer of 15 to 1396, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 12

10 When tested against Reh cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activation site) pathway. Thus, it is likely that this gene activates B-cells through the Jaks-STAT signal transduction pathway. GAS is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal  
15 transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. This gene maps to chromosome 7, and therefore, is used as a marker in linkage analysis for chromosome 7.

20 This gene is expressed primarily in brain, and in the developing embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, behavioral, immune, and developmental disorders.  
25 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and developmental systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural,  
30 developing, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue

or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
5 epitopes shown in SEQ ID NO: 114 as residues: Lys-60 to Asn-67. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions.  
10 Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,  
15 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the tissue distribution in developing  
20 embryo indicates that the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the biological activity within B-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of  
25 immune system disorders. Activation of genes within B-cells indicates a role for this protein in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of  
30 cancer (e.g., by boosting immune responses).



Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1055 of SEQ ID NO:22, b is an integer of 15 to 1069, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 13

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

LLSFKIRGLRTEDAGWAQSSSGGLCVRGDAFWMPSSSSGLGSPSRPPSSFLCL

LLLLLPPAALALLFFLDFFPPRAAVSPFLPDHCSARQPRVWRRETLNRSASGL

GCWARSTEQGA VGVATGTVLDI SLPASCLSLWPPGPSGGI (SEQ ID NO: 209)

. Polynucleotides encoding these polypeptides are also provided.

In a specific embodiment polypeptides of the invention comprise the following amino acid sequence:

5 QLGLCLTSASLPPASRCGHQAPLGASDLSAHSAPGFSDSYFTMSCQSSLSRA  
EILQCPLVPSVSPPTLHPQGRANKSSRASLPLLPQTHWCLFPSARGWRRGIQSG  
LPPGGSCTSPRSPPQTLHQHITLVNHNTSYWQSPST (SEQ ID NO: 210),  
HQPCLPLAVATRPLWGHLTCLPIHLVSVTLTSPCLANQAFQGQRSYNAL  
WCPLFLLLPTSPKGEQTNHPEPACPCFPKLTGVFSLQHVVGAEEFSQVFLLD  
10 PVPVLDHLLKLFTSTSHLLIIPHIGKAPAPDSSL EELSLSLATHCKVAVARFT  
(SEQ ID NO: 211). Also preferred are the polynucleotides encoding these  
polypeptides. Polynucleotides of the invention do not consist of the nucleic acid  
sequence shown as GeneSeq Accession No. X04377, which is hereby incorporated  
herein by reference.

15 This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, behavioral and neurological disorders. Similarly, polypeptides and  
20 antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the central nervous system,  
expression of this gene at significantly higher or lower levels is routinely detected in  
certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily  
25 fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
tissue or cell sample taken from an individual having such a disorder, relative to the  
standard gene expression level, i.e., the expression level in healthy tissue or bodily  
fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
30 epitopes shown in SEQ ID NO: 115 as residues: Pro-2 to Gly-7, Ser-10 to Ser-16,

Pro-52 to Val-62, Arg-64 to Ser-73. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1644 of SEQ ID NO:23, b is an

integer of 15 to 1658, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 14

5           The translation product of this gene was shown to have homology to the lysosomal mannosidase alpha-B protein (See Genebank Accession No. P34098) which is thought to be important in protein metabolism. One embodiment of this gene comprises polypeptides of the following amino acid sequence:

MAAEGSRFSSQSPGLVDRQGPKCDPSRLVSPWGRHGLRILQIGHHHGRDGGQH  
10 EATHHLLRVLRAPRVGKADEGAVDSDPSTPLQLKHEAAHAEDHAQQVHVVR  
RRVVQGRVTFARRGLVPQHFRPPWVRHIVSGHSESKARSRLFRNRNRSFRR  
AS (SEQ ID NO: 212) , and/or

RLVSPWGRHGLRILQIGHHHGRDGGQHEATHHLL RVLRA (SEQ ID NO: 213) .

15           An additional embodiment is the polynucleotides encoding these polypeptides. This gene maps to chromosome 19, and therefore, is used as a marker in linkage analysis for chromosome 19.

          This gene is expressed primarily in brain, placenta, fetal liver, and to a lesser extent in most tissues.

          Therefore, polynucleotides and polypeptides of the invention are useful as  
20           reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, reproductive, and hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
25           a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, hepatic, or cancerous and wounded tissues) or bodily fluids (e.g., bile, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a  
30           disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 116 as residues: Asn-34 to Lys-42, Leu-60 to Trp-70. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution predominantly in brain indicates a role in the  
5 detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Alternatively, the tissue distribution in liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of  
10 liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
20 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1063 of SEQ ID NO:24, b is an integer of 15 to 1077, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

This gene is expressed primarily in spinal cord, Merkel cells, and adipose tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as  
30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, disorders of the nervous and immune systems, particularly those disorders relating to the CNS involving lipid metabolism disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For

5 a number of disorders of the above tissues or cells, particularly of the nervous and immune systems and adipose tissue, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an

10 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spinal cord, Merkel cells and adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

15 treatment and/or diagnosis of diseases the nervous systems, such as spinal cord injury, neurodegenerative diseases, muscular dystrophy or obesity. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

25 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1191 of SEQ ID NO:25, b is an integer of 15 to 1205, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

The translation product of this gene shares sequence homology with the human uncoupling protein-2 which is thought to be important in energy metabolism, obesity, and the predisposition of hyperinsulinemia (See Genebank Accession No. gi|1857278). Recently, another group published on this gene, designating it brain mitochondrial carrier protein-1 (BCMP1) (J Biol Chem 1998 Dec 18;273(51):34611-5). One embodiment of this gene comprises polypeptides of the following amino acid sequence: PTDVLKIRMQAQ (SEQ ID NO: 214) , and/or TYEQLKR (SEQ ID NO: 215) . An additional embodiment is the polynucleotides encoding these polypeptides. This gene maps to the X chromosome, and therefore, is used as a marker in linkage analysis for the X chromosome.

This gene is expressed primarily in manic depression brain tissue, epileptic frontal cortex, human erythroleukemia cell line, T-helper cells, and to a lesser extent in endothelial and amygdala cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the central nervous system or hematopoietic/immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system or hematopoietic/immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, hemolymphoid, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 118 as residues: Ser-34 to Thr-39, Gln-198 to Leu-205. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in neural tissues combined with the homology to the human uncoupling protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and/or treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and preception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Alternatively, given the homology to uncoupling proteins, the gene and/or its translation product may also be used in the diagnosis, treatment, and/or prevention of thermogenesis disorders such as obesity, cachexia, and hyperinsulinemia. Uncoupling proteins dissipate the proton gradient created from the oxidation of fuels by the electron transport chain, thus releasing stored energy as heat. Dysfunction of thermogenesis can induce disorders such as obesity and cachexia. It is thought that obesity may result from decreased thermogenesis in humans. Alternatively, cachexia is a metabolic state in which energy expenditure exceeds food intake, for example in anorexia nervosa. Uncoupling proteins is useful for the treatment and/or prevention of diseases and/or disorders involved with aberrant metabolic and thermogenic pathways. The following method provides for the determination of respiration uncoupling activity of the polypeptides of the present invention, including fragments and variants of the full length proteins.

Briefly, yeast are transfected with an expression vector expressing polypeptide of the present invention as previously described by Bouillaud et al., EMBO J., 13:1990 (1994) (incorporated by reference herein in its entirety). Rates of growth in liquid medium of transformed yeast are measured in the presence of galactose, which induces expression, as described in International Publication No. WO 98/31396



(incorporated by reference herein in its entirety). Instantaneous generation times are compared between the polypeptide of the present invention and appropriate controls. An in vivo decrease of membrane potential associated with uncoupling of respiration is analyzed by flow cytometry of yeast labeled with the potential sensitive probe

5 DiOC6 (3) (3,3'-dihexyloxacarbocyanine iodine, Molecular Probes, Eugene, OR). The ability of a polypeptide of the present invention to influence mitochondrial activity and uncouple respiration is thus determined.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

10 related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO:26, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 17

20 The translation product of this gene shares sequence homology with 55 kD deglycosylated zona pellucida protein which is known to be important in egg fertilization (See Genbank Accession No.R39356). Preferred polypeptides of the invention comprise the following amino acid

sequence:

25 RPRPSASSLARSASLLPAAHGXGVGGAGGGSSXLRORYQQQLQNEEESGEPEQ  
AAGDAPPPYSSISAESAHXFDYKDESGFPKPPSYNVATTLPSYDEAERTKAEA  
TIPLVPGRDEDFVGRDDFDDADQLRIGNDGIF (SEQ ID NO: 216) ,  
RYQQQLQNEEESGEPEQAAGD (SEQ ID NO: 217) , and/or  
PGRDEDFVGRDDFDDADQLRIG (SEQ ID NO: 218) . Polynucleotides encoding

30 these polypeptides are also provided.

Preferred polypeptide fragments of the invention comprise the following amino acid sequence: MLTFFMAFLFNWIGFFLSFCLTTSAAGRYG AISGFGLSLIKWILIVRFSTYFPGYFDGQY WLWWVFLVLGFLFLRGFINYAKVRKMPET FSNLPRTRVLFIY (SEQ ID NO:

5 219). Polynucleotides encoding these polypeptides are also provided.

Preferred polypeptide variants of the invention comprise the following amino acid sequence:

MKKSLENLNLRLQVMLLHLTA AFLQRAQHXYFDYKDESGFPKPPSYNVATTLP  
 YDEAERTKAEATIPLVGRDEDFVGRDDFDDADQLRIGNDGIFMLTFFMAFLF  
 10 NWIGFFLSFCLTTSAAGRYGAISGFGLSLIKWILIVRFSTYFPGYFDGQYWLW  
 WVFLVLGFLFLRGFINYAKVR KMPETFSNLPRTRVLFIY (SEQ ID NO: 220),  
 MLLHLTA AFLQRAQFSTYFPGYFDGQYWLWWVFLVLGFLFLRGFINYAKV  
 RKMPETFSN LPRTRVLFIY (SEQ ID NO: 221), MLTFFMAFLFNWIGFFLSFCLT  
 TSAAGRYGAISGFGLSLIKWILIVRFSTYFPAFMNSLSRSKRTPAGSESRCRTQ  
 15 RNNHLL (SEQ ID NO: 222), and/or  
 MKKSLENLNLRLQVMLLHLTA AFLQRAHXIL TTRMSLGFSPLTM (SEQ ID  
 NO: 223) . Polynucleotides encoding these polypeptides are also provided.

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter  
 20 element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, other immune and hematopoietic cells and JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the  
 25 Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in adult kidney, colon adenocarcinoma, and fetal brain, and to a lesser extent, ubiquitously expression in many tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, disorders of kidney, colon cancers, and central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal and neural systems, and cancers, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., renal, neural, urogenital, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 119 as residues: Cys-15 to Gly-36. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution adult kidney, colon adenocarcinoma, and fetal brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of kidney diseases, colon cancers, and disorders of the central nervous system. Additionally, the homology to the zona pellucida protein indicates that the gene product is used for male contraceptive development, and infertility diagnosis etc. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1951 of SEQ ID NO:27, b is an

integer of 15 to 1965, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 18

5       The translation product of this gene shares sequence homology with the chicken transferrin receptor in addition to a human prostate-specific protein homolog (See Genebank Accession Nos. *pir*|JH0570|JH0570 and *gi*|2565338 (AF026380), respectively). This gene also shares significant homology with both the murine and the rat hematopoietic lineage switch 2 proteins (See Genbank Accession Nos. 10 *g*3169729 and *g*3851632, respectively), which are induced during an erythroid to myeloid lineage switch.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MTVMDPKQMNVA<sup>AA</sup>VWAVVSYVVADME<sup>EML</sup> PRS (SEQ ID NO: 224). Polynucleotides encoding these polypeptides are also provided.

15       This gene is expressed primarily in fetal tissues, such as liver/spleen and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pre-natal disorders, anomalies, deficiencies. Similarly, polypeptides 20 and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developing, cancerous and wounded tissues) or bodily fluids 25 (e.g., amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic 30 epitopes shown in SEQ ID NO: 120 as residues: Arg-31 to Lys-37, Lys-58 to Glu-65,

Asp-157 to Gly-168, Ile-219 to Gly-225, Ala-260 to Ser-268, Thr-276 to Glu-282.

Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of pre-natal disorders, anomalies and deficiencies. The homology to the hematopoietic lineage switch 2 proteins indicates that The translation product of this gene is useful for the detection and/or treatment of immune system disorders. In addition, the homology to the transferrin receptor indicates that the translation product of the present invention may have utility in the regulation of iron metabolism as well as the numerous genes under the stringent control of physiologic iron levels. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1849 of SEQ ID NO:28, b is an integer of 15 to 1863, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 19

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

PRVRSREPVAGAPGCGTAGPPAMATLWGLLRLGSLLSLSCLALSVLLLAHC  
QTPPSDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIIYLSILGLLL  
LYMVYLTLEVILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANV

LNKVEYAAQQRWKLQVQEQRKSVFDRHVVL (SEQ ID NO: 225):

Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 72 - 88 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 89 to 167 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

A preferred polypeptide variant of the invention comprise the following amino acid sequence:

MATLWGGLRLGSLLSCLALSLLLLAHCQTPPRISMSDVNVSAPIKKNS  
GHIYNKNISQKDCDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIII  
YLSILGLLLLYMVYLTLEPILKRRRLFHQAQLIQSDDDIGDHQPFANAHDVLA  
RSRSRANVLNKVEYGTAALEASSPRAAKSLSLTGMLSSANWGIEFKVTRKKQ

ADNWKGTDWVLLGFILIPC (SEQ ID NO: 226). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in infant brain tissue, and to a lesser extent in other cell types and tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and neurodegenerative diseases of the brain and nervous system, such as depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, mania, dementia, paranoia, addictive behavior, sleep disorders, epilepsy, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic

fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 121 as residues: Gln-110 to Pro-120, Val-152 to Val-159. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in infant brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis  
10 of developmental, degenerative and behavioral conditions of the brain and nervous system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of schizophrenia, Alzheimer's Disease, Parkinson's  
15 Disease, Huntington's Disease, Tourette Syndrome, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD), mania, depression, dementia, paranoia, addictive behavior, obsessive-compulsive disorder and sleep disorders. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to  
20 identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
30 formula of a-b, where a is any integer between 1 to 1612 of SEQ ID NO:29, b is an

integer of 15 to 1626, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 20

5           The translation product of this gene shares sequence homology with a recently published gene Dysferlin, which is thought to be a skeletal muscle gene that is mutated in Miyoshi myopathy and limb girdle muscular dystrophy (See Genbank Accession No. g3600028, and Nat. Genet. 20 (1), 31-36 (1998)).

          This gene is expressed primarily in fetal liver, fetal heart tissue, and T-cells.

10           Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, lymphomas, auto-immunities, cancer, inflammation, anemias (leukemia) and liver disorders, vascular disorders, and

15           cancers (e.g., hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver and

20           immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, developmental, vascular, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard

25           gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies

30           (e.g., AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product is applicable in conditions of general



microbial infection, inflammation or cancer. Expression in liver may suggest a role for this gene product in the treatment and detection of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Alternatively, the tissue distribution in fetal heart tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Additionally, the homology to the dysferlin gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases related to degenerative myopathies that are characterized by the weakness and atrophy of muscles without neural degradation; such as Duchenne and Becker's muscular dystrophies. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 591 of SEQ ID NO:30, b is an integer of 15 to 605, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

This gene is expressed primarily in haemopoietic cells and tumor cells, such as pancreatic tumor tissue, and to a lesser extent in bladder cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic disorders, diseases of the renal and pancreatic systems, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haemopoietic, pancreatic, and renal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pancreas, renal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the renal, pancreatic and haemopoietic systems, and cancers thereof. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 917 of SEQ ID NO:31, b is an integer of 15 to 931, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

30

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 22

This gene is expressed primarily in liver tissue, cancer cells and fetal lung tissue, and to a lesser extent in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic disorders, diseases of developing systems and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetus, metabolic systems and cancers, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developing, metabolic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 124 as residues: His-44 to Gly-49. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the fetus, metabolic systems and cancers. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1393 of SEQ ID NO:32, b is an integer of 15 to 1407, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

This gene is expressed primarily in central nervous system tissues and cancers, such as endometrial tumors, and to a lesser extent in other tissues and organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the CNS and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and cancerous tissues, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 125 as residues: Tyr-16 to Ser-22, Asp-209 to Leu-215. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of the central nervous system, as well as cancers of tissues where expression of this gene has been observed, such as in  
5 endometrial tumors. The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive  
10 disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein  
15 may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of  
20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1512 of SEQ ID NO:33, b is an  
25 integer of 15 to 1526, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

The translation product of this gene shares sequence homology with low-  
30 density lipoprotein receptor (See Genbank Accession No. >dbj|BAA24580.1), which is thought to be important in the pathogenesis of atherosclerosis and other disorders.

The translation product of this gene also shares sequence homology with a rat homolog of the human CD94 (See Genbank Accession No. gb|AAC10220.1).

This gene is expressed primarily in macrophages, eosinophils, neutrophil and other cells of the haemopoietic and immune system.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune and haemopoietic systems and diseases of the endothelial and vascular system. Similarly, polypeptides and antibodies directed to  
10 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, haemopoietic and vascular system, expression of this gene at significantly higher or lower levels is routinely detected in  
15 certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
20 epitopes shown in SEQ ID NO: 126 as residues: Lys-9 to Ala-17, Met-55 to Leu-61, Tyr-105 to Cys-127, Asp-132 to Lys-141, Ser-165 to Tyr-172, Pro-178 to Met-186, His-222 to Gln-227. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution and homology to LDL receptor and rat CD94 homolog indicates that polynucleotides and polypeptides corresponding to this gene are useful  
25 for the treatment and/or diagnosis of disorders of the immune, haemopoietic and vascular systems. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or  
30 differentiation of hematopoietic lineages. Expression of this gene product in eosinophils and macrophage also strongly indicates a role for this protein in immune

function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1723 of SEQ ID NO:34, b is an integer of 15 to 1737, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

A preferred polypeptide fragment of the invention comprises the following amino acid sequence:

MAAAGRLPSSWALFSPLLAGLALLGVGPVPARALHNVTAELFGAEAWGTLA  
AFGDLNSDKQTDLFVLRERNDLIVFLADQNAPYFKPKVKVSFKNHSALITSVV  
20 PGDYDGDSQMDVLLTYLPKNYAKSELGAVIFWGQNQTLDPNNMILTNRFTQ  
DEPLIMDFNGDLIPDIFGITNESNQPIILLGGNLSWHPALTTTSMRIPHSHAFI  
DLTEDFTADLFLTTLNATTSTFQFEIWENLDGNFSVSTILEKPQNMMVVGQSA  
FADFDGDGHMDHLLPGCEDKNCQKSTIYLVRSGMKQWVPVLQDFSNGKTL  
WGFVPFVDEQQPTEIPIPTLHIGDYNMDGYPDALVILKNTSGSNQQAFLLENV  
25 PCNNASCEEARRMFKVYWELTDLNQIKDAMVATFFDIYEDGILDIVVLSKGY  
TKNDFAIHTLKNNFEADAYFVKVIVLSGLCS NDCPRR (SEQ ID NO: 227).

Polynucleotides encoding these polypeptides are also provided.

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter  
30 element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, other immune and hematopoietic cells and tissue cell types, through the JAK-STAT

signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the  
5 GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in infant brain and placental tissues, and to a lesser extent in several other tissues including cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as  
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain disorders and diseases of developing systems and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell  
15 type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and fetal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
20 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 127 as residues: Leu-56 to Thr-62, Gln-80 to Pro-87,  
25 Gly-106 to Gln-113, Pro-122 to Lys-127, Gln-138 to Asn-146. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in neural tissues and developing tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the central nervous system, disorders of  
30 developing systems, and cancers. The tissue distribution in infant brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful



for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product is produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product is produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 2228 of SEQ ID NO:35, b is an integer of 15 to 2242, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 26

Preferred polypeptides of the invention comprise the following amino acid sequence:

MTKREDGGYTFTATPEDFPKKHKAPVIDIGIANTGKFIMTASSDITVLIWSLK  
 GQVLSTINTNQMNNTAAVSPCGRFVASCFTPDVKVWEVCFGKKGEFQEV  
 10 VRAFELKGHSAAVHSFAFSNDSRRMASVSKDGTWKLWDTXVEYKKKQDPY  
 LLKTGRFEEAAGAXPCRLALSPNAQVLALASGSSIHLYNTRRGEKEECFERVH  
 GECIANLSFDITGRFLASCGDRAVRLFHNTPGHRAMVEEMQGHILKRASNEST  
 RQRLQQQLTQAQETLKSGLGALKK (SEQ ID NO: 228). Polynucleotides encoding  
 such polypeptides are also provided.

15 The gene encoding the disclosed cDNA is thought to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates  
 20 myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS  
 25 element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Recently, another group published this gene, naming it WS beta-transducin repeats protein (See Human Genetics 103 (5), 590-599 (1998); which is hereby incorporated herein by reference), in which it was suggested that the protein is involved in William's Disease.

30 The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 12 - 28 of the amino acid sequence referenced in

Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

VIRHEGSTNMELSQMSXLMGLSVLLGLLALMATAAVXRGWLRAGEERSGRP  
ACQKANGFPPDKSSGSKKQKQYQIRKEKPQQHNFTHRLLAAALKSHSGNIS  
CMDFSSNGKYLATCADDRITIRIWSTKDFLQREHRSMRANVELDHATLVRFP  
10 DCRAFIVWLANGDTLRVFKMTKREDGGYTFTATPEDFPKKHKAPVIDIGIAN  
TGK  
FIMTASSDTTVLIWSLKGQVLSTINTNQMNNTAAVSPCGRFVASCFTPDVK  
VWEVCFGKKGEFQEVVRAFELKGHSAAVHSFAFSNDSRRMASVSKDGTWK  
LWDTXVEYKKKQDPYLLKTGRFEEAAGAXPCRLALSPNAQVLALASGSSIHL  
15 YNTRRGEKEECFERVHGECIANLSFDITGRFLASCGDRAVRLFHNTPGHRAM  
VEEMQGHILKRASNESTRQLQQQLTQAQETLKSLGALKK (SEQ ID NO: 229).  
Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in testes, synovial sarcoma and fetal tissues, and to a lesser extent in several other tissues.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive and developing systems and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
25 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and developing systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
30 plasma, seminal fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in testes tissue, synovial sarcoma, and fetal tissues, indicates that polynucleotides and polypeptides corresponding to this gene are useful  
5 for the treatment and/or diagnosis of disorders of the reproductive and developing systems, and cancers. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm  
10 maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene  
15 expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Furthermore, the tissue distribution indicates that polynucleotides and  
20 polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in  
25 proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in  
30 pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. This protein is useful for

the treatment, detection, and/or prevention of William's Disease. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2221 of SEQ ID NO:36, b is an integer of 15 to 2235, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 27

Preferred polypeptides of the invention comprise the following amino acid sequence positions 1-363, 2-363, 4-363, 5-363, 30-363, 31-363, 32-363, 75-363, 76-363 and 82-363 of the following amino acid sequence:

MSVMVVRKKVTRKWEKLPGRNTFCCDGRVMMARQKGIFYLTLFLILGTCTL  
FFAFECRYLAVQLSPAIPVFAAMLFLFSMATLLRTSFSDPGVIPRALPDEAAFIE  
MEIEATNGAVPQGRPPPRIKNFQINNQIVKLKYCYTCKIFRPPRASHCSICDN  
CVERFDHHCPWVGNCVGKRNYRYFYLFILSLSLLTIYVFAFNIVYVALKSLKI  
GFLETLKETPGTVLEVLCFFILWSVVGLTGFHTFLVALNQTTNEDIKGSWTG  
KNRVQNPYSHGNIVKNCCEVL CGPLPPSVLDRRGILPLEESGSRPPSTQETSSS  
LLPQSPAPTEL NSNEMPEDSSTPEEMPPPEPPPEPPQEA AEAEAEK (SEQ ID NO:  
230). Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide variant of the invention comprises the following amino acid sequence: MLFLFSMATLLRTSFSDPGVIPRALPDEAA

FIEMEIEATNGAVPQGQRPPRIKNFQINNQIVKLKCYTCKIFRPPRASHCSIC  
DNCVE RFDHHCPWVGNCV GKRNRYFYLFILSLSLLTIYVFAFNIVYVALK  
SLKIGFLET LKGNS WNC SRSPHLLLYTLVRRGTDWISYFPRGSQ PDNQ (SEQ  
ID NO: 231). Polynucleotides encoding these polypeptides are also provided.

5           This gene is expressed primarily in ovarian and endometrial tumors, fetal liver, spleen and brain tissues, and to a lesser extent in several other tissues and organs.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
10       biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the developing systems, and cancers of the female reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above  
15       tissues or cells, particularly of the developing, female reproductive and fetal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a  
20       disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 129 as residues: Pro-44 to Lys-54, Cys-88 to His-95, Val-103 to Tyr-108, Gln-181 to Ser-190, Thr-192 to Ile-206, Glu-233 to Ser-245, Ser-  
25       252 to Ala-286. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution in developing systems indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of developing and fetal systems, and cancers. Furthermore, the tissue distribution in ovarian and endometrial tumor tissues indicates that the  
30       translation product of this gene is useful for the detection, diagnosis, and/or treatment of cancers of the female reproductive system. Accordingly, preferred are antibodies

which specifically bind a portion of The translation product of this gene. Also provided is a kit for detecting these tumors. Such a kit comprises in one embodiment an antibody specific for The translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which  
5 comprises a step of contacting an antibody specific for The translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are  
10 more particularly described elsewhere herein.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2957 of SEQ ID NO:37, b is an integer of 15 to 2971, where both a and b correspond to the positions of nucleotide  
20 residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 28

This gene is expressed primarily in normal and cancerous colon tissue, macrophages, endothelial cells and placental tissue, and to a lesser extent in several  
25 other tissues and organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, colon cancer and gastrointestinal disorders, immune disorders, vascular  
30 diseases and disorders of developing systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, vascular and developing systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, gastrointestinal, developmental, vascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 130 as residues: Thr-27 to Ser-33. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in macrophage, endothelial and placental tissues, and normal and cancerous colon tissues, indicates that polynucleotides and polypeptides  
15 corresponding to this gene are useful for the treatment and/or diagnosis of immune, gastrointestinal and vascular disorders and diseases. Expression of this gene product in colon tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general. Accordingly, preferred are  
20 antibodies which specifically bind a portion of the translation product of this gene. Also provided is a kit for detecting colon cancer. Such a kit comprises in one embodiment an antibody specific for The translation product of this gene bound to a solid support. Also provided is a method of detecting colon cancer in an individual which comprises a step of contacting an antibody specific for The translation  
25 product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Alternatively, the tissue  
30 distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders



of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product is produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta and endothelial cells also indicates that this gene product is produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Additionally, expression of this gene product in macrophage also strongly indicates a role for this protein in immune function and immune surveillance. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1149 of SEQ ID NO:38, b is an integer of 15 to 1163, where both a and b correspond to the positions of nucleotide  
5 residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene shares homology with HNK-sulfotransferase, which directs glycan synthesis (see Genbank Accession no.  
10 AF033827).

This gene is expressed primarily in activated T cells, osteoclastoma, and glioblastoma, and to a lesser extent in various other normal and transformed cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as  
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, immune defects, cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of  
20 disorders of the above tissues or cells, particularly of the immune and hemopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative  
25 to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 131 as residues: Pro-32 to Gly-48, Gln-63 to Thr-69, Pro-77 to Trp-84, Val-88 to Leu-94. Polynucleotides encoding said polypeptides are  
30 also provided.

The tissue distribution in T-cells and various types of neoplasms indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, study and/or treatment of inflammatory and general immune defects, and various types of neoplasms. Expression of this gene product in T cells strongly indicates a role for this protein in immune function and immune surveillance. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in various cancerous tissues indicates that the translation product of the gene is useful for the detection, diagnosis, and/or treatment of these cancers, as well as cancers of other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1918 of SEQ ID NO:39, b is an integer of 15 to 1932, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 30**

Preferred polypeptides of the invention comprise the following amino acid sequence:

- 5 LHECLPGSISYLHP RTPWLCLPPQHLSFSTFSPPWQPAMSPVPGTGGPPCGL  
(SEQ ID NO: 232), and/or  
MLPLLIIICLLPAIEGKNCLRCWPELSALIDYDLQILWVTPGPPTELSQSIHSLFLE  
DNNFLKPWYLD RDHLEEETAKFFTQVHQAIKTLRDDKT VLL EEIYTHKNLFT  
ERLNKISDGLKEKGAPPLHECLPGSISYLHP RTPWLCLPPQHLSFSTFSPPWQP  
10 AMSPVPGTGGPPCGL (SEQ ID NO: 233). Polynucleotides encoding these  
polypeptides are also provided.

This gene is expressed primarily in infant brain, testes and activated T cells, and to a lesser extent in various other normal and transformed cell types.

- Therefore, polynucleotides and polypeptides of the invention are useful as  
15 reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, neurological, reproductive and inflammatory conditions. Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For  
20 a number of disorders of the above tissues or cells, particularly of the neural, immune  
and male reproductive systems, expression of this gene at significantly higher or  
lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune,  
reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
25 from an individual having such a disorder, relative to the standard gene expression  
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
having the disorder.

- Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 132 as residues: Gly-41 to Leu-46, Asp-67 to Thr-75,  
30 Ile-114 to Ala-123. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in infant brain tissue, testes tissue, and activated T-cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and/or treatment of neurological, reproductive and immune system disorders. Expression of this gene product in T-cells indicates a role  
5 in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

10 Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease,  
15 sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell type. Alternatively, the tissue distribution in testes tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions  
20 concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis  
25 of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

30 Furthermore, the tissue distribution in infant brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 867 of SEQ ID NO:40, b is an integer of 15 to 881, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The translation product of this gene shares sequence homology with some human and rodent melanoma and leukocyte specific antigens (see, for example, Genbank accession nos: gi|189384, gi|205898 and gi|180926). In addition, The translation product of this gene shares sequence homology with Tetraspan protein (see, for example, Genbank accession number: GI 3152703). Therefore, it is likely that the polypeptide of this gene shares some biological functions, such as cell-to-cell signaling, adhesion, proliferation, and differentiation with Tetraspan.

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 52-68 and 197 - 213 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed

that the protein product of this gene shares structural features to type IIIa membrane proteins.

The transmembrane 4 superfamily (TM4SF) or tetraspan superfamily has at least 16 members (including CD9, CD20, CD37, CD53, CD63, CD81, CD82, A15, CO-029, Sm23, RDS, Uro B, Uro A, SAS, Rom-1, PETA3, and YKK8), is the second biggest subfamily among CD antigen superfamily. and activation antigen of T- cells. All TM4SF member contains four putative transmembrane domains, two extracellular loops, and two short cytoplasmic tails. They are variously expressed on Immature, early, mature, activated lymphocytes, monocytes, macrophages, granulocytes, platelets, eosinophils, basophils, certain leukemic and lymphoma cells, and a variety of other cells and tissues. CD9 cell surface protein is expressed by both hematopoietic and neural cells, and may play a role for CD9 in intercellular signaling in the immune and nervous system. CD63 is a 53-Kd lysosomal membrane glycoprotein that has been identified as a platelet activation molecule, which play important role in cell adhesion of platelets and endothelial cells. Increased mRNA for CD63 antigen was found in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits, suggesting a potential role of CD63 in progression of atherosclerosis. CD63 is also a mast cell marker.

CD82 was originally identified as the target of several mAbs inhibitory to syncytium formation induced by human T-cell leukemia virus type I (HTLV-I), the etiological agent of adult T-cell leukemia. Therefore, this gene could be a target for the development of a drug for this leukemia. CD81 is the target of an antiproliferative antibody. A diverse group of human cell lines, including hematolymphoid, neuroectodermal, and mesenchymal cells, express the CD81 protein. Many of the lymphoid cell lines, in particular those derived from large cell lymphomas, were susceptible to the antiproliferative effects of the antibody. CD81 may therefore play an important role in the regulation of lymphoma cell growth. CD9, CD20, CD37, CD63, CD81 and CD82 have been implicated in the regulation of cell growth, adhesion, and signal transduction of B, T lymphocytes and some other non-lymphoid cells. They associate with CD2, CD21, CD4, CD8, MHC Class II molecules, integrins, function as co-receptor for T, B and other lymphoid cells. Some

TM4SF are leukocyte antigens, highly expressed in activated leukocytes, lymphocytes, are highly specific surface marker for lymphoblastic leukemia, lymphoma, melanoma, and neuroblastoma. CD9 has been show to be involved in cell motility and tumor metastasis. These antigen could be a valuable immunogen or  
5 target to implement active and passive immunotherapy in patients with cancer. Others have been shown to be involved in inhibition of prostate cancer metastasis. This gene has close homology to C33 antigen (CD82). whic is a member of the transmembrane 4 superfamily (TMSF) and activation antigen of T- cells. C33 Ag (CD82 was originally identified as the target of several mAbs inhibitory to syncytium formation  
10 induced by human T-cell leukemia virus type I (HTLV-I), the etiological agent of adult T-cell leukemia. Therefore, this gene could be very important target for developing drug for leukemia. Other members of this family are Sm23, CO-029, R2, TAPA-1, CD9, CD37, CD53, and CD63. CD63 is a 53-Kd lysosomal membrane glycoprotein that has been identified as a platelet activation molecule.

15       There is strong evidence indicating that CD63 and Pltgp40, a platelet membrane glycoprotein are the same molecule and that CD63/Pltgp40 is identical to the well-characterized, stage-specific melanoma-associated antigen ME491. These antigen could be valuable immunogens or target to implement active and passive immunotherapy in patients with cancer.

20       This gene is expressed primarily in fetal tissue (kidney, heart, liver, spleen, brain), macrophages, dendritic cells, retina and to a lesser extent in various other tissues, mostly of lymphoid origin or epithelial cell types. In addition       This gene is expressed in cancerous tissues (e.g. breast).

      Therefore, polynucleotides and polypeptides of the invention are useful as  
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders and cancers in a variety of organs and cell types. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
30 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at



significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, proliferating, immune, hematopoietic, integumentary, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid, spinal fluid, or amniotic fluid) or another tissue or cell sample taken  
5 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 133 as residues: Tyr-123 to Tyr-131, Cys-134 to Ser-  
10 145, Tyr-234 to Tyr-244. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution fetal cells and tissues and homology to tumor antigens indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of lymphoid and epithelial disorders and  
15 neoplasms. Additionally, tissue distribution in immune cells and other tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting hematopoiesis, including cancers. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere  
20 herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

25 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,  
30 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
5 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of  
10 cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern  
15 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
20 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
25 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
30 insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue

markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
10 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1918 of SEQ ID NO:41, b is an integer of 15 to 1932, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

The translation product of this gene shares limited sequence homology with VEGF which is thought to be important in regulation of endothelial cell growth. Therefore, it is likely that the protein encoded by this gene would share some similar  
20 biological functions.

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, other immune and hematopoietic cells and tissue cell types, through the Jak-STAT signal transduction pathway. The gamma activating  
25 sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and  
30 differentiation of cells.

This gene is expressed in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, nervous system disease and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 134 as residues: Thr-25 to Pro-46. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to  
5 identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1150 of SEQ ID NO:42, b is an integer of 15 to 1164, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

20 The translation product of this gene shares sequence homology with human p150 which is thought to be important in signal transduction in neuronal cells. Therefore, it is likely that the protein encoded by this polynucleotide would share some similar biological functions with p150.

This gene is expressed primarily in whole embryo and cerebellum.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and growth defects/disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
30 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS, expression of this gene

at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene  
5 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of central nervous system, neurodevelopmental, cognitive, and memory disorders. The tissue distribution  
10 also indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not  
15 limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive  
20 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,  
25 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show  
30 utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Moreover, the expression within embryonic tissue and other cellular sources marked

by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1091 of SEQ ID NO:43, b is an integer of 15 to 1105, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 34

This gene is expressed primarily in PMA stimulated HL-60 cells and to a lesser extent in 6 week embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting cell differentiation, particularly hematopoietic disorders and/or defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 136 as residues: Pro-61 to Asp-68. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study of cellular differentiation and for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia. The tissue distribution also



indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the

5 expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Moreover, the protein may

10 represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, the expression within embryonic tissue and other

15 cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the

"Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere

20 herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain

25 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,

30 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue

differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:44, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 35**

This gene is expressed primarily in colon.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and/or defects of the digestive tract including but not limited to cancers of the gastrointestinal tract. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at

significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene  
5 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the digestive system particularly disorders involving the colon. Further, expression of this  
10 gene product in colon tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the colon and/or other gastrointestinal tissue  
15 including, but not limited to, stomach, small intestine, large intestine, and rectum.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
20 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 503 of SEQ ID NO:45, b is an integer of 15 to 517, where both a and b correspond to the positions of nucleotide  
25 residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

This gene is expressed primarily in blood cells.

Therefore, polynucleotides and polypeptides of the invention are useful as  
30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, immune and hematopoietic diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 138 as residues: Pro-19 to Cys-29, Thr-35 to Glu-44, Val-72 to Lys-78. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis and/or treatment of disorders of the immune and hematopoietic system. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 844 of SEQ ID NO:46, b is an

integer of 15 to 858, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 37

5           This gene is expressed in multiple tissue systems such as brain, immune cells, prostate, uterus, testes, placenta, and fetal heart as well as in cancerous tissues such as ovarian tumors. .

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
10       biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune, reproductive, urogenital, and central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
15       particularly of the central nervous system and immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, urogenital, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative  
20       to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 139 as residues: Tyr-33 to Lys-38. Polynucleotides encoding said polypeptides are also provided.

25           The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, urogenital, reproductive, and central nervous systems. The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis  
30       of diseases of the central nervous system, as well as cancers of tissues where expression of this gene has been observed, such as in ovarian tumors. The tissue

distribution in central nervous system tissues also indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo. . Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in

proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution in uterus indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed

against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 6093 of SEQ ID NO:47, b is an integer of 15 to 6107, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 38**

This gene is expressed in a wide range of tissue systems such as brain, immune cells, fetal liver, kidney, testes, breast, and pancreas as well as cancerous tissue such as ovarian tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the central nervous system, immune system, urogenital, and reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, CNS, urogenital, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 140 as residues: Met-1 to Ser-7, Asp-32 to Pro-43, Ser-96 to Arg-102. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides  
5 corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, reproductive, urogenital and central nervous systems. The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of the central nervous system, as well as cancers of tissues where  
10 expression of this gene has been observed, such as in ovarian tumors. The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,  
15 schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders.  
20 Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation  
25 of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such  
30 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's

5 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the

10 protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Moreover, the expression within

15 embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below

20 and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain

25 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,

30 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue

differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 689 of SEQ ID NO:48, b is an integer of 15 to 703, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

This gene is expressed primarily in macrophages and fetal cells and to a lesser extent in cancerous ovarian tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune diseases, disorders of developing tissues, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in

providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal and immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous  
5 and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides  
10 corresponding to this gene are useful for treatment and diagnosis of developmental abnormalities and disorders of the immune systems. The tissue distribution cancerous ovaries indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of these tumors. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker  
15 and/or immunotherapy target for the above listed tissues. Expression of this gene product in macrophage cells strongly indicates a role for this protein in immune function and immune surveillance. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). This gene  
20 product may have clinical utility in the treatment of immune dysfunction; in the correction of autoimmunity; in immune modulation; and in the control of inflammation.

The tissue distribution indicates polynucleotides and polypeptides  
corresponding to this gene are useful for the diagnosis and treatment of a variety of  
25 immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene  
30 product is involved in the regulation of cytokine production, antigen presentation, or

other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution also indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders such as melanomas.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 625 of SEQ ID NO:49, b is an integer of 15 to 639, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 40

This gene is expressed primarily in neutrophils, bone marrow, brain, and fetal cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders, Limbic system disfunction/defects and disorders of the immune system and developing systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, Limbic system and developing systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 142 as residues: Ala-84 to Gln-93. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, Limbic system, CNS and developing systems. Expression of this gene product in bone marrow, eosinophils, and neutrophils strongly indicates a role for this protein in hematopoiesis and immune surveillance. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). This gene product may have clinical utility in the treatment of immune dysfunction; in the correction of autoimmunity; in immune modulation; and in the control of inflammation. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune

Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, and other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury.

Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Additionally, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the



"Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 853 of SEQ ID NO:50, b is an

integer of 15 to 867, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 41

5           This gene is expressed primarily in ovary and to a lesser extent in fetal tissue, colon, and immune cells.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
10       not limited to, ovarian cancer, gastrointestinal and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower  
15       levels is routinely detected in certain tissues or cell types (e.g., reproductive, gastrointestinal, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
20       individual not having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 143 as residues: Ile-23 to Ala-29. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution indicates that polynucleotides and polypeptides  
25       corresponding to this gene are useful for diagnosis and treatment of ovarian cancer and related metastases. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The tissue distribution in colon tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders  
30       involving the gastrointestinal tract. This may include diseases associated with digestion and food absorption, as well as hematopoietic disorders involving the

Peyer's patches of the small intestine, or other hematopoietic cells and tissues within the body. Similarly, expression of this gene product in colon tissue indicates again involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
10 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1555 of SEQ ID NO:51, b is an integer of 15 to 1569, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 42**

The translation product of this gene shares sequence homology with retrovirus-related reverse transcriptase pseudogene. In addition, this gene shares homology with human interferon-beta (Genseq accession number T35524; all references available through this accession are hereby incorporated herein by  
20 reference), therefore, it is likely that this gene and the protein encoded by this gene shares some similar biological functions with this protein.

This gene is expressed primarily in frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
25 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system,  
30 expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily

fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in frontal cortex and homology to retrovirus-related reverse transcriptase pseudogene and human interferon-beta indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurodegenerative diseases of the brain, particularly of the frontal cortex. The tissue distribution indicates polynucleotides and polypeptides  
10           corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of  
15           Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, cystic fibrosis, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,  
20           learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

                  Potentially, this gene product is involved in synapse formation,  
25           neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show  
30           utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1182 of SEQ ID NO:52, b is an integer of 15 to 1196, where both a and b correspond to the positions of nucleotide  
10 residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

This gene is expressed primarily in immune cells, brain, fetal tissue, and cancerous tissues (such as testes, stomach, lung, pancreas, ovaries) and to a lesser  
15 extent in other numerous tissues including, but not limited to, testes and kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative diseases. Similarly, polypeptides and antibodies  
20 directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and immune cells expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids  
25 (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
30 epitopes shown in SEQ ID NO: 145 as residues: Lys-23 to Lys-35, Met-46 to Tyr-52. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurodegenerative disorders of the frontal cortex, as well as, cancer or a number of tissues including but not limited to testes, stomach, lung, pancreas, and ovaries. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell

lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene  
5 product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and  
10 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
15 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their  
20 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility  
25 in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

30 Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent



of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 931 of SEQ ID NO:53, b is an integer of 15 to 945, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

#### 30 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

This gene is expressed primarily in epithelioid sarcoma and to a lesser extent in pancreatic carcinoma, aorta endothelial cells induced with TNF-alpha, and amniotic cells induced with TNF. This gene is also expressed, to a lesser extent, in cancerous lung and ovary tissue and fetal tissue.

5        Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, epithelioid sarcoma and related cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
10       probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., amniotic, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
15       tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 146 as residues: Tyr-39 to Arg-51. Polynucleotides  
20       encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of certain cancers, including epithelioid sarcoma and pancreatic carcinoma. The tissue distribution in tumors of lung, ovary, and pancreas origins indicates that polynucleotides and  
25       polypeptides corresponding to this gene are useful for the diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues. Moreover, the expression within embryonic tissue and other cellular sources marked  
30       by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of

developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern  
5 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
10 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
15 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
20 insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
25 immunotherapy targets for the above listed tissues. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the  
30 expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including

blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene  
5 product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and  
10 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
15 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their  
20 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
30 formula of a-b, where a is any integer between 1 to 474 of SEQ ID NO:54, b is an

integer of 15 to 488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 45

5 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

PPVPPWISLPLTGSPPRPGFVPVSPFCFSPMTNGHQVLLLLLLTSAVAAGPWPQ

10 VHAGQWGWMLPPLPSVQARSGLGGLPGGPQWVPGGARGY (SEQ ID NO: 234). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in fetal and infant tissue, particularly infant brain and fetal liver/spleen libraries, and to a lesser extent in breast, ovary tumor, pharynx carcinoma, endometrial stromal cells, thymus, islet cell tumors, and adult  
15 cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders. Similarly, polypeptides and  
20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and breast, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, developmental, hematopoietic, and cancerous and  
25 wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution in developing cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis

and treatment of cancer and other proliferative disorders. The expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and  
5 other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell  
10 death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may  
15 also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of  
20 degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue  
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
 5 formula of a-b, where a is any integer between 1 to 2846 of SEQ ID NO:55, b is an integer of 15 to 2860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 46

10 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

IQQWGDSVLGRRCDLLQLYLQRPELRVPVPEVLLHSEGAASSSVCKLDGLI  
 15 HRFITLLADTSDSRALENRGADASMACRKLAVAHPLLLLRHLPMAIALLHGR  
 THLNFEFRQQNHLSCFLHVLGLLELLQPHVFRSEHQGALWDCLLSFIRLLN  
 YRKSSRHAAAFINKFVQFIHKYITYNAPAAISFLQKHADPLHDLSFDNSDLVM  
 LKSLLAGLSLPSRDDRTDRGLDEEGEEESSAGSLPLVSVSLFTPLTAAEMAPY  
 MKRLSRGQTVEDLLEVLSIDIDEMSRRRPEILSFFSTNLQRLMSSAECCRNLA  
 20 FSLALRSMQNSPSIAAFLPTFMVCLGSQDFEVVQTALRNLPEYALLCQEHA  
 AVLLHRAFLVGMYGQMDPSAQISEALRILHMEAVM (SEQ ID NO: 235).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in breast cancer, and to a lesser extent in a variety of other cancers, including uterine cancer, synovial sarcoma, and pharynx  
 25 carcinoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer; proliferative diseases and/or disorders. Similarly,  
 30 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For

a number of disorders of the above tissues or cells, particularly of the breast, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, breast, proliferative, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, breast milk, urine, 5 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic 10 epitopes shown in SEQ ID NO: 148 as residues: Glu-35 to His-41, Ser-62 to Ala-67, Pro-145 to Leu-155, Glu-157 to Ser-163, Arg-190 to Val-197, Asp-208 to Pro-215, Ser-247 to Pro-252. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast cancer tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or 15 treatment of cancer. Elevated expression of this gene product in cancers, such as breast cancer, suggest that it is involved in the abnormal proliferation of cells, dedifferentiation, angiogenesis, and other processes that accompany the development of cancer. Thus, therapeutics targeted against this gene product is useful therapeutic products in and of themselves. Alternately, expression of this gene product at elevated 20 levels in breast tissue is reflective of expression within breast lymph nodes, and may suggest a hematopoietic role for this protein. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

25 Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have 30 applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the



polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of  
5 degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue  
10 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1545 of SEQ ID NO:56, b is an integer of 15 to 1559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The translation product of this gene shares limited sequence homology with cytochrome-c oxidase. An alternative embodiment is the polypeptide comprising the following amino acid sequence:

MLLKHLQRMVSPQVKASALKVVTLTANDKTSVSFSSLPQGVIYNVIVWD  
30 PFLNTSAAAYIPAHTYACSFEGEGSCASLGRVSSKVFFTLFALLGFFICFFGHR  
FWKTELFFIGFIIMGFFFYILITRLTPIKYDVNLILTAVTGSVGGMFLVAVVWR

FGILSICMLCVGLVLGFLISSVTFFTPLGNLKFHDDGVFWVTFSCIAILPVVF  
MGCLRILNLTGCVIGSYSVVLADS YWSTSLSYITLNVLKRALNKDFHRAFTN  
VPFQTNDFIILAVWGMLAVSGITLQIRRERGRPFPPHPYKLWKQERERRVTNI  
LDPSYHIPPLRERLYGRLTQIKGLFQKEQPAGERTPLLL (SEQ ID NO: 236).

5 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

WARLRGPGAHARTSPQPWRGSPQAAMGFLQLLVVXVLXSEHRVAGAAE  
10 VFGNSSEGLIEFSVGKFRYF  
ELNRPFPEEAILHDISSNVTFILFIQIHSQYQNTTVSFSPRRRSPTM (SEQ ID NO:  
237). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in keratinocytes, brain, and spinal cord and to a lesser extent in hematopoietic cells and tissues.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders; hematopoietic disorders; integumentary disorders; immune dysfunction; learning disabilities. Similarly, polypeptides and  
20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., integumentary, neural, developmental,  
25 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution in brain and spinal cord cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

- diagnosis and treatment of a variety of neurological and hematopoietic disorders. For example, elevated levels of expression of this gene product in brain and spinal cord indicates that it is involved in neurodegenerative disorders. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in
- 5 Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms,
- 10 hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.
- 15 Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Alternately, expression of this gene product in hematopoietic cells indicates that it is involved in the proliferation, differentiation, survival, and activation of all hematopoietic lineages, including stem and progenitor cells. Expression of this gene
- 20 product in keratinocytes indicates that it is involved in normal skin function, and could be involved in skin disorders, dermatitis, and fibrosis. The protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma,
- 25 malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and
- 30 xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox,

molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2050 of SEQ ID NO:57, b is an integer of 15 to 2064, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 48

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

30 PRVRPASPPVRSPARWGSMAGSPLLWGPRAGGVGLLVLLLLGLFRPPPALCA  
RPVKEPRGLSAASPPLARLALLAASGGQCPEVRRRGRCRPGAGAGASAGAER

QERARAEAQRLRISRRASWRSCCASGAPPATLRLWAWTTTPTRLQRSSLALC  
SAPALTLPP (SEQ ID NO: 238). Polynucleotides encoding these polypeptides are  
also provided.

5 This gene is expressed primarily in human pituitary and to a lesser extent in  
pineal gland, and other areas of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, pituitary dysfunction; abnormal growth; neurological defects;  
10 insufficient milk secretion; abnormal smooth muscle contraction. Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For  
a number of disorders of the above tissues or cells, particularly of the endocrine and  
nervous systems, expression of this gene at significantly higher or lower levels is  
15 routinely detected in certain tissues or cell types (e.g., endocrine, developmental,  
reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph,  
serum, plasma, urine, amniotic fluid, breast milk, synovial fluid and spinal fluid) or  
another tissue or cell sample taken from an individual having such a disorder, relative  
to the standard gene expression level, i.e., the expression level in healthy tissue or  
20 bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 150 as residues: Pro-36 to Gly-42, Pro-64 to Ala-76,  
Gly-83 to Ala-90, Ser-100 to Cys-108, Thr-126 to Ser-135. Polynucleotides encoding  
said polypeptides are also provided.

25 The tissue distribution primarily in pituitary cells and tissues indicates that  
polynucleotides and polypeptides corresponding to this gene are useful for the  
diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene  
product in the pituitary indicates that it is possibly a hormone-like substance that  
either controls pituitary development itself, or various processes controlled by the  
30 pituitary. These include growth, milk secretion, smooth muscle contraction, diuresis,  
blood pressure, and homeostasis. Thus, this gene product may have numerous clinical

applications. Expression of this gene product in other regions of the brain also indicates that it is involved in normal neurological function, and is useful in the treatment of a variety of neurological disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1036 of SEQ ID NO:58, b is an integer of 15 to 1050, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 49

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

PRVRLATPNIWDL SMLFAFISLLV MLPTWWIVSSWL VWGVILFVYLVIRALRL

WRTAKLQVTLKKYSVHLEDMATNSRAFTNLVRKALRLIQETEVISRGFTLVS  
AACPFNKAGQHPSQHLIGLRKAVYRTLRFQARLATLYMLKNYPLNSES  
DNVTNYICVVPFKELGLGLSEEQISEEEAHNFTDGFSLPALKVLFQLWVAQSS  
EFFRRLALLLSTANSPPGPLLTPALLPHRILSDVTQGLPHAHSACLEELKRSYE  
5 FYRYFETQHQSVPQCLSKTQQKSRELNNVHTAVRSLQLHLKALLNEVILEDE  
LEKLVCTKETQELVSEAYPILEQKLKLIQPHVQASNNCWEEAISQVDKLLRRN  
TDKKGKPEIACENPHCTVSTFEAAYSTHCRQRSNPRGAGIRSLCR (SEQ ID  
NO: 239). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane  
10 domain at about amino acid position 7 - 23 of the amino acid sequence referenced in  
Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 24 to  
390 of this protein has also been determined. Based upon these characteristics, it is  
believed that the protein product of this gene shares structural features to type Ib  
membrane proteins.

15 The gene encoding the disclosed cDNA is believed to reside on chromosome  
12. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 12.

This gene is expressed primarily in prostate and placenta and to a lesser extent  
in pancreatic tumors and hematopoietic cells.

20 Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, prostate cancer; pancreatic cancer; prostate dysfunction; hematopoietic  
disorders; reproductive diseases and/or disorders, and pancreatitis. Similarly,  
25 polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For  
a number of disorders of the above tissues or cells, particularly of the endocrine and  
immune systems, expression of this gene at significantly higher or lower levels is  
routinely detected in certain tissues or cell types (e.g., reproductive, prostate,  
30 pancease, placental, vascular, and cancerous and wounded tissues) or bodily fluids  
(e.g., lymph, serum, seminal fluid, plasma, urine, synovial fluid and spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 151 as residues: Pro-85 to Ser-94, Pro-127 to Thr-136, Glu-154 to Glu-160, Phe-240 to Ser-250, Leu-255 to Leu-265, Leu-341 to Lys-351, Thr-372 to Gly-384. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in prostate and placental cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of reproductive disorders. Elevated expression of this gene product in the prostate indicates that it is involved in normal prostate function, and is a diagnostic marker for prostate cancer. Alternately, expression of this gene product in placenta indicates that it may play a role in normal vascular function, and is involved in such processes as angiogenesis and endothelial cell chemotaxis. Thus, this gene product is useful in the treatment of myocardial infarction, cancer, ischemia, and diabetic retinopathy. Expression of this gene product in placenta may also be indicative of fetal health and development.

Similarly, expression of this gene product in hematopoietic cells indicates that it is involved in the proliferation, differentiation, survival, or activation of all hematopoietic cell lineages. Finally, expression of this gene product in pancreatic cancers indicates that it may play a role in cancer in general, or in pancreatic function. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases



and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating  
5 infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as,  
10 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of  
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2519 of SEQ ID NO:59, b is an  
20 integer of 15 to 2533, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 50**

When tested against Jurkat and K562 cell lines, supernatants removed from  
25 cells containing this gene activated the GAS (gamma activating sequence) and ISRE (interferon-sensitive responsive element ) promoter elements, respectively. Thus, it is likely that this gene activates myeloid, leukemia, and to a lesser extent, other immune or hematopoietic cells and tissue cell-types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes  
30 which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. ISRE is also a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

AAPHPLLRPLCLWCPLWPAWPLRGRPRSAWKRWPLPVGPAKLGCSMTTR  
QPTAVSWPCWLMSSSLSTACLAWTLTGSLAREATRRARSLSPWNCARQV  
PPSPPHSGLGRRGWAHCHLT CLLVTQLFRVGRIHPILSLPLVT (SEQ ID NO:  
240). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in brain and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular diseases; aberrant angiogenesis; neurological disorders; learning disorders; placental insufficiency; and fetal distress. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular and neurological systems (CNS/PNS), expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 152 as residues: Met-1 to Thr-7, Glu-36 to Ser-43,  
5 Pro-46 to Gly-63. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain and placental cells and tissues, combined with the detected GAS and ISRE biological activities, indicates that the protein products of this gene are useful for the diagnosis and/or treatment of a variety of neural, reproductive, and vascular diseases and/or disorders. neurodegenerative disease  
10 states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,  
15 encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and  
20 perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Expression of this gene product in placenta indicates that it may play a role  
25 in blood vessel development or function, as the placenta is a highly vascularized organ. Thus, this gene product is involved in such processes as angiogenesis, endothelial cell chemotaxis, and vascular cord formation. Thus, it is useful in the treatment of such conditions as myocardial infarction; ischemia; and cancer. Alternately, expression of this gene product in the brain indicates that it may play a  
30 role in the survival, proliferation, or function of neurons, and thus is useful in the diagnosis and treatment of such neurological disorders as ALS, schizophrenia, and

Alzheimer's Disease. It may likewise be involved in learning disorders as well.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

- 5 Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of  
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 885 of SEQ ID NO:60, b is an  
15 integer of 15 to 899, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 51

In another embodiment, polypeptides comprising the amino acid sequence of  
20 the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

LQLASQSAGIKGMSHCARPTFLTLLASCFWAAIPNRNVILSVSFRPLHMQ  
FTLSILVFILRILILLRSFL (SEQ ID NO: 241). Polynucleotides encoding these

- 25 polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 40 - 56 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 57 to 60 of this protein has also been determined. Based upon these characteristics, it is  
30 believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in spleen derived from patients with chronic lymphocytic leukemia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chronic lymphocytic leukemia; hematopoietic disorders; impaired immune function; cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spleen cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of hematopoietic disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Elevated expression of this protein in the spleens of patients with CLL indicates that it is a useful marker for this Disease. Alternately, it is associated with the development and/or progression of the disease, and is a useful target for therapeutic intervention. Additionally, this gene

product may play more general roles in hematopoiesis, and may serve to control cellular decisions regarding proliferation, survival, activation, and/or differentiation of all hematopoietic cell lineages. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate  
5 ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1065 of SEQ ID NO:61, b is an integer of 15 to 1079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

## 20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 52**

The translation product of this gene shares sequence homology with a putative tyrosine protein kinase from the Chilo iridescent virus. See, for example, Genbank accession no. gi|2738451 (AF003534). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities  
25 with tyrosine kinase and signaling proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed in a variety of tissues, including microvascular endothelial cells, dendritic cells, and fetal tissues. as well as several tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as  
30 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, vascular, immune, and developmental diseases and/or disorders, particularly cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

5 tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, immune, developmental, proliferative, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having

10 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 154 as residues: Ala-21 to Lys-31, Arg-41 to Cys-56, Thr-92 to Cys-102, Arg-132 to Val-137, Lys-152 to Ile-159, Pro-199 to Ser-205, Arg-

15 210 to Asp-219, Ser-225 to Lys-230, Tyr-236 to Ala-241, Lys-243 to Leu-249, Thr-375 to Asp-381. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution and homology to a tyrosine kinase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27,

20 and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes

25 suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

30 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the protein is useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1914 of SEQ ID NO:62, b is an



integer of 15 to 1928, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 53

5           The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 2 - 18 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

          This gene is expressed primarily in neutrophils.

10           Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly cancer and immune suppression. Similarly, polypeptides and antibodies directed to  
15 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids  
20 (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic  
25 epitopes shown in SEQ ID NO: 155 as residues: Gly-63 to Ser-72. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful as a marker for neutrophil monitoring in cancer and/or immune suppressed patients and/or during chemotherapy  
30 or radiation therapy. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and

elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 767 of SEQ ID NO:63, b is an integer of 15 to 781, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 54

This gene is expressed primarily in IL-1 and LPS induced neutrophils, and to a lesser extent, in fetal brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and neural diseases and/or disorders, particularly cancer and immune suppression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 156 as residues: Ile-28 to Trp-37, Ser-68 to Lys-81. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful as a marker in neutrophils to monitor patients who are immune suppressed or cancer patients during chemotherapy or radiation therapy. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in

regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune  
5 responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
10 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
15 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively,  
20 polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in  
25 addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
30 related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1180 of SEQ ID NO:64, b is an integer of 15 to 1194, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 55

This gene is expressed primarily in prostate.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, urogenital diseases and/or disorders, particularly prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urogenital system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., urogenital, prostate, renal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 157 as residues: Arg-30 to Gln-36. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in prostate cancer cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of prostate cancer and other urogenital disorders. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis,

treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation  
5 and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
10 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
15 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
20 insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1663 of SEQ ID NO:65, b is an integer of 15 to 1677, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 56

A preferred polypeptide of the invention comprises the following amino acid sequence:

MVLVLRHPLCARERAFREPGRGLLTRTGQHDGAPAVTAVPGPLGAVAAAE  
10 RRSAGWAGGSSPPRKVLWGDMRGRRAGVDVLGPALSSEAAGAEARGWGM  
PGMGVGVGASETRGALFLGREGVHGPCPMDGLGPWPWGPW (SEQ ID NO:  
242). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in rejected kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as  
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the kidney. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of  
20 disorders of the above tissues or cells, particularly of the urinary tract, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., urogenital, renal, kidney, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative  
25 to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 158 as residues: Ala-30 to Gly-36, Asp-45 to Trp-50, Lys-65 to Cys-71, Pro-80 to Cys-87. Polynucleotides encoding said polypeptides are  
30 also provided.

The tissue distribution in kidney indicates the protein product of this gene could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. The protein is useful for modulating the immune response to aberrant proteins, as may exist in proliferating cells and tissues. Such modulation of the immune response would also show utility in inhibiting the rejection of transplanted tissues, particularly of the renal system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1223 of SEQ ID NO:66, b is an integer of 15 to 1237, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 57

The translation product of this gene shares sequence homology with both human and mouse Fibulin-2 which is an extracellular matrix protein found in heart tissue (See Genbank Accession Nos. emb|CAA57876.1 and emb|CAA53040.1, respectively; all references available through these accessions are hereby incorporated



herein by reference; for example, J. Cell Biol. 123 (5), 1269-1277 (1993)). Preferred polypeptides encoded by this gene comprise the following amino acid sequence:

MGPAVKMWTNAWKGLDDCHYNQLCENTPGGHRCSGPCRGMQGPSLPCL  
DVNECLQLPKACAYQCHNLQGSYRCLCPPGQTLLRDGKACTSLERNQGNVT  
5 TVSHRGPLLPWLRPWASIPGTSYHAWVSLRPGPMALSSVGRAWCPPGFIRQN  
GVCTDLDECRVRNLCQHACRNTEGSYQCLCPAGYRLLPSGKNCQDINECEEE  
SIECGPGQMCFNTRGSYQCVDTPCPATYRQGPSPGTCFRRCSQDCGTGGPSTL  
QYRLLPLPLGVRAHHDVARLTAFASEVGPANRTELSMLEPDPRSPFALRPLRA  
GLGAVYTRRALTRAGLYRLTVRAAAPRHQS VFVLLIAVSPYPY (SEQ ID NO:

10 243). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence:

MRVLVVVTIPIYWALARESGEALNGHSLTGGKFRQSHTWSLLQGAHDDPV  
ARGLDPDGLLLLDVVVNGVVPRAWLTQIFKCRTLKKHYVQTRAWPAVRG  
15 LHTALLPGRPPLVPTLQPQHPVQRGPGPPAPAGAAPAGLSYQLGL (SEQ ID  
NO: 244). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the

20 following amino acid sequence:

HASGAFLVVRGEPQGSWGSMTGVINGRKFGVATLNTSVMQEAHSGVSSIHSS  
IRHVPANVGPLMRVLVVVTIPIYWALARESGEALNGHSLTGGKFRQESHVEF  
ATGELLTMTQWPGVWIPMASCSSTWWSMALSPDSLADADLQVQDFEEHYV  
QTGPGQLFVGSTQRFFQGGLPSFLRCNHSIQYNAARGPQPQLVQHLRASAIS  
25 AFDPEAEALRFQLATALQAEENEVGCPEGFELDSQGAFCVDVDECAWDAHL  
CREGQRCVNLLGSYRCLPDCGPGFRVADGAGCEDVDECLEGLDDCHYNQLC  
ENTPGGHRCSGPCRGMQGPSLPCLDVNECLQLPKACAYQCHNLQGSYRCL  
CPPGQTLLRDGKACTSLERNQGNVTTVSHRGPLLPWLRPWASIPGTSYHAWV  
SLRPGPMALSSVGRAWCPPGFIRQNGVCTDLDECRVRNLCQHACRNTEGSY  
30 QCLCPAGYRLLPSGKNCQDINECEEEESIECGPGQMCFNTRGSYQCVDTPCPAT  
YRQGPSPGTCFRRCSQDCGTGGPSTLQYRLLPLPLGVRAHHDVARLTAFASEV

GVPANRTELSMLEPDPRSPFALRPLRAGLGAVYTRRALTRAGLYRLTVRAAA  
PRHQSVFVLLIAVSPYPY (SEQ ID NO: 245). Polynucleotides encoding these  
polypeptides are also provided.

When tested against U937 and Jurkat cell lines, supernatants removed from  
5 cells containing this gene repeatedly activated the GAS (gamma activating sequence)  
promoter element. Thus, it is likely that this gene activates myeloid, T-cells, and to a  
lesser extent, other immune and hematopoietic cells and tissue cell types, through the  
JAK-STAT signal transduction pathway. GAS is a promoter element found upstream  
of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway  
10 is a large, signal transduction pathway involved in the differentiation and proliferation  
of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of  
the GAS element, can be used to indicate proteins involved in the proliferation and  
differentiation of cells.

This gene is expressed primarily in kidney.

15 Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, diseases and/or disorders affecting the kidney and renal system.  
Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
20 providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
urinary tract, expression of this gene at significantly higher or lower levels is  
routinely detected in certain tissues or cell types (e.g., renal, urogenital, kidney, and  
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,  
25 synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
individual having such a disorder, relative to the standard gene expression level, i.e.,  
the expression level in healthy tissue or bodily fluid from an individual not having the  
disorder.

Preferred polypeptides of the present invention comprise immunogenic  
30 epitopes shown in SEQ ID NO: 159 as residues: Lys-32 to Ser-37, His-89 to Gly-94,  
Asn-124 to Gln-130, Ala-163 to Val-168, Cys-196 to Arg-201, Gln-244 to Gln-264,

His-288 to Tyr-294, Leu-314 to Gln-319, Ala-392 to Ser-399, Pro-412 to Asp-419, Ala-452 to Pro-460, Arg-466 to Thr-473. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in rejected kidney, the homology to the conserved  
5 Fibulin-2 protein, in addition to the detected GAS biological activity, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting kidneys, particularly proliferative disorders. Representative uses are described here and elsewhere herein. The protein product of this gene could be used in the treatment and/or detection of kidney diseases  
10 including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Furthermore, the protein may also be used  
15 to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
25 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1920 of SEQ ID NO:67, b is an integer of 15 to 1934, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

30

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 58

Preferred polypeptides of the invention comprise the following amino acid sequence:

MGEKFLLLAMKENHPECFCCKILKILHCMDPGEWLPQTEHCVHLPKEFLIWT  
MDIASNERSEIQSVALLRLASKVISHHMQTCVENRELIAAELKQWVQLVILSC  
5 DHLPTESRLAVVEVLTSTTPLFLTNPHPILELQDTLALWKCVLTLQSEEQAV  
RDAATETVTTAMSQENTCQSTEFACQVDASIALALALAVLCDLLQQWDQL  
APGLPILLGWLLGESDDLACVESMHQVEEDYLFKAENVNFWAETLIFVKYL  
CKHLFCLLSKSGWRPPSPEMLCHLQRMVSEQCHLLSQFFRELPPAAEFVKTV  
EFTRLRIQEERTLACRLALAFLEGKEGEDTLVLSVWDSYAESRQLTLPRTEAA  
10 C (SEQ ID NO: 246). Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MGEPNRHPSM

FLLLLVLERLYASPMGTSSALSMGPFVPFIMRCGHSPVYHSREMAARALVP  
FVMIDHIPNTIRTLLSTL  
15 PSCTDQCFAKPHSWGHSRFFHLLQAYSDDSKTRNEFRLPARAD (SEQ ID NO:  
247). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
20 following amino acid sequence:

MTGREFFSRFPELYPFLKQLETVANTVDSMDGEPNRHPSMFLLLLVLERLY  
ASPMGTSSALSMGPFVPFIMRCGHSPVYHSREMAARALVPFVMIDHIPNTIR  
TLLSTLPSCTDQCFRQNHIGTLLQVFHLLQAYSDDSKHGTNSDFQHELTDTV  
CTKAKLWLAKRQNPCLVTRAVYIDILFLLTCCLNRSKDNQPVLES LGFWEE  
25 VRGIISGSELITGFPWAFKVPGLPQYLSLRLAIAAVWAAAASGERETNPVI  
SFSQLESAPFEVRSLEALLEKFLAAASGLGEKGVPLLNCNMGEKFLLLAM  
KENHPECFCCKILKILHCMDPGEWLPQTEHCVHLPKEFLIWTMDIASNERSEIQ  
SVALRLASKVISHHMQTCVENRELIAAELKQWVQLVILSCEDHLPTESRLAVV  
EVLSTTTPFLTNPHPILELQDTLALWKCVLTLQSEEQAVRDAATETVTTAM  
30 SQENTCQSTEFACQVDASIALALALAVLCDLLQQWDQLAPGLPILLGWLLG  
ESDDLACVESMHQVEEDYLFKAENVNFWAETLIFVKYLCKHLFCLLSKSG

WRPPSPEMLCHLQRMVSEQCHLLSQFFRELPPAAEFVKTVEFTRLRIQEERTL  
 ACLRLLAFLEGKEGEDTLVLSVWDSYAESRQLTLPRTEAAC (SEQ ID NO:  
 248). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have two transmembrane  
 5 domains at about amino acid position 144 - 160, and 462 - 478 of the amino acid  
 sequence referenced in Table 1 for this gene. Based upon these characteristics, it is  
 believed that the protein product of this gene shares structural features to type IIIa  
 membrane proteins. Included in this invention as a preferred domain is the formate  
 and nitrite transporters domain, which was identified using the ProSite analysis tool  
 10 (Swiss Institute of Bioinformatics). A number of bacterial and archaeobacterial  
 proteins involved in transporting formate or nitrite have been shown [1] to be related:  
 - focA and focB, from *Escherichia coli*, transporters involved in the bidirectional  
 transport of formate. - fdhC, from *Methanobacterium formicicum* and  
*thermoformicicum*, a probable formate transporter. - nirC, from *Escherichia coli* and  
 15 *Salmonella typhimurium*, a probable nitrite transporter. - *Bacillus subtilis*  
 hypothetical protein yrhG. - *Bacillus subtilis* hypothetical protein ywcJ (ipa-48R).  
 These transporters are proteins of about 280 residues and seem to contain six  
 transmembrane regions. As signature patterns, we selected two conserved regions.  
 The first one is located in what seems to be a cytoplasmic loop between the second  
 20 and third transmembrane domains; the second is part of the fourth transmembrane  
 region. The 70 Kd yeast hypothetical protein YHL008c is highly similar, in its N-  
 terminal section, to the prokaryotic members of this family. The consensus pattern is  
 as follows: [LIVMA]-[LIVMY]-x-G-[GSTA]-[DES]-L-[FI]-[TN]-[GS].

Preferred polypeptides of the invention comprise the following amino acid  
 25 sequence: IISGSELITG (SEQ ID NO: 249). Polynucleotides encoding these  
 polypeptides are also provided. Further preferred are polypeptides comprising the  
 formate and nitrite transporter domain of the sequence referenced in Table for this  
 gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid  
 residues of this referenced sequence. The additional contiguous amino acid residues is  
 30 N-terminal or C- terminal to the formate and nitrite transporter domain. Alternatively,  
 the additional contiguous amino acid residues is both N-terminal and C-terminal to

the formate and nitrite transporter domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to formate and nitrite transporter proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with formate and nitrite transporter proteins. Such activities are known in the art, some of which are described elsewhere herein. It is believed that this gene maps to chromosome 2. Accordingly, polynucleotides derived from this gene are useful in linkage analysis as markers for chromosome 2.

10 This gene is expressed primarily in cells of the immune system, primarily T-cells and to a lesser extent in spleen, liver, thymus, tonsils, and testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly disorders affecting hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of hematopoietic cells, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 160 as residues: Gly-2 to Pro-8, Ser-82 to His-92, Tyr-107 to Asp-117, Arg-162 to Pro-169, Ser-224 to Thr-229, Leu-310 to His-315, Ser-333 to Glu-338, Glu-381 to Ser-388, Gln-428 to Ala-433, Met-446 to Thr-455, Ser-548 to Ser-554, Gly-613 to Asp-618, Ser-627 to Gln-633. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting hematopoiesis, including cancers. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
 5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3286 of SEQ ID NO:68, b is an integer of 15 to 3300, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

#### 10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 59**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

15 VDGDIDKLDIEFLQQFLETHSRGPRLHSPGHASQEATPGANMSSGTELLWPGAA  
 LLVLLGVAASLCVRCSPGAKRSEKIYQQRSLREDQQSFTGSRTYSLVGQAW  
 PGPLADMAPTRKDKLLQFYPSLEDPASSRYQNFSKGSRHGSEEAYIDPIAMEY  
 YNWGRFSKPPEDDDANSYENVLICKQKTTTETGAQQEGIGGLCRGDLSSLAL  
 KTGPTSGLCPSASPEEDEGI (SEQ ID NO: 250). Polynucleotides encoding these  
 20 polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 10 - 26 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

25 The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in bone marrow, CD34 positive cells, and immune cells, including, neutrophils, T-cells, B-cells, macrophages, monocytes, and  
 30 dendritic cells and to a lesser extent in brain and tonsils.



Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the immune and hematopoietic systems, particularly hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the the immune system and hematopoietic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 161 as residues: Ser-29 to Thr-57, Pro-74 to Lys-79, Pro-85 to Glu-107, Tyr-118 to Tyr-136, Gln-144 to Gln-152, Ala-182 to Glu-188. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune and hematopoietic cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for

immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities.

Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors);

hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the  
5 corresponding nucleic acid in gene therapy procedures.

Based upon the the proteins immune cell specific message distribution, it may be involved in many aspects of the immune response, especially its initial stages, inflammation, allograft rejection, infectious disease response etc. The expression of this clone is  
10 frequently found in the hematopoietic cell cDNA libraries. Thus, this factor could be involved in the control of hematopoietic cell proliferation, differentiation, and function. Based on this one can postulate its use in the management of anemias, leukemias, neutropenia, thrombocytopenia, autoimmune  
15 diseases, blood tissue engraftment, and poikilothromerythromatosis. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
25 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1783 of SEQ ID NO:69, b is an integer of 15 to 1797, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

30

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 60

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

5 VLWREASALVLSNRLSSGLLHDLQLQPAIHSRLFRRSRGLSEGEGLSSVSLQRS  
RVLSAMKHVLNLYLLGVVLTLLSIFVRVMESLEGLLESPPGTSWTTRSQLAN  
TEPTKGLPDHPSRSM (SEQ ID NO: 251). Polynucleotides encoding these  
polypeptides are also provided.

This gene is expressed primarily in immune cells including activated T cells,  
10 macrophages, jurkat cells, bone marrow cells, and osteoblasts and to a lesser extent in  
kidney cortex, brain, placenta and lung.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, immune and hematopoietic diseases and/or disorders, particularly  
inflammation and diseases related to inflammatory activity. Similarly, polypeptides  
and antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the immune system, expression  
20 of this gene at significantly higher or lower levels is routinely detected in certain  
tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded  
tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal  
fluid) or another tissue or cell sample taken from an individual having such a  
disorder, relative to the standard gene expression level, i.e., the expression level in  
25 healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 162 as residues: Pro-34 to Met-63. Polynucleotides  
encoding said polypeptides are also provided.

The tissue distribution in immune cells and tissues indicates that  
30 polynucleotides and polypeptides corresponding to this gene are useful for treating or  
diagnosing disease related to the normal or abnormal activation of T cells.

Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein.

Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell

5 lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for

10 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

15 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful

20 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

25 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of

30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:70, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 61

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

YTFHTQIFLDFFPMIFLTVLPLAFLFLHSGFYHYISFSLFSLSLALFFFLDVATFR  
RPGQLFCERSVLFDMMFHFVSLFLHEWQAKHFWAGLF  
IVLPDVFVSVHHLEAPDGSFPNIAKLSLIILLR (SEQ ID NO: 252).

Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 2 - 18 and 22 - 38 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

This gene is expressed in many tissues including brain, liver, prostate, testes, cartilage, gall bladder. Expression is also seen in a number of tumors including colon carcinoma, pancreas tumor, osteoclastoma, ovarian cancer, B cell lymphoma and acute lymphocytic leukemias.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors of various organs including the pancreas, colon, and bone. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the

major organs, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, hepatic, metabolic, reproductive, testicular, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or  
5 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors and proliferative tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or  
10 diagnosing tumors of several major organs including the pancreas and large intestine. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below  
15 and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain  
20 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,  
25 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in  
30 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the

protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
5 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1565 of SEQ ID NO:71, b is an integer of 15 to 1579, where both a and b correspond to the positions of nucleotide  
15 residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 62**

This gene is expressed primarily in dendritic cells and fetal liver/spleen and to a lesser extent in many tissues including tonsils, fetal lung, stromal cell lines, bone  
20 marrow cell lines, placenta and tumors including hepatocellular carcinoma, pancreas tumor and osteosarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25 not limited to, diseases and/or disorders of the immune and hematopoietic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is  
30 routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,



synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in dendritic cells and fetal liver/spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating disorders of the immune system particularly related to the control and generation of precursor cells. polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic  
10 related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow  
15 transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

          The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of  
20 stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies  
25 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

          Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:72 and may have been publicly available prior to conception of  
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1014 of SEQ ID NO:72, b is an integer of 15 to 1028, where both a and b correspond to the positions of nucleotide  
5 residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 63

This gene is expressed primarily in adrenal gland tumor and endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as  
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and vascular diseases and/or disorders, particularly diseases associated with the vascular endothelium. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for  
15 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., endocrine, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
20 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in endothelial cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating  
25 disorders that involve the vascular system including diseases such as atherosclerosis, neoangiogenesis associated with tumor growth and conditions associated with inflammation. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke,  
30 embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Alternatively, the protein is useful in the treatment, detection, and/or

prevention of metabolic disorders, particularly lethargy and depression. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3660 of SEQ ID NO:73, b is an integer of 15 to 3674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 64**

The translation product of this gene is related to bovine PAM precursor. See Genbank record gi|163482 incorporated herein by reference. Moreover, see following patent publications are also incorporated herein by reference: J04311386 and WO8902460. Many bioactive peptides terminate with an amino acid alpha-amide at their COOH terminus. The enzyme responsible for this essential posttranslational modification is known as peptidyl-glycine alpha-amidating monooxygenase or PAM. An NH<sub>2</sub>-terminal signal sequence and short propeptide precede the NH<sub>2</sub> terminus of purified PAM. The sequences of several PAM cyanogen bromide peptides were localized in the NH<sub>2</sub>-terminal half of the predicted protein. The forms of PAM purified from bovine neurointermediate pituitary is generated by endoproteolytic cleavage at a subset of the 10 pairs of basic amino acids in the precursor. High levels of PAM mRNA have been found in bovine pituitary and cerebral cortex. In

corticotrophic tumor cells, levels of PAM mRNA and pro-ACTH/endorphin mRNA are known to be regulated in parallel by glucocorticoids and CRF.

This gene is expressed primarily in endometrial tumors, dendritic cells, a multiple sclerosis library, kidney, hematopoietic cells, melanocytes, osteoblasts, the spleen, colon, ovary, stromal cells, fetal and adult brain, heart, and in tissues undergoing wound repair.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometriosis, endometrial cancer, multiple sclerosis, hematopoietic diseases, bone disease, and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly the hematopoietic system and female reproduction, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, immune, hematopoietic integumentary, skeletal, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in dendritic and hematopoietic cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful as a therapeutic or diagnostic agent i's Diseases of hematopoietic origin as well as the female reproductive track due to the gene's primary pattern of expression. polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses

include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The protein may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 2783 of SEQ ID NO:74, b is an integer of 15 to 2797, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 65

The translation product of this gene shares sequence similarity with several G-protein coupled receptors (See Genbank Accession No. gb|AAC77910.1| (AF061443); all references available through this accession are hereby incorporated herein by reference; for example, Mol. Endocrinol. 12, 1830-1845 (1998)). G-protein coupled receptors are well known in the art and affect a variety of functions. In particular, the translation product of this gene shares similarity with Follicular Stimulating Hormone Receptor.

Preferred polypeptides encoded by this gene comprise the following amino acid sequence:

15 GTRFPTGETPSLGFTVTLVLLNSLAFLLMAYIYTKLYCNLEKEDLSENSQSSMI  
KHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFP (SEQ ID NO:  
253). Polynucleotides encoding such polypeptides are also provided.


A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MIKHVAWLIFTNCIFFCP

20 VAFFSFAPLITAISISPEIMKSVTLIFFPCLLA (SEQ ID NO: 254). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
25 following amino acid sequence:

GTRFPTGETPSLGFTVTLVLLNSLAFLLMAYIYTKLYCNLEKEDLSENSQSSMI  
KHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFPLPACLNPVLYVF  
FNPKFEDWKLLKRRVTKKSGSVSVSISSQGGCLEQDFYYDCGMYSHLQGN  
LTVCDCCESFLLTKPVSCKHLIKSHSCPALAVASCQRPEGYWSDCGTQSAHS  
30 DYADEEDSFVSDSSDQVQACGRACFYQSRGFPLVRYAYNLPRVKD (SEQ ID  
NO: 255). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 43 - 59 of the amino acid sequence referenced in Table I for this gene. Moreover, a cytoplasmic tail encompassing amino acids 60 to 207 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins. Included in this invention as preferred domains are Zinc finger, C2H2 type domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). 'Zinc finger' domains [1-5] are nucleic acid-binding protein structures first identified in the *Xenopus* transcription factor TFIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides. A schematic representation of a zinc finger domain is shown below:



Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom

coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc- dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include

5 C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains is present. In addition to the conserved zinc ligand residues it has been shown that a number of other positions are also important for the structural integrity of the C2H2

10 zinc fingers. The best conserved position is found four residues after the second cysteine; it is generally an aromatic or aliphatic residue. The consensus pattern is as follows: C-x(2,4)-C-x(3)-[LIVMFYWC]-x(8)-H-x(3,5)-H.

Preferred polypeptides of the invention comprise the following amino acid sequence: CDCCESFLLTKPVSKHLIKSH (SEQ ID NO: 256). Polynucleotides

15 encoding these polypeptides are also provided. Further preferred are polypeptides comprising the Zinc finger, C2H2 type domain of the sequence referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues is N-terminal or C- terminal to the Zinc finger, C2H2 type domain.

20 Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the Zinc finger, C2H2 type domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to zinc finger proteins. Based on the sequence similarity, the translation product of this gene is expected to

25 share at least some biological activities with G-coupled proteins, their receptors, and zinc finger proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in adult and fetal liver, human placenta, colon carcinoma cell lines and fibroblasts and to a lesser extent in the fetal and adult

30 brain, the developing nervous system, lung, pancreas, salivary gland, breast tissue, and dendritic cells.



Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the liver, developmental abnormalities, neurologic diseases, lung cancer, pancreatic cancer, and colon cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological and hepatic origin, as well as the proliferation and/or differentiation of numerous types of tissues, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, immune, hematopoietic, neural, gastrointestinal, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 167 as residues: Pro-62 to Asp-67, Arg-74 to Gly-80, Gln-146 to Glu-168. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for a diagnostic marker or therapeutic in a wide variety of disease states. polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the

5 differentiation and/or proliferation of various cell types. Alternatively, the protein expression in placental and brain tissue indicates the protein is useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble

10 factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. The protein is useful in the treatment, detection, and/or prevention of

15 bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's Disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic

20 depression, delirium, severe mental retardation and dyskinesias, such as Huntington's Disease or Gilles de la Tourette's syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed

25 against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:75 and may have been publicly available prior to conception of

30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2689 of SEQ ID NO:75, b is an integer of 15 to 2703, where both a and b correspond to the positions of nucleotide  
5 residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 66

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by  
10 the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

ALENSGSPGLQDSARAHFNXSLRSFSFLRNQMYIFELSLYLEGTSFVVVLLFLL  
ISVSLDSPPTTKGWDSVLHIWVPLIVQ (SEQ ID NO: 257). Polynucleotides  
encoding these polypeptides are also provided.

15 This gene is expressed primarily in placenta and in hematopoietic cells, especially those of T-cell and monocyte origin and to a lesser extent in the brain, endothelial cells, and the lungs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic, vascular, and developmental diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the  
25 immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene  
30 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 168 as residues: Ser-30 to Trp-37. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in hematopoietic cells indicates that polynucleotides  
5 and polypeptides corresponding to this gene are useful for therapeutic and/or  
diagnostic intervention in hematopoietic and developmental disorders. Representative  
uses are described in the "Immune Activity" and "infectious disease" sections below,  
in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses  
include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow  
10 reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be  
used in immune disorders such as infection, inflammation, allergy, immunodeficiency  
etc. In addition, this gene product may have commercial utility in the expansion of  
stem cells and committed progenitors of various blood lineages, and in the  
15 differentiation and/or proliferation of various cell types. Alternatively, the protein is  
useful in the detection, treatment, and/or prevention of vascular conditions, which  
include, but are not limited to, microvascular disease, vascular leak syndrome,  
aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this  
gene product may represent a soluble factor produced by smooth muscle that  
20 regulates the innervation of organs or regulates the survival of neighboring neurons.  
Likewise, it is involved in controlling the digestive process, and such actions as  
peristalsis. Similarly, it is involved in controlling the vasculature in areas where  
smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein  
may also be used to determine biological activity, to raise antibodies, as tissue  
25 markers, to isolate cognate ligands or receptors, to identify agents that modulate their  
interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
antibodies directed against the protein may show utility as a tumor marker and/or  
immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
30 available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:76 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 728 of SEQ ID NO:76, b is an integer of 15 to 742, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 67**

10 This gene is expressed primarily in the prostate and to a lesser extent in human B-cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, prostate cancer and diseases of hematopoietic origin, particularly of B-cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate and immune systems, expression of this gene at significantly higher or lower  
20 levels is routinely detected in certain tissues or cell types (e.g., prostate, reproductive, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
25 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 169 as residues: Asp-33 to Lys-42. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in prostate tissue indicates that polynucleotides and  
30 polypeptides corresponding to this gene are useful as a therapeutic or diagnostic marker for prostate cancer and disorders involving hematopoietic cells, especially

those of B-cell origin. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative  
5 conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell  
10 death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may  
15 also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of  
20 degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The protein is useful in modulating the immune response to aberrant proteins and polypeptides, as may exist  
25 in rapidly proliferating cells and tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the  
30 above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1811 of SEQ ID NO:77, b is an integer of 15 to 1825, where both a and b correspond to the positions of nucleotide  
10 residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 68

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter  
15 element. Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of  
20 the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
25 following amino acid sequence:  
GHESICGSCRSWIYFSIRCRRMRPWWSLLLEACATCAQTGPTRSTSCTQEVS  
HSSSTAYPAPMRRRCCL PSPRSCT (SEQ ID NO: 258). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
30 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in the brain and the developing embryo and to a lesser extent in the heart, colon, adipose tissue, kidney, mammary tissue, activated T-cells and dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as  
5 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases, developmental conditions, colon cancer, and hematopoietic diseases, especially of T-cell origin. Similarly, polypeptides and  
10 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, cardiovascular, adipose,  
15 immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
20 epitopes shown in SEQ ID NO: 170 as residues: Thr-18 to Cys-26, Glu-29 to Thr-36, Ser-50 to Thr-55. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, combined with the detected GAS biological activity, indicates that polynucleotides and polypeptides corresponding to this gene are useful for therapeutic and/or diagnostic agents in neurological diseases,  
25 developmental abnormalities, colon cancer, and hematopoietic diseases, especially those of T-cell origin. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,  
30 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal



cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated  
5 expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity,  
10 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO:78, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 69

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 2 - 18 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein  
30 product of this gene shares structural features to type II membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

- 5 K R A G V E V G G L V M A L A G S V F V L G G V L V L C V E R N G E G E M G W P Q H L P K S Q P L S  
P P V A V R R C S F E R S W I D L L V E T S S S M V T C R Q Q V G T P N G M E G R G G G P K T T F P I R L  
Q L S G A C A V R P E I Q W E V (SEQ ID NO: 259). Polynucleotides encoding these polypeptides are also provided.

- 10 This gene is expressed primarily in activated monocytes, dendritic cells, and in the tonsils.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly
- 15 leukemia, lymphomas, tumors of hematopoietic origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels is routinely detected in
- 20 certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 25 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 171 as residues: Gln-30 to Leu-38, Asn-75 to Thr-86. Polynucleotides encoding said polypeptides are also provided.

- The tissue distribution in activated monocytes, dendritic cells, and tonsils indicates that polynucleotides and polypeptides corresponding to this gene are useful
- 30 as a therapeutic and/or diagnostic agent for leukemias, lymphomas, and other diseases associated with cells of hematopoietic origin. Representative uses are described in the

"Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene  
5 product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for  
10 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity  
15 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful  
20 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
25 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of  
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2177 of SEQ ID NO:79, b is an integer of 15 to 2191, where both a and b correspond to the positions of nucleotide  
5 residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 70

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter  
10 element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, other immune cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.  
15 Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in  
20 linkage analysis for chromosome 12.

This gene is expressed primarily in the placenta, brain, and liver and to a lesser extent in most other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
25 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic, neurological, vascular, and developmental diseases and/or disorders, particularly cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above  
30 tissues or cells, particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or

cell types (e.g., hematopoietic, neurological, vascular, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression  
5 level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful therapeutic and/or diagnostic agent in a multitude of disease states, particularly those involving the immune and  
10 neurologic systems. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating  
15 diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated  
20 expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein is useful in the detection, treatment, and/or prevention  
25 of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
30 that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1321 of SEQ ID NO:80, b is an integer of 15 to 1335, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 71

The translation product of this gene shares sequence homology with the murine Fig1 (interleukin-four induced gene 1) which shares homology to the monoamine oxidases, particularly in domains responsible for FAD binding. Preferred polypeptides encoded by this gene comprise the following amino acid sequence:  
QDWKAERSQDPFEKCMQDPDYEQLLKVTILEADNRIGGRIFTYRDQXTGWIG  
ELGAMRMPSSHRILHKLCQGLGLNLTKFTQYDKNTWTEVHEXKLRNYVVEK  
VPEKLGALRPQEKGHSPEDIYQMALNQALKDLKALGCRKAMKKFERHTLL  
EYLLGEGNLSRPAVQLLGDVMSDGGFFYLSFAEALRAXSCLSDRLQYSRIVG  
GWDLLPRALLSSLSGLVLLNAPVVAMTQGPHDVHVQIETSPPARNLKVLEAD  
VLLTASGPAVKRITFS (SEQ ID NO: 260), and/or  
LPRHMQEALRRLHYVPATKVFLSFRRPFWREEHIEGGHSNTDRPSRMIFYPPP  
REGALLASYTWSDAAAAFAGLSREEALRLALDDVAALHGPVVRQLWDGT  
GVVKRWAEDQHSQGGFVVQXPALWQTEKDDWTVPYGRIYFAGEHTAYPHG  
WVETAVKSALRAAIKINSRKGPASDTASPEGHASDMEGQGHVHGVASSPSH  
DLAKEEGS (SEQ ID NO: 261). Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence:

MAPLALHLLVLVPILLSLVASQDWKAERSQDPFEKCMQDPDYEQLLKVTIL  
EADNRIGGRIFTYRDQXTGWIGELGAMRMPSSHRILHKLCQGLGLNLTKFTQ  
5 YDKNTWTEVHEXKLRNYVVEKVPEKLG YALRPQEKGHSPEDIYQMALNQA  
LKDLKALGCRKAMKKFERHTLLEYLLGEGNLSRPAVQLLGDVMSEDGFFYL  
SFAEALRAXSCLSDRLQYSRIVGGWDLLPRALLSSLSGLVLLNAPVVAMTQG  
PHDVH

VQIETSPARNLKV LKADVLLTASGPAVKRITFSPRCPATCRRRCGGCTTCR  
10 PPRCS (SEQ ID NO: 262). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with monoamine oxidases, disintegrins, metalloproteinases, and apoptosis modulating proteins. Such activities are known in the art, some of which are described elsewhere herein. Polynucleotides encoding these polypeptides are also provided.

15 The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 235 - 251 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 252 to 319 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia  
20 membrane proteins.

This gene is expressed primarily in hematopoietic cells, particularly in dendritic cells, and activated monocytes and to a lesser extent in T-cells, endothelial cells, and cells associated with ulcerative colitis.

Therefore, polynucleotides and polypeptides of the invention are useful as  
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukemias, lymphomas, and diseases associated with antigen presenting cells, in addition to apoptosis dependant events. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
30 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression

of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a  
5 disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 173 as residues: Gln-22 to Gln-44, Ala-90 to Gly-95, Lys-137 to Trp-146, Arg-171 to Asp-181, Glu-370 to Ser-380, Asp-447 to Gly-452,  
10 Gln-463 to Trp-469, Asn-504 to Ala-510, Asp-512 to His-519, Ala-541 to Val-550, Asn-558 to His-566. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution immune and hematopoietic cells and tissues, combined with the homology to the murine Fig 1 gene indicates that polynucleotides and polypeptides corresponding to this gene are useful as a therapeutic and/or diagnostic  
15 agent for hematopoietic diseases, especially those associated with antigen presenting cells. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell  
20 lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for  
25 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity  
30 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's



Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1853 of SEQ ID NO:81, b is an integer of 15 to 1867, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector        | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|---------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 1        | HISCN02       | 209878<br>05/18/98       | pSport1       | 11              | 1113          | 1                   | 1113                | 232                  | 232                             | 103             | 1                   | 26                 | 27                           | 106            |
| 2        | HHGDM70       | 209878<br>05/18/98       | Lambda ZAP II | 12              | 983           | 102                 | 983                 | 69                   | 69                              | 104             | 1                   | 57                 | 58                           | 86             |
| 3        | HHPGO40       | 209878<br>05/18/98       | Uni-ZAP XR    | 13              | 973           | 1                   | 973                 | 68                   | 68                              | 105             | 1                   | 37                 | 38                           | 302            |
| 3        | HHPGO40       | 209878<br>05/18/98       | Uni-ZAP XR    | 82              | 984           | 1                   | 984                 | 74                   | 74                              | 174             | 1                   | 37                 | 38                           | 224            |
| 4        | HAMGG68       | 209878<br>05/18/98       | pCMVSPORT 3.0 | 14              | 1458          | 1                   | 1458                | 312                  | 312                             | 106             | 1                   | 20                 | 21                           | 55             |
| 5        | HAPOM49       | 209878<br>05/18/98       | Uni-ZAP XR    | 15              | 2005          | 1                   | 2005                | 251                  | 251                             | 107             | 1                   | 22                 | 23                           | 189            |
| 5        | HAPOM49       | 209878<br>05/18/98       | Uni-ZAP XR    | 83              | 2664          | 1                   | 2664                | 448                  | 448                             | 175             | 1                   | 1                  | 2                            | 123            |
| 6        | HBGBA69       | 209878<br>05/18/98       | Uni-ZAP XR    | 16              | 943           | 1                   | 933                 | 62                   | 62                              | 108             | 1                   | 38                 | 39                           | 60             |
| 7        | HBIFJ26       | 209878<br>05/18/98       | Uni-ZAP XR    | 17              | 1503          | 588                 | 1480                | 290                  | 290                             | 109             | 1                   | 26                 | 27                           | 128            |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date                | Vector        | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|---|---------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 7        | HBJF126       | 209878<br>05/18/98                      | Uni-ZAP XR    | 84              | 1328          | 413                 | 1305                | 591                  | 591                             | 176             | 1                   | 20                 | 21                           | 59             |
| 8        | HCEDH38       | 209878<br>05/18/98                      | Uni-ZAP XR    | 18              | 1512          | 1                   | 1438                | 222                  | 222                             | 110             | 1                   | 26                 | 27                           | 68             |
| 9        | HDPOJ08       | 209878<br>05/18/98                      | pCMVSPORT 3.0 | 19              | 1655          | 1                   | 1655                | 159                  | 159                             | 111             | 1                   | 18                 | 19                           | 122            |
| 10       | HDPRX82       | 209878<br>05/18/98                      | pCMVSPORT 3.0 | 20              | 2525          | 1                   | 2525                | 128                  | 128                             | 112             | 1                   | 32                 | 33                           | 82             |
| 11       | HELK31        | 209878<br>05/18/98                      | Uni-ZAP XR    | 21              | 1396          | 25                  | 1334                | 209                  | 209                             | 113             | 1                   | 29                 | 30                           | 344            |
| 11       | HCNUA40       | 97898<br>02/26/97<br>209044<br>05/15/97 | pBluescript   | 85              | 1342          | 949                 | 1237                | 960                  | 960                             | 177             | 1                   | 33                 | 34                           | 105            |
| 12       | HFPCX64       | 209878<br>05/18/98                      | Uni-ZAP XR    | 22              | 1069          | 1                   | 1069                | 181                  | 181                             | 114             | 1                   | 28                 | 29                           | 181            |
| 12       | HFPCX64       | 209878<br>05/18/98                      | Uni-ZAP XR    | 86              | 1154          | 84                  | 1154                | 257                  | 257                             | 178             | 1                   | 28                 | 29                           | 87             |
| 12       | HCEBW71       | 209225<br>08/28/97                      | Uni-ZAP XR    | 87              | 1197          | 141                 | 1197                | 257                  | 257                             | 179             | 1                   | 28                 | 29                           | 87             |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date                | Vector        | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|---|---------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 13       | HFEDO60       | 209878<br>05/18/98                      | Lambda ZAP II | 23              | 1658          | 1                   | 1658                | 131                  | 131                       | 115             | 1                   | 46                 | 47                           | 115            |
| 14       | HHEPG41       | 209878<br>05/18/98                      | pCMVSPORT 3.0 | 24              | 1077          | 385                 | 1043                | 514                  | 514                       | 116             | 1                   | 35                 | 36                           | 70             |
| 14       | HAUA183       | 209626<br>02/12/98                      | Uni-ZAP XR    | 88              | 910           | 1                   | 886                 | 253                  | 253                       | 180             | 1                   | 37                 | 38                           | 49             |
| 14       | HJPAZ83       | 209626<br>02/12/98                      | Uni-ZAP XR    | 89              | 1076          | 398                 | 1076                |                      | 575                       | 181             | 1                   | 11                 | 12                           | 23             |
| 15       | HKGAH42       | 209878<br>05/18/98                      | pSport1       | 25              | 1205          | 1                   | 1205                | 143                  | 143                       | 117             | 1                   | 21                 | 22                           | 63             |
| 16       | HMIAP86       | 209878<br>05/18/98                      | Uni-ZAP XR    | 26              | 1674          | 13                  | 1674                | 182                  | 182                       | 118             | 1                   | 19                 | 20                           | 334            |
| 17       | HMUAP70       | 209878<br>05/18/98                      | pCMVSPORT 3.0 | 27              | 1965          | 531                 | 1914                | 183                  | 183                       | 119             | 1                   | 16                 | 17                           | 221            |
| 17       | HMUAP70       | 209878<br>05/18/98                      | pCMVSPORT 3.0 | 90              | 1842          | 407                 | 1783                | 413                  | 413                       | 182             | 1                   | 25                 | 26                           | 103            |
| 17       | HAGFY16       | 97923<br>03/07/97<br>209071<br>05/22/97 | Uni-ZAP XR    | 91              | 1963          | 209                 | 1922                | 251                  | 251                       | 183             | 1                   | 28                 | 29                           | 198            |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date                | Vector          | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|---|-----------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 17       | HBMCF37       | 209683<br>03/20/98                      | pBluescript     | 92              | 1487          | 79                  | 1487                | 170                  | 170                             | 184             | 1                   | 44                 | 45                           | 70             |
| 17       | HFLQB16       | 209641<br>02/25/98                      | Uni-ZAP XR      | 93              | 1653          | 394                 | 1637                | 413                  | 413                             | 185             | 1                   | 25                 | 26                           | 82             |
| 17       | HAGFY16       | 97923<br>03/07/97                       | Uni-ZAP XR      | 94              | 1830          | 87                  | 1786                | 128                  | 128                             | 186             | 1                   | 26                 | 27                           | 45             |
| 18       | HRACJ35       | 209878<br>05/18/98                      | pCMVSPORT 3.0   | 28              | 1863          | 8                   | 1863                | 99                   | 99                              | 120             | 1                   | 24                 | 25                           | 472            |
| 18       | HAWAZ34       | 209141<br>07/09/97                      | pBluescript SK- | 95              | 1134          | 472                 | 1132                | 687                  | 687                             | 187             | 1                   |                    |                              | 33             |
| 19       | HTWDE26       | 209878<br>05/18/98                      | pSport1         | 29              | 1626          | 1                   | 1626                | 68                   | 68                              | 121             | 1                   | 30                 | 31                           | 167            |
| 19       | HMHBN40       | 97901<br>02/26/97<br>209047<br>05/15/97 | Uni-ZAP XR      | 96              | 1772          | 69                  | 1772                | 129                  | 129                             | 188             | 1                   | 30                 | 31                           | 231            |
| 20       | HUSIB13       | 209878<br>05/18/98                      | pSport1         | 30              | 605           | 1                   | 605                 | 172                  | 172                             | 122             | 1                   | 32                 | 33                           | 46             |
| 21       | HBAFA02       | 209877<br>05/18/98                      | pSport1         | 31              | 931           | 359                 | 931                 | 46                   | 46                              | 123             | 1                   | 21                 | 22                           | 108            |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector          | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|-----------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 22       | H2CBT75       | 209877<br>05/18/98       | pBluescript SK- | 32              | 1407          | 1                   | 1407                | 32                   | 32                              | 124             | 1                   | 23                 | 24                           | 60             |
| 23       | HAGDQ42       | 209877<br>05/18/98       | Uni-ZAP XR      | 33              | 1526          | 1                   | 1526                | 126                  | 126                             | 125             | 1                   | 18                 | 19                           | 248            |
| 24       | HBMCI42       | 209877<br>05/18/98       | pBluescript     | 34              | 1737          | 41                  | 1580                | 244                  | 244                             | 126             | 1                   | 44                 | 45                           | 248            |
| 25       | HDPBQ71       | 209877<br>05/18/98       | pCMVSPORT 3.0   | 35              | 2242          | 6                   | 2242                | 24                   | 24                              | 127             | 1                   | 33                 | 34                           | 612            |
| 26       | HCEJG71       | 209877<br>05/18/98       | Uni-ZAP XR      | 36              | 2235          | 2                   | 2235                | 28                   | 28                              | 128             | 1                   | 25                 | 26                           | 447            |
| 27       | HELHL48       | 209877<br>05/18/98       | Uni-ZAP XR      | 37              | 2971          | 560                 | 2557                | 629                  | 629                             | 129             | 1                   | 16                 | 17                           | 291            |
| 27       | HSKCT36       | 209580<br>01/14/98       | Uni-ZAP XR      | 98              | 1955          | 1                   | 1955                | 31                   | 31                              | 190             | 1                   | 18                 | 19                           | 184            |
| 28       | HISAQ04       | 209877<br>05/18/98       | pSport1         | 38              | 1163          | 1                   | 1163                | 61                   | 61                              | 130             | 1                   | 21                 | 22                           | 78             |
| 29       | HJACB89       | 209877<br>05/18/98       | pBluescript SK- | 39              | 1932          | 28                  | 1930                | 95                   | 95                              | 131             | 1                   | 23                 | 24                           | 333            |
| 30       | HTECC05       | 209877<br>05/18/98       | Uni-ZAP XR      | 40              | 881           | 1                   | 881                 | 27                   | 27                              | 132             | 1                   | 15                 | 16                           | 164            |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector        | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|---------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 31       | HBJLF01       | 209877<br>05/18/98       | Uni-ZAP XR    | 41              | 1932          | 201                 | 1931                | 217                  | 217                             | 133             | 1                   | 46                 | 47                           | 244            |
| 32       | HBXGP60       | 209877<br>05/18/98       | ZAP Express   | 42              | 1164          | 1                   | 1164                | 143                  | 143                             | 134             | 1                   | 22                 | 23                           | 55             |
| 33       | HCE5B20       | 209877<br>05/18/98       | Uni-ZAP XR    | 43              | 1105          | 1                   | 1105                | 237                  | 237                             | 135             | 1                   | 25                 | 26                           | 54             |
| 34       | HCMSQ56       | 209877<br>05/18/98       | Uni-ZAP XR    | 44              | 1262          | 1                   | 1262                | 148                  | 148                             | 136             | 1                   | 19                 | 20                           | 88             |
| 35       | HCNAH57       | 209877<br>05/18/98       | Lambda ZAP II | 45              | 517           | 1                   | 517                 | 35                   | 35                              | 137             | 1                   | 33                 | 34                           | 61             |
| 36       | HCUEP91       | 209877<br>05/18/98       | ZAP Express   | 46              | 858           | 2                   | 858                 | 266                  | 266                             | 138             | 1                   | 20                 | 21                           | 105            |
| 37       | HDPCJ91       | 209877<br>05/18/98       | pCMVSPORT 3.0 | 47              | 6107          | 1                   | 6107                | 131                  | 131                             | 139             | 1                   | 28                 | 29                           | 51             |
| 38       | HDPGK25       | 209877<br>05/18/98       | pCMVSPORT 3.0 | 48              | 703           | 1                   | 703                 | 345                  | 345                             | 140             | 1                   | 33                 | 34                           | 119            |
| 39       | HE2DY70       | 209877<br>05/18/98       | Uni-ZAP XR    | 49              | 639           | 1                   | 639                 | 137                  | 137                             | 141             | 1                   | 45                 | 46                           | 58             |
| 40       | HE2NV57       | 209877<br>05/18/98       | Uni-ZAP XR    | 50              | 867           | 1                   | 867                 | 99                   | 99                              | 142             | 1                   | 36                 | 37                           | 99             |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector          | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|-----------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 41       | HETBR16       | 209877<br>05/18/98       | Uni-ZAP XR      | 51              | 1569          | 1                   | 1569                | 161                  | 161                             | 143             | 1                   | 21                 | 22                           | 64             |
| 42       | HFXDGI3       | 209877<br>05/18/98       | Lambda ZAP II   | 52              | 1196          | 1                   | 1196                | 43                   | 43                              | 144             | 1                   | 37                 | 38                           | 66             |
| 43       | HFXKY27       | 209877<br>05/18/98       | Lambda ZAP II   | 53              | 945           | 1                   | 945                 | 44                   | 44                              | 145             | 1                   | 19                 | 20                           | 58             |
| 44       | HHPEC09       | 209877<br>05/18/98       | Uni-ZAP XR      | 54              | 488           | 1                   | 488                 | 71                   | 71                              | 146             | 1                   | 19                 | 20                           | 55             |
| 45       | HISAD54       | 209877<br>05/18/98       | pSport1         | 55              | 2860          | 1                   | 2860                | 172                  | 172                             | 147             | 1                   | 19                 | 20                           | 65             |
| 46       | HJBCY35       | 209877<br>05/18/98       | pBluescript SK- | 56              | 1559          | 93                  | 1272                | 232                  | 232                             | 148             | 1                   | 23                 | 24                           | 327            |
| 47       | HKAEA19       | 209877<br>05/18/98       | pCMVSPORT 2.0   | 57              | 2064          | 1                   | 1909                | 83                   | 83                              | 149             | 1                   | 21                 | 22                           | 89             |
| 48       | HKGDL36       | 209877<br>05/18/98       | pSport1         | 58              | 1050          | 1                   | 1050                | 55                   | 55                              | 150             | 1                   | 33                 | 34                           | 148            |
| 49       | HLDBS43       | 209877<br>05/18/98       | pCMVSPORT 3.0   | 59              | 2533          | 1                   | 2533                | 73                   | 73                              | 151             | 1                   | 26                 | 27                           | 390            |
| 50       | HLWAD92       | 209877<br>05/18/98       | pCMVSPORT 3.0   | 60              | 899           | 1                   | 899                 | 197                  | 197                             | 152             | 1                   | 34                 | 35                           | 98             |



| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector         | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|----------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 51       | HL YBI15      | 209877<br>05/18/98       | pSport1        | 61              | 1079          | 1                   | 1079                | 92                   | 92                              | 153             | 1                   | 22                 | 23                           | 60             |
| 52       | HMEJE05       | 209889<br>05/22/98       | Lambda ZAP II  | 62              | 1928          | 1                   | 1928                | 25                   | 25                              | 154             | 1                   | 30                 | 31                           | 392            |
| 53       | HNGIX55       | 209889<br>05/22/98       | Uni-ZAP XR     | 63              | 781           | 1                   | 781                 | 121                  | 121                             | 155             | 1                   | 19                 | 20                           | 74             |
| 54       | HNHEX30       | 209889<br>05/22/98       | Uni-ZAP XR     | 64              | 1194          | 1                   | 1194                | 138                  | 138                             | 156             | 1                   | 15                 | 16                           | 81             |
| 55       | HPJBI33       | 209889<br>05/22/98       | Uni-ZAP XR     | 65              | 1677          | 1                   | 1677                | 236                  | 236                             | 157             | 1                   | 31                 | 32                           | 53             |
| 56       | HRABA80       | 209889<br>05/22/98       | pCMV Sport 3.0 | 66              | 1237          | 1                   | 1237                | 130                  | 130                             | 158             | 1                   | 28                 | 29                           | 102            |
| 57       | HRACD80       | 209889<br>05/22/98       | pCMV Sport 3.0 | 67              | 1934          | 1                   | 1934                | 191                  | 191                             | 159             | 1                   | 16                 | 17                           | 575            |
| 57       | HRACD80       | 209889<br>05/22/98       | pCMV Sport 3.0 | 99              | 1958          | 1                   | 1958                | 191                  | 191                             | 191             | 1                   | 16                 | 17                           | 146            |
| 58       | HSLCX03       | 209889<br>05/22/98       | Uni-ZAP XR     | 68              | 3300          | 984                 | 2729                | 677                  | 677                             | 160             | 1                   | 22                 | 23                           | 643            |
| 58       | HSLCX03       | 209889<br>05/22/98       | Uni-ZAP XR     | 100             | 2444          | 1                   | 2444                | 392                  | 392                             | 192             | 1                   | 22                 | 23                           | 124            |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector          | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|-----------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 59       | HT5GJ57       | 209889<br>05/22/98       | Uni-ZAP XR      | 69              | 1797          | 92                  | 1797                | 122                  | 122                             | 161             | 1                   | 25                 | 26                           | 190            |
| 60       | HTACS42       | 209889<br>05/22/98       | Uni-ZAP XR      | 70              | 1373          | 1                   | 1373                | 213                  | 213                             | 162             | 1                   | 29                 | 30                           | 63             |
| 61       | HTEKE40       | 209889<br>05/22/98       | Uni-ZAP XR      | 71              | 1579          | 1                   | 1579                | 173                  | 173                             | 163             | 1                   | 47                 | 48                           | 117            |
| 62       | HTOBX69       | 209889<br>05/22/98       | Uni-ZAP XR      | 72              | 1028          | 1                   | 1028                | 28                   | 28                              | 164             | 1                   | 20                 | 21                           | 42             |
| 63       | HUVEO77       | 209889<br>05/22/98       | Uni-ZAP XR      | 73              | 3674          | 1                   | 3674                | 55                   | 55                              | 165             | 1                   | 27                 | 28                           | 47             |
| 64       | H2CBG48       | 209889<br>05/22/98       | pBluescript SK- | 74              | 2797          | 1                   | 2797                | 125                  | 125                             | 166             | 1                   | 25                 | 26                           | 45             |
| 65       | H2CBU83       | 209889<br>05/22/98       | pBluescript SK- | 75              | 2703          | 1                   | 2703                | 157                  | 157                             | 167             | 1                   | 30                 | 31                           | 207            |
| 65       | H2CBU83       | 209889<br>05/22/98       | pBluescript SK- | 101             | 2709          | 1                   | 2709                | 157                  | 157                             | 193             | 1                   | 30                 | 31                           | 51             |
| 66       | HAPNY94       | 209889<br>05/22/98       | Uni-ZAP XR      | 76              | 742           | 1                   | 742                 | 94                   | 94                              | 168             | 1                   | 29                 | 30                           | 50             |
| 67       | HBJHZ58       | 209889<br>05/22/98       | Uni-ZAP XR      | 77              | 1825          | 1                   | 1825                | 102                  | 102                             | 169             | 1                   | 29                 | 30                           | 42             |

| Gene No. | cDNA Clone ID | ATCC Deposit Nr and Date | Vector        | NT SEQ ID NO: X | Total NT Seq. | 5' NT of Clone Seq. | 3' NT of Clone Seq. | 5' NT of Start Codon | 5' NT of First AA of Signal Pep | AA SEQ ID NO: Y | First AA of Sig Pep | Last AA of Sig Pep | First AA of Secreted Portion | Last AA of ORF |
|----------|---------------|--------------------------|---------------|-----------------|---------------|---------------------|---------------------|----------------------|---------------------------------|-----------------|---------------------|--------------------|------------------------------|----------------|
| 68       | HCE2B33       | 209889<br>05/22/98       | Uni-ZAP XR    | 78              | 1674          | 1                   | 1668                | 67                   | 67                              | 170             | 1                   | 18                 | 19                           | 55             |
| 69       | HDPBQ02       | 209889<br>05/22/98       | pCMVSPORT 3.0 | 79              | 2191          | 291                 | 2191                | 460                  | 460                             | 171             | 1                   | 24                 | 25                           | 108            |
| 70       | HFIYI70       | 209889<br>05/22/98       | pSPORT1       | 80              | 1335          | 1                   | 1335                | 43                   | 43                              | 172             | 1                   | 15                 | 16                           | 50             |
| 71       | HDPOZ56       | 209889<br>05/22/98       | pCMVSPORT 3.0 | 81              | 1867          | 415                 | 1867                | 103                  | 103                             | 173             | 1                   | 21                 | 22                           | 566            |
| 71       | HDPOZ56       | 209889<br>05/22/98       | pCMVSPORT 3.0 | 102             | 1722          | 1                   | 1722                | 59                   | 59                              | 194             | 1                   | 21                 | 22                           | 319            |

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further

below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed

sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the  
5 desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides  
10 produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains  
15 secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced  
20 version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

25

#### Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal  
30 charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the

information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two  
5 methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a  
10 protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes  
15 vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely  
20 uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the  
25 naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

30 **Polynucleotide and Polypeptide Variants**

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

- 5 By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the
- 10 polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire
- 15 sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

- As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known
- 20 computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences
- 25 are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty
- 30 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.



If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95%

"identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the the

query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter

the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced  
5 for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These  
10 allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA  
15 technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after  
20 deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological  
25 activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every  
30 possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See,

Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

(Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

15

#### **Polynucleotide and Polypeptide Fragments**

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

20

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-

30

1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or  
5 smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid  
10 sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-  
15 40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

20 Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the  
25 mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

30 Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and



alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

- 5 Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

- Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

#### Epitopes & Antibodies

- 15 In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

- Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

- 25 In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

20

#### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous

30

functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., *Nature* 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See,

D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide.

- 5 In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein.
- 10 Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

15

#### **Vectors, Host Cells, and Protein Production**

- The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral
- 20 vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

- The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate,
- 25 such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

- The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac
- 30 promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The

expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,

phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

- 5 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, 10 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine 15 encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.
- 20 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide 25 sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 30 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al.,

Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

5

#### Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

10

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

15

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

20

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

25

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however,

30

polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques." Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression,



chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods  
5 rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J.  
10 Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can  
15 be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate  
20 manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.  
25 In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA  
30 markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using  
5 this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification  
10 techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co.  
15 (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

20 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by  
25 organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences  
30 in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA

antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### Uses of the Polypeptides

5 Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M.,  
10 et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such  
15 as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo  
20 imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for  
25 the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or  
30 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety

needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.

- 5 In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which  
10 involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

- 15 Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to  
20 activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can  
25 also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as  
30 molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also

be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

5

#### **Biological Activities**

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

10

#### **Immune Activity**

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

15

20

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency,

25

30

Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

5           Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood  
10 disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

15           A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the  
20 present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

          Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic  
25 anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary  
30 Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

#### **Hyperproliferative Disorders**

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

### **Infectious Disease**

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the



present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis,

opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis,

5 Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

10 Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and  
15 Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these  
20 symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the  
25 patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### Regeneration

30 A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See,

Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, 5 reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration 10 occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used 15 prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a 20 polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral 25 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

30

#### Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

#### Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell  
5 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

10 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,  
15 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

20 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers.  
25 The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

30 Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a

candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

#### **Other Activities**

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

#### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95%

identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
5 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which  
10 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of  
20 at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

25 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule  
30 comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.



A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least

one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted  
5 protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a  
10 nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at  
15 least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise  
20 a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence  
25 encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the  
30 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in

the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence  
5 at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a  
10 polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
15 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group  
20 consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least  
25 one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence  
30 selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide

comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino

acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

- 5           In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at  
10   least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number  
15   shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide  
20   comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25           Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

30           Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is

expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of  
5 SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
10 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an  
15 isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

20

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.  
25 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being  
30 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

|    | <u>Vector Used to Construct Library</u> | <u>Corresponding Deposited</u> |
|----|---|--------------------------------|
|    | <u>Plasmid</u>                          |                                |
|    | Lambda Zap                              | pBluescript (pBS)              |
|    | Uni-Zap XR                              | pBluescript (pBS)              |
| 5  | Zap Express                             | pBK                            |
|    | lafmid BA                               | plafmid BA                     |
|    | pSport1                                 | pSport1                        |
|    | pCMVSPORT 2.0                           | pCMVSPORT 2.0                  |
|    | pCMVSPORT 3.0                           | pCMVSPORT 3.0                  |
| 10 | pCR <sup>®</sup> 2.1                    | pCR <sup>®</sup> 2.1           |

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain



XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with <sup>32</sup>P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for

bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the  
5 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the  
3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired  
cDNA using the deposited cDNA plasmid as a template. The polymerase chain  
reaction is carried out under routine conditions, for instance, in 25 µl of reaction  
mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is  
10 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 µM each of dATP, dCTP, dGTP, dTTP, 25  
pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR  
(denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1  
min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The  
amplified product is analyzed by agarose gel electrophoresis and the DNA band with  
15 expected molecular weight is excised and purified. The PCR product is verified to be  
the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding  
portions of a gene which may not be present in the deposited clone. These methods  
include but are not limited to, filter probing, clone enrichment using specific probes,  
20 and protocols similar or identical to 5' and 3' "RACE" protocols which are well  
known in the art. For instance, a method similar to 5' RACE is available for  
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et  
al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a  
25 population of RNA presumably containing full-length gene RNA transcripts. A  
primer set containing a primer specific to the ligated RNA oligonucleotide and a  
primer specific to a known sequence of the gene of interest is used to PCR amplify  
the 5' portion of the desired full-length gene. This amplified product may then be  
sequenced and used to generate the full length gene.

30 This above method starts with total RNA isolated from the desired source,  
although poly-A+ RNA can be used. The RNA preparation can then be treated with

phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction  
5 leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific  
10 to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

**Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

15 A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

**Example 3: Tissue Distribution of Polypeptide**

20 Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with  $P^{32}$  using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After  
25 labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H)  
30 or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to

manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

5    **Example 4: Chromosomal Mapping of the Polynucleotides**

          An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is  
10    repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in  
15    the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

          A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA  
20    sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc.,  
25    Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

          The pQE-9 vector is digested with BamHI and XbaI and the amplified  
30    fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain

M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>).

Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and

5 confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG

10 (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is

15 removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The

20 QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

25 The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4,

30 containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250

mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further  
5 includes an expression vector comprising phage operator and promoter elements  
operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC  
Accession Number 209645, deposited on February 25, 1998.) This vector contains:  
1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of  
replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a  
10 Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The  
origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The  
promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with *NdeI* and  
*XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating  
15 the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA  
insert is generated according to the PCR protocol described in Example 1, using PCR  
primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or  
*Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible  
enzymes. The insert and vector are ligated according to standard protocols.

20 The engineered vector could easily be substituted in the above protocol to  
express protein in a bacterial system.

#### **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide  
25 expressed in *E. coli* when it is present in the form of inclusion bodies. Unless  
otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell  
culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at  
15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit  
30 weight of cell paste and the amount of purified protein required, an appropriate  
amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM

Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate  
5 is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the  
10 pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA  
15 by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The  
20 filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

25 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40  
30 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium

acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

5 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5  $\mu$ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

10

**Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector  
15 contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak  
20 *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such  
25 as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

30 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in



Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in  
5 Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment  
10 then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a  
15 commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified  
20 by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™  
25 baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are  
30 added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded

in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

- 5        After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell
- 10    culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded
- 15    in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

- To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of
- 20    infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of <sup>35</sup>S-methionine and 5 µCi <sup>35</sup>S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation.
- 25    The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

- 30    **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a

chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo

contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### 15 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

30 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These

primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)
```

**Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the  
5 production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are  
10 monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures  
15 involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about  
20 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are  
25 selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can  
30 be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is

possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody  
5 whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the  
10 antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic  
15 chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in  
20 the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

25

**Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in  
30 Examples 13-20.



First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O; 0.050 mg/L of Fe(NO<sub>3</sub>)<sub>3</sub>·9H<sub>2</sub>O; 0.417 mg/L of FeSO<sub>4</sub>·7H<sub>2</sub>O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl<sub>2</sub>; 48.84 mg/L of MgSO<sub>4</sub>; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO<sub>3</sub>; 62.50 mg/L of NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O; 71.02 mg/L of Na<sub>2</sub>HPO<sub>4</sub>; 4320 mg/L of ZnSO<sub>4</sub>·7H<sub>2</sub>O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

- 5        On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the  
10       polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

15       **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The  
20       binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in  
25       many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus  
30       upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,

Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

|    | Ligand                           | tyk2 | JAKs<br>Jak1 | Jak2 | Jak3 | STATs | GAS(elements) or ISRE       |
|----|----------------------------------|------|--------------|------|------|-------|-----------------------------|
|    | <u>IFN family</u>                |      |              |      |      |       |                             |
| 5  | IFN-a/B                          | +    | +            | -    | -    | 1,2,3 | ISRE                        |
|    | IFN-g                            |      | +            | +    | -    | 1     | GAS (IRF1>Lys6>IFP)         |
|    | IL-10                            | +    | ?            | ?    | -    | 1,3   |                             |
|    | <u>gp130 family</u>              |      |              |      |      |       |                             |
| 10 | IL-6 (Pleiotrophic)              | +    | +            | +    | ?    | 1,3   | GAS (IRF1>Lys6>IFP)         |
|    | IL-11(Pleiotrophic)              | ?    | +            | ?    | ?    | 1,3   |                             |
|    | OnM(Pleiotrophic)                | ?    | +            | +    | ?    | 1,3   |                             |
|    | LIF(Pleiotrophic)                | ?    | +            | +    | ?    | 1,3   |                             |
|    | CNTF(Pleiotrophic)               | -/+  | +            | +    | ?    | 1,3   |                             |
| 15 | G-CSF(Pleiotrophic)              | ?    | +            | ?    | ?    | 1,3   |                             |
|    | IL-12(Pleiotrophic)              | +    | -            | +    | +    | 1,3   |                             |
|    | <u>g-C family</u>                |      |              |      |      |       |                             |
|    | IL-2 (lymphocytes)               | -    | +            | -    | +    | 1,3,5 | GAS                         |
| 20 | IL-4 (lymph/myeloid)             | -    | +            | -    | +    | 6     | GAS (IRF1 = IFP >>Ly6)(IgH) |
|    | IL-7 (lymphocytes)               | -    | +            | -    | +    | 5     | GAS                         |
|    | IL-9 (lymphocytes)               | -    | +            | -    | +    | 5     | GAS                         |
|    | IL-13 (lymphocyte)               | -    | +            | ?    | ?    | 6     | GAS                         |
|    | IL-15                            | ?    | +            | ?    | +    | 5     | GAS                         |
| 25 | <u>gp140 family</u>              |      |              |      |      |       |                             |
|    | IL-3 (myeloid)                   | -    | -            | +    | -    | 5     | GAS (IRF1>IFP>>Ly6)         |
|    | IL-5 (myeloid)                   | -    | -            | +    | -    | 5     | GAS                         |
|    | GM-CSF (myeloid)                 | -    | -            | +    | -    | 5     | GAS                         |
| 30 | <u>Growth hormone family</u>     |      |              |      |      |       |                             |
|    | GH                               | ?    | -            | +    | -    | 5     |                             |
|    | PRL                              | ?    | +/-          | +    | -    | 1,3,5 |                             |
|    | EPO                              | ?    | -            | +    | -    | 5     | GAS(B-CAS>IRF1=IFP>>Ly6)    |
| 35 | <u>Receptor Tyrosine Kinases</u> |      |              |      |      |       |                             |
|    | EGF                              | ?    | +            | +    | -    | 1,3   | GAS (IRF1)                  |
|    | PDGF                             | ?    | +            | +    | -    | 1,3   |                             |
|    | CSF-1                            | ?    | +            | +    | -    | 1,3   | GAS (not IRF1)              |
| 40 |                                  |      |              |      |      |       |                             |

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCG  
GAAATGATTTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCGAAA  
TGATTTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG  
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTCCGCCCATTCT  
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
25 AGGCTTTTGCAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter  
30 molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

**Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells

30

(ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-  
5 SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is  
10 demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life  
15 Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25  
20 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in  
25 Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100  
30 million cells) are required.



Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred  
5 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed  
10 in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The  
15 plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
20 stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by identifying  
factors, such as growth factors and cytokines, that may proliferate or differentiate  
25 myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

30 To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell

Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

- 5        Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2$ , and 675 uM  $\text{CaCl}_2$ . Incubate at  $37^\circ\text{C}$  for 45 min.

- 10        Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at  $37^\circ\text{C}$  for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 15        These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- 20        Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at  $37^\circ\text{C}$  for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

**Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- 25        When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

- 5 The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene  
10 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

- Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified  
15 product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

- To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30  
20 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

- PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-  
25 inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

- Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine  
30 protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine

growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF- $\kappa$ B (Nuclear Factor  $\kappa$ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- $\kappa$ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-  $\kappa$ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF-  $\kappa$ B is retained in the cytoplasm with I- $\kappa$ B (Inhibitor  $\kappa$ B). However, upon stimulation, I-  $\kappa$ B is phosphorylated and degraded, causing NF-  $\kappa$ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF-  $\kappa$ B include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- $\kappa$ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- $\kappa$ B would be useful in treating diseases. For example, inhibitors of NF- $\kappa$ B could be used to treat those diseases related to the acute or chronic activation of NF- $\kappa$ B, such as rheumatoid arthritis.

To construct a vector containing the NF- $\kappa$ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- $\kappa$ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:  
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:  
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2- promoter plasmid (Clontech) with this NF- $\kappa$ B/SV40 fragment using XhoI and

HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- $\kappa$ B/SV40/SEAP cassette is removed from the above NF- $\kappa$ B/SEAP vector using restriction enzymes  
5 SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF- $\kappa$ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- $\kappa$ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly,  
10 the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### **Example 17: Assay for SEAP Activity**

15 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15  $\mu$ l of 2.5x  
20 dilution buffer into Optiplates containing 35  $\mu$ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50  $\mu$ l Assay Buffer and incubate at room  
25 temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50  $\mu$ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

30 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

| # of plates | Rxn buffer diluent (ml) | CSPD (ml) |
|-------------|-------------------------|-----------|
| 10          | 60                      | 3         |
| 11          | 65                      | 3.25      |
| 12          | 70                      | 3.5       |
| 13          | 75                      | 3.75      |
| 14          | 80                      | 4         |
| 15          | 85                      | 4.25      |
| 16          | 90                      | 4.5       |
| 17          | 95                      | 4.75      |
| 18          | 100                     | 5         |
| 19          | 105                     | 5.25      |
| 20          | 110                     | 5.5       |
| 21          | 115                     | 5.75      |
| 22          | 120                     | 6         |
| 23          | 125                     | 6.25      |
| 24          | 130                     | 6.5       |
| 25          | 135                     | 6.75      |
| 26          | 140                     | 7         |
| 27          | 145                     | 7.25      |
| 28          | 150                     | 7.5       |
| 29          | 155                     | 7.75      |
| 30          | 160                     | 8         |
| 31          | 165                     | 8.25      |
| 32          | 170                     | 8.5       |
| 33          | 175                     | 8.75      |
| 34          | 180                     | 9         |
| 35          | 185                     | 9.25      |
| 36          | 190                     | 9.5       |
| 37          | 195                     | 9.75      |
| 38          | 200                     | 10        |
| 39          | 205                     | 10.25     |
| 40          | 210                     | 10.5      |
| 41          | 215                     | 10.75     |
| 42          | 220                     | 11        |
| 43          | 225                     | 11.25     |
| 44          | 230                     | 11.5      |
| 45          | 235                     | 11.75     |
| 46          | 240                     | 12        |
| 47          | 245                     | 12.25     |
| 48          | 250                     | 12.5      |
| 49          | 255                     | 12.75     |
| 50          | 260                     | 13        |

**Example 18: High-Throughput Screening Assay Identifying Changes in Small****5 Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants

which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

5           The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

10           For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

          A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To  
15   load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

          For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10<sup>6</sup> cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml  
20   fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10<sup>6</sup> cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final  
25   volume.

          For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

          To measure the fluorescence of intracellular calcium, the FLIPR is set for the  
30   following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm;



and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular  $\text{Ca}^{++}$  concentration.

5    **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

10    Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

20    Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

25    Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St.

Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar

- 5 Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

- To prepare extracts, A431 cells are seeded onto the nylon membranes of
- 10 Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM
- 15 Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well
- 20 catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

- Test the filtered extracts for levels of tyrosine kinase activity. Although many
- 25 methods of detecting tyrosine kinase activity are known, one method is described here.

- Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include
- 30 PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and

PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2+</sub> (5mM  
5 ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

10 The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide.  
15 Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and  
20 incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

25 **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be  
30 used. For example, as described below one particular assay can detect tyrosine

phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

**Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv.

et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

10 A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

15 For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to  
20 the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

25 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

30 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard

curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

5

**Example 23: Formulating a Polypeptide**

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1  $\mu\text{g/kg/day}$  to 10  $\text{mg/kg/day}$  of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01  $\text{mg/kg/day}$ , and most preferably for humans between about 0.01 and 1  $\text{mg/kg/day}$  for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50  $\mu\text{g/kg/hour}$ , either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 5 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions 10 also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and 15 EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is 20 formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other 25 compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood 30 of the recipient. Examples of such carrier vehicles include water, saline, Ringer's



solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical

compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the  
5 polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

It will be appreciated that conditions caused by a decrease in the standard or  
10 normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to  
15 increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

20

**Example 25: Method of Treating Increased Levels of the Polypeptide**

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as  
25 cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense  
30 polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.

The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

#### **Example 27: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection

into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

#### **Example 28: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-

mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones  
5 containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene  
10 in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et  
15 al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is  
20 to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only  
25 that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the  
30 recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA



expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also  
5 be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more  
10 than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for  
15 screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not  
20 limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

25 **Example 29: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by  
30 reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding

regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*, animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and  
5 Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For  
10 example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological  
15 function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

It will be clear that the invention may be practiced otherwise than as  
20 particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other  
25 disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |  |
|--|--|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>178</u> , line <u>N/A</u>                                     |  |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |  |
| Name of depositary institution American Type Culture Collection  |  |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |  |
| Date of deposit<br>May 18, 1998  | Accession Number<br>209878   |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |  |
|  |  |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |  |
|  |  |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |  |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |  |
|  |  |
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application   | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>Mick Walker<br>International Division<br>709-601-2032<br>fishman@worldnet.att.net  | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM


(PCT Rule 13bis)

|  |                           |
|--|---------------------------|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>179</u> , line <u>N/A</u>                                     |                           |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |                           |
| Name of depositary institution American Type Culture Collection  |                           |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                           |
| Date of deposit<br>February 26, 1997   | Accession Number<br>97898 |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |                           |
|  |                           |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |                           |
|  |                           |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |                           |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                           |
|  |                           |

|   |  |
|---|--|
| For receiving Office use only   | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application        | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>Mary Tucker<br>Intern. Model Division<br>TOS-200-2002<br>Washington, D.C. 20540 | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |   |
|--|---|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>179</u> . line <u>N/A</u>   |   |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |   |
| Name of depositary institution American Type Culture Collection  |   |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America   |   |
| Date of deposit<br>May 15, 1997  | Accession Number<br>209044  |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>  |   |
|  |   |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |   |
|  |   |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |   |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")   |   |
|  |   |
| For receiving Office use only<br><input checked="" type="checkbox"/> This sheet was received with the international application<br>Authorized officer<br> | For International Bureau use only<br><input type="checkbox"/> This sheet was received by the International Bureau on:<br>Authorized officer |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |  |
|--|--|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>179</u> , line <u>N/A</u>                                     |  |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |  |
| Name of depositary institution American Type Culture Collection  |  |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |  |
| Date of deposit<br>August 28, 1997   | Accession Number<br>209225   |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |  |
|  |  |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |  |
|  |  |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |  |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |  |
|  |  |
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application   | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>[Signature]<br>703-015-2000  | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |  |
|--|--|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>180</u> , line <u>N/A</u>                                     |  |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |  |
| Name of depositary institution American Type Culture Collection  |  |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |  |
| Date of deposit<br>March 7, 1997   | Accession Number<br>97923  |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |  |
|  |  |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |  |
|  |  |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |  |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |  |
|  |  |
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application   | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>M. J. Walker<br>International Division<br>708-505-3000   | Authorized officer   |



## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|   |                            |
|---|----------------------------|
| <b>A.</b> The indications made below relate to the microorganism referred to in the description<br>on page <u>180</u> , line <u>N/A</u>   |                            |
| <b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>   |                            |
| Name of depositary institution American Type Culture Collection   |                            |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America  |                            |
| Date of deposit<br>May 22, 1997   | Accession Number<br>209071 |
| <b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>  |                            |
| <br><br><br><br><br>  |                            |
| <b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)   |                            |
| <br><br><br><br><br>  |                            |
| <b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)  |                            |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")<br><br><br><br><br>  |                            |
| <div style="display: flex; justify-content: space-between;"><div style="width: 45%;"><b>For receiving Office use only</b><br/><input checked="" type="checkbox"/> This sheet was received with the international application<br/><br/>Authorized officer: <u>Patricia A. Miller</u><br/><u>Depository Division</u><br/><u>705-495-0032</u><br/><u>microbial@atcc.org</u></div><div style="width: 45%;"><b>For International Bureau use only</b><br/><input type="checkbox"/> This sheet was received by the International Bureau on:<br/><br/>Authorized officer: _____</div></div> |                            |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |                            |
|--|----------------------------|
| <b>A.</b> The indications made below relate to the microorganism referred to in the description<br>on page <u>180</u> , line <u>N/A</u>                              |                            |
| <b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>  |                            |
| Name of depositary institution American Type Culture Collection  |                            |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                            |
| Date of deposit<br>February 12, 1998   | Accession Number<br>209626 |
| <b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                       |                            |
|  |                            |
| <b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)  |                            |
|  |                            |
| <b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)   |                            |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                            |
|  |                            |

|  |  |
|--|--|
| <b>For receiving Office use only</b>   | <b>For International Bureau use only</b>   |
| <input checked="" type="checkbox"/> This sheet was received with the international application | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>J. M. H. H. H.<br>International Division<br>709-602-6662                 | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |                            |
|--|----------------------------|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>181</u> , line <u>N/A</u>                                     |                            |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |                            |
| Name of depositary institution American Type Culture Collection  |                            |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                            |
| Date of deposit<br>March 20, 1998  | Accession Number<br>209683 |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |                            |
|  |                            |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |                            |
|  |                            |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |                            |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                            |
|  |                            |

|  |  |
|--|--|
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>[Signature]<br>703-403-0000  | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)


|  |                            |
|--|----------------------------|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>181</u> , line <u>N/A</u>                                     |                            |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |                            |
| Name of depositary institution American Type Culture Collection  |                            |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                            |
| Date of deposit<br>February 25, 1998   | Accession Number<br>209641 |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |                            |
|  |                            |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |                            |
|  |                            |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |                            |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                            |
|  |                            |

|  |  |
|--|--|
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>[Signature]<br>[Stamp]   | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)


|  |                            |
|--|----------------------------|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>181</u> . line <u>N/A</u>                                     |                            |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |                            |
| Name of depositary institution American Type Culture Collection  |                            |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                            |
| Date of deposit<br>July 9, 1997  | Accession Number<br>209141 |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |                            |
|  |                            |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |                            |
|  |                            |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |                            |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                            |
|  |                            |

|   |  |
|---|--|
| For receiving Office use only   | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application            | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br> | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM


(PCT Rule 13bis)

|  |                           |
|--|---------------------------|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>181</u> , line <u>N/A</u>                                     |                           |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |                           |
| Name of depositary institution American Type Culture Collection  |                           |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                           |
| Date of deposit<br>February 26, 1997   | Accession Number<br>97901 |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |                           |
|  |                           |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |                           |
|  |                           |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |                           |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                           |
|  |                           |

|   |  |
|---|--|
| For receiving Office use only   | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application            | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br> | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |  |
|--|--|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>181</u> , line <u>N/A</u>                                     |  |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |  |
| Name of depositary institution American Type Culture Collection  |  |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |  |
| Date of deposit<br>May 15, 1997  | Accession Number<br>209047   |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |  |
|  |  |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |  |
|  |  |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |  |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |  |
|  |  |
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application   | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>  | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |                            |
|--|----------------------------|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>181</u> , line <u>N/A</u>                                     |                            |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |                            |
| Name of depositary institution American Type Culture Collection  |                            |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |                            |
| Date of deposit<br>May 18, 1998  | Accession Number<br>209877 |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |                            |
|  |                            |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |                            |
|  |                            |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |                            |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |                            |
|  |                            |

|  |  |
|--|--|
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer<br>Misty Walker<br>International Division<br>703-605-6832                   | Authorized officer   |



## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |  |
|--|--|
| A. The indications made below relate to the microorganism referred to in the description<br>on page <u>182</u> , line <u>N/A</u>                                     |  |
| B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>   |  |
| Name of depositary institution American Type Culture Collection  |  |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America     |  |
| Date of deposit<br>January 14, 1998  | Accession Number<br>209580   |
| C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>                              |  |
|  |  |
| D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)   |  |
|  |  |
| E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  |  |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") |  |
|  |  |
| For receiving Office use only  | For International Bureau use only  |
| <input checked="" type="checkbox"/> This sheet was received with the international application   | <input type="checkbox"/> This sheet was received by the International Bureau on: |
| Authorized officer   | Authorized officer   |

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

|  |  |
|--|--|
| <b>A.</b> The indications made below relate to the microorganism referred to in the description<br>on page <u>185</u> , line <u>N/A</u>  |  |
| <b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>  |  |
| Name of depositary institution American Type Culture Collection  |  |
| Address of depositary institution (including postal code and country)<br>10801 University Boulevard<br>Manassas, Virginia 20110-2209<br>United States of America                         |  |
| Date of deposit<br>May 22, 1998  | Accession Number<br>209889   |
| <b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>   |  |
| <br><br><br><br><br>   |  |
| <b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)  |  |
| <br><br><br><br><br>   |  |
| <b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)   |  |
| The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")<br><br><br><br><br> |  |
| <b>For receiving Office use only</b><br><input checked="" type="checkbox"/> This sheet was received with the international application<br><br>Authorized officer<br>71-615-5832          | <b>For International Bureau use only</b><br><input type="checkbox"/> This sheet was received by the International Bureau on:<br><br>Authorized officer |

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit
- 10 No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
- 20 having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
- 5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 25 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
- 30 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - 5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
  - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included  
10 in ATCC Deposit No:Z;
  - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - 15 (g) a variant of SEQ ID NO:Y;
  - (h) an allelic variant of SEQ ID NO:Y; or
  - (i) a species homologue of the SEQ ID NO:Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-  
20 terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
- 25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
- (a) culturing the recombinant host cell of claim 14 under conditions such that  
30 said polypeptide is expressed; and
  - (b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount  
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:  
(a) determining the presence or absence of a mutation in the polynucleotide of  
10 claim 1; and  
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to  
15 a pathological condition in a subject comprising:  
(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and  
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.  
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:  
(a) contacting the polypeptide of claim 11 with a binding partner; and  
(b) determining whether the binding partner effects an activity of the  
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the  
30 method comprises:  
(a) expressing SEQ ID NO:X in a cell;  
(b) isolating the supernatant:

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

1

## Sequence Listing

&lt;110&gt; Human Genome Sciences, Inc., et al.

&lt;120&gt; 71 Human Secreted Proteins

&lt;130&gt; PZ030PCT

&lt;140&gt; Unassigned

&lt;141&gt; 1999-07-14

&lt;150&gt; 60/092,956

&lt;151&gt; 1998-07-15

&lt;150&gt; 60/092,921

&lt;151&gt; 1998-07-15

&lt;150&gt; 60/092,922

&lt;151&gt; 1998-07-15

&lt;160&gt; 262

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 733

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

|            |             |            |            |            |            |     |
|------------|-------------|------------|------------|------------|------------|-----|
| gggatccgga | gcccaaattct | tctgacaaaa | ctcacacatg | cccaccgtgc | ccagcacctg | 60  |
| aattcgaggg | tgcaccgtca  | gtcttcctct | tcccccaaa  | acccaaggac | accctcatga | 120 |
| tctcccggac | tcctgaggtc  | acatgcggtg | tggtggacgt | aagccacgaa | gaccctgagg | 180 |
| tcaagttcaa | ctggtacgtg  | gacggcggtg | aggtgcataa | tgccaagaca | aagccgcggg | 240 |
| aggagcagta | caacagcacg  | taccgtgttg | tcagcgctct | caccgtcctg | caccaggact | 300 |
| ggctgaatgg | caaggagtac  | aagtgcaagg | tctccaacaa | agccctccca | accccatcgc | 360 |
| agaaaaccat | ctccaaagcc  | aaagggcagc | cccgagaacc | acaggtgtac | accctgcccc | 420 |
| catcccggga | tgagctgacc  | aagaaccagg | tcagcctgac | ctgcctgggc | aaaggcttct | 480 |
| atccaagcga | catcgccgtg  | gagtgggaga | gcaatgggca | gccggagaac | aactacaaga | 540 |
| ccacgcctcc | cgtgctggac  | tccgacggct | ccttcttctc | ctacagcaag | ctcaccgtgg | 600 |
| acaagagcag | gtggcagcag  | gggaacgtct | tctcatgtct | cgtgatgcat | gaggctctgc | 660 |
| acaaccacta | cacgcagaag  | agcctctccc | tgtctccggg | taaatgagtg | cgacggccgc | 720 |
| gactctagag | gat         |            |            |            |            | 733 |

&lt;210&gt; 2

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; Site

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 2

Trp Ser Xaa Trp Ser

1

5



<210> 3  
<211> 86  
<212> DNA  
<213> Homo sapiens

<400> 3  
gcgctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaaatat ctgccatctc aattag 86

<210> 4  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 4  
gcggcaagct ttttgcaaag cctaggc 27

<210> 5  
<211> 271  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gcccctaact cgcgccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcgccctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6  
<211> 32  
<212> DNA  
<213> Homo sapiens

<400> 6  
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 7  
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
<211> 12  
<212> DNA  
<213> Homo sapiens

<400> 8  
ggggactttc cc 12

<210> 9  
 <211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 ggggactttc cggggactt tccggggact ttccgggact ttccatcctg 60  
 ccattctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctccgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tccgcgccct aactccgccc atcccgcccc taactccgcc 120  
 cagttccgcc catttccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

<210> 11  
 <211> 1113  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (393)  
 <223> n equals a,t,g, or c

<400> 11  
 gatgtcctt tagcttgag gagtttgta ttaccacct tctgaagcct acttctgtca 60  
 attcatccaa ctcatctca gtccagtttt gtttccttgc tggtaggag ttgtgaccc 120  
 ttggaggaga agaggcattc tgggttttgg aatttttagc cattttgttc tggtttcttc 180  
 ccattcttgt ggatttatct acctttcatc ttcaatgta gtgacctatg gatggggtct 240  
 ctgagtggat gtgtcttctc tttctgtttg twagttttct ttctaacagt tagccctct 300  
 gctgtaggtc tgctggaktt tgctggaggt ccactccaga ccctgtttgc ctgggtatca 360  
 ccagtggagg ctgcagaaca gcaaagattg ctncctgttc tttcctctgg aagcttcgtc 420  
 tcagagggca cctgccagat gccagccaga gctctcctgt atgaggtgtc tgttggccca 480  
 tactgggaga ttcctcccag tcaggatata aggaggtcag ggacctactt gaggaggcag 540  
 tctgaccctt agcagagggt gaacactgtg ctaggaggtc ctctgtctctt ttcagagctg 600  
 tcaggcgggg cgtataagtc tgctgaatct gtgtccgag ccaccccttc cccaggtgc 660  
 tctgtcccag ggagatgggg gttttatttt taagtcccca actggggctg ctgccttttt 720  
 ttcagagatg ccctgcccag agaggagaaa tctggcagtc tggcctcaga ggccttgctg 780  
 agctgcccgtt ggctccaccc agttcaaaact tcccaagggg ctttgtttat actgtaaggg 840  
 gaaaaccgcc tactcgagcc tcatcaatgg cagacacccc tcccgcgcc aagcttaagt 900  
 gtcccagggt gatctcagac tgctgtgtg ctggcagtg gaatttcaag ccagtggatc 960  
 ttagtttctg gtgtctgtg ggggtgggac ccattgaacc agactactcg gctccctggc 1020  
 ttcagcccc tttccaggag agtgaagggt tctgtctcat tggcattcca ggagtcactg 1080  
 gtgtatggaa aaaaaaaaaa aaaggcgccg cgc 1113

<210> 12

<211> 983  
<212> DNA  
<213> Homo sapiens

<400> 12  
ggcacgaggg cagctgcaga gctccagggt tctctgcccc caagggcagg ggctgccccct 60  
cgcccaggat gactctgcct tccagagcct tggcctccct gggggtggga gtgtggggga 120  
tgctaagggt aaatcagggt acagtaagtt gtggggggcag cagggtggagc agcagagtgg 180  
cactggggagc tttctcttgg gtgtgcggtg tggccttggt tctgcagcca tcagggtgggg 240  
gcttgggact gacttctcct tctgaaggat gctgggaagg tgagctggct ttggcagtgc 300  
ttagagctcc ggggggttcc cctcctaga acatgcaagc tctcacaccg gtgcgtcatc 360  
atcacaccca tcatcaagcc cacagtggta tactgaacac ctgccccaca aagacggtgg 420  
actgctctca gaggagcccc atgaaccacc gatggttaca actatccaat gcctgatggc 480  
agacagccag gccaacctcg gcttccactc tctctctctc accctacaat cagccaaagt 540  
gacctgagtc atgtagtgtg aagttgcttt ctgctttctc ttgtttgtgc ttttgcgttt 600  
tcttctgccc catactttgt taactccatg agttaaattgc taccattttt cccagacaag 660  
tgctgcttct gcaaggaaac ccttctgat cccccaccta tctgaaaagt acctctccag 720  
cttgcttctt caggggtgctg agcgttcctt cccagcctgt catcaccttc ctccatacgc 780  
tatgggtgtg tctgtctctc tctagtcttg tctctttttt tctgttagat tgtagctcct 840  
tgctgacagg aaccacgcct gctccagctt catacctccc actgctacag cacagaacct 900  
gcttctcaga cttacagcaa atgtttgttt gctgaatgaa ttaattaaag ataaagcaaa 960  
aaaaaaaaa aaaaaaactc gag 983

<210> 13  
<211> 973  
<212> DNA  
<213> Homo sapiens

<400> 13  
ggcacgagcc cagcggaagc caagccacca ggccccccag cgtccacgcg gagcatgaac 60  
attgaggatg gcgcgtgccc gcggtctccc gtgccccccg ctgcccgcgc gtaggatgtc 120  
ctggccccac ggggcattgc tcttctctg gctcttctcc ccaccctgg gggccggtgg 180  
aggtggagtg gccgtgacgt ctgcccgcgc agggggctcc ccgcccggca cctcctgccc 240  
cgtggcctgc tctgacagca accaggccag ccgggtgatc tgcacacgga gagacctggc 300  
cgaggtcccc gccagcatcc cgttcaaacac gcggtacctg aacctgcaag agaacggcat 360  
ccaggtgatc cggacggaca cgttcaagca cctgcccgcac ctggagattc tgcagctgag 420  
caagaacctg gtgcgcaaga tgcaggtggg cgccttcaac gggctgcccc gcctcaacac 480  
gctggagctt tttgacaacc ggctgaccac ggtgcccacg caggccttcg agtacctgtc 540  
caagctgcgg gagctctggc tgcggaacaa ccccatcgag agcatccct cctacgcctt 600  
caaccgcgtg cctcgcgtgc ggcgcctgga cctgggcgag ctcaagcggc tggaatacat 660  
ctcggaggcg gccttcgagg ggctgggtcaa cctgcgctac ctcaacctgg gcatgtgcaa 720  
cctcaaggac atccccaaac tgacggccct ggtgcgctg gaggagctgg agctgtcggg 780  
caaccggctg gacctgatcc gcccggtctc cttccagggt ctcaccagcc tgcgcaagct 840  
gtggctcatg cacgcccagg tagccaccat cgagcgcaac gccttcgacg acctcaagtc 900  
gctggaggag ctcaacctgt cccacaacaa cctgatgtcg ctgccccacg acctcttcac 960  
gccccgcac cgc 973

<210> 14  
<211> 1458  
<212> DNA  
<213> Homo sapiens

<400> 14  
ccacgcgtcc gggaattttc aaaagatcca aacagagact tcttgcattc tctgcctttc 60  
caacagaagc ggtgatcgtc taagtatgag cctgtggctt cctttgtgca tttgagcatg 120  
ctgtaattaa gatgagatca gtttcttaga aaaagctttc ctgaatccct ctgacgttgc 180

|            |             |            |            |            |             |      |
|------------|-------------|------------|------------|------------|-------------|------|
| ctgggatctt | tctgttgatt  | cgtcttttct | ggagattggg | acagagcatc | tgtggtccag  | 240  |
| ggaagttagt | cctctggcct  | caattctgtt | gtggatgtgc | agtgataagc | gggcatctgc  | 300  |
| tgcctcgggg | gatgcctagt  | tcgtaggctt | ctggctgttt | tgtccttctg | tgtctttagt  | 360  |
| ctgtagggtg | ccagctcagg  | gagtggggtg | ttggcgcggt | ttccgcgggt | ggcctccttg  | 420  |
| ctttgccgca | cctccagggt  | ctgggcatga | gaggccgtgg | cctcatttct | ggtaggataac | 480  |
| cttttttagt | taatagcatc  | tttaattaga | tcacagcatt | gaattcaaaa | tttcttctgc  | 540  |
| aaagaaagt  | gtggggcata  | agacaccggg | aatgaggagg | gaggaagaca | gttgtgtttt  | 600  |
| ctctttaaac | cttgagctct  | agccgatgca | tttgtcagga | aatacagcac | tttgtcttaa  | 660  |
| gaaaacaagg | aaggaggccg  | ggcgagtggt | ctcacgcctg | taatccagc  | actttgggag  | 720  |
| gccgaggcgg | gcggatcacc  | tgaggtgggg | agtatgagac | caccctgact | aacatggaga  | 780  |
| gaccctgtct | ctactaaaag  | tacagaatta | gccgggctgt | gttgcgcatt | cccataatcc  | 840  |
| cagctactga | ggagacttga  | ggtaggagaa | tcacttgaa  | ctcagcggtg | gaggttgtag  | 900  |
| tgagtcgaga | tcgcgccagt  | gcactccagc | ctgggcaaga | agagcgaaac | tgggtctcaa  | 960  |
| gttaaaaaaa | gaaagcaagg  | aaagagtaat | ttacaacgaa | ggaaaaaaac | ccacagcaca  | 1020 |
| cccttcgcgg | ctgtcagcgc  | tctcctgatg | tcacagtggc | tgcgtgtcct | tgggtggggt  | 1080 |
| gaggtgtggg | gagccagcgc  | cctggccctg | cctccgcgcg | cccgtctccc | ttctctctct  | 1140 |
| tactcgggta | agccatagcg  | aggcctccgc | tcgtttcaga | tatgaatttg | ttttatagat  | 1200 |
| tataaatatg | catatacagt  | gtatgtataa | agcagaatgc | ctgcctttcc | tgggtatttt  | 1260 |
| ttgtaccata | ttgtaaaatta | tattatttat | tctttaccac | ttttgggaat | aaaaggtgtt  | 1320 |
| ttggttattt | aatataataa  | gagctgttaa | acttctgttt | aaatttccag | ttcaacttgt  | 1380 |
| aaatgttttt | attgtgcata  | aatacatact | aatgttgatc | taaaaaaaaa | aaaaaaaaaa  | 1440 |
| aaaaaaaaaa | aaaaaaaaaa  |            |            |            |             | 1458 |

&lt;210&gt; 15

&lt;211&gt; 2005

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

|             |            |            |             |             |             |      |
|-------------|------------|------------|-------------|-------------|-------------|------|
| ggttgctggc  | ccaggtgagc | gggcgcgctg | gtccagggtga | gcgggcgcggt | ccccgcgacg  | 60   |
| gcgctgcctg  | cccagggcgg | ttcacgtaaa | gacagcgaga  | tcctgagggc  | cagccgggaa  | 120  |
| ggaggcggtg  | atatggagct | ggctgctgcc | aagtccgggg  | cccgcgcgcg  | tgccctagcgc | 180  |
| gtcctggggg  | ctctgtgggg | acgcgccccg | cgccgcggct  | cggggacccg  | tagagcccg   | 240  |
| cgctgcgcgc  | atggccctgc | tctcgcgcc  | cgcgctcacc  | ctcctgtctc  | tcctcatggc  | 300  |
| cgctgttgct  | aggtgccagg | agcaggccca | gaccaccgac  | tggagagcca  | ccctgaagac  | 360  |
| catccggaac  | ggcggtcata | agatagacac | gtacctgaac  | gccgccttgg  | acctcctggg  | 420  |
| aggcgaggac  | ggctctctgc | agtataaatg | cagtgcagga  | tctaagcctt  | tcccacgtta  | 480  |
| tgggtataaa  | ccctccccac | cgaatggatg | tggtctctca  | ctgtttgggt  | ktcatcttaa  | 540  |
| cattgggtatc | ccttccttga | caaagtgttg | caaccaacac  | gacaggtgct  | atgaracctg  | 600  |
| tggcaaaaagc | aagaatgact | gtgatgaaga | attccagtat  | tgctcttcca  | agatctgcgc  | 660  |
| agatgtacag  | aaaacactag | gactaactca | gcattgttcag | gcattgtgaa  | caacagtggg  | 720  |
| gctcttggtt  | gacagtgtta | tacatttagg | ttgtaaaacca | tatctggaga  | gccaacgagc  | 780  |
| cgcatgcagg  | tgtcattatg | aagaaaaaac | tgatctttta  | aggagatgcc  | gacagctagt  | 840  |
| gacagatgaa  | gatggaagaa | cataaccttt | gacaaaataac | taatgttttt  | acaacataaa  | 900  |
| actgtcttat  | ttttgtgaaa | ggattatttt | gagaccttaa  | aataatttat  | atcttgatgt  | 960  |
| taaaacctca  | aagcaaaaaa | agtgaggagg | atagtgaggg  | gagggcacgc  | ttgtcttctc  | 1020 |
| aggtatcttc  | cccagcattg | ctcccttact | tagtatgcca  | aatgtcttga  | ccaatatcaa  | 1080 |
| aaacaagtgc  | ttgttttagc | gagaattttg | aaaagaggaa  | tatataactc  | aattttcaca  | 1140 |
| accacattta  | ccaaaaaaag | agatcaaata | taaaattcat  | cataatgtct  | gttcaacatt  | 1200 |
| atcttatttg  | gaaaatgggg | aaattatcac | ttacaagtat  | ttgtttacta  | tgaaatttta  | 1260 |
| aatacacatt  | tatgcctaga | aggaacggac | tttttttttc  | tatttttaatt | acacataata  | 1320 |
| tgtaattaaa  | gtmcaacata | atatgttggt | tctctgtagc  | ccgttgagca  | tatgagtaag  | 1380 |
| tcacatttct  | attaggacta | cttmcaagga | caagggtttc  | atttttccag  | ttgtaaaatt  | 1440 |
| ggaaccatca  | gctgataacc | tcgtaggagg | caacccacag  | atagctaagt  | gttatgtaat  | 1500 |
| atgcctagaa  | ggtagatgtg | atgcgattca | gaagcatagc  | cactcccat   | ttatgagcta  | 1560 |
| ctcacatgac  | aaatgtcatc | ttttgctata | acctttgcca  | agttagagaa  | aagatggatt  | 1620 |
| taatgagata  | aatgaaaaga | tatttamcct | aatatatcaa  | ggcactattt  | gctgttatgc  | 1680 |

|            |            |            |            |            |            |      |
|------------|------------|------------|------------|------------|------------|------|
| tttgttattt | atttcccagc | acttggtcct | tattgtagat | tttttaaaga | ctgtaacctt | 1740 |
| ttactaactg | tggtcttact | aaaatttgtg | cttgatactg | cttttcaaaa | agcctttaat | 1800 |
| tagagccaaa | aggatggaaa | aggcaagata | taaatgcctt | ttatagatct | cttatttaca | 1860 |
| ttgaaaatta | ttaccatatt | tttagagcaa | atccaagaaa | acttcaacag | cttctgaaga | 1920 |
| tgtctatgaa | tggtgaaaac | ttttcaatst | cttggratgc | tcakttaatt | cgcagaccgg | 1980 |
| cttaacggat | taaacgcccc | cccc       |            |            |            | 2005 |

<210> 16  
 <211> 943  
 <212> DNA  
 <213> Homo sapiens

|             |             |             |             |             |             |     |
|-------------|-------------|-------------|-------------|-------------|-------------|-----|
| <400> 16    |             |             |             |             |             |     |
| ggcacgagct  | cgcgccggcc  | cgcaggggct  | ctccccggag  | gctcagcccc  | ctctgctccc  | 60  |
| catgggcaac  | tgccaggcag  | ggcacaacct  | gcacctgtgt  | ctggcccacc  | acccacctct  | 120 |
| ggtctgtgcc  | actttgatcc  | tgtctgctcct | tggectctct  | ggcctgggccc | ttggcagctt  | 180 |
| cctcctcacc  | cacaggactg  | gcttgccgac  | cctgacatcc  | cccaggactg  | ggctctcttt  | 240 |
| ttgagatctt  | ttggccagct  | gacctgtgt   | cccaggaaatg | ggacagtcac  | agggaaagtgg | 300 |
| caggggtctc  | acgtcgtggg  | cttgctgacc  | accttgaact  | tcggagacgg  | tccagacagg  | 360 |
| aacaagaccc  | ggacattcca  | ggccacagtc  | ctgggaagtc  | agatgggatt  | gaaaggatct  | 420 |
| tctgcaggac  | aactggtcct  | tatcacagcc  | aggggtgacca | cagaaaggac  | tgcaaggacc  | 480 |
| tgccatatatt | ttagtgtctgt | tccagggaatc | ctacctcca   | gccagccacc  | catatcctgc  | 540 |
| tcagaggagg  | gggctggaaa  | tgccaccctg  | agccctagaa  | tgggtgagga  | atgtgttagt  | 600 |
| gtctggagcc  | atgaaggcct  | tgtgctgacc  | aagctgtctc  | cctcggagga  | gctggctctg  | 660 |
| tgtggctcca  | ggctgctggg  | cttgggctcc  | ttcctgcttc  | tcttctgtgg  | ccttctctgc  | 720 |
| tgtgtcaactg | ctatgtgctt  | ccaccgcgcg  | cgggagctcc  | actggtctag  | aacccggctc  | 780 |
| tgagggcact  | ggcctagtgc  | ccgactgtgt  | tctcaggtgt  | gaatcaactt  | cttgggcctt  | 840 |
| ggctctgagt  | tggaaaagggt | tttagaaaaa  | gtgaagagct  | ggaatgtggg  | ggaaaataaa  | 900 |
| aagctttttt  | gccccaaaaa  | aaaaaaaaaa  | aaaaaaaaaa  | aaa         |             | 943 |

<210> 17  
 <211> 1503  
 <212> DNA  
 <213> Homo sapiens

|             |            |             |            |             |            |      |
|-------------|------------|-------------|------------|-------------|------------|------|
| <400> 17    |            |             |            |             |            |      |
| cagggttcctc | tcagtamarc | ctcarsccga  | ggttcccttc | ctcttgcatc  | catgtgtgtg | 60   |
| tttcaraggc  | ggccatcctt | ccctacttcc  | agatccttgt | agggcagttg  | gtggagggtg | 120  |
| ggaggcacc   | cgggtgttgc | tccatgaagc  | cctgtgccag | tcactgggct  | gcaaggctga | 180  |
| ggaaattgtg  | tccgtgtcag | aaagctcctc  | agctcagagg | tgctggtagc  | tcttgcgtgg | 240  |
| taggaaggca  | gggggaagag | gccctgcttc  | tctgtttctc | tttgccctta  | tgagacttga | 300  |
| gagtctgtgt  | catctgtgac | ttgcatgtct  | ttttttcaga | ctccctgcga  | caaggactgt | 360  |
| gtactgcatg  | aatgaggctg | agatagttag  | tgttgctctg | ggaatcctga  | ttgagagccg | 420  |
| yaaacaggam  | aaggcctgcg | agcagccggc  | cctggcgggg | gctgataacc  | cagagcactc | 480  |
| ccctccctgc  | tccgtgtgac | ctcacacaag  | ttctgggagc | agcagttagg  | aagaggacag | 540  |
| tgggaaacag  | gcactgrctc | caggccctcag | cccttcccag | aggccggggg  | gttccagctc | 600  |
| tgccctgtagc | aggagccctg | aggaggagga  | ggaagaggat | gtgctgaaat  | acgtccggga | 660  |
| gatctttttc  | agctagggca | taaactgtgc  | actgaactgt | ctgccgagag  | cagctggagg | 720  |
| acagctgagc  | ttccactggg | gctgctgggc  | cgcccgcctg | tgggaaatggg | gctctctgtg | 780  |
| ctcctacctt  | tgtgccttct | tgggcctggc  | agattcacct | caggccagaa  | gccctgggac | 840  |
| actccggccc  | ttggggctgc | cgttctgagt  | gtgcggaaag | caggactcaa  | aatgagatcc | 900  |
| catttgactc  | cctctgtatg | tactgtgccc  | tctcctggct | cttgaggctc  | tggagtccca | 960  |
| attgtctgtg  | ttagtcatgt | accaggttcc  | agggaaaatg | atgtcatgtg  | gtggccaac  | 1020 |
| ttactggaac  | caaagagaca | gtacttttga  | aagaaaagga | tcactgccag  | gtgactgga  | 1080 |
| attgtacag   | tttagtccgc | atgatctctc  | ctgaaggagg | aagcctgttt  | caaaaatagt | 1140 |
| ttccatcatg  | agtctatcaa | tgagctccca  | cctctccagc | cagcctagaa  | agcaaacgag | 1200 |

|            |            |            |             |            |            |      |
|------------|------------|------------|-------------|------------|------------|------|
| ctgcccacag | ttctctgccc | tgtctgggag | gttgaggcca  | cagtgtatag | actggtaagc | 1260 |
| cagacaggcc | tcctcccgca | agctgctacc | ttgctttcac  | ctgtaccttg | gtccccgggc | 1320 |
| agctagctat | aaagcaagag | ggacaggagc | ccagaagaga  | cactgaggac | aagagatcac | 1380 |
| accagagtac | atgtctctgc | ctctgttttc | agtgtggcct  | tggacaggaa | tatatgaata | 1440 |
| aatcactgcc | atacagggtt | tccaatacac | aagtgtctaga | aaatacacac | aattccccaa | 1500 |
| tga        |            |            |             |            |            | 1503 |

&lt;210&gt; 18

&lt;211&gt; 1512

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (207)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (209)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (521)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 18

|             |             |            |             |             |             |      |
|-------------|-------------|------------|-------------|-------------|-------------|------|
| gcagagcccc  | tgggtgtgag  | aagctcgtct | cccggtgggt  | gcattggctc  | tgccctatct  | 60   |
| ctgcctccag  | cacccagggc  | ggccgcagat | ggcagtgtct  | ctggggacag  | cagctgcgaa  | 120  |
| tgagtcacac  | ggccaacgct  | gagctgtctc | ggctgaggcg  | gtgtgctcag  | cacagagccc  | 180  |
| ccggaactgg  | catctgcagg  | gcgtgancna | aggccgccgc  | gatgccgcac  | ttcctggact  | 240  |
| ggttcgtgcc  | ggctctacttg | gtcatctcgg | tcctcattct  | gggtgggcttc | ggcgccctgca | 300  |
| tctactactt  | cgagccgggc  | ctgcaggagg | cgacaaagt   | gcgcatgcag  | cgccccctgg  | 360  |
| tggaccgcsa  | cctccgcaag  | acgctaattg | tgcgcgacaa  | cctggccttc  | ggcggcccgg  | 420  |
| aggtctgagc  | cgacttgcaa  | aggggatagg | csggcgggc   | cgggcgccct  | ccccagccc   | 480  |
| gccccgcccc  | cccagcccgg  | agacccccaa | ggcagaggga  | ngccggcctg  | ttggccctcc  | 540  |
| acgctatccc  | tctgcagcct  | gggccctccc | gacagaggcc  | ccagggtgcg  | tgscagtgra  | 600  |
| gggtggggcac | ttaggtgcct  | ggctggccca | gggcttgctc  | tcctgtgcaa  | gccgactcac  | 660  |
| ccagagccca  | ccctcccagg  | ctcaggggca | tcctccgctg  | ggccccagtg  | cctttgcrct  | 720  |
| gcgcagcact  | ctgccctcca  | ctggactcag | gcattgtctat | ggctgcctgt  | cctgaggctc  | 780  |
| cggagccctc  | atttcttcgt  | gaagtcccca | gtccccctgc  | ctccactcaa  | tggcacgggc  | 840  |
| cctgcaactt  | taggcaggtc  | gaagccaacc | caaggaaaga  | acctaagaac  | ctcgtttgga  | 900  |
| gggatgtcag  | cttggggccag | mccagccgca | ccccgcgggg  | ctcaggcttg  | gaactggtga  | 960  |
| gggtgtgtgg  | tgggggtatg  | cagagggata | agaccgtggt  | agaggagagg  | gttgggtgagg | 1020 |
| agagagagag  | agagagagag  | agagagagtc | tgggggggagc | gggcaagcat  | ggggagatga  | 1080 |
| gatgtgtata  | tgtgagagag  | agtgtggggg | ccccaggcag  | ggcaggagggt | gggtggaaacg | 1140 |
| gggtgaactc  | cgtgggctgt  | gtgaggactg | tccatagtgg  | gtccmaaccc  | cctccctctg  | 1200 |
| ctggagtttc  | ctagcccttc  | cccctcccya | agactgwggc  | agcaggcagg  | agccccctgc  | 1260 |
| ctccctccct  | gtcctgtgcc  | acacttcttg | ggccaaaccc  | agcccccttg  | agccaggccc  | 1320 |
| tgccagactc  | caagcccacc  | ctagaaccct | cctcctgtgt  | ggagactctg  | ttggcccact  | 1380 |
| ttggacacag  | attggcaacc  | tgccctcacm | ckccccctw   | cgctggggct  | tccatcttaa  | 1440 |
| tttattctca  | ataataaaga  | cttcatgatg | amaaaaaaaa  | aaaaaaaaaa  | aaaaaaaaaa  | 1500 |
| aaaaaaaaaa  | aa          |            |             |             |             | 1512 |

&lt;210&gt; 19

<211> 1655  
 <212> DNA  
 <213> Homo sapiens

<400> 19  
 ccacgcgtcc gggcaaagaa ttaaacctgg tgtttggact tcaacttagc atggctagaa 60  
 ttggaagtac agtaaacaatg aacctcatgg gatggctgta ttctaagatt gaagctttgt 120  
 taggttctgc tgggtcacaca accctcggga tcacacttat gattgggggt ataacgtgta 180  
 ttctttcact aatctgtgcc ttggctcttg cctacttgga tcagagagca gagagaatcc 240  
 ttcataaaga acaaggaaaa acagggtgaag ttattaaatt aactgatgta aaggacttct 300  
 ccttaccctt gtggcttata ttatcatctt gtgtctgcta ttatgttgct gtgtccctt 360  
 ttattggact tgggaaagt ttctttacag agaaatttgg attttcttcc caggcagcaa 420  
 gtgcaattaa cagtgttgta tatgtcatat cagctcccat gtccccgggt tttgggctcc 480  
 tgggtggataa aacagggaag aacatcatct gggttctttg cgcatagcag ccactcttgt 540  
 gtcccacatg atgctggcct ttacgatgtg gaacccttgg attgctatgt gtcttctggg 600  
 actctcctac tcattgcttg cctgtgcatt gtggccaatg gtggcatttg tagttcctga 660  
 acatcagctg ggaactgcat atggcttcat gcagtcatt cagaatcttg ggttggccat 720  
 catttccatc attgctggta tgatactgga ttctcggggg tatttgtttt tgggaagtgtt 780  
 cttcattgcc tgtgtttctt tgctactttt atctgtggtc ttactctatt ggtgaatcgt 840  
 gcccaggggtg ggaacctaaa ttattctgca agacaaagga agaaataaaa ttcccatac 900  
 tgaatgagaa gttaaaatga atgtgtcaga gaatgggctt aacacatcgt tggtttgaaa 960  
 acttccattt taaaaattta gatttttagtc attagaaaaa ataattggact ggaaagtatt 1020  
 atttatatcc aaatatacct atttcaaagt gtatttgtga ggctgtttt agcctgtgtc 1080  
 ttttgtattg tgtgttgcta aagaattcta ctttttagtag gctaataaac aatgaaaggg 1140  
 ttagaaaatt gctgtggaac atccaggtga acttcaggaa agacagtga aaatggaaaa 1200  
 cgttggagct tctgttgaga taatcttcat taggtatata tcttagggat acagcctttt 1260  
 ctttatctta tagcaggaaa aaaaaacttt tgagggaaat agaagggtcg cgttacacaa 1320  
 aataaacaat ggcattgtca taggccttcc ttttactagt agggcataat gctagggaat 1380  
 atgtgaagat gtttttttga agtctcttcc tgatcacgaa caatagcttg cgtctactc 1440  
 tgtagttatg tggattgccg agcaatgacc cttttcaatt tcttatttct gtgttactga 1500  
 ggaccctaata cacttaggga tgtaatttta tagtataaac tttctgtaca gtttttctta 1560  
 tagtctaata agtaaaaagt gtccttcaaa ttatgataat tgcctatgta catggataaa 1620  
 ttaaaacact gcacacggaa aaaaaaaaaa aaaaa 1655

<210> 20  
 <211> 2525  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (5)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (10)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1354)  
 <223> n equals a,t,g, or c

<400> 20  
 tgacnctatn gtaaggtagc cctgcaggta ccggctccga attccccggg cgacccacgc 60  
 gtccgggtctg ccaacaaggt cgttcatgaa agtgtttttc tctttaaggt aattaaaaaa 120

|             |             |             |            |            |             |      |
|-------------|-------------|-------------|------------|------------|-------------|------|
| cagtggaaatg | gaaaaaacagt | gctgtagtca  | tcctgtaata | tgctccttgt | caacaatgta  | 180  |
| tacattcctg  | ctaggtgcc   | tattcattgc  | tttaagctca | agtcgcatct | tactagtga   | 240  |
| gtattctgcc  | aatgaaggta  | agttaagact  | tggtatatgc | atggagcact | tccatcta    | 300  |
| cacacatctc  | tctcttgcc   | ttggttctgt  | tatatataac | atggaaataa | taatgccttt  | 360  |
| tgcttcattg  | gagtgataaa  | gcataattaa  | atttgattat | ttaaccttgc | attcctcaac  | 420  |
| aagaaaaaat  | gtttgataat  | ggatgaaatg  | tgagtcaatc | agatacaaaa | atcaaacctt  | 480  |
| ttggtgaaga  | accagtcgta  | acatttgact  | gttaattcaa | tcaacaggtg | tttctggacc  | 540  |
| tatagcaaaa  | tgtgtaattg  | cgccttattt  | tgaagtagaa | ggatatattt | gtttgggtcac | 600  |
| ttggcatttg  | tgaggctact  | actattgtaa  | ttattgtatc | aatggtaagg | tgtcagcatt  | 660  |
| atatgtgtcg  | gtcatattgt  | atcaacagta  | taaattataa | gctttgataa | gtatgtattt  | 720  |
| aagaaatctt  | tttttatgta  | gggatttaag  | caaacacttt | aattccacca | aactgtattg  | 780  |
| agtaactctt  | actagttatt  | gagtgaaagg  | gtgggttgcc | cctccacatc | tggtgggtgt  | 840  |
| tctcgttagg  | tggaacgaga  | gacttgga    | agaaaggac  | atagacaaag | tatagagaaa  | 900  |
| gaaaaaagg   | ggcccagg    | accggcgctc  | agcacacgga | ggatctctgc | cagcctctga  | 960  |
| gttccmttag  | tatttatgta  | tcattattgg  | gtgtttctcg | gagagtggga | tggtggcagg  | 1020 |
| tcataggata  | gtagtggaga  | gaggtgcaac  | aggtaaacac | gtgaacaaag | gtctttgcat  | 1080 |
| cataracaak  | gtaaagratt  | aagtgcctktg | cttttagata | tgcatacaca | taaacatctc  | 1140 |
| aatgctttac  | aaagcagtat  | tgctgccgc   | akgtcccacc | tccagcccta | aggcggtttt  | 1200 |
| ycctatctc   | agtagatgga  | gcatacaatc  | gggttttata | ccgagacatt | ccattgcccc  | 1260 |
| gggacrggca  | ggagacagat  | gccttcctct  | tgctcaact  | gcaagaggcr | ttccttcctc  | 1320 |
| ttttactaat  | cctcctcagc  | acagaccctt  | tacngggtgt | cgggctgggg | gacggctcagg | 1380 |
| tctttccctt  | cccacgaggc  | catatttcag  | actatcacat | ggggagaaac | cttggacaat  | 1440 |
| acctggcttt  | cctaggcaga  | ggtcscgtcg  | gcyttccrca | gtgttttgtg | tccttgshta  | 1500 |
| cttgagatta  | gggagtgggt  | atgactctta  | asgagcatgc | tgcttcaag  | catctgttta  | 1560 |
| acaaagcaca  | tcttgcaccg  | cccttaatcc  | atttaaccct | gagtkgacac | agcacatgtt  | 1620 |
| tcagagagca  | crgggttggg  | ggtaagggtta | cagattgcag | aacaaaatgg | agtctcctat  | 1680 |
| gtctacttct  | ttctamacag  | acacagtaac  | aatctgatct | ctcttttccc | cacaattgag  | 1740 |
| gacacataca  | atcatgatat  | gacctttaat  | ggcttactac | ttggagagtc | agatgtgtac  | 1800 |
| ccaagtctct  | actgcagtta  | acatttacct  | gccaggcact | aggctaagta | ttagcagcag  | 1860 |
| gttcaaagt   | cataagatat  | agaccttgct  | ctcaagactt | agtttattag | gagagacatg  | 1920 |
| aatgtaaaaa  | catcatgaaa  | atccattata  | ataactgcaa | taattgatat | atcctgaaga  | 1980 |
| tgagagagatt | gtctagagga  | taaagttata  | tattctgttt | ggtaggggat | gatgtggagt  | 2040 |
| tcaaatggat  | cagagaacac  | ttcgttgatt  | agaagtcagt | tgatccacta | gaagtcaagg  | 2100 |
| tgaaacaagg  | gattcaaaa   | agaggcaaca  | gcctgtaaaa | gggaacagag | gcataaaaaa  | 2160 |
| gcaggatatg  | ttgtgagaac  | atgtagtttg  | aaattaccaa | gcaaaaagtt | taaggactcg  | 2220 |
| tagccaggca  | cagtggctca  | tgctgtaatc  | ccagcacttt | aggaggccaa | ggccggcgga  | 2280 |
| tcacttgagg  | tcaggaatatt | gagaccaggc  | tggccaacat | ggtgaaaccc | atctctacta  | 2340 |
| gaaatacaaa  | aaattagctg  | ggtttgttgg  | cgtgtgcctg | taatcccagc | tatgaggagag | 2400 |
| actgaagcag  | gagaatgaac  | ccgggaggca  | gagattgcag | tgagccgaga | tcatgccact  | 2460 |
| gcactccagc  | ctgggcaaca  | gagcaaaact  | gtctcaagaa | aaaaaaaaaa | aaaaagggcg  | 2520 |
| gcgcg       |             |             |            |            |             | 2525 |

&lt;210&gt; 21

&lt;211&gt; 1396

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

|             |            |            |            |            |            |     |
|-------------|------------|------------|------------|------------|------------|-----|
| aagtctctgta | tcgcgcccgg | gaggcgccgg | agcccagcgg | ctggcgccag | atccaggctc | 60  |
| ctggaagaac  | catgtccggc | agctactggg | catgccaggc | acacactgct | gcccagagg  | 120 |
| agctgctgtt  | tgaattatct | gtgaatgttg | ggaagaggaa | tgccagagct | gccggctgaa | 180 |
| aattacccaa  | ccaagagaaa | tctgcaggat | ggactttctg | gtcctcttct | tgttctacct | 240 |
| ggcttcgggtg | ctgatgggtc | ttgttcttat | ctgcgtctgc | tcgaaaaccc | atagcttgaa | 300 |
| aggcctggcc  | aggggaggag | cacagatatt | ttcctgtata | attccagaat | gtcttcagag | 360 |
| agccrtgcat  | ggattgcttc | attacctttt | ccatacgaga | aaccacacct | tcattgtcct | 420 |
| gcacctgggtc | ttgcaaggga | tggtttatac | tgagtaaccc | tggaagatat | ttggctactg | 480 |
| tcaggagctg  | gagttgtcct | tgcattacct | tcttctgccc | tatctgctgc | taggtgtaaa | 540 |



10

|             |             |            |            |            |             |      |
|-------------|-------------|------------|------------|------------|-------------|------|
| cctgtttttt  | ttcaccctga  | cttgtggaac | caatcctggc | attataacaa | aagcaaata   | 600  |
| attattattt  | cttcatgttt  | atgaatttga | tgaagtgatg | tttccaaaga | acgtgaggtg  | 660  |
| ctctacttgt  | gatttaagga  | aaccagctcg | atccaagcac | tgcagtgtgt | gtaactgggtg | 720  |
| tgtgcaccgt  | ttcgaccatc  | actgtgtttg | ggtgaacaac | tgcacgggg  | cctggaacat  | 780  |
| caggtaactt  | ctcatctacg  | tcttgacctt | gacggcctcg | gctgccaccg | tcgccattgt  | 840  |
| gagcaccact  | tttctgggtcc | acttgggtgt | gatgtcagat | ttataaccag | agacttacat  | 900  |
| cgatgacctt  | ggacacctcc  | atgttatgga | cacggctctt | cttattcagt | acctgttcct  | 960  |
| gacttttcca  | cggattgtct  | tcatgctggg | ctttgtcgtg | gttctgagct | tcctcctggg  | 1020 |
| tggctacctg  | ttgtttgtcc  | tgtatctggc | ggccaccaac | cagactacta | acgagtggta  | 1080 |
| cagagggtgac | tgggcctggg  | gccagcgttg | tccccttgtg | gcctggcctc | cgtcagcaga  | 1140 |
| gccccaaagt  | caccggaaca  | ttcactccca | tgggcttcgg | agcaaccttc | aagagatctt  | 1200 |
| tctacctgcc  | tttccatgtc  | atgagaggaa | gaaacaagaa | tgacaagtgt | atgactgcct  | 1260 |
| ttgagctgta  | gttccccgtt  | atttacacat | gtggatcctc | gttttccaaa | aaaaaaaaaa  | 1320 |
| aaaaaaaaaa  | aaaaaaaaaa  | aaaactcgag | ggggggcccg | gtaccaaat  | cgccctggag  | 1380 |
| ttcaagtaga  | catcaa      |            |            |            |             | 1396 |

&lt;210&gt; 22

&lt;211&gt; 1069

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (508)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 22

|            |             |            |             |             |             |      |
|------------|-------------|------------|-------------|-------------|-------------|------|
| ggcacgagca | cagcctcagg  | cctgccccca | gacctgcaga  | atcagaaact  | ctgggggtgag | 60   |
| gcctggttat | ctgctgtaac  | agaccttcca | gtgggttctg  | atgccctcta  | gagcaggaga  | 120  |
| accactagct | tagaggttgc  | agtatgtttg | gcaccttgcc  | atttgtgtta  | gttcagagga  | 180  |
| atggctgacc | cccatgtctc  | atttctaagc | ttcaggcagc  | ttttctcctg  | ggcagctgtc  | 240  |
| attctgttga | ggggaatcct  | ggggactgtg | gctcctctc   | cctgtccgtg  | tgctcttgat  | 300  |
| ctggcagttc | acccccctta  | tctccccgtg | gaggctccat  | gcctagagggt | ggctcttcaa  | 360  |
| cagaagaatg | gcaaagataa  | ttgtctcgtg | ttttaccctg  | acccatttcc  | tttaagaggg  | 420  |
| tcacttcttg | gcccattcat  | tataaaccaa | tgtcatagtt  | ctgtgattcc  | actatcagac  | 480  |
| agtgccacgt | ccaaggcgcg  | ggctcttnac | ctccctggaa  | gagagactgt  | gctgtctgtg  | 540  |
| cttctctgtg | tctccagttc  | cacgctccca | cggaccacag  | cccttggaga  | ctccctcggt  | 600  |
| gtcccagggc | ttctggtgtg  | ttcagagacc | tcacactca   | acgaccactg  | gtgctgcaga  | 660  |
| agggccgggt | cttacattcc  | aattaacaga | cgcttttccc  | atctaagtcc  | tcttgcttcc  | 720  |
| tcctaaccac | acctcgggag  | tgtttatgtc | tattctaagt  | gaatttcaact | gtgtgaaaaa  | 780  |
| attcacacct | gttgtccccag | cgatttggga | ggccggggcg  | ggtgtatcat  | ttgagccag   | 840  |
| gagtttgagg | ctagcctggg  | caggatgtgt | aaaccccgct  | tctataaaga  | aattttaaaa  | 900  |
| attagctggg | catagtggca  | cgtgcctgta | gttccatcta  | ctggggaggc  | tgggggtggga | 960  |
| ggatcgcatg | agccccgggag | tttgaggctg | cagtgcagctg | tgatcgagc   | actgcactcc  | 1020 |
| agtctgggca | acagagcaag  | acctgtgtct | ttataaaaaa  | aaaaaaaaaa  |             | 1069 |

&lt;210&gt; 23

&lt;211&gt; 1658

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| ggcacgagcc | ggcctgccag | agccatgccc | ctgactcctc | agcttcaaaa | tcaggggtct | 60  |
| caggacagag | gatgctgggt | gggctcagag | ctcatcaggg | gggctgtgtg | tgagagggga | 120 |
| tgccctcttg | atgccctcat | cctcctcggg | gctgggggtc | ccctcaaggc | caccagctc  | 180 |
| cttcctttgt | ttgctgctgc | tactcctgcc | gctgctgccc | ttggccctgc | tgctcttctt | 240 |

11

|             |             |             |             |            |             |      |
|-------------|-------------|-------------|-------------|------------|-------------|------|
| cttggaacttc | ttccctccca  | gggcagctgt  | gtcccccctc  | ttgcgggacc | actgctctgc  | 300  |
| caggcaacct  | aggggtgtgga | ggagagagac  | cctcaacaga  | agtgcctcag | ggctgggggtg | 360  |
| ctgggcaagg  | agcactgagc  | agggagccgt  | gggagtagca  | actgggactg | tgcttgacat  | 420  |
| cagcctccct  | gcctcctgcc  | tctcgctgtg  | gccaccaggc  | ccctctgggg | gcacttgact  | 480  |
| tgtctgcccc  | tcattctgca  | cctgggttca  | gtgactctta  | cttcaccatg | tcttgccaat  | 540  |
| caagcctttc  | aagggcagag  | atcctacaat  | gccctctggg  | gccctctgtt | tctcctccta  | 600  |
| cccacctccc  | ccaagggaga  | gcaaacaaat  | catccagagc  | cagcctgccc | ttgcttcccc  | 660  |
| aaactcactg  | gtgtcttttc  | ccttcagcac  | gtggttggcg  | cagaggaatt | cagtcagggtc | 720  |
| ttcctcctgg  | tggatcctgt  | accagtcctc  | gatcacctcc  | tcaaactctt | caccagcaca  | 780  |
| tcacacttgt  | taatcataat  | acctcatatt  | ggcaaagccc  | cagcacctga | ctcgctccta  | 840  |
| gaggagctca  | gcctaagcct  | cgcaaccac   | tgcaaggtag  | cagtggcacg | gttcacctaa  | 900  |
| ggaaactgag  | gccagagagg  | tgaaatgacc  | tgaccaaagc  | caccccggcc | tgggtggact  | 960  |
| tcctcagagc  | agacccaatc  | cccaccagcc  | cttcactggg  | cacagcaacc | cttccaaggg  | 1020 |
| ctgaagggcc  | tgtacctgct  | tcttgagggtc | agccacttct  | gcagaagtct | cgttcaacag  | 1080 |
| ctcatagggg  | atgtccatca  | ccaccttgac  | ccctttgtgt  | accaggttgt | gtaatgtctc  | 1140 |
| aaaggtctct  | gacatgccct  | ggaagaagcg  | accagatatg  | gcaggcggag | ctcccttctc  | 1200 |
| tcctccccc   | cctcgtctcc  | cagtgggtggc | taagaaccca  | gctataagac | caatgctcaa  | 1260 |
| cgccctctaa  | ggatcctcat  | cctttttttt  | ttgagaagga  | gtctcactct | gtcgcccagg  | 1320 |
| ttggagcgct  | tcagctcact  | gcaacctctg  | cctcccagggt | tcaagcgatt | ttcctgcctc  | 1380 |
| agcctcccaa  | gcagctggga  | ctacaaaggc  | gtgccaccat  | acccggctaa | tttttgtaga  | 1440 |
| gttggggttt  | tgtcatgttg  | gtcaggctgg  | tctcgaaact  | ctagcatcaa | gttttccact  | 1500 |
| cacctcagcc  | tcccaaagtg  | ctgagattac  | aggcgtgagc  | caccgcacct | ggcctcatcc  | 1560 |
| ttgacctgac  | cttcctcttc  | cctcttttag  | gcctgcttcc  | cacaacccct | gcacatatac  | 1620 |
| cccctgatct  | gcctctgcac  | acctcatcgc  | ttcaaaaa    |            |             | 1658 |

&lt;210&gt; 24

&lt;211&gt; 1077

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1036)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1038)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 24

|            |             |             |             |             |             |     |
|------------|-------------|-------------|-------------|-------------|-------------|-----|
| ggcacgaggg | gaaagccatg  | ctcccaggac  | tccttccttg  | cagccttaaa  | tcgggtctgta | 60  |
| cggaaaattc | cgcgcccttag | aaacccacgc  | ttgggtgttaa | cttattattg  | ttcttcctga  | 120 |
| cctacttcct | gtttatcact  | tccgggttca  | tcattttggc  | atttcgggtga | tcgggttgga  | 180 |
| actattgaag | cccgctttca  | ggttcctttc  | cccattttcc  | ctttgaaagg  | aagacttctg  | 240 |
| gcttctccta | aatctcogtt  | ctctgggtaa  | ggggagtcca  | agcctctgtc  | atgaggaacg  | 300 |
| gaaatgcgag | ggcctcgggt  | gttactctaa  | aatccgccct  | cagcttgac   | gccggaagct  | 360 |
| gcgattcctg | cagcgggaaga | ggcgtgatct  | ggccttcgac  | tcgctatgtc  | cactaacaat  | 420 |
| atgtcggacc | cacggaggcc  | gaacaaagtg  | ctgaggtaca  | agcccccgcc  | gagcgaatgt  | 480 |
| aacccggcct | tggacgaccc  | gacgccggac  | tacatgaacc  | tgctgggcat  | gatcttcagc  | 540 |
| atgtcgggcc | tcatgcttaa  | gctgaagtgg  | tgtgcttggg  | tcgctgtcta  | ctgctccttc  | 600 |
| atcagctttg | ccaactctcg  | gagctcggag  | gacacgaagc  | aaatgatgag  | tagcttcatg  | 660 |
| ctgtccatct | ctgccgtggg  | gatgtcctat  | ctgcagaatc  | ctcagcccat  | gacgccccca  | 720 |
| tgggtatacc | agcctagaag  | ggtcacattt  | tggaccctgt  | ctatccacta  | ggcctgggct  | 780 |
| ttggctgcta | aacctgctgc  | cttcagctgc  | catectggac  | ttccctgaat  | gaggccgtct  | 840 |
| cggtgccccc | agctggatag  | agggaaacctg | gccttttct   | agggaaacac  | ctaggcttac  | 900 |
| ccctcctgcc | tccttcccc   | tgccctgctgc | tgggggagat  | gctgtccatg  | tttctagggg  | 960 |

12

|            |            |            |            |            |            |      |
|------------|------------|------------|------------|------------|------------|------|
| tattcatttg | ctttctcggt | gaaacctgtt | gttaataaag | tttttcactc | tgaaaaaaaa | 1020 |
| aaaaaaaaaa | aaaaancncg | agggggggcc | cggaacccaa | ttccccggat | agtgagt    | 1077 |

<210> 25  
 <211> 1205  
 <212> DNA  
 <213> Homo sapiens

<400> 25

|             |            |            |            |            |             |      |
|-------------|------------|------------|------------|------------|-------------|------|
| cccacgcgtc  | cgcagaggca | gggcaatagt | ggagttctgg | cttggccaag | cagcctagaa  | 60   |
| ctcaaagtcc  | atggcccctt | ctgggcctgg | agaaattgga | tggttatagc | accaggcagc  | 120  |
| ccttgtgggt  | gggggacagc | aaatgaggga | cctctctttt | ctctacactc | tcctttggct  | 180  |
| cccggagatc  | tggcaggccc | tggctggagg | cataagatta | gatgaggttg | agctgttgga  | 240  |
| gaatgaagct  | gtgttgggag | aagaaatgag | gttgtaccgg | aagatcaacg | aggttgtgct  | 300  |
| gtcagggaat  | gaggtggtac | ttgggggcaa | gtgaggctgc | attattagat | aaatgaggtt  | 360  |
| gtactgtcag  | gggatgaagt | gtacttgtag | tagagatgac | gtcctgctgg | atcagtcggc  | 420  |
| ttttgtctca  | tcagagaaca | cagccacacc | acaggaggaa | ggagagtgtc | cgactcagag  | 480  |
| gataaatgag  | ggtgtcctgc | tggataaatg | agggggcccg | tcaggtgaat | ggagtgtgtg  | 540  |
| tagcaaatga  | ggttgtaact | gctggataaa | tgggactggg | gtgctggata | aatggggttg  | 600  |
| tgctgtcagg  | tgaatgcatt | actgtctgtg | ggtgaagggc | atcctgggaa | taatgagggg  | 660  |
| gtcctgctgg  | atagatgagc | tgccaccacc | aaatggatca | gaccctgtcc | atgaaggagg  | 720  |
| caccatcagc  | aacgacgagg | ttatcctgtt | cccactgggg | ctcctggagc | gtcttctggc  | 780  |
| ccaggggaaa  | ctcgggtgtg | gccaccctgg | gttatccaa  | tctctctggg | gagcaggggtg | 840  |
| gggggctggg  | gagggcaggc | agctgcattg | tgccaccgtg | gacctctcct | tcaccccaa   | 900  |
| tggatgccct  | actcctctcc | ctggcaccct | tcagtgggtc | agactgcttc | ggacattctc  | 960  |
| accccaactgc | ctgcttctca | tcctgcctgt | gtcttctttc | tgcccagttt | ggaaaagccc  | 1020 |
| ctattatgtg  | tcagccactc | tgcccagttc | tatttaattc | ccctataaca | cagtattact  | 1080 |
| cctccttgca  | catacacact | ttctcttatt | cattcatcca | ttcattcatt | tgacaaacat  | 1140 |
| ttaagtgtct  | agtatgtacc | aaacacatga | ggtacagttt | taaaaagaat | aaaaaaaaaa  | 1200 |
| aaaaa       |            |            |            |            |             | 1205 |

<210> 26  
 <211> 1674  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1663)  
 <223> n equals a,t,g, or c

<400> 26

|             |             |            |            |             |             |     |
|-------------|-------------|------------|------------|-------------|-------------|-----|
| cccagagcagc | tgagtccect  | cctgtctctt | cactcttctg | gcacggtgg   | ttttacttct  | 60  |
| togattgaac  | cctgcttctt  | cgacccccct | gggaggccgc | cttcttcagg  | cgcctccctt  | 120 |
| ctctccacga  | gtcgtctctg  | acagctgagg | aactggcaag | atcctgctac  | ccagaggggtg | 180 |
| aatgggtatc  | tttcccggaa  | taatccta   | ttttctaagg | gtgaagtgtg  | caacggcggc  | 240 |
| cgtgattgta  | agcggagtaa  | gcaaacacct | ccattgtatt | agtcaccaga  | aaagtaccac  | 300 |
| tgtaagtcat  | gagatgtctg  | gtctgaattg | gaaacccctt | gtatatggcg  | gccttgccctc | 360 |
| tatcgtggct  | gagtttgagg  | ctttccctgt | ggaccttacc | aaaacacgac  | ttcaggttca  | 420 |
| aggccaaagc  | attgatgccc  | gtttcaaaga | gataaaatat | agagggatgt  | tccatgcgct  | 480 |
| gtttcgcac   | tgtaaaagg   | aaggtgtatt | ggctctctat | tcagggaattg | ctcctgcgtt  | 540 |
| gctaagacaa  | gcacatcatg  | gcaccattaa | aattgggatt | taccaaagct  | tgaagcgctt  | 600 |
| attcgtagaa  | cgttttagaag | atgaaactct | tttaattaat | atgatctgtg  | gggtagtgtc  | 660 |
| aggagtgtata | tcttccacta  | tagccaatcc | caccgatgtt | ctaaagattc  | gaatgcaggc  | 720 |
| tcaagggaagc | ttgttccaag  | ggagcatgat | tgggaagctt | atcgatatat  | accaacaaga  | 780 |
| aggcaccagg  | ggtctgtgga  | gggggtgtgt | tccaactgct | cagcgtgtgt  | ccatcgttgt  | 840 |

|            |            |             |            |            |            |      |
|------------|------------|-------------|------------|------------|------------|------|
| aggagtagag | ctaccagtct | atgatattac  | taagaagcat | ttaatatgt  | caggaatgat | 900  |
| ggcgataca  | attttaactc | acttcgtttc  | cagctttaca | tgtggtttgg | ctggggctct | 960  |
| ggcctccaac | cgggttgatg | tgttcgaac   | tcgcatgatg | aaccagaggg | caatcgtggg | 1020 |
| acatgtggat | ctctataagg | gcactgttga  | tggatattta | aagatgtgga | aacatgaggg | 1080 |
| cttttttgca | ctctataaag | gattttggcc  | aaactggctt | cggcttgga  | cctggaacat | 1140 |
| catttttttt | attacatacg | agcagctaaa  | gaggcttcaa | atctaagaac | tgaattatat | 1200 |
| gtgagccag  | ccctgccagc | ctttctactc  | ctttgccctt | ttcccgtgtt | ctaagtatt  | 1260 |
| ttgacaatgt | tgttaagtgt | taccaagccg  | ttggtctcct | aagggcctcc | tgatggaaga | 1320 |
| acagtggggt | ggttcaaagt | tattttctatg | tttgtgttac | catgttaact | tttccccgag | 1380 |
| agaaagtgtt | aacattgaga | ctctggcccc  | agattggtat | cttctatgaa | gatggatact | 1440 |
| gatgggtgac | attgaaaacg | gcctgctttc  | caaagtgtgt | taaatgtaat | tggttagccc | 1500 |
| cagacttggg | ctagagcaga | aggcataggg  | caggggtggt | attgctatat | gtgttacaga | 1560 |
| cctcggttct | cattaaagta | tttattggca  | gaatcaaaaa | aaaaaaaaaa | aaaaaaaaaa | 1620 |
| aaactcgagg | gggggccccg | taccaattc   | gcctatggt  | gantcgaatg | ggct       | 1674 |

&lt;210&gt; 27

&lt;211&gt; 1965

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (333)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1961)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 27

|             |            |             |             |            |             |      |
|-------------|------------|-------------|-------------|------------|-------------|------|
| ggatcctcgc  | ggcggcgcg  | gtgcttacag  | cctgagaaga  | gcgtctcgcc | cgggagcggc  | 60   |
| ggcggccatc  | gagaccaccc | caaggcgcg   | ccccctcggc  | ctcccagcgc | tcccaagccg  | 120  |
| cagcggccgc  | gccccttcag | ctagctcgct  | cgctcgctct  | gcttccctgc | tgccggctgc  | 180  |
| gcctggcggt  | ggcgttgccg | gcgctggcgg  | cggctgcagc  | ggcctgcggc | agccggtacc  | 240  |
| agcagttgca  | gaatgaagaa | gagtcctggag | aaactgaaca  | ggctgcaggt | gatgtcctc   | 300  |
| caccttacag  | cagcatttct | gcagagagcg  | cancatattt  | tgactacaag | gatgagtctg  | 360  |
| ggtttccaaa  | gcccccatct | tacaatgtag  | ctacaacact  | gcccagttat | gatgaagcgg  | 420  |
| agaggaccaa  | ggctgaagct | actatccctt  | tggttctctg  | gagagatgag | gattttgtgg  | 480  |
| gtcgggatga  | ttttgatgat | gctgaccagc  | tgaggatagg  | aaatgatggg | attttcatgt  | 540  |
| taactttttt  | catggcattc | ctctttaact  | ggattggggt  | tttctgtct  | ttttgcctga  | 600  |
| ccacttcagc  | tgcaggaagg | tatggggcca  | tttcaggatt  | tggtctctct | ctaattaaat  | 660  |
| ggatcctgat  | tgtcagggtt | tccacctatt  | tccttgata   | ttttgatggt | cagtactggc  | 720  |
| tctggtgggt  | gttccttgtt | ttaggctttc  | tcctgtttct  | cagaggattt | atcaattatg  | 780  |
| caaaagttcg  | gaagatgcc  | gaaactttct  | caaactctcc  | caggaccaga | gttctcttta  | 840  |
| tttattaaag  | atgttttctg | gcaaaggcct  | tcctgcattt  | atgaattctc | tctcaagaag  | 900  |
| caagagaaca  | cctgcaggaa | gtgaatcaag  | atgcagaaca  | cagaggaata | atcacctgct  | 960  |
| ttaaaaaat   | aaagtactgt | tgaagaagac  | atttctctct  | atttgttct  | aggtgtaaaa  | 1020 |
| ttttaatagt  | taatgcagaa | ttctgtaatc  | attgaatcat  | tagtggttaa | tgtttgaaaa  | 1080 |
| agctcttgca  | atcaagtctg | tgatgtatta  | ataatgcctt  | atatattgtt | tgtagtcat   | 1140 |
| ttaaagtagc  | tgagccatgt | ccctgtagtc  | ggtagggggc  | agtcttgctt | tattcatcct  | 1200 |
| ccatctcaaa  | atgaacttgg | aattaaatat  | tgtaaagatat | gtataatgct | ggccatttta  | 1260 |
| aaggggtttt  | ctcaaaagtt | aaacttttgt  | tatgactgtg  | tttttgcaca | taatccatat  | 1320 |
| ttgctgttca  | agttaatcta | gaaatttatt  | caattctgta  | tgaacacctg | gaagcaaaat  | 1380 |
| catagtgc    | aaatacattt | aaggtgtggt  | caaaaataag  | tccttaattg | gtaaaataata | 1440 |
| agcatttaatt | ttttatagcc | tgtattcaca  | attctgcggt  | accttattgt | acctaaggga  | 1500 |
| ttctaaaggt  | gttgtcactg | tataaaacag  | aaagcactag  | gatacaaatg | aagcttaatt  | 1560 |

14

|            |            |             |            |            |            |      |
|------------|------------|-------------|------------|------------|------------|------|
| actaaaatgt | aattcttgac | actctttcta  | taattagcgt | tcttcacccc | cacccccacc | 1620 |
| cccaccccc  | ttattttcct | tttgtctcct  | ggtgattagg | ccaaagtctg | ggagtaagga | 1680 |
| gaggattagg | tacttaggag | caaagaaaaga | agtagcttgg | aacttttgag | atgatcccta | 1740 |
| acatactgta | ctacttgctt | ttacaatgtg  | ttagcagaaa | ccagtgggtt | ataatgtaga | 1800 |
| atgatgtgct | ttctgcccc  | gtggtaattc  | atcttggttt | gctatgttaa | aactgtaaat | 1860 |
| acaacagAAC | attaataaat | atctcttggt  | tagcaccttt | aaaaaaaaaa | aaaaaaaaaa | 1920 |
| aaaaaaaaaa | aaaaaaaaaa | aaaaaaaaaa  | aaaaaaaaaa | naaaa      |            | 1965 |

<210> 28  
 <211> 1863  
 <212> DNA  
 <213> Homo sapiens

|            |             |             |             |             |             |      |
|------------|-------------|-------------|-------------|-------------|-------------|------|
| <400> 28   |             |             |             |             |             |      |
| gactaggccg | cgagcttagt  | cctgggagcc  | gcctccgtcg  | ccgccgtcag  | agccgcccta  | 60   |
| tcagattatc | ttaacaagaa  | aaccaactgg  | aaaaaaaaat  | gaaattcctt  | atcttcgcct  | 120  |
| ttttcgggtg | tgttcacctt  | ttatccctgt  | gctctgggaa  | agctatatgc  | aagaatggca  | 180  |
| tctctaagag | gacttttgaa  | gaaataaaaag | aagaaatagc  | cagctgtgga  | gatgttgcta  | 240  |
| aagcaatcat | caacctagct  | gtttatggta  | aagcccagaa  | cagatccctat | gagcgattgg  | 300  |
| cacttctggt | tgatactgtt  | ggacccagac  | tgagtggctc  | caagaacctta | gaaaaagcca  | 360  |
| tccaaattat | gtacccaaac  | ctgcagcaag  | atgggctgga  | gaaagtccac  | ctggagccag  | 420  |
| tgagaatacc | ccactgggag  | aggggagaag  | aatcagctgt  | gatgctggag  | ccaagaattc  | 480  |
| ataagatagc | catcctgggt  | cttggcagca  | gcattgggac  | tcctccagaa  | ggcattacag  | 540  |
| cagaagttct | gggtggtgac  | tctttcgatg  | aactgcagag  | aagggcctca  | gaagcaagag  | 600  |
| ggaagattgt | tgtttataac  | caaccttaca  | tcaactactc  | aaggacggtg  | caataccgaa  | 660  |
| cgcagggggc | gggtggaagct | gccaaggttg  | gggctttggc  | atctctcatt  | cgatccgtgg  | 720  |
| cctccttctc | catctacagt  | cctcacacag  | gtattcagga  | ataccaggat  | ggcgtgccca  | 780  |
| agattccaac | agcctgtatt  | acggtggaag  | atgcagaaat  | gatgtcaaga  | atggcttctc  | 840  |
| atgggatcaa | aattgtcatt  | cagctaaaga  | tgggggcaaa  | gacctacca   | gatactgatt  | 900  |
| ccttcaacac | tgtagcagag  | atcactggga  | gcaaatatcc  | agaacagggt  | gtactgggtca | 960  |
| gtggacatct | ggacagctgg  | gatgttgggc  | aggggtgccat | ggatgatggc  | gggtggagcct | 1020 |
| ttatatcatg | ggaagcactc  | tcacttatta  | aagatcttgg  | gctgcgtcca  | aagaggactc  | 1080 |
| tgccgctggt | gctctggact  | gcagaagaac  | aagggtggagt | tggtgccttc  | cagtattatc  | 1140 |
| agttacacaa | ggtaaatatt  | tccaactaca  | gtctgggtgat | ggagtctgac  | gcaggaaacct | 1200 |
| tcttaccac  | tgggctgcaa  | ttcactggca  | gtgaaaaggc  | caggggccatc | atggaggagg  | 1260 |
| ttatgagcct | gctgcagccc  | ctcaatatca  | ctcagggtcct | gagccatgga  | gaagggacag  | 1320 |
| acatcaactt | ttggatccaa  | gctggagtgc  | ctggagccag  | tctacttgat  | gacttataca  | 1380 |
| agtatttctt | cttccatcac  | tcccacggag  | acaccatgac  | tgatcatggat | ccaaagcaga  | 1440 |
| tgaatgttgc | tgctgctgtt  | tgggctgttg  | ttctctatgt  | tgttgcagac  | atggaagaaa  | 1500 |
| tgctgcctag | gtcctagaaa  | cagtaagaaa  | gaaacgtttt  | catgcttctg  | gccaggaatc  | 1560 |
| ctgggtctgc | aactttggaa  | aactcctctt  | cacataacaa  | ttcatccaa   | ttcatcttca  | 1620 |
| aagcacaact | ctatttcatg  | ctttctgtta  | ttatctttct  | tgatactttc  | caaattctct  | 1680 |
| gattctagaa | aaaggaatca  | ttctcccctc  | cctcccacca  | catagaatca  | acatatggta  | 1740 |
| gggattacag | tgggggcatt  | tctttatata  | acctcttaaa  | aacattgttt  | ccactttaaa  | 1800 |
| agtaaacact | taataaattt  | ttggaagatc  | tctgaaaaaa  | aaaaaaaaaa  | aaagggcggc  | 1860 |
| cgc        |             |             |             |             |             | 1863 |

<210> 29  
 <211> 1626  
 <212> DNA  
 <213> Homo sapiens

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| <400> 29   |            |            |            |            |            |     |
| cccacgcgtc | cgagccggg  | agccgggtcg | gggggctccg | ggctgtggga | ccgctggggc | 60  |
| cccagcgatg | gcgaccctgt | ggggaggcct | tcttcggctt | ggctccttgc | tcagcctgtc | 120 |
| gtgcctggcg | ctttccgtgc | tgctgctggc | gcactgtcag | acgccgccaa | gtgattgcct | 180 |

15

|            |             |            |             |            |            |      |
|------------|-------------|------------|-------------|------------|------------|------|
| tcattgtgtg | gagcccatgc  | ctgtgcgggg | gcctgatgta  | gaagcatact | gtctacgctg | 240  |
| tgaatgcaaa | tatgaagaaa  | gaagctctgt | cacaatcaag  | gttaccatta | taatttatct | 300  |
| ctccattttg | ggccttctac  | ttctgtacat | ggtatatctt  | actctgggtg | agcccatact | 360  |
| gaagaggcgc | ctctttggac  | atgcacagtt | gatacagagt  | gatgatgata | ttggggatca | 420  |
| ccagcctttt | gcaaatgcac  | acgatgtgct | agcccgcctc  | cgagtcgag  | ccaacgtgct | 480  |
| gaacaaggta | gaatatgcac  | agcagcgtg  | gaagcttcaa  | gtccaagagc | agcgaagtc  | 540  |
| tgtctttgac | cggcatgttg  | tcctcagcta | attgggaatt  | gaattcaagg | tgactagaaa | 600  |
| gaaacaggca | gacaactgga  | aagaactgac | tgggttttgc  | tgggtttcat | tttaatacct | 660  |
| tgttgatttc | accaaactgtt | gctggaaatt | caaaactgga  | agcaaaaact | tgcttgattt | 720  |
| ttttttcttg | ttaacgtaat  | aatagagaca | tttttaaaag  | cacacagctc | aaatcagcca | 780  |
| ataatctttt | cctattgtga  | cttttactaa | taaaaataaa  | tctgcctgta | aattatcttg | 840  |
| aagtccttta | cctggaacaa  | gcactctctt | tttcaccaca  | tagttttaac | ttgactttca | 900  |
| agataatttt | cagggttttt  | gttgtgtgtg | ttttttgttt  | gtttgttttg | gtgggagagg | 960  |
| ggagggatgc | ctgggaagtg  | gttaacaact | tttttcaagt  | cactttacta | aacaaacttt | 1020 |
| tgtaaataga | ccttaccttc  | tattttcgag | tttcatttat  | attttgcagt | gtagccagcc | 1080 |
| tcatacaaga | gctgacttac  | tcatttgact | tttgcaactg  | ctgtattatc | tgggtatctg | 1140 |
| ctgtgtctgc | acttcatggt  | aaacgggata | taaaaatgcct | ggtggctttt | cacaaaaagc | 1200 |
| agattttctt | catgtactgt  | gatgtctgat | gcaatgcata  | ctagaacaaa | ctggccattt | 1260 |
| gctagtctac | tctaaagact  | aaacatagtc | ttggtgtgtg  | tggtcttact | catcttctag | 1320 |
| tacctttaag | gacaaatcct  | aaggacttgg | acacttgcaa  | taaagaaatt | ttattttaaa | 1380 |
| cccaagcctc | cctggattga  | taatataac  | acatttgta   | gcatttccgg | tcgtggtgag | 1440 |
| aggcagctgt | ttgagctcca  | atgtgtgcag | ctttgaacta  | gggctggggt | tgtgggtgcc | 1500 |
| tcttctgaaa | ggtctaacca  | ttattggata | actggctttt  | ttcttctctt | ttggaaatga | 1560 |
| acaataaaaa | taatttttga  | aacatcaaaa | aaaaaaaaaa  | aaaaaaaaaa | aaaaaaaaaa | 1620 |
| aaaaaa     |             |            |             |            |            | 1626 |

<210> 30  
 <211> 605  
 <212> DNA  
 <213> Homo sapiens

|            |   |
|------------|---|
| <400> 30   |   |
| ccacgcgtcc | gcccacgcgt cccggaaaatg accttggaga ttgtagcaga gagtgagcat 60  |
| gaggagcggc | ctgctggcca gggccgggat gagcccaaca tgaaccctaa gcttgaggac 120  |
| ccaaggcgcc | cgcacacctc ctctctgtgg ttacctccc catacaagac catgaagttc 180   |
| atcctgtggc | ggcgtttccg gtgggccatc atcctcttca tcatcctctt catcctgtcg 240  |
| ctgttcctgg | ccatcttcat ctacgccttc ccgaactatg ctgccatgaa gctgggtgaag 300 |
| cccttcagct | gaggactctc ctgccctgta gaaggggccc tgggggtccc tccagcatgg 360  |
| gactggcctg | cctcctccgc ccagctcggc gagctcctcc agacctccta ggctgattg 420   |
| tcctgccagg | gtgggcagac agacagatgg accggccccc actcccagag ttgctaacat 480  |
| ggagctctga | gatacccca ctccatcat ttcttctcc cccaacccaa cgcttttttg 540     |
| gatcagctca | gacatatctc agtataaaac agttggaacc acaaaaaaaaa aaaaaaaaaa 600 |
| aaaaa      | 605   |

<210> 31  
 <211> 931  
 <212> DNA  
 <213> Homo sapiens

|             |   |
|-------------|---|
| <400> 31    |   |
| gagagtgcct  | aagcgggggt gaaagaggac gtgttaccca ctgccatgca ccaggactgg 60   |
| ctgtgttaacc | ttgggtggcc cctgctgtct ctctgggctg cagagtctgc cccacatgtg 120  |
| gccatggcct  | ctgcaactgc tcagctctgg tccaggccct gtggcaggac acacatgggtg 180 |
| agcctagccc  | tgggacatca ggagactggg ctctggctct gttcggcctt tgggtgtgtg 240  |
| gtggattctc  | cctgggcctc agtgtgcca tctgtaaagg ggcagctgac agttgtggc 300    |
| atcttgccaa  | gggtccctgt gtgtgtgtat gtgtgtgcat gtgtgcgtgt ctccatgtgc 360  |

16

|            |            |             |             |            |            |     |
|------------|------------|-------------|-------------|------------|------------|-----|
| gtccatattt | aacatgtaaa | aatgtccsc   | crckcgctccg | cccaaacatg | ttgtacattt | 420 |
| caccatggcc | ccctcatcat | agcaataaca  | ttcccactgc  | caggggttct | tgagccagcc | 480 |
| aggccctgcc | agtggggaag | gaggccaagc  | agtgcctgcc  | tatgaaattt | caacttttcc | 540 |
| tttcatacgt | ctttattacc | caagtcttct  | cccgtccatt  | ccagtcaa   | ctgggctcac | 600 |
| tcaccccagc | gagctctcaa | atccctctcc  | aactgcctaa  | ggccctttgt | gtaagggtgc | 660 |
| tttaactgt  | cctttttttt | tttttaacag  | tgtttttag   | atttcagatg | actatgcaga | 720 |
| ggcctggggg | accctgggt  | ctgggcccgg  | cctggggctc  | cgaaattcca | aggcccagac | 780 |
| ttgccccggg | tgggggggta | tccagaattg  | gttgtaaata  | ctttgcatat | tgtctgatta | 840 |
| aacacaaaca | gacctcaaaa | aaaaaaaaaa  | aaaaaaaaaa  | aaaaaaaaaa | aaaaaaaaaa | 900 |
| aaaaaaaaaa | aaaaaaaaaa | aaaggggcggc | c           |            |            | 931 |

<210> 32  
 <211> 1407  
 <212> DNA  
 <213> Homo sapiens

|             |             |            |            |            |             |      |
|-------------|-------------|------------|------------|------------|-------------|------|
| <400> 32    |             |            |            |            |             |      |
| gaattcggca  | cgagggcagg  | ctcagaagac | gatgcggggc | tgtgtgccgg | ccttcttctg  | 60   |
| gcatgtactc  | agcctcagga  | gagcttgctg | caccagggcc | gccagggtct | tcacagcaca  | 120  |
| actgcctgga  | aggcaggttg  | cgagaaggag | aggcggtatg | catgagcagc | aagggggacc  | 180  |
| gatgctgtgc  | agctcacacc  | actccagaac | ctgacaaggc | accagcagga | ccccttgcca  | 240  |
| ggagcatgtc  | tgtgcagcag  | tgtttttgcc | cctgcacatt | ccagaagccc | tcattgggaag | 300  |
| ggatgcagcc  | aggcagactc  | ctgccagatg | gggcaggtag | tttattcaaa | gagaactctg  | 360  |
| tatcccatag  | gccagggtgc  | tcctttctgt | tggcggtggc | tttctgtggc | cagtgtgtgc  | 420  |
| tcctggctca  | gcagaaacat  | ccatttgagt | tggcatccct | gtagggatcc | cagagcgttg  | 480  |
| taagccttct  | tgtgattggg  | agggatggct | gtgggggtgc | ttccaggagg | gggccaccat  | 540  |
| tgcgcacatc  | acttctagac  | tccaaaagga | gccagggtc  | aggcaggcct | ggccagagt   | 600  |
| cacgctggca  | accacgagtt  | tgggaagcag | tcgtattctc | tctctctctc | tctctctctc  | 660  |
| agtatccatg  | acagggtatga | aacatattgt | ctctttataa | atgtcatttt | acaaattatg  | 720  |
| tgattatctg  | gaagctctaa  | gatgagagca | aatgcctgat | cactctggcc | aaatgtcaga  | 780  |
| tactaaagcc  | cattcttggc  | cgggcatgtt | ggctcccgcc | kgtaatccca | gcactttggg  | 840  |
| aagcccaagt  | gggtgaatca  | cctgaggtca | ggagtccaag | accagcctga | ccaacatggg  | 900  |
| gataccccgt  | ctctactaaa  | aatacaagcc | ggcggtgggt | ggcagtcct  | gtaatcccag  | 960  |
| ctactcagga  | ggctgaggca  | ggaataacac | ttgaactcgg | gaggcagagg | ttgcagtggg  | 1020 |
| ctgagatcgc  | gccattgcac  | tcaggcctgg | gtgacagagc | aagactctgt | ctcataaata  | 1080 |
| aatacaaaagc | ccattcttcc  | agagtcttgt | gccttaaata | aaacacacct | ctctgtctgt  | 1140 |
| ggaagactgt  | gcaatggcac  | agccgcagag | cttggtttgg | gaggttgaag | tgctctgggg  | 1200 |
| agaattcgta  | gatcatcctc  | agaaaagcct | tgccctgggt | ttctaccaga | aaaacgtctc  | 1260 |
| ccaatcacc   | aggaaagctg  | tccacagtag | tccccctta  | tccacgggtg | cactttccat  | 1320 |
| gggttcagtt  | atctgcggtc  | aaccacggtc | tgacaatatt | aaatggaaaa | ttcttcaaac  | 1380 |
| agttaaaaaa  | aaaaaaaaaa  | aactcga    |            |            |             | 1407 |

<210> 33  
 <211> 1526  
 <212> DNA  
 <213> Homo sapiens

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| <400> 33   |            |            |            |            |            |     |
| ggcacgagaa | aaaaccttca | ggcgggccat | gggtatgccc | aagaggacag | agaacgaatg | 60  |
| cacagaaata | ttgtcagcct | tgacagaaat | ctcctgaact | ttatgattgg | ctctatcttg | 120 |
| gatttatggc | aatgcttcc  | ctggttttac | attggttctt | cattgaatgg | tactcgggga | 180 |
| aaaagagttc | cagcgactt  | ttccaacaca | tcactgcatt | atttgaatgc | agcatggcag | 240 |
| ctattatcac | cttactttgt | agtgatccag | ttggtgttct | ttatattcgt | tcattgtcag | 300 |
| tattgatgct | ttctgactgg | tacacgatgc | tttacaaccc | aagtccagat | tacgttacca | 360 |
| cagtacactg | tactcatgaa | gccgtctacc | cactatatac | cattgtattt | atctattacg | 420 |
| cattctgctt | ggtattaatg | atgctgctcc | gacctcttct | ggtgaagaag | attgcatgtg | 480 |

17

|             |            |            |            |            |            |      |
|-------------|------------|------------|------------|------------|------------|------|
| ggtagggaa   | atctgatcga | tttaaaagta | tttatgctgc | actttacttc | ttcccaattt | 540  |
| taaccgtgct  | tcaggcagtt | ggtggaggcc | ttttatatta | cgccttccca | tacattatat | 600  |
| tagtggtatc  | tttggttact | ctggctgtgt | acatgtctgc | ttctgaaata | gagaactgct | 660  |
| atgatcttct  | ggtcagaaag | aaaagactta | ttgttctctt | cagccactgg | ttacttcatg | 720  |
| cctatggaat  | aatctccatt | tccagagtgg | ataaacttga | gcaagatttg | cccccttggg | 780  |
| ctttggtacc  | tacaccagcc | cttttttact | tggttactgc | aaaatttacc | gaaccttcaa | 840  |
| ggatactctc  | agaaggagcc | aatggacact | gagtgtagac | atgtgaaatg | ccaaaaacct | 900  |
| gagaagtgc   | cctaataaaa | aagtaaatca | atcttaacag | tgtagagaa  | ctattctatc | 960  |
| atatatggga  | acaagattgt | cagtatatct | taatgtttgg | gtttgtcttt | gttttgttta | 1020 |
| tggttagact  | tacagacttg | gaaaatgcaa | aactctgtaa | tactctgtta | cacagggtaa | 1080 |
| tattatctgc  | tacactggaa | ggcgcgtagg | aagcccttgc | ttctctcaac | agttcagctg | 1140 |
| ttcttttaggg | caaaatcatg | tttctgtgta | cctagcaatg | tggtcccat  | ttattaagaa | 1200 |
| aagctttaac  | acgtgtaatc | tgcatgcctt | aacagtggcg | taattgtacg | tacctgttgt | 1260 |
| gtttcagttt  | gtttttcacc | tataatgaat | tgtaaaaaca | aacatacttg | tggggtctga | 1320 |
| tagcaaacat  | agaaatgatg | tatatgtttt | ttgttatctt | atttattttc | atcaatacag | 1380 |
| tattttgatg  | tattgcaaaa | atagataata | atttatataa | cagggtttct | gtttatagat | 1440 |
| tggttcaaga  | tttgtttgga | ttattgttcc | tgtaaaagaa | acaataataa | aaagcttacc | 1500 |
| tacataaaaa  | aaaaaaaaaa | aaaaaa     |            |            |            | 1526 |

&lt;210&gt; 34

&lt;211&gt; 1737

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1674)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1731)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 34

|            |             |            |            |            |            |      |
|------------|-------------|------------|------------|------------|------------|------|
| gtcgaccac  | gcgtccgccc  | acgcgtccgc | ccacgcgtcc | ggtttataaa | cagaagttta | 60   |
| aacttgtaag | cttaagcttc  | cgttttataa | cagaagttta | aaattatagg | tcctgtttta | 120  |
| cattcagctc | tgtaactca   | ctcatctttt | tgtgttttta | cactttgtca | agatttcttt | 180  |
| acatattcat | caatgtctga  | agaagtact  | tatgcagatc | ttcaattcca | gaactccagt | 240  |
| gagatggaaa | aaatcccaga  | aattggcaaa | tttggggaaa | aagcacctcc | agctccctct | 300  |
| catgtatggc | gtccagcagc  | cttgtttctg | actcttctgt | gccttctgtt | gctcattgga | 360  |
| ttgggagtct | tggaagcat   | gtttcatgta | actttgaaga | tagaaatgaa | aaaaatgaac | 420  |
| aaactacaaa | acatcagtga  | agagctccag | agaaatattt | ctctacaact | gatgagtaac | 480  |
| atgaatatct | ccaacaagat  | caggaaacct | tccaccacac | tgcaaacat  | agccaccaaa | 540  |
| ttatgtcgtg | agctatatag  | caaagaacaa | gagcacaat  | gtaagccttg | tccaaggaga | 600  |
| tggaatttgg | ataaggacag  | ctgttatttc | ctaagtgatg | atgtccaaac | atggcaggag | 660  |
| agtaaaatgg | cctgtgctgc  | tcagaatgcc | agcctgttga | agataaacia | caaaaatgca | 720  |
| ttggaattta | taaaatccca  | gagtagatca | tatgactatt | ggctgggatt | atctcctgaa | 780  |
| gaagattcca | ctcgtgggtat | gagagtggat | aatataatca | actcctctgc | ctgggttata | 840  |
| agaaacgcac | ctgacttaaa  | taacatgtat | tgtggatata | taaatagact | atatgttcaa | 900  |
| tattatcact | gcacttataa  | acaaagaatg | atatgtgaga | agatggccaa | tccagtgcag | 960  |
| cttggttcta | catatttttag | ggaggcatga | ggcatcaatc | aaatacattg | aaggagtgtg | 1020 |
| kgggggtggg | gttctaggct  | ataggtaaat | ttaaataatt | tctgggtgac | aattagttga | 1080 |
| gtttgtctga | agacctggga  | ttttatcatg | cagatgaaac | atccaggtag | caagcttcag | 1140 |
| agagaataga | ctgtgaatgt  | taatgccaga | gaggtataat | gaagcatgtc | ccacctccca | 1200 |
| ctttccatca | tggcctgaac  | cctggaggaa | gaggaagtcc | attcagatag | tgtggggggc | 1260 |
| cttcgaattt | tcattttcat  | ttacgttctt | ccccctctgg | ccaagatttg | ccagaggcaa | 1320 |



18

|            |             |             |             |            |            |      |
|------------|-------------|-------------|-------------|------------|------------|------|
| catcaaaaac | cagcaaaattt | taattttgtc  | ccacagcggt  | gctaggggtg | catggctccc | 1380 |
| catctcgggt | ccatcctata  | cttccatggg  | actccctatg  | gctgaaggcc | ttatgagtc  | 1440 |
| aaggacttat | agccaattga  | ttgttctagg  | ccaggttaaga | atggatatgg | acatgcattt | 1500 |
| attacctctt | aaaattatta  | ttttaagtaa  | aagccaataa  | acaaaaacga | aaaggcaagt | 1560 |
| tacgagactg | acttattttt  | aacttctgtg  | tggtgagcta  | ctgtaagctt | ggcttttgtt | 1620 |
| aaagacatac | agcaatttagc | tatgcaaaaca | taagcattgt  | tctgaaaaaa | aatntataga | 1680 |
| tagatatgtt | tatctcccat  | aactcataac  | tggggagtat  | tataccccgg | nggcttt    | 1737 |

&lt;210&gt; 35

&lt;211&gt; 2242

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

|            |            |            |            |            |             |      |
|------------|------------|------------|------------|------------|-------------|------|
| tgcacccacg | cgtccggggt | gccatggcgg | cggcggggcg | gctcccgagc | tcctggggccc | 60   |
| tcttctcgcc | gctcctcgca | gggcttgac  | tactgggagt | cgggcccgtc | ccagcgcggg  | 120  |
| cgctgcacaa | cgtcacggcc | gagctctttg | gggcccaggc | ctggggcacc | cttgcggctt  | 180  |
| tcggggacct | caactccgac | aagcagacgg | atctcttcgt | gctgcgggaa | agaaatgact  | 240  |
| taatcgtctt | tttggcagac | cagaatgcac | cctattttta | acccaaagta | aaggatatct  | 300  |
| tcaagaatca | cagtgcattg | ataacaagt  | tagtccctgg | ggattatgat | ggagattctc  | 360  |
| aaatggatgt | ccttctgaca | tatcttccca | aaaattatgc | caagagtga  | ttaggagctg  | 420  |
| ttatcttctg | gggacaaaat | caaacattag | atcctaacaa | tatgaccata | ctcaatagga  | 480  |
| cttttcaaga | tgagccacta | attatggatt | tcaatgggtg | tctaattcct | gatatttttg  | 540  |
| gtatcacaaa | tgaatccaac | cagccacaga | tactattagg | agggaaattt | tcatggcatc  | 600  |
| cagcattgac | cactacaagt | aaaatgcgaa | ttccacattc | tcatgcattt | attgatctga  | 660  |
| ctgaagattt | tacagcagat | ttattcctga | cgacattgaa | tgccaccact | agtaccttcc  | 720  |
| agtttgaaat | atgggaaaat | ttggatggaa | acttytstgw | magtacymta | ttggaaaaac  | 780  |
| ctcaaaatat | gatgggtggt | ggacagtcag | catttgcaga | ctttgatgga | gatggacaca  | 840  |
| tggatcattt | actgccaggc | tgtgaagata | aaaattgcc  | aaagagtacc | atctacttag  | 900  |
| tgagatctgg | gatgaagcag | tgggttccag | tcctacaaga | tttcagcaat | aagggcacac  | 960  |
| tctggggctt | tgtgcccatt | gtggatgaac | agcaaccaac | tgaaatacca | attccaatta  | 1020 |
| cccttcatat | tggagactac | aatatggatg | gctatccaga | cgctctgggt | ataactaaaga | 1080 |
| acacatcttg | aagcaaccag | caggcccttt | tactggagaa | cgctccctgt | aataatgcaa  | 1140 |
| gctgtgaaga | ggcgcgtcga | atgtttaaag | tctactggga | gctgacagac | ctaaatcaaa  | 1200 |
| ttaaggatgc | catggttgcc | accttctttg | acatttacga | agatggaatc | ttggacattg  | 1260 |
| tagtgctaag | taaaggatat | acaaagaatg | attttgccat | tcatacacta | aaaaataact  | 1320 |
| ttgaagcaga | tgcttatttt | gttaaagtta | ttgttcttag | tggtctgtgt | tctaagtact  | 1380 |
| gtcctcgtaa | gataacaccc | tttggagtga | atcaacctgg | accttatatc | atgtatacaa  | 1440 |
| ctgtagatgc | aaatgggtat | ctgaaaaatg | gatcagctgg | ccaactcagc | caatccgcac  | 1500 |
| atttagctct | ccaactacca | tacaacgtgc | ttggttttag | tcggagcgca | aattttcttg  | 1560 |
| accatctcta | cgttgggtat | ccccgtccat | ctggagaaaa | atctatacga | aaacaagagt  | 1620 |
| ggactgcaat | cattccaaat | tcccagctaa | ttgtcattcc | ataccctcac | aatgtccctc  | 1680 |
| gaagtggag  | tgccaaactg | tatcttacac | caagtaatat | tgttctgctt | actgctatag  | 1740 |
| ctctcatcgg | tgtctgtgtt | ttcatcttgg | caataattgg | cattttacat | tggcaggaaa  | 1800 |
| agaaagcaga | tgatagagaa | aaacgacaag | aagcccaccg | gtttcatttt | gatgctatgt  | 1860 |
| gacttgccct | taatattaca | taatggaatg | gctgttcact | tgattagttg | aaacacaaat  | 1920 |
| tctggcttga | aaaaataggg | gagattaaat | attatttata | aatgatgtat | cccatggtaa  | 1980 |
| ttattggaaa | gtattcaaat | aaatatgggt | tgaatatgtc | acaaggctct | tttttttaaa  | 2040 |
| gcactttgta | tataaaaatt | tgggttctct | attctgtagt | gctgtacatt | tttgttcctt  | 2100 |
| tgtggaatgt | gttgcatgta | ctccagtggt | tgtgtattta | taatcttatt | tgcacatga   | 2160 |
| tgatggaaaa | agtttgtgta | ataaaaataa | ttaaatgagc | aggaaaaaaa | aaaaaaaaaa  | 2220 |
| aaaaaaaaaa | aagggcggcc | gc         |            |            |             | 2242 |

&lt;210&gt; 36

&lt;211&gt; 2235

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

|             |             |             |            |             |             |      |
|-------------|-------------|-------------|------------|-------------|-------------|------|
| gtaattcggc  | acgaggggttc | caccaacatg  | gagctctcgc | agatgtcgcsa | gctcatgggg  | 60   |
| ctgtcgggtg  | tgcttgggct  | gctggccctg  | atggcgacgg | cggcggtasc  | gcgggggtgg  | 120  |
| ctgcgcgcyg  | gggaggagag  | gagcggccgg  | cccgcctgcc | aaaaagcaaa  | tggatttcca  | 180  |
| cctgacaaat  | cttcgggatc  | caagaagcag  | aaacaatatc | agcggattcg  | gaaggagaag  | 240  |
| cctcaacaac  | acaacttcac  | ccaccgcctc  | ctggctgcag | ctctgaagag  | ccacagcggg  | 300  |
| aacatatctt  | gcatggactt  | tagcagcaat  | ggcaaatacc | tggtacctg   | tgcagatgat  | 360  |
| cgcaccatcc  | gcatctggag  | caccaaggac  | ttcctgcagc | gagagcaccg  | cagcatgaga  | 420  |
| gccaacgtgg  | agctggacca  | cgccaccctg  | gtgcgcttca | gccctgactg  | cagagccttc  | 480  |
| atcgtctggc  | tggccaacgg  | ggacaccctc  | cgtgtcttca | agatgaccaa  | gcgggaggat  | 540  |
| gggggctaca  | ccttcacagc  | caccccagag  | gacttcccta | aaaagcacia  | ggcgccctgtc | 600  |
| atcgacattg  | gcattgctaa  | cacaggggaag | tttatcatga | ctgcctccag  | tgacaccact  | 660  |
| gtcctcatct  | ggagcctgaa  | gggtcaagtg  | ctgtctacca | tcaacaccaa  | ccagatgaac  | 720  |
| aacacacacg  | ctgctgtatc  | tccttgtggc  | agattttag  | cctcgtgtgg  | cttcacccca  | 780  |
| gatgtgaagg  | tttgggaagt  | ctgcttttga  | aagaaggggg | agttccagga  | ggtggtgcga  | 840  |
| gccttcgaac  | taaagggccca | ctccgcggct  | gtgcactcgt | ttgctttctc  | caacgactca  | 900  |
| cggaggatgg  | cttctgtctc  | caaggatggt  | acatggaaac | tgtgggacac  | aratgtggaa  | 960  |
| tacaagaaga  | agcaggaccc  | ctacttgctg  | aagacaggcc | gctttgaaga  | ggcgccgggt  | 1020 |
| gccgmgccgt  | gccgcctggc  | cctctccccc  | aacgcccagg | tcttggcctt  | ggccagtggc  | 1080 |
| agtagtatcc  | atctctacaa  | taccgcggcg  | ggcgagaagg | aggagtgtct  | tgagcgggtc  | 1140 |
| catggcgagt  | gtatcgccaa  | cttgtccttt  | gacatcactg | gccgctttct  | ggcctcctgt  | 1200 |
| ggggacccgg  | cgggtgcggct | gtttcacaa   | actcctggcc | accgagccat  | ggtggaggag  | 1260 |
| atgcaggggc  | acctgaagcg  | ggcctccaac  | gagagcacc  | gccagaggct  | gcagcagcag  | 1320 |
| ctgaccacgg  | cccaagagac  | cctgaagagc  | ctgggtgccc | tgaagaagtg  | actctgggag  | 1380 |
| ggcccgccgc  | agaggattga  | ggaggaggga  | tctggccctc | tcatggcact  | gctgccatct  | 1440 |
| ttcctccag   | gtggaagcct  | ttcagaagga  | gtctcctggt | tttyttactg  | gtggccctgc  | 1500 |
| ttcttccat   | tgaaactact  | cttgtctact  | taggtctctc | tcttcttgct  | ggctgtgact  | 1560 |
| cctccctgac  | tagtgggcaa  | ggtgcttttc  | ttcctccag  | gcccagtggg  | tggaaatctgt | 1620 |
| ccccacctgg  | cactgaggag  | aatggtagag  | aggagaggag | agagagagag  | aatgtgattt  | 1680 |
| ttggccttgt  | ggcagcacat  | cctcacacc   | aaagaagttt | gtaaatgttc  | cagaacaacc  | 1740 |
| tagagaacac  | ctgagtacta  | agcagcagtt  | ttgcaaggat | gggagactgg  | gatagcttcc  | 1800 |
| catcacagaa  | ctgtgttcca  | tcaaaaagac  | actaagggat | ttccttctgg  | gcctcagttc  | 1860 |
| tattttgtaag | atggagaata  | atcctctctg  | tgaactcctt | gcaaagatga  | tatgaggcta  | 1920 |
| agagaatatc  | aagtccccag  | gtctggaaga  | aaagtagaaa | agagtagtac  | tattgtccaa  | 1980 |
| tgtcatgaaa  | gtggtaaaag  | tgggaaccag  | tgtgctttga | aaccaaatta  | gaaacacatt  | 2040 |
| ccttggggaag | gcaaagtttt  | ctgggacttg  | atcatacatt | ttatatgggt  | gggacttctc  | 2100 |
| tcttcgggag  | atgatatctt  | gtttaaggag  | acctcttttc | agttcatcaa  | gttcatcaga  | 2160 |
| tatttgagtg  | cccactctgt  | gccccaaata  | atatgagctg | gggattaaaa  | aaaaaaaaaa  | 2220 |
| aaaaaaaaaa  | ctcga       |             |            |             |             | 2235 |

&lt;210&gt; 37

&lt;211&gt; 2971

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| gacgtgagga | gcgttccatt | tggccagtgg | tggcgcggtg | ccacagctgg | tttagggccc | 60  |
| cgaccactgg | ggccctctgt | caggaggaga | cagcctcccg | gcccggggag | gacaagtgcg | 120 |
| tgccaccttt | ggctgcgcag | gtgattccct | gggacgggtc | gtttcctgcc | ctcagctgcc | 180 |
| ggccgagttg | ggtctccgtg | gttcaggccg | gtcccccctt | cctggtctcc | gtctcccgcc | 240 |
| tgggcccgtt | tatcgggagg | agattgtctt | ccagggctag | caattggact | tttgatgatg | 300 |
| tttgaccag  | cggcaggaat | agcaggcaac | gtgatttcaa | agctgggctc | agcctctggt | 360 |
| tcttctctcg | tgtaatcgca | aaacccattt | tggagcagga | attccaatca | tgtctgtgat | 420 |
| ggtggtgaga | aagaaggtga | cacggaaatg | ggagaaactc | ccaggcagga | acaccttttg | 480 |
| ctgtgatggc | cgcgtcatga | tggcccggca | aaagggcatt | ttctacctga | cccttttctt | 540 |

|             |            |            |             |             |            |      |
|-------------|------------|------------|-------------|-------------|------------|------|
| catcctgggg  | acatgtacac | tcttcttcgc | ctttgagtg   | cgctacctgg  | ctgttcagct | 600  |
| gtctcctgcc  | atccctgtat | ttgtgccat  | gctcttcctt  | ttctccatgg  | ctacactgtt | 660  |
| gaggaccagc  | ttcagtgacc | ctggagtgat | tcctcgggcg  | ctaccagatg  | aagcagcttt | 720  |
| catagaaatg  | gagatagaag | ctaccaatgg | tgcggtgccc  | cagggccagc  | gaccaccgcc | 780  |
| tcgtatcaag  | aatttccaga | taaacaacca | gattgtgaaa  | ctgaaatact  | gttacacatg | 840  |
| caagatcttc  | cggcctcccc | gggcctcccc | ttgcagcatc  | tgtgacaact  | gtgtggagcg | 900  |
| cttcgaccat  | cactgcccct | gggtggggaa | ttgtgttgga  | aagaggaaact | accgctactt | 960  |
| ctacctcttc  | atcctttctc | tctccctcct | cacaatctat  | gtcttcgcct  | tcaacatcgt | 1020 |
| ctatgtggcc  | ctcaaatctt | tgaatttg   | cttcttgagg  | acattgaaag  | aaactcctgg | 1080 |
| aactgttcta  | gaagtccca  | tttgcctctt | tacactctgg  | tccgtcgtgg  | gactgactgg | 1140 |
| atttcatact  | ttcctcgtgg | ctctcaacca | gacaaccaat  | gaagacatca  | aaggatcatg | 1200 |
| gacagggag   | aatcgctcc  | agaatcccta | cagccatggc  | aatattgtga  | agaactgctg | 1260 |
| tgaagtgtg   | tgtggccct  | tgccccccag | tgtgctggat  | cgaaggggta  | ttttgccact | 1320 |
| ggaggaaagt  | ggaagtcgac | ctcccagtac | tcaagagacc  | agtagcagcc  | tcttgccaca | 1380 |
| gagccagcc   | cccacagAAC | acctgaactc | aaatgagatg  | ccggaggaca  | gcagcactcc | 1440 |
| cgaagagatg  | ccacctccag | agcccccaga | gccaccacag  | gaggcagctg  | aagctgagaa | 1500 |
| gtagcctatc  | tatggaagag | acttttggtt | gtgtttaatt  | agggctatga  | gagatttcag | 1560 |
| gtgagaagtt  | aaacctgaga | cagagagcaa | gtaagctgtc  | ccttttaact  | gtttttcttt | 1620 |
| ggctcttagt  | caccagttg  | cacactggca | ttttcttgct  | gcaagctttt  | ttaaatttct | 1680 |
| gaactcaagg  | cagtggcaga | agatgtcagt | cacctctgat  | aactggaaaa  | atgggtctct | 1740 |
| tgggcccctg  | cactggttct | ccatggcctc | agccacaggg  | tccccttggg  | ccccctctct | 1800 |
| tcctccaga   | tcacagccct | cctgcttggg | gtcactggtc  | tcattctggg  | gctaaaagtt | 1860 |
| tttgagactg  | gctcaaatcc | tcocaagctg | ctgcacgtgc  | tgagtccaga  | ggcagtcaca | 1920 |
| gagacctctg  | gccaggggat | cctaactggg | ttcttgggg   | cttcaggact  | gaagaggagg | 1980 |
| gagagtgggg  | tcagaagatt | ctcctggcca | ccaagtgcc   | gcattggcca  | caaatccttt | 2040 |
| taggaatggg  | acaggtacct | tcacttgtt  | gtatttatta  | gtgtagcttc  | tcctttgtct | 2100 |
| cccatccact  | ctgacacct  | agccccactc | ttttccatt   | agatatatgt  | aagtagttgt | 2160 |
| agtagagata  | ataattgaca | tttctcgtag | actaccacaga | aactttttta  | atacctgtgc | 2220 |
| cattctcaat  | aagaatttat | gagatgccag | cggcatagcc  | cttcacactc  | tctgtctcat | 2280 |
| ctctcctcct  | ttctcattag | ccccctttta | ttgttttttc  | cttttgactc  | ctgctcccat | 2340 |
| taggagcagg  | aatggcagta | ataaaagtct | gcactttggt  | catttctttt  | cctcagagga | 2400 |
| agcctgagtg  | ctcacttaaa | cactatcccc | tcagactccc  | tgtgtgaggg  | ctgcagaggg | 2460 |
| cctgaaatgca | caaattggaa | accaaggcac | agagaggctc  | tcctctctct  | tcctctcccc | 2520 |
| cgtgttacc   | tcaaaaaaaa | aaaaaatgct | aaccagttct  | tccattaaag  | ctcggctcag | 2580 |
| tgagggaaag  | cccagcactg | ctgcctctct | gggtaactca  | ccctaaggcc  | tcggccacc  | 2640 |
| tctggctatg  | gtaaccacac | tgggggcttc | ctccaagccc  | cgctcttcca  | gcacttccac | 2700 |
| cggcagagtc  | ccagagccac | ttcacctggg | gggtgggctg  | tggccccag   | tcagctctgc | 2760 |
| tcaggaacctg | ctctatttca | gggaagaaga | tttatgtatt  | atatgtggct  | atatcttcta | 2820 |
| gagcactctg  | gttttctct  | ttctaagcca | gggtcctgtc  | tggatgactt  | atgcggtggg | 2880 |
| ggagtgtaaa  | ccggaacttt | tcactatatt | gaaggcgatt  | aaactgtgtc  | taatgcaaaa | 2940 |
| aaaaaaaaa   | aaaaaaaaa  | aaaaaaaaa  | a           |             |            | 2971 |

&lt;210&gt; 38

&lt;211&gt; 1163

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

|             |            |            |             |            |            |     |
|-------------|------------|------------|-------------|------------|------------|-----|
| ccacgcgtcc  | gccaagggtg | ctgattaggg | aatgggttatg | gactaggagt | atcagtaaca | 60  |
| atggtttagaa | agtggctaac | atgtgttgag | cacctgctgt  | gtgcctggcc | ccggctggga | 120 |
| gccttcgtgc  | ccagagtgc  | cccgtctgaa | tgcagttctt  | tgccctattc | aaactgggga | 180 |
| gtgggaggca  | gagctgcaca | actcacaggt | gccgagctca  | agactcactc | ctgggtctgc | 240 |
| ctgggctggg  | ctgtgcttgt | tgcctctgtg | gccaacacac  | gcgcaccttt | cacctgaaag | 300 |
| ccaggatccg  | cagaacgttc | cccaggagg  | tcattgtttg  | gcactatgat | ttgtctcttc | 360 |
| ctaaaaaggt  | gatagagtta | cactggagag | agcagcatcc  | aggtgcagca | gggatgggac | 420 |
| tggggtcac   | gggcaggggc | tctgtgtccg | gctggggcct  | gggtcctgc  | gctgcactg  | 480 |
| tgtgtcagaa  | gcactcagta | aatctttgct | gatgaaggat  | gacaggatat | aggacatgat | 540 |

21

|             |            |             |            |            |            |      |
|-------------|------------|-------------|------------|------------|------------|------|
| gcttgctgct  | gcattgcctg | caatcctgga  | tgaatgccca | ggttggtttt | gctccccgtc | 600  |
| gggtggatgt  | gacgttagct | gtgatgttag  | gtccctggct | ttaaaaatac | acggaactgg | 660  |
| gaattgaggg  | agcagttggg | gcagaaaagga | cagccccgca | gaggcctgga | gctgagcagt | 720  |
| gcgggcgacc  | caggagcagt | gagtgcctcc  | gtcacagcct | tcacgcgacc | ctgtggtcct | 780  |
| cataaagggg  | atggaatcta | cgaatttagt  | tttccagcc  | tccttaaaaa | ctcattcatg | 840  |
| ccagggggcag | tggctcacac | ctgaaatccc  | accactttgg | gaggctgagg | caggctgatt | 900  |
| acttgaggtc  | aggagtttga | gaccagccta  | gccaacatgg | tgaacccccg | tgtctactca | 960  |
| aagtacaaaa  | aaaaaaatta | gtcagacgtg  | gtgtcacgca | cctgtaatcc | cagctctttg | 1020 |
| ggaggctgag  | gcaggagaat | cacttgaacc  | caggaggcag | aggttatagt | gagccagtat | 1080 |
| tgcgccactg  | acctccatct | gggcaataga  | gtgagaccct | gtctcaaaaa | aaaaaaaaaa | 1140 |
| aaaaaaaaaa  | aaaaaaaaaa | aaa         |            |            |            | 1163 |

&lt;210&gt; 39

&lt;211&gt; 1932

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1624)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 39

|            |            |            |             |            |             |      |
|------------|------------|------------|-------------|------------|-------------|------|
| ggcacgagcc | aggccctgg  | gcggggcgct | gaggcgggcc  | cctctgggca | gggccccggc  | 60   |
| ggggctgggt | gggcccggcc | tgctgctgcc | gtccatgctg  | atgtttgcgg | tgatcgtggc  | 120  |
| ctccagcggg | ctgtgctca  | tgatcgagcg | gggcatcctg  | gccgaratga | agccctggcc  | 180  |
| cctgcacccg | cccggccgcg | arggcacagc | ctggcgcggg  | aaagcccca  | agcctggggg  | 240  |
| cctgtccctc | agggctgggg | acgcggactt | gcaagtgcgg  | caggacgtcc | ggaacaggac  | 300  |
| cctgcggggc | gtgtgcggac | agccaggcat | gccccgggac  | ccctgggact | tgccggtggg  | 360  |
| gcagcggcgc | accctgctgc | gccamatcct | cgtaagtgcg  | cgttaccgct | tcctctactg  | 420  |
| ctacgtcccc | aagtggtcct | gctctaactg | gaagcgggtg  | atgaagggtg | tggcaggcgt  | 480  |
| cctggacagc | gtggacgtcc | gcctcaagat | ggaccaccgc  | agtgcacctg | tggtcctggc  | 540  |
| cgacctgcgg | cctgaggaga | ttcgctaccg | cctgcagcac  | tactttaagt | tcctgtttgt  | 600  |
| gcgggagccc | ttggaacgcc | tcctctctgc | ctaccgcaac  | aagtttggcg | agatccgaga  | 660  |
| gtaccagcaa | cgctatgggg | ctgagatagt | gaggcggtac  | agggctggag | cggggcccag  | 720  |
| ccctgcaggc | gacgatgtca | cattccccga | gttcctgaga  | tacctggtgg | atgaggacct  | 780  |
| tgagcgcacg | aatgagcatt | ggatgcccgt | gtaccacctg  | tgccagcctt | gtgcccgtga  | 840  |
| ctatgacttt | gtgggtcctc | atgagaggct | ggaggctgat  | gcaaatcagg | tgctggagtg  | 900  |
| ggtacgggca | ccacctcacg | tcagatttcc | agctcgccag  | gcctggtacc | ggccagccag  | 960  |
| ccccgaaagc | ctgcattacc | acttgtgcag | tgcccccccg  | gcctgctgc  | aggatgtgct  | 1020 |
| gcctaagtat | atcctggayt | tytccctctt | tgccctacca  | ctgcctaata | tcaccaagga  | 1080 |
| ggcgtgtcag | cagtgacct  | gggtgtgggg | ccagcagctg  | gtggggactg | gtttcaacgc  | 1140 |
| cagctttctg | tgcttctgcc | tgctattcgg | agaaactctg  | gctctggggc | ttggggcttc  | 1200 |
| tcaggatcct | ggatggcaga | gactgccctc | agaarttcct  | tgccagggt  | gggacccac   | 1260 |
| agtgactcag | aggacagggc | taggcaggag | acctgctgct  | cctcattggg | gggatctctt  | 1320 |
| ggggggcaga | caccagtttg | ccaatgaagc | aacacatctg  | atctaaagac | tggtccaga   | 1380 |
| ccccgggctg | ccaggattat | gcagtccact | tggtctacct  | taatttaacc | tggtggccaaa | 1440 |
| ctcagagatg | gtaccagcca | ggggcaagca | tgaccagagc  | cagggaccct | gtggctctga  | 1500 |
| tcccccattt | atccacccca | tgtgcctcag | gactagagtg  | agcaatcata | ccttataaat  | 1560 |
| gacttttgtg | cctttctgct | ccagtctcaa | aatttcttac  | acctgccagt | tcctttacatt | 1620 |
| tttnccaagg | aaaggaaaac | ggaagcaggg | ttcttgccctg | gtagctccag | gaccagctc   | 1680 |
| tgagggcacc | caaagaccct | ctgtgccag  | cctcttctct  | gagttctcgg | aacctcctcc  | 1740 |
| ctaattctcc | cttccttccc | cacaaggcmt | ttgaggttgt  | gactgtggct | ggtatatctg  | 1800 |
| gtgcgcattt | ttctgatgca | tttatttaaa | atttgtactt  | ttgatagaa  | cccttgtaag  | 1860 |
| ggctttgttt | tcctaatagc | tgacttttta | ataaagcagt  | tttatataaa | aaaaaaaaaa  | 1920 |
| aaaaaaaaaa | aa         |            |             |            |             | 1932 |

<210> 40  
<211> 881  
<212> DNA  
<213> Homo sapiens

<400> 40  
gaattcggca cgaggggaacc cagaagatgc tgctctctct gatcatctgt ctctgcctg 60  
ccattgaagg gaagaactgc ctccgctgct ggccagaact gtctgccttg atagactatg 120  
acctgcagat cctctgggtg accccagggc caccacaga actttctcaa agtattcact 180  
ccttgcttct agaggataat aattttctca aacctggta ccttgatcgt gaccatttgg 240  
aagaagaaac agccaaattc ttactcaag tacaccaagc cattaanaacg ttacgagatg 300  
ataaaacagt acttctggaa gagatctaca cgcacaagaa tctctttact gagaggctga 360  
ataagatata tgatgggctg aaggagaagg gagccccacc cytctccatg aatgccttcc 420  
cggctccatc tcctacttgc accccagAAC ccttggctc tgtctgcctc ccagcacct 480  
cagtttctct accttctcac ctccctggca gcctgcaatg agtctgtgc caggaaccgg 540  
cggacctccc tgtgggctgt gactctcagc agtctctac tcctggccat agctggagat 600  
gtttctttta ctggcaagg aagaaggagg cagtaaaggc acagggcagc ccgcatgtct 660  
tccagaagtg aacagaggcc gcagctacca ccgtcacaaa gttcactcat ctctgggtcc 720  
cggtgacccc atcccccat accctccatc ctgggtcctg gggcccaaaa gctctgaggc 780  
ctaggagact gcgctgtctc gtggtttgcc tactcctaca cctttgtaa gagtctcttc 840  
attaaaaccc ctcttcataa aaaaaaaaaa aaaaaactcg a 881

<210> 41  
<211> 1932  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (2)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1022)  
<223> n equals a,t,g, or c

<400> 41  
cncggcgcg ctcggctcat gccccgggc gcggggcaca caggccggcc ggcagccgct 60  
gggaaatagg cccccgggg cggtggcggc ggccggggcca tggcgcgag accccgggcg 120  
ccggccgect ccggggagga gttctccttc gtcagccgc tggtgaaata cctgctcttc 180  
ttcttcaaca tgctcttctg ggtgatttcc atggtgatgg tggctgtggg tgtctacgct 240  
cggctaatag agcatgcaga agcagcccta gcctgcctgg cagtggacc tgccatcctg 300  
ctgatcgtgg tgggtgtcct catgttctct ctcaccttct gtggctgcat tgggtccctc 360  
cgcgagaaca tctgcctcct gcagacgttc tccctctgcc tcaccgctgt gttcctgctg 420  
cagctggccg ctgggacatc gggcttcgtc ttctcagaca aggtctgagg gaaagtggat 480  
gagatcatca acaatgccat tgtgcactac cgagatgact tggatctgca gaacctcatt 540  
gattttggcc agaaaaagtt tagctgctgt ggagggattt cctacaagga ctggtctcag 600  
aacatgtatt tcaactgctc agaagacaac ccagctcgag agcgtgctc tgtgccttac 660  
tcctgttgct tgcctactcc tgaccaggca gtgatcaaca ctatgtgtgg ccaaggatg 720  
caggcctttg actacttggg agctagcaaa gtcacttaca ccaatggctg tattgacaag 780  
ttggtcaact ggatacacag caacctatc ttacttgggt gtgtggctct aggcctggcc 840  
atccccagc tgggtgggaat tctgctgtcc cagatcctag tgaatcagat caaagatcag 900  
atcaagctac agctctacaa ccagcagcac cgggctgacc catgggtactg agaatccatc 960  
ctgcacctcc tcaccatgga aactggcaag cctcataaac gaacagcagt ggggtgctgaa 1020  
ancagacca aatggagatt tggattccag cccccagtg acagcccagt gggagaagac 1080

23

|            |             |            |             |            |            |      |
|------------|-------------|------------|-------------|------------|------------|------|
| aaactccaga | tgggcagaag  | gcagggtgca | cagggtggctc | cagtctcagg | aggatgcgcc | 1140 |
| tcctctcccc | catcccagcc  | ctcagcattg | tgccagagtg  | atacccttaa | gtgtttgggt | 1200 |
| ttatgttttc | agttttgttt  | gggaaacagc | agttgcacag  | agagttgggg | gtactgctgc | 1260 |
| tgccttttca | ccgaggcact  | gccaccacca | gctctascag  | ggatgctcct | gagcttggcg | 1320 |
| gacatactta | gacctaacg   | tgccagttag | acctggctgt  | ggagagtagc | actggcagcc | 1380 |
| ctgcctggac | tccacttggc  | atgataccag | ctccagaagg  | gaagggagtg | gagcaggcag | 1440 |
| tgaggagaga | gcctgggggt  | cgctggggga | cagccgtatg  | tgctaggtag | gagtggaggg | 1500 |
| agatatgttt | accaaagtc   | tgtcctgcc  | tcctcccagg  | tagtcagagt | gagctacatc | 1560 |
| ctgccccgcc | ttcattttcca | tggaacatg  | gcagctagga  | cacggggtag | aacagcagcc | 1620 |
| aaattcttcc | ccacctccct  | tacttcgaaa | aaaagtgttg  | aacctgggtc | cctatactct | 1680 |
| gcagtcagaa | gtgggactga  | gccatacatg | cccttgaatt  | cctccctgtc | tgccctccc  | 1740 |
| tctccagcaa | gcagggtttt  | ctttaacttg | gcagtgtgca  | gaggagaagt | ggtaacaccc | 1800 |
| ccacccatt  | cccctgcac   | ggagctcagt | attcctacag  | ggtaagaggt | aggaatcttg | 1860 |
| ctgggacgag | gggagccaga  | agtggcaata | aaagcgtgtt  | gacctggaaa | aaaaaaaaa  | 1920 |
| aagggcggcc | gc          |            |             |            |            | 1932 |

&lt;210&gt; 42

&lt;211&gt; 1164

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (582)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (592)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 42

|            |            |             |             |             |            |      |
|------------|------------|-------------|-------------|-------------|------------|------|
| ggcacgagct | tgtgtgtcac | cagcctcctg  | atctgccagg  | gtctgctctg  | ggttggcact | 60   |
| gaccagggtg | tcacgtcct  | gctgcccgtg  | cctcggttg   | aaggcatccc  | caagatcaca | 120  |
| gggaaaggca | tgtgtcact  | caatgggcac  | tgtgggcctg  | tgccctcct   | ggctgtggct | 180  |
| accagcatcc | tggccctga  | catcctgcgg  | agtgaccagg  | aggaggctga  | ggggcccg   | 240  |
| gctgaggagg | acaagccaga | cgggcaggca  | cacgagccca  | tgcccagacag | ccacgtgggc | 300  |
| cgagagctga | cccgcaagaa | gggcacccctc | ttgcagtacc  | gcctgcgctc  | caccgcacac | 360  |
| ctcccgggcc | cgctgctctc | catgcccggag | ccggcgccctg | ctgatggcgc  | agctttggag | 420  |
| cacagcgagg | aggacggctc | catttacgag  | atggccgacg  | accccgacgt  | ctgggtgcgc | 480  |
| agccggccct | gcgcccgcga | cgcccaccgc  | aaggagattt  | gctctgtggc  | catcatctcg | 540  |
| gcgggcagg  | ctaccgcaac | tttggcagcg  | ctctgggcac  | antgggaagc  | angcccgtg  | 600  |
| tggggagacg | gacagcacc  | tcctcatctg  | gcagtgcct   | tgatgctata  | gcgcctcccc | 660  |
| tctccctca  | gagggcacag | ctgcaggcct  | gaccaaggcc  | acgcccggct  | ctcgtgctct | 720  |
| aggacctgca | cgggacttgt | ggatgggcct  | ggactctcca  | gaaactactt  | gggccagagc | 780  |
| aaaggaaaac | ctcttgtttt | aaaaaaattt  | ttttcagagt  | gttttgggga  | ggagttttag | 840  |
| ggcttgggga | gagggaggac | acatctggag  | gaaatggcct  | tctttttaa   | agcaaaaaac | 900  |
| acaaaacctc | acaactgcct | ggcaagccca  | gtatcacttg  | tttgggcct   | agcgggactc | 960  |
| caaggcagcc | acacgcccct | cctggaagg   | tgtgtgcgtg  | tgagtgtgtg  | cgagtgtgtg | 1020 |
| ggctggtgtg | tgaatatcta | tataaagta   | tatatggtgt  | atattatatg  | tgtataaata | 1080 |
| aagtctgtac | atattggagc | tctgggagat  | gctggaataa  | aagacaagag  | ttacatctcg | 1140 |
| acttgaaaaa | aaaaaaaaa  | aaaa        |             |             |            | 1164 |

&lt;210&gt; 43

&lt;211&gt; 1105

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

|             |            |             |             |             |             |      |
|-------------|------------|-------------|-------------|-------------|-------------|------|
| gaattcggca  | cgagaacaaa | ttgaaaccat  | ctgggtcatga | actttttattt | gttaagaggt  | 60   |
| tttctaatat  | tgattcaatc | tcttttgctta | ttctaaatgt  | gttcagattt  | tccacttctt  | 120  |
| gagtcaattt  | ggtaatttat | ttgtttctag  | gaatttgtcc  | atttcactta  | gtttacctaa  | 180  |
| tttttgacat  | ataaaattat | atatggaaat  | ttctaaaata  | tttaaaaatt  | tctgtaattg  | 240  |
| caatagtaat  | gtccccctct | ttgtttaccaa | ttgtttattt  | gaatcttctc  | cttttttttg  | 300  |
| tcaatctagc  | taaaaatttg | tcaattttgt  | tcgtctcttc  | aaaaaaatat  | acgtttgtct  | 360  |
| tcatgatttc  | tctawtgttt | ttccatcyat  | atttcatttg  | aatacatttt  | taaaacyttay | 420  |
| ctttattatt  | tcattccttc | tgggagcttt  | gggtctcatt  | tttttttcct  | gataatctag  | 480  |
| ttgtttattg  | tataagatta | agtatttatt  | tgaatctgt   | atgttcttta  | atgtaggcat  | 540  |
| tcactactat  | aaatttactt | ctcaggagca  | tctctgccgc  | attccatggt  | ttagtatggt  | 600  |
| gtgttttaat  | ttgtattcat | aactagaggg  | aaacagaggt  | gacggagaaa  | aagacgtaca  | 660  |
| aatatcatcc  | acttgcaaa  | tatagatttg  | ttgtattgk   | ratatgaatr  | aaaattattac | 720  |
| gagacagata  | agaaaatttg | aacactgacc  | attgatgcag  | ttacagttaa  | ttttaaaatc  | 780  |
| aaggtttaata | acattttagt | tatttttaa   | aatgatagta  | atttagagat  | gtattctgaa  | 840  |
| tgtttttaaa  | tgaaaagata | tgcctgggat  | ttcttccaaa  | atgaatcttg  | taggttggga  | 900  |
| agaaaatgag  | aacatagtgg | aaacaagact  | gacaatgagt  | tgttgagggt  | gggcaatgcg  | 960  |
| tacactaaag  | cttattttat | cttattttac  | tgtatatact  | gttaaagctt  | gcattatttt  | 1020 |
| cataaatgca  | tttgctaagt | gcaactgtta  | tcaaataaag  | tggattgggc  | tctaaaaaaa  | 1080 |
| aaaaaaaaaa  | aaactcgagg | ggggg       |             |             |             | 1105 |

&lt;210&gt; 44

&lt;211&gt; 1262

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

|             |            |             |             |             |             |      |
|-------------|------------|-------------|-------------|-------------|-------------|------|
| cagcatgtac  | ccagttgttc | tttctctga   | gaaagcaaaa  | tgctgatata  | ttcttataat  | 60   |
| ccaggtctgc  | acgtttacct | tgtaaaaatca | atacttaatt  | tttagatttt  | tatatttatct | 120  |
| tttctcgtga  | agcaagactt | ctaaattatg  | gctataatat  | cttttgaatt  | gttggtctta  | 180  |
| atgaatcttc  | caactgtaaa | ctcatctaat  | ttcaaaactta | tcataacctga | ggatgtaaca  | 240  |
| ttgtcctttg  | tttctcatct | tgatattacc  | gtcaatcatt  | ttgtatttct  | gagtacattt  | 300  |
| gaacttgctg  | gagtaataga | gggaaaaacct | ctgcctgatt  | ctaaatcaga  | tctttgtcct  | 360  |
| atactcggac  | aattatgggt | tcataatttta | ttatttttta  | ttttctgggt  | ttaacaaatg  | 420  |
| agataaacatt | ttagacataa | tattttgtaa  | catcttgact  | tatttcagca  | ttttcctttt  | 480  |
| ttgtgtatct  | tcagagaggt | tgttgaaagt  | agcaatttcc  | aagtaatttt  | aaattattga  | 540  |
| agtctactag  | cacgaaaggt | caaattctta  | ggatatttta  | aaaatgttgt  | ttaataatca  | 600  |
| aactcatctt  | aaaaaatggt | catcagactc  | tgtctttgat  | gcacattttg  | ccaaaagaga  | 660  |
| gccttatttc  | tgtgaaagaa | atacagtatg  | tactttggga  | tttactaaag  | taaaactggt  | 720  |
| actttaaggc  | acagagcaga | tatagaatoc  | ccctctctcc  | ccactcctag  | tgactgggtat | 780  |
| tctacattaa  | tatttatctt | ccatgcatag  | tgtacttgag  | ggaaaaaac   | aataactctt  | 840  |
| aattgtttta  | tatcaaacaa | taaaatcctg  | tgtatcagtg  | actgtcaata  | gatggctttc  | 900  |
| tgtttaaaaa  | ctgaagctac | tccagaagta  | ggaattaatt  | tatttagtaa  | acaaagtcag  | 960  |
| tcaaaccaga  | gccatgtcct | ggggaactgt  | caaaagaatg  | gttcctaagg  | gccagaggcc  | 1020 |
| acatccactg  | gtagatgaca | gaacaacat   | acttcagatg  | gcaaaaccgg  | tcagtttggt  | 1080 |
| ttgcgttggt  | tgcctatcct | ctttctgtgt  | gcttcagctg  | aattaagtgc  | ttggagagct  | 1140 |
| caaatagttc  | aagatagcca | agatgaccaa  | ttctgccagg  | tggcaagcct  | gatcttgcaa  | 1200 |
| ttttgattaa  | aataaagaac | attccccaag  | aacagtttgt  | tgcaaaaaaa  | aaaaaaaaaa  | 1260 |
| aa          |            |             |             |             |             | 1262 |

&lt;210&gt; 45

&lt;211&gt; 517

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<400> 45  
gaattcggca cgagtgcact tccaccagct atgtatgaga ctcccattg ctccacatct 60  
ccagtatttt atgtggtcag tccttttgtt tttggtcatt ttgggtggata tgaaatggca 120  
tctcagtgtg gcttttcatt atatttcctt gatgactaat ggtattcctt caccctttca 180  
gtgcttattg gccattcatg tatctttgtt ttttgtag cacttcaggt cttttgcccc 240  
tagatttagt ggggtgattg ctctttatta atgatttgta gggatgttat atatatctg 300  
gacacaagat tattgttaga gatacgact tcagatattt tctcccagtc tgtagcttgc 360  
ctaattatta ttattattat tatttgagat gaagtctcac tctgtcgccc aggcagaggt 420  
tgcagtgggc cgagatagca ccactacact caagcctggc tgacagagtg agactctgtc 480  
tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aactcga 517

<210> 46  
<211> 858  
<212> DNA  
<213> Homo sapiens

<400> 46  
agaaaaaatc ctacatggat attggttaga aagagagaaa ggaagtggcc agtgtccgt 60  
ggcctcttcc accttctgga ttgttgaagc tggggcctgg aggggatggc cctgccactc 120  
agcagggggc actaatggga ccaagctaac ctgtccagtg agaatcctgc agggagacct 180  
gagggtagca ggaaagtgcg ggggaaggcc cgggaaatgg agagagctgg tctggagggg 240  
aggagcaagc cgcgtggggc aggccatgtg ccttttgctt gggggagtat tactcatttg 300  
gagctgtgcg tctggaacgc ctgcctcaca caaaaggac tggggcagat gtaagtctc 360  
tgcagcaacg aagcgcacag ctgagagtaa cttagaaagc acccagctaa tgctggcatc 420  
ccagatcgac cccctcctcg ctgaatgttg gcatctctgt gcctcagttt cctcatctgt 480  
aaatgggggt gataagaaat gtgtacacac ctcccgggca gtggggagga ttaaactgtg 540  
ctctgacacg atccgggcat gtacagggtg gtatctgcag taaaccgccc tcggaaaatg 600  
gctgacacg agggccagcg gtgggagctc tccgtgcttg gcttgacgcc attgtggagg 660  
tgaggagggg gctgcaagac tctgagcagg aagacccgc aaagcaggaa agcagagcca 720  
gagttggggg ccagccgcag aaacgagagc ccccgtagt ttgaggcacc ctttgagag 780  
ggcaggaagc aggaagggtg aattttctcc aaaacccaag aggcagagtg accccacatg 840  
ataactgagt ttctcgag 858

<210> 47  
<211> 6107  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (5749)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (5892)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (5896)  
<223> n equals a,t,g, or c

<220>  
<221> SITE



<222> (5906)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (5957)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (5966)  
 <223> n equals a,t,g, or c

<400> 47  
 gcagttagtt ccttgatgtc agtagtgggc taaaggcagc ttactgtgtg tttgctggag 60  
 ctttctactca gccaaagtgt agagtcagga aacccattga ggcaatggcg tcaaatgggtg 120  
 tttcacaaaga atgagccatt cagtctttgc tcactatata tttaatatatt tattattgtt 180  
 gttattgtta ttattaattg gctttctgta ttctatgcct tttatttata aagacactaa 240  
 gaaaacccat gtttgtaatt ttaataacat tttcccatc ttgtaatatc cagagctact 300  
 ttataaattc tctgaaccaa agttatttct ctcagtgtat ctcttctccc ccagccctta 360  
 ttgggaaaaa ttaccagta tagttcaggt tatgaggagg atcagccaca caatccagtg 420  
 cttcagtttg aaaatgtaaa attctaacc taaagtaggg ttggttgaaa tttcagacaa 480  
 agcaaaccca gcaggtataa aaagtagtat aaatacaaat ctgtaagtta tttttgaatt 540  
 ttctgaactt ttttctaaga gattacatag gagactaaag aaatctatct gttcaagttc 600  
 taattaggat gattgttaat actgcactgt ggatgaagtg gcgactggct tgtgtgctga 660  
 cttctgtggt ttagcaagag gtttattgtt atcaaagtct aattggcaat gccaaagtcac 720  
 tgggaccaat tttctgtttt ataatatcta agtttagaac agaatatata cctgaactgt 780  
 agtggtttga tcggatggag acagaaaacc cgatttttat tctcataaat tttgtggtta 840  
 tttatacaag ggctgtgcta tgcataccata ttcttgttca ataataatag gtttgtgtt 900  
 ttttttacct tgttaaatgt tccttaccoc taaagggtcaa tgttaagtac aacattctga 960  
 aaatacaatt tggctacgaa gattattcat cttctttgaa gctcagtggt tgatatttgt 1020  
 gctaataatg caatttctct attcctgtta caagttatag ctacatatgg gagagactca 1080  
 gtgagccagc aaaggccata gaaacaacaa tttattaaat gtatttatgg cagaaggacc 1140  
 taaataaact gtgagccacc ttttcttctt tatattgtta catttaagt tttctgtctt 1200  
 cagcaactca cattaatgct tggagcttat ctcttctctc ctctctctct ctctctctct 1260  
 ctgtgtgtgt gtgtgtatgt gtgtgtgtgt gtgtgtgtgt ttcttatttg tcatccatt 1320  
 atatatccac accaactatg gtgacgataa ttcaaagtca tattttgcct ctaagcttga 1380  
 tcatgttacc tttatgatta aagtatcatg ttatttagcc aatgcaaatc tgttttaaaa 1440  
 caaatagttt aaaaaaagaa caagttttta agggctttat tatagaagaa gtattaatga 1500  
 aggactttcc ttctctctcc cctttctctc cctcctgcc tcccttcttc ccttccatct 1560  
 cccctctctc cctgcctctt ttgtttctcc ttcccttatt cctcctctcc tctttctcc 1620  
 cttctctctt ttcttccatt catccttctt tgccttttat ttttattttt tgtaatatca 1680  
 catgtgctgt agtttggaa tttattctag tgcatttctt gctcatcaga acctcagcta 1740  
 atctacctag gaaaaatagt atcaaaggaa atgagaaagt tgtatctgag tccctccaga 1800  
 actaagataa ttctttttga ccatttaagc ctttataaat gcgttttgac catttaagcc 1860  
 tttataaatg cttgttttag gaaagtgaat ctgttagatg catcaacaaa taatgaccag 1920  
 gacaaaaacga ttttaataatt aaagtctcaa atcaccatgg ttatacattt tcaccagaaa 1980  
 tagtaattctt acaatttttc atttttctga tgaagatttc tgttccaata tctgtttcct 2040  
 aatagatttt ttaaattaat tagcttttct ctgctttatg accacagggt ttatccctaa 2100  
 ccgagacagc tgtcttatat ctgcatgcct tagactgtgt ggagggactc catgaagaaa 2160  
 gaccataggt tagaaaaata actcatagta tataccctag taagtgggtt agtagaatct 2220  
 cataacatgt attaaaaaga ggttttcttc tctgctgtgt tgtgtcacta gagcaaaatt 2280  
 gtagagataa tgcataaat cgagtaataa tcagaataat ctacaatatc atttgtggat 2340  
 ggtcccaggt cccagtgtct tagttacttt acttcttttt ttttttttga gatggagtct 2400  
 tgctctgtct ctcaggctag agcagtgtgc gatctcagct cactgcagcc tccacctccc 2460  
 aggttcaagc gattctctct cctcagctcc ccaagtagcc aggattacag gcacctccca 2520  
 ctaggcccg ctaatttttt ttgtattttt ttagttaga tggggttttg ccatgttggc 2580  
 caggctggtt tcgaactcct aacctccagt gatccacctg cctcgcgctc ccaaagtgtc 2640

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| aggattacag  | gcattgagcca | ccacatccgg  | cctaattact  | tctttaatcc  | ccattttattt | 2700 |
| ttatgccatt  | ctagcctcat  | ttattaataa  | aattatgttt  | ttactttctc  | tttcaggaaa  | 2760 |
| tttttttaaat | taatatttta  | tatctagatc  | taatgctatg  | gaaaagtgcc  | tttttatcat  | 2820 |
| ttataaatttc | atttttcact  | atttccaaaa  | acacataaac  | aaatagtttc  | agtaggtccc  | 2880 |
| agctttttact | ttttccattt  | aaaccttctt  | ttctccattt  | cttccctttg  | gcttaagaat  | 2940 |
| aaaagaaaaag | gtacattgct  | agaattgttt  | ctttgggaga  | gggtaaaaa   | ttacagaatt  | 3000 |
| agactgtttca | gccttttatat | aaactaaatt  | tgtcttcac   | tcaaccagct  | aatggtaggt  | 3060 |
| cttatctgaa  | tactcatgag  | aatttttagca | tctgtgaaac  | tccatgcacc  | agatgtgtgt  | 3120 |
| aaatttcagg  | aagaaagtgt  | tgaaagcatt  | ttctctgatg  | tttaattgat  | ggaaataaat  | 3180 |
| cactaaaaaca | tagtttaggt  | aaagcctgat  | tatgccactt  | ttttttaact  | agacagggga  | 3240 |
| aagttgttta  | tgtttagtga  | cttcttgctt  | atcctcagtt  | aatttaccta  | gacaaaaagt  | 3300 |
| gtcaaaggaa  | atgagaaaaa  | ggttatatct  | gactccctcc  | agacctaaga  | taattccctt  | 3360 |
| tgatcagata  | cagtcagatg  | gagtgccctg  | gtttttgtta  | attttgctc   | tattccagct  | 3420 |
| ccttaccaca  | gcgtgtgtgc  | ttaaagaaag  | gatcatcagc  | aacaggtcag  | gatagttcta  | 3480 |
| cctttgggat  | agggctgctt  | tccccgtgct  | agtatttctg  | tgactgttag  | tggcactgag  | 3540 |
| gactgcaaac  | ttttatgcaa  | tattcttaaat | accctattga  | tattatgcac  | tttaactcat  | 3600 |
| ccaaagaagc  | caagaatgct  | gtatagtgat  | gattccttcc  | taatgaattc  | atcttaacta  | 3660 |
| tttagaatgt  | tatgtccctt  | ttcttttggg  | tagccaaact  | gggtataaat  | ttatatggat  | 3720 |
| ttttctaaaa  | tgactatata  | ggacttaaga  | ctttgaaatg  | taattttact  | ataaggggaa  | 3780 |
| ataattatgc  | tttagcacat  | catttttagaa | acgtcacatt  | ttagaaacat  | tcagcttgct  | 3840 |
| aacctacatg  | tttgggaatt  | cattaaaaacc | agttgtctat  | atattttgtg  | ccatgtatat  | 3900 |
| aagaacatta  | caatatatct  | ttttctacat  | atgtagtatg  | tgcaaccagt  | ggttctcaga  | 3960 |
| gtatggttct  | cagcccacca  | gctagtatca  | gtatcacctg  | ggaaactagt  | agaaatgtaa  | 4020 |
| attctttggc  | cccatcccag  | acatactgag  | tcagaaattc  | tggaataggg  | cccccgcaat  | 4080 |
| ctgttttcac  | aagccctcca  | ggtgattctg  | atgcacactt  | taaagtttag  | gaaccactgg  | 4140 |
| gctaagactc  | tggtgagata  | tagagttttt  | cttccactca  | gactgatata  | gttatacatt  | 4200 |
| gttcttcatg  | taaattcagc  | ttaacctggt  | tatctataat  | cttttattgg  | caaaagttaa  | 4260 |
| ttctcagtac  | tgccctataga | gatacagtgt  | attttatgta  | catacacaat  | tagtctaatt  | 4320 |
| cttgataatt  | cagtttaattt | agtttggtcat | tttccctacca | cttactaaaa  | ggtttacatt  | 4380 |
| aaatgactga  | tttaaatata  | taggtgcaat  | gttctatgtt  | tatttttaatt | gttatgacat  | 4440 |
| ttaagtagct  | aatataattg  | accggtgcta  | aagtctcctg  | tttatccata  | aaatgggtac  | 4500 |
| attatgggca  | gtgtaataca  | agctttcttt  | tcattgccta  | gtactttacc  | agcagaccac  | 4560 |
| agttttgccc  | tggtctagacc | aacctctaga  | acaaaatcat  | cattccttgt  | atttatattt  | 4620 |
| gtactctgaga | tagtaaacaa  | gatggctggc  | caggtcaaca  | tggtcacctta | acttattttt  | 4680 |
| tttaactagta | aaacttcttc  | aaaagttagct | tgctttgtat  | aagaactaag  | ctatcagtat  | 4740 |
| agatatagct  | atccttgagg  | cttatgtttc  | agacaagaat  | tatttactaa  | aataaataat  | 4800 |
| aaacaagata  | atgcattata  | caatttgagg  | atttctcgtt  | tctcaagtgt  | atgcacatg   | 4860 |
| gtaaatataa  | actaaccaca  | agataggtag  | attgattcat  | ttcattttta  | tctccttggt  | 4920 |
| taattcagta  | cctccataat  | tgttctaate  | ttcttcccac  | tgtttacaaa  | ttaccagtta  | 4980 |
| attaactcgt  | gaaagaaaaa  | ttcacatata  | agaataaaaa  | taaatgtata  | ctcactttat  | 5040 |
| aaaaatcacc  | actgctgtct  | ttccttaata  | ctagcagtg   | aaatgtaagt  | ggcttactct  | 5100 |
| acaaattttg  | gtgctggcaa  | atacataggc  | aaactgttgg  | gagctgctct  | agttacattc  | 5160 |
| ctcccttctt  | attccctttt  | tctcttcttc  | actttattgc  | ataacatatt  | cctgtaccca  | 5220 |
| aagcattcta  | ccacagttct  | atttgactcc  | cacttgtaat  | aactccttta  | aaaaattcca  | 5280 |
| tgtttaacca  | tatgacctcg  | cttgcttact  | catattctcc  | ctccctctcc  | ccttcttctc  | 5340 |
| tctctcttcc  | agaagtcatt  | tgcttggttt  | gaaatatttt  | gtagggattg  | cttattatat  | 5400 |
| tattttagct  | gatgaacctc  | aggacaacgt  | ctacacacac  | acacatacat  | acacgcacac  | 5460 |
| aaaatctcag  | ctgttgaaga  | gtgggcttgg  | aatcagactt  | ctgtgtccag  | taaaaaactc  | 5520 |
| ctgcactgaa  | gtcattgtga  | cttgagttag  | tacagactga  | ttccagtga   | cttgatctaa  | 5580 |
| tttcttttga  | tetaatgaat  | gtgtctgctt  | acctgttttc  | cttttaattg  | ataagctcca  | 5640 |
| agtagttgct  | aattttttga  | caacttttaa  | tgagtttcat  | tcacttcttt  | tacttaattgt | 5700 |
| tttaagtata  | gtaccaataa  | tttcattaac  | ctgttctcaa  | gtggtttanc  | taccattctg  | 5760 |
| ccatttttaa  | tttttattta  | attttatttg  | cttgagcaca  | ctgatcaacc  | actgaactgc  | 5820 |
| cttcttccat  | tgctctgcaa  | tgatataagg  | gttaccattt  | tggtgatatg  | gctttcatag  | 5880 |
| ttgggatttc  | anagcnctga  | taccanatat  | tttcagtttg  | ttctctgggg  | gaatttcatt  | 5940 |
| tgcatctatg  | tttttancta  | tctgttnataa | cttgttaaat  | attaaaaaga  | tattttgctt  | 6000 |
| ctattggaac  | atttgtatac  | tcgcaactat  | atttctgtaa  | acagctgcag  | tcaaaaaata  | 6060 |
| aacactgaaa  | gttttcaaaa  | aaaaaaaaaa  | aaaaaaaaaa  | aaaaaaa     |             | 6107 |

<210> 48  
 <211> 703  
 <212> DNA  
 <213> Homo sapiens

<400> 48  
 ccacgcgtcc gcaggacatc gttttctaca tgggtggctgt gttcctgacc ttctctcatgc 60  
 tcttccgtgg cagggtcacc ctggcatggg ctctgggtta cctgggcttg tatgtgttct 120  
 atgtgggtcac tgtgattctc tgcacctgga tctaccaacg gcaacggaga ggatctctgt 180  
 tctgccccat gccagttact ccagagatcc tctcagactc cgaggaggac cgggtatctt 240  
 ctaataccaa cagctatgac tacggtgatg agtaccggcc gctgttcttc taccaggaga 300  
 ccaacggctca gatcctgggtc cgggccctca atccccctgga ttacatgaag tggagaagga 360  
 aatcagcata ctggaaagcc ctcaagggtg tcaagctgcc tgtggagttc ctgctgctcc 420  
 tcacagtccc cgtcgtggac ccggacaagg atgaccagaa ctggaaacgg cccctcaact 480  
 gtctgcatct ggttatcagc cccctggttg tggctcctgac cctgcagtcg gggacctatg 540  
 gtgtctatga gataggcggc ctcgttcccg tctgggtcgt ggtgggtgac gcaggcacag 600  
 ccttggtctc agtgaccttt tttgccacat ctgacagcca gccccccagg cttcactggc 660  
 tctttgcttt cctgggcttt ctgaccagcg cctgtgggat caa 703

<210> 49  
 <211> 639  
 <212> DNA  
 <213> Homo sapiens

<400> 49  
 ggcacgagca ttcacagggtt acaaatgctg ctgccaaactg tcttggccaa atgactctgc 60  
 atcacaaacc tttccttgca tgtggagggg atggatttac tcagtccaac tttgatggct 120  
 gcataccttc tgcctatgtg gttctggaag ctttaaagaa ttatatattag tgcctatctc 180  
 cttattctct acatgtgtat tgggttttta ttttcacaat tttctgttat tgattatctt 240  
 gttttctatt ttgctaagaa aaattactgg aaaattgttc ttcaattatt atcatttttc 300  
 atgtggagta taaaatcaat tttgtaattt tgatagttac aacctatgct agaattggaaa 360  
 ttctctcacac cttgcacctt cctacttttt ctgaattgct atgactactc cttgttggag 420  
 gaaaagtggg acttaaaaaa taacaaacga ctctctcaaa aaaattacat taaatcacaa 480  
 taacagtgtt tatgccaaaa acttgattat ccttatgaaa atttcaattc tgaataaaga 540  
 ataatacat tatcaaaagg ccaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 600  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 639

<210> 50  
 <211> 867  
 <212> DNA  
 <213> Homo sapiens

<400> 50  
 ggcacgagca ggtactgggt gactgcctgg ctgaggaaaa gttaactaga cacttgggga 60  
 aaggagatcc aaggagataa gagggcaaat gcctttgcat gcttttcttc ctatctcttt 120  
 ttctttctct ccttctcact ctctcccttc ctctctttct tcttttctct ttcttttttt 180  
 tttctctttt cccccacctc tctgctgccc tcttctcttc cctccctccc cctccctccc 240  
 cctccctccc ctccctccc tcttctcttc ctctctcttc tcttctcttc tcttctcttc 300  
 tctctctccc ctcttctccc gccttctttc ctctgtcttg ccaacttgcc agaaggagcc 360  
 caagaaaaag caccagatg cttcagtcac cttcttagaa ttcttctttt ttttatgttc 420  
 agaaaagatg gaaattcatt tctgctaaag agaaagaaaa aattggaaga cagggatgaag 480  
 gtgaacaggc ccattataag aaagaaacaa aaatctatat tctgtctaca aggaagcgag 540  
 agagagaaag agagagaaga aagaagttcc aggaattctaa tgtaccaaag ggatctcctt 600  
 tttcttgttt tgttctgaaa atttcaccaa aagagcacag gagaacatct tggctaattc 660

29

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| attggcgatg | atgtaagaaa | actgagagaa | atgaaagaaa | tgaagaatta | ctgctgcaga | 720 |
| taatatacag | ccttgaggaa | agaaaggctt | ttaagattat | agatataaag | gctattgctg | 780 |
| tattctggga | taaaagaaa  | tctgatgtca | gggaaagggg | aagttggaaa | aactggaaaa | 840 |
| agaaaaaaga | aaaaaaaaaa | aaaaaaa    |            |            |            | 867 |

<210> 51  
 <211> 1569  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (341)  
 <223> n equals a,t,g, or c

|             |             |            |            |             |            |      |
|-------------|-------------|------------|------------|-------------|------------|------|
| <400> 51    |             |            |            |             |            |      |
| gtattggcca  | ggctgggtctc | aaactcctga | cctcgatgac | cacccacctt  | ggcctcccaa | 60   |
| agtgcagaga  | ttacaggcat  | gagccactgc | acctggcctc | aagaaaaatt  | atatatcacg | 120  |
| tggaaatagga | tagtagtctc  | tgcactgatt | ttcgttgata | atggctgttc  | ttcttatcac | 180  |
| cattttgcta  | tttctttgtc  | tgggctatta | cagggttatt | acagaaattt  | ccagaaagac | 240  |
| ccctgcctgt  | cgaatgttta  | cttcaagctt | gagctcctgg | tatattatga  | ggaaattata | 300  |
| tgatacccca  | ggagaggtct  | tcctttccca | tgccattgta | naattcctaa  | agtaaaatta | 360  |
| atgtgccttc  | ttgtcaaaga  | aggagccaat | gttgttttaa | aatttttagct | tgagagatag | 420  |
| gtggggaaga  | aattaaatag  | acaagtaatc | mtatttcaga | agagaaggga  | gagtcattgt | 480  |
| acgaggccca  | agatacttgc  | ccaaaaatat | cgcagagaaa | aactagtctt  | tggggtccta | 540  |
| ttttttgagt  | ggaacatttg  | agttatttaa | aattagaatt | ttattttggt  | cagattagaa | 600  |
| tttctagggt  | atgtcatatg  | tgtttttaa  | ttgaaagctc | ttaaaactcc  | tattgtagtt | 660  |
| taatgtcatt  | atccattaat  | ttacataaat | ctgatttggg | tctctatttt  | catcgtagac | 720  |
| tgtgtagggg  | caatttttcc  | ttaaagttct | gtgacatagt | gctacctttt  | ttttaaaacc | 780  |
| tgtcttgccc  | aggcattatt  | gagtgcccc  | tgggtgccgc | atgtgtattt  | cacgactgta | 840  |
| tcaacaaatc  | atgatcatct  | tctctggcca | ttgtgccctt | tcagattcca  | aacttgttac | 900  |
| ctctcagtc   | ttcctacaaa  | cttagaaagt | ctaatactt  | aatgtttact  | tatgtagcaa | 960  |
| cctccctttc  | tcccatccct  | aaatcctctt | gtaattaatt | attttccttt  | ggaacttttt | 1020 |
| aaatctacaa  | tttctttata  | atatggtaac | caatattaat | tttcttggtc  | tgcgccaagt | 1080 |
| ttgattttat  | acaaattggt  | tccagtttgg | gtcatgagca | caaaaccagg  | tattttttaa | 1140 |
| aatctatata  | acccttcaat  | gaggcagtat | taattttatt | aactcattaa  | ttcaaccaat | 1200 |
| aattcttgat  | tgtttactgt  | gttagatatt | ggggatatcc | caatacctga  | cagctgtgag | 1260 |
| caaaacaaat  | gccctacaca  | catgaggtgt | acagtcagct | agaaaagata  | aacaataagc | 1320 |
| aaattaatag  | ataatatgat  | gtccaataag | gacttcaaag | gaaaataaag  | cagagtaaag | 1380 |
| agccagagaa  | tgacagtgtg  | ctgtttttca | catgagtcac | cagaaaaggc  | ctctttaaag | 1440 |
| aattgacatt  | tgaacagaaa  | aacgaatcaa | gggcgtcaac | tgtttattgc  | ttttattgct | 1500 |
| taccatttga  | ccaagcaatt  | ctacacatag | gattcacctt | aaaaaaaaaa  | aaaaaaaaaa | 1560 |
| aaactcgag   |             |            |            |             |            | 1569 |

<210> 52  
 <211> 1196  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (590)  
 <223> n equals a,t,g, or c

|            |            |            |            |            |            |    |
|------------|------------|------------|------------|------------|------------|----|
| <400> 52   |            |            |            |            |            |    |
| gattgggtct | gtttatgtga | tagattactt | ttattgattt | gtatgttgaa | ccagccttgc | 60 |

|            |            |            |             |             |             |      |
|------------|------------|------------|-------------|-------------|-------------|------|
| atcctagggg | tgaagccgac | ttggttgtgg | tggataagct  | ttttgatgtg  | ctgctggggt  | 120  |
| tggcttgcca | gtgttttatt | agggattttt | gcgtcaatat  | tcatcagggg  | tattggcctg  | 180  |
| gaattttctt | tttttggtat | gtgtctgcca | ggttttggta  | tcaggggtgat | gctggcctca  | 240  |
| taaaataagt | tagggagggc | tcctctttt  | tctttcattt  | ggaagaattt  | cagaaggaat  | 300  |
| ggtaccagat | ccyctttgta | cctctggtag | aatttggctg  | tgaatccatc  | tggtcckgag  | 360  |
| cttttttttt | gttggtaggc | tattaattac | tgccccaatt  | tcagaacttg  | ttattgggtc  | 420  |
| attcagggat | ttgacttctt | cctggtttag | tcttggggagg | ttgtatgtgt  | gcaggaattt  | 480  |
| attcatttct | tctagatttt | ctcgtttatt | tgtgtagagg  | tgtttatagc  | atytctctgat | 540  |
| ggtagtttgt | attctgtggg | atcagtggtg | atctcccctt  | tatcattttt  | attgtgtcta  | 600  |
| tttgatttct | ctctcttktc | ttctttatta | ttctygcata  | tggtctatgt  | attttgttaa  | 660  |
| tctyttacaa | aaacaggctt | ctagattcat | ggatgttttg  | aaaggtytyt  | cgtgtctcta  | 720  |
| tctccttcag | ttcttccctg | atcttagcta | ttcttgtct   | tctgctagct  | tttgaaattg  | 780  |
| tttgcttttg | cttctctagt | tcttttaacc | gtgatgtcca  | gtgtgtcaat  | ttcagatctt  | 840  |
| tccagccttc | tgatatgggc | atttaatgct | ataaatttcc  | ctcttaacac  | tgcttttagct | 900  |
| gtgtcctaga | gattctggta | cggtgtctct | ttgttctcat  | tggtttcaaa  | taacttcatt  | 960  |
| atttctgcct | taattttgtt | atttaccag  | cagtcattca  | agagcagggt  | gttcaatttc  | 1020 |
| catgtagttg | tgtgggtttg | agtgaatttc | ttaatcttga  | gttctaattt  | gattgcactg  | 1080 |
| tggtctgaga | gacgggtaca | atttccattc | ttttgcattt  | gctgagaagt  | gttttacttc  | 1140 |
| caattgtgtc | tcgtgccgaa | ttcgatatca | agcttatcga  | taccgtcgac  | ctcgag      | 1196 |

<210> 53  
 <211> 945  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (295)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (875)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (914)  
 <223> n equals a,t,g, or c

|             |             |            |             |            |            |     |
|-------------|-------------|------------|-------------|------------|------------|-----|
| <400> 53    |             |            |             |            |            |     |
| gaatggtgaa  | atattaagtg  | ctttctcccc | caggttcagg  | attatgacag | ctatgtccat | 60  |
| tcacctcttc  | tgtacagcat  | tgtcctgtgg | aagttctggc  | cagtgcataa | aggcaattaa | 120 |
| aagaaataaa  | atatcaaacg  | attggaaaga | tgtaaatgtg  | tcatcattca | tagaaaacat | 180 |
| gattcataga  | tatacataca  | cgaatgcttt | gaattcataa  | gtagattcag | ccagttgctg | 240 |
| gatataaagt  | caatatacaa  | aaactatttt | tatagacatg  | aaacacgcaa | tgagnaaaaa | 300 |
| aatttaacca  | tttttagtag  | catcaaaaaa | cccccatacc  | taggaatatg | aattttagtg | 360 |
| actatttggg  | atatgttgat  | ggatatttat | catttccagt  | ttgggattat | tataaagaaa | 420 |
| atagccctga  | acatttgtaa  | tatatgactt | ttgggtgaatg | tagcattcat | ttctgttgat | 480 |
| tacaaactca  | ggggtgaaat  | tgttgagtcc | taaggagagct | atagatgtat | tcaacttcag | 540 |
| ctgatatggc  | taaataaatt  | tgcgaaaaag | attgcatcaa  | gttatgctcc | catcagcaat | 600 |
| atgagagttc  | ctgtttttcc  | acattgtcag | caacactttg  | tactgttact | ccttttaatt | 660 |
| ttagccgatt  | tggctgaagg  | tgttgtaata | tctcattgta  | gtggccaggc | gtgggtgtca | 720 |
| cgctctgtaat | cccagcaactg | tgggaagcca | aggtgggccc  | atcacgaggt | caggagatcc | 780 |
| agaccatcct  | ggctaacatg  | atgaaacctt | gttgccctgta | gtcccaacta | cttgggaggc | 840 |
| tgaggcagga  | gaatggcatg  | aactcgggag | gcgngcttg   | cagtgagcct | ccagcctggg | 900 |
| caacagagtg  | agantctctc  | aaaaaaaaaa | aaaaaaaaac  | tcgag      |            | 945 |

<210> 54  
 <211> 488  
 <212> DNA  
 <213> Homo sapiens

<400> 54  
 ggcacgagga gagtagagggc tattcatgta atgtctataa aaaaataaca ccaaggctgg 60  
 gattacagggc atgagccact gcacctggcc agtttgctta ttttggttgg tgcctcctcc 120  
 catgggagac ctcaaggagg tatgcctgcc ccacagatgc cctggaagga cagcttgctg 180  
 ctctactca gaaccacacc tgcagacaga ggaggacaga cggacactca tttgctgagc 240  
 acccatgtaa catgaactaa gagctgggtg gagacaatga acggtggagc catcgttccc 300  
 gatgtggagg gagaacagct caagaccacg gaacagcctg ctctcccgt tccgtgcttc 360  
 cgtgcgcttt tgtccaatca ggctttttga ccaatcggcc aggcgcgcta tgtaaatctc 420  
 tgacattttc aaagctgtct ttttaataaa cctttcagtg taaaaataaa aaaaaaaaaa 480  
 aaaaaaaaaa 488

<210> 55  
 <211> 2860  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (753)  
 <223> n equals a,t,g, or c

<400> 55  
 ggcacacagg gctggcaggc ccgcggtggc tgggtgtgag gcatgaacaa attgtaccgg 60  
 gtatccccca cccactctg accaccagtt cctccttga tatcactccc cctgacagggc 120  
 agcccaccca ggctggatt tgcctctgtc tcccccttt gcttttcccc catgactaat 180  
 gggcaccagg tcttgctgct cctgcttctc acctctgcag tggcagcagg cccctggccc 240  
 cagggtcatg ccggtcagtg ggggtggatg tgccttctc caggcctgcc ctctgtccaa 300  
 gccccgagtg ggcttggttg gctccctggg gccccccagt ggggtgccagg tgggtgccgg 360  
 ggttattgag ggggtggttg atcactgtag ggacaggctt cttgccccag cctggagagc 420  
 tgttttcttc aggaaggctc tggagatgga gacttggttg cgaattcacc acaactccag 480  
 gctgggagggc tgggtctctg ctctcagagc cgagacacca gggaggatag ccaggctgcc 540  
 ctgcctggga attctgctgg gccgtcaa atcaacccgca ccaacgtggg caggaggcca 600  
 cagtgtcctg ccaggagcag agggctgaag gtctgcagga ggaagaccct atcctggtgg 660  
 ggggcacctg ctgcccaccc tgcctccagc gtgcctgggg ggagcacacc tgggcatgga 720  
 ggagtccagg gtgctgggccc acacaagaga gnggggggag aggcctggac agtaggaaga 780  
 tcttgccagg ggtcctggat ccgccactct gggggtgacc ttggacaaac ctctgccttg 840  
 gccctcagtc tccccatcaa ggtttttcca ttcaggaggg tttgggcat cttcagccac 900  
 cctaccagcc ctgaaaagga tgtgactcct gtttctggga agtgtgtggt gtgttaggtg 960  
 ggccctacagc cctgggttggt gggagggaag gatggagaga cagcacagtg acagagccca 1020  
 gactgcaggc tggagtgagg gtccacttc ccgctgctg tgtgtcctgg accagtgcct 1080  
 ctgaaccttg gcacttgggg cagtggatat taacatcttt ccaagcccaa ttcttggggc 1140  
 atcagggcct ccggtcctct gggaggtggc aggtcctcag attggagatg ccattggggg 1200  
 gggaggtgcc tctccttttg aggggtatgga agtggagaca ggagtggcct ggcgcagctg 1260  
 ccgtgggtct taggggctgg gcccggggag cccatggggc ttgtgcctag aaagcctggg 1320  
 ctctcactg ggggtctagat gtgcagactt catgtctccc cagctccagc tctgttctct 1380  
 atagggtcaag cctccacaat gccagaggcc cagggtcagc cccctccagc tccctcctag 1440  
 atctacagct gcccttttga tgacagcgcc attgagctcc ctgggctggg ggggtcatgc 1500  
 aggggtgagg cagctgcctg ccgcccgtac tcattgctg gccaggcagg acacaggtg 1560  
 gcgggcactg agagtgggccc ccacgaaatc cattgtcagg ttaccaggat gaagaaccca 1620  
 ggctggtcgt ggagtgcagg gcggggcctg ccggaagaat tatgggcaact gcagcaggag 1680

|             |            |            |            |            |            |      |
|-------------|------------|------------|------------|------------|------------|------|
| ggcagcctgg  | gccattagct | cctgatgtca | tcgatttggg | tgaggggaca | gggaagtcag | 1740 |
| aggaagctgg  | ccagtggctc | tcacgcagac | ttacagcagt | ggagtgggtg | ctgattcctg | 1800 |
| gtacagctgc  | tccactgag  | tctccaggga | tctgtgggtc | aggacccct  | gcaacccct  | 1860 |
| cccagacccc  | tgtactggg  | ggaggagagg | acctagagga | aagggtgctg | gcagataagc | 1920 |
| agctgagggg  | ggccctgggt | ttagcttata | agtcttctgg | gccctcctgc | cccaggaagg | 1980 |
| gcagcgagga  | ccatgggtgt | gccctgtca  | tcgttatcgt | cctggccatg | agcttgacag | 2040 |
| actgggaggg  | ccggagtcag | ccaggcagac | ggcagcacag | catttgctg  | ttggcaggtg | 2100 |
| gccttgggtg  | cttcccaaag | gcaatcgctc | cacgcagAAC | aaaactcact | tttttggggg | 2160 |
| gtgaagcacc  | ttgggtcatt | tgtttagttc | gttaattcca | gcagtctgtt | tctaaggga  | 2220 |
| acatggctgc  | agccggtcct | gcgcctccca | ccctccacc  | aggtgccag  | tggtcccaag | 2280 |
| ggcccccgaat | cccaacctta | ttcaggcgtc | agcatctctg | caccccaaat | gcctgttagg | 2340 |
| gaggatagtg  | aaggctgagc | cctcctgggc | ccatcaaaag | ccagcagtga | gagaacaccc | 2400 |
| ccatctctct  | gaggtgacct | tgtagggcag | tccgtgctgt | ctggctggcc | tgggtgaggt | 2460 |
| gggcaggggc  | caaggcctgg | cgccctgggc | tcgctggcct | tgctctgcgt | gctgacttca | 2520 |
| tcctgatagt  | accttgatgt | tcctactgtg | acttccctt  | ctgtcgactt | cctcaccaac | 2580 |
| tttaaaattc  | cgtattgaga | gcagtttctt | aagttacctc | aaatcctatt | cagaagaagg | 2640 |
| ttcttctctg  | aagttgggag | ggcggaaaac | aagtttagtc | acagaagact | actccatgtt | 2700 |
| tgagcttctg  | tttcaaggga | agtgaagAAC | tgccggagga | gccctgcccc | tctgcagtgt | 2760 |
| gtggtgtgtg  | cctgatactt | ttcagattga | ggtgttactt | acatgtaata | aatgcacag  | 2820 |
| acttaagtgt  | aaaaaaaaaa | aaaaaaaaaa | aaaaaaaaaa |            |            | 2860 |

&lt;210&gt; 56

&lt;211&gt; 1559

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1445)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1551)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 56

|            |            |             |            |             |            |      |
|------------|------------|-------------|------------|-------------|------------|------|
| atccagcagt | ggggagacag | cgtgctgggc  | aggcgctgcc | gagacottct  | cctgcagctc | 60   |
| tacctacagc | ggccggagct | gcgggtgccc  | gtgcctgagg | tcctactgca  | cagcgaagg  | 120  |
| gctgccagca | gcagcgtctg | caagctggac  | ggactcatcc | accgcttcat  | cacgctcctt | 180  |
| gcggacacca | gcgactcccc | ggcggtggag  | aaccgagggg | cggatgccag  | catggcctgc | 240  |
| cggaaagctg | cggtggcgca | cccgctgctg  | ctgctcaggc | acctgcccat  | gatcgcgcg  | 300  |
| ctcctgcacg | gccgcaccca | cctcaacttc  | caggagtctc | ggcagcagaa  | ccacctgagc | 360  |
| tgcttctctg | acgtgctggg | cctgctggag  | ctgctgcagc | cgcacgtgtt  | ccgcagcgag | 420  |
| caccaggggg | cgctgtggga | ctgccttctg  | tccttcatcc | gcctgctgct  | gaattacagg | 480  |
| aagtcctccc | gccatctggc | tgcccttcatc | aacaagtctt | tgcatgttcat | ccataagtac | 540  |
| attacctaca | atgccccagc | agccatctcc  | ttcctgcaga | agcacgcaga  | cccgctccac | 600  |
| gacctgtcct | tcgacaacag | tgacctgggt  | atgctgaaat | ccctccttgc  | agggctcagc | 660  |
| ctgcccagca | gggacgacag | gaccgaccga  | ggcctggacg | aagagggcga  | ggaggagagc | 720  |
| tcagccgggt | ccttgcctcc | ggtcagcgtc  | tcctgtttca | ccctctgac   | cgcggccgag | 780  |
| atggccccct | acatgaaacg | gctttcccg   | ggccaaacgg | tgaggatct   | gctggaggtt | 840  |
| ctgagtga   | tagacgagat | gtcccggcgg  | agaccgaga  | tcctgagctt  | cttctcgacc | 900  |
| aacctgcagc | ggctgatgag | ctcgcccgag  | gagtgttgcc | gcaacctcgc  | cttcagcctg | 960  |
| gccctgcgct | ccatgcagaa | cagccccagc  | attgcagccg | ctttcctgcc  | cacgttcatg | 1020 |
| tactgcctgg | gcagccagga | ctttgaggtg  | gtgcagacgg | ccctccggaa  | cctgctgag  | 1080 |
| taegctctcc | tgtgccaaga | gcacgcggct  | gtgctgctcc | accgggcctt  | cctgggtggc | 1140 |
| atgtacggcc | agatggaccc | cagcgcgag   | atctccgagg | ccctgaggat  | cctgcatatg | 1200 |

|            |            |            |             |             |            |      |
|------------|------------|------------|-------------|-------------|------------|------|
| gaggccgtga | tgtgagcctg | tggcagccga | ccccccctcca | agccccggcc  | cgccccgtcc | 1260 |
| ccggggatcc | tcgaggcaaa | gcccaggaag | cgtgggcgtt  | gctggctctgt | ccgaggaggt | 1320 |
| gagggcgccg | agccctgagg | ccaggcaggc | ccaggagcaa  | tactccgagc  | cctgggggtg | 1380 |
| ctccgggccc | gccgctggca | tcaggggccc | tccagcaagc  | cctcattcac  | cttctgggcc | 1440 |
| acagncctgc | gcggagcggc | ggatcccccc | gggcatggcc  | tgggctggtt  | ttgaatgaaa | 1500 |
| cgacctgaac | tgtcaaaaaa | aaaaaaaaaa | aaaccogrpg  | gggggcccgg  | nacccaatt  | 1559 |

&lt;210&gt; 57

&lt;211&gt; 2064

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2001)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2024)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2049)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 57

|            |             |            |            |             |             |      |
|------------|-------------|------------|------------|-------------|-------------|------|
| atgggcgagg | ctgcggggcc  | ccggcgcgca | cgcccgaccc | tctccccagc  | cctggcggtg  | 60   |
| gcccagcccc | gcccaggcag  | caatgggggt | cctgcagctg | ctggtcgtar  | cggtgctggy  | 120  |
| atccgaacac | cggggtggctg | gtgcagccga | ggtcttcggg | aattccagcg  | arggtcttat  | 180  |
| tgaattttct | gtggggaaat  | ttagatactt | cgagctcaat | aggccctttc  | cagagggaagc | 240  |
| tattttgcat | gatatttcaa  | gcaatgtgac | ttttcttatt | ttccaaatac  | actcacagta  | 300  |
| tcagaataca | actgtttcct  | tttctccgag | gcgtagatcc | cccaccatgt  | gacgctggga  | 360  |
| cagaccagga | ctccagggtg  | aggttgcagt | atgatgtcta | tcagtatttt  | ctgcctgaga  | 420  |
| atgacctcac | tgaggagatg  | ttgctgaagc | atctgcagag | gatggtcagt  | gtgccccagg  | 480  |
| tgaaggccag | tgctctcaag  | tggtttacc  | taacagctaa | tgataagaca  | agtgtttcct  | 540  |
| tctctccct  | ccggggacaa  | ggtgtcatat | acaatgtcat | tgtttgggac  | cogtttctaa  | 600  |
| atacatctgc | tgccctacatt | cctgctcaca | catacgcttg | cagctttgag  | gcaggagagg  | 660  |
| gtagtgtgtc | ttccctagga  | agagtgtctt | ccaaagtgtt | cttccactctt | tttgccctgc  | 720  |
| ttggtttctt | cattttgttc  | tttggacaca | gattctggaa | aacagaatta  | ttcttcatag  | 780  |
| gctttatcat | catgggaattc | ttcttttata | tactgattac | aagactgaca  | cctatcaagt  | 840  |
| atgatgtgaa | tctgattctg  | acagctgtca | ctggaagcgt | cggtggaatg  | ttcttggtag  | 900  |
| ctgtgtgggt | gcgatttgga  | atcctctcga | tctgcagtct | ctgtgttgga  | ctagtgtctg  | 960  |
| ggttcctcat | ctcgtcagtg  | actttcttta | ctccactggg | aaacctaaag  | atttttcatg  | 1020 |
| atgatgggtg | attctgggtc  | actttctctt | gcatagctat | cctcattcca  | gtagttttca  | 1080 |
| tgggctgcct | aagaatactg  | aacatactga | cttgtggagt | cattgggtcc  | tattcggtgg  | 1140 |
| ttttagccat | tgacagttac  | tggtccacaa | gccttttcta | catcactttg  | aacgtactca  | 1200 |
| agagagcgct | caacaaggat  | ttccacagag | ctttcacaaa | tgtgcctttt  | caaactaatg  | 1260 |
| acttcattat | cctggcagta  | tggggcatgc | tggtgtgaag | tggaattacg  | ttacagattc  | 1320 |
| gaagagagag | aggacgaccg  | ttcttccttc | cccaccata  | caagttatgg  | aagcaagaga  | 1380 |
| gagagcgccg | agtgacaaa   | attctggacc | ctagctacca | cattcctcca  | ttgagagaga  | 1440 |
| ggctctatgg | ccgattaacc  | cagattaaag | ggctcttcca | gaaggagcag  | ccagctggag  | 1500 |
| agagaacgcc | tttgcttctg  | tagatgccca | gggcttggt  | cagtgtgcct  | cagctttgga  | 1560 |
| gttcatgcct | ggagtgggtc  | aacagtctct | ggtgcaagtc | taataagaga  | tcaggcatat  | 1620 |
| atatctgttc | tttgcataat  | attatggtgc | ccttattgat | atatggtaag  | ggtgtactag  | 1680 |
| gggattagga | tgattgtgaag | agaatgagaa | agatgaccaa | aagggttggtg | gtagggaggc  | 1740 |



34

|            |             |            |            |            |            |      |
|------------|-------------|------------|------------|------------|------------|------|
| tttttcttat | ttccaaatac  | ttgagaaatt | accttttggg | ttacaaatct | atgatcaact | 1800 |
| tattccatta | aatagatata  | ttaaaaaaat | taaaaactga | ttcttctgca | gagcactggg | 1860 |
| gtttcttttt | ataaccctt   | gaaacaagtc | tctcacctga | gcctgtctaa | actttcggag | 1920 |
| ggagtttatt | attgagtcct  | tatctgtgac | agtatttggg | gatttaggga | tttgatactt | 1980 |
| aggcctttga | atttttagaat | ncaaaaaggg | gagccagcca | gacngggggg | ccaaccggga | 2040 |
| tccccaacng | ggaccagggg  | ggtc       |            |            |            | 2064 |

<210> 58  
 <211> 1050  
 <212> DNA  
 <213> Homo sapiens

|             |   |
|-------------|---|
| <400> 58    |   |
| ccacgcgtcc  | ggccagccag tccgcccgtc cggagcccgg ctcgctgggg cagcatggcg 60   |
| gggtcgccgc  | tgctctgggg gccgcggggc gggggcgctc gccttttggg gctgctgctg 120  |
| ctcggcctgt  | ttcggccgcc cccgcgctc tgcgcggcgc cggtaaagga gccccgcggc 180   |
| ctaagcgag   | cgtctccgcc cttggctaga ctggcgctcc tcgcccgttc cggcggtcag 240  |
| tgccccgagg  | tgaggcggcg ggggcgggtc agadctggcg cgggcgctgg cgcctctgct 300  |
| ggagccgaac  | gtcaggagcg ggcgcggggc gagcgcgaga ggctgaggat cagcaggcgc 360  |
| gcgtcctggc  | gcagctgctg cgcgtctggg gcgcccccg caactctgat cgggctctgg 420   |
| gcctggacga  | cgaccccgac gcgcctgcag cgcagctcgc tcgcgctctg ctcgcgcgcc 480  |
| gccttgaccc  | tgccgcctta gcagcccagc ttgtccccgc gcccgctccc gccgcggcgc 540  |
| tccgaccccc  | gcccccggtc tacgacgacg gccccgcggg cccggatgct gaggaggcag 600  |
| gcgacgagac  | accgcagctg gaccccgagc tgttgaggta cttgctggga cggattcttg 660  |
| cgggaagcgc  | ggactccgag ggggtggcag ccccgcgccg cctccgcccgt gccgcccagc 720 |
| acgatgtggg  | ctctgagctg cccctgagg gcgtgctggg ggcgctgctg cgtgtgaaac 780   |
| gcctagagac  | cccggcgccc cagggtgcctg cagcgcgcct cttgccaccc tgagcactgc 840 |
| ccggatcccc  | tgacccctgg gaccocagaag tgcccccgcc atcccgccac caggactgct 900 |
| ccccgccagc  | acgtccagag caacttacct cggccagcca gccctctcac ccgaggatcc 960  |
| ctacccccctg | gccccacaat aaacatgatc tgaagcagca aaaaaaaaaa aaaaaaaaaa 1020 |
| aaaaaaaaaa  | aaaaaaaaaa aaaaaaaaaa                                       |
|             | 1050  |

<210> 59  
 <211> 2533  
 <212> DNA  
 <213> Homo sapiens

|             |   |
|-------------|---|
| <400> 59    |   |
| ccacgcgtcc  | gcctggcaac ccctaataatt tgggatctct caatgctatt tgccttcatt 60  |
| agcttgctcg  | ttatgcttcc cacttggtgg attgtgtctt cctggctggg atggggagtg 120  |
| attctatattg | tgtatctggg cataagagct ttgagattat ggaggacagc caaactacaa 180  |
| gtgaccctaa  | aaaaatacag cgttcatttg gaagatatgg ccacaaacag ccgagctttt 240  |
| actaacctcg  | tgagaaaagc tttacgtctc attcaagaaa ccgaagtgat ttccagagga 300  |
| tttacactgg  | tcagtgtctg ttgcccattt aataaagctg gacagcatcc aagttagcat 360  |
| ctcatcggtc  | ttcggaaagc tgtctaccga actctaagag ccaacttcca agcagcaagg 420  |
| ctagctaccc  | tatatatgct gaaaaactac cccctgaact ctgagagtga caatgtaacc 480  |
| aactacatct  | gtgtggtgcc ttttaaagag ctgggccttg gacttagtga agagcagatt 540  |
| tcagaagagg  | aagcacataa ctttacagat ggcttcagcc tgccctgcat gaaggttttg 600  |
| ttccaactct  | gggtggcaca gagttcagag ttcttcagac ggtagccct attactttct 660   |
| acagccaatt  | cacctcctgg gcccttactt actccagcac ttctgectca tcgtatctta 720  |
| tctgatgtga  | ctcaaggctc acctcatgct cattctgcct gtttgggaaga gcttaagcgc 780 |
| agctatgagt  | tctatcggtg ctttgaaact cagcaccagt cagtaccgca gtgtttatcc 840  |
| aaaactcaac  | agaagtcaag agaactgaat aatgttcaca cagcagtgcg tagcttgagc 900  |
| ctccatctga  | aagcattact gaatgaggta ataattcttg aagatgaact tgaaaagctt 960  |
| gtttgtacta  | aagaacaca agaactagt tcagaggctt atcccatcct agaacagaaa 1020   |
| ttaaagttga  | ttcagcccca cgttcaagca agcaacaatt gctgggaaga ggccattttc 1080 |

|             |            |             |            |             |            |      |
|-------------|------------|-------------|------------|-------------|------------|------|
| caggctcgaca | aactgctacg | aagaaatata  | gataaaaaag | gcaagcctga  | aatagcatgt | 1140 |
| gaaaaaccac  | attgtacagt | aagtaccttt  | gaagcagcct | actctacaca  | ttgcagacaa | 1200 |
| agatccaatc  | ccagaggagc | aggaattaga  | agcttatgta | gatgatatag  | atattgatag | 1260 |
| tgatttcaga  | aaggatgatt | tttattactt  | gtctcaagaa | gacaaagaga  | gacagaagcg | 1320 |
| tgagcatgaa  | gaatccaaga | gggtgctcca  | agaattaaaa | tctgtgctgg  | gatttaaagc | 1380 |
| ttcagaggca  | gaaaggcaga | agtgggaagca | acttctattt | agtgatcatg  | tgtttcttca | 1440 |
| tatagcttta  | aaattatgct | attgacatta  | tgggaaagat | ttatcaatga  | gagaaatgtg | 1500 |
| tctctttttc  | agccgtgttg | aaatccttgt  | ctcctgtaga | cccagtggaa  | cccataagta | 1560 |
| attcagaacc  | atcaatgaat | tcagatatgg  | gaaaagtcag | taaaaatgat  | actgaagagg | 1620 |
| aaagtaataa  | atccgccaca | acagacaatg  | aaataagtag | gactgagtat  | ttatgtgaaa | 1680 |
| actctctaga  | aggtaaaaa  | aaagataatt  | cttcaaatga | agtcttcccc  | caaggagcag | 1740 |
| aagaaagaat  | gtgtttacca | tgtgagagtg  | aagatgaacc | acaagcagat  | ggaagtggct | 1800 |
| tgaccactgc  | cctcccaact | cccagggact  | cattacagcc | ctccattaag  | cagaggctgg | 1860 |
| cacggctaca  | gctgtcacca | gattttacct  | tcactgctgg | ccttgctgca  | gaagtggctg | 1920 |
| ctagatctct  | ctcctttacc | accatgcagg  | aacagacttt | tgggtgatgag | gaggaagAAC | 1980 |
| aaataataga  | agaaaataaa | aatgagatag  | aagaaaagta | agaaccaaga  | ttcatatgaa | 2040 |
| gtgatattag  | attgttcctt | ttacaaaagt  | gtttagcttc | aagactggaa  | agggaaatag | 2100 |
| agtgtaaagt  | tactatatat | aaagctaaga  | tgtggattta | caggaagaac  | cctggtttga | 2160 |
| ataactgata  | tgaaattagt | agttacctgt  | aaatggcaga | tcttttagga  | aaataagaga | 2220 |
| aaggtaaggg  | ctcttttgaa | taaactgctg  | ttttatttgt | ggcacaaactg | atcaatcttg | 2280 |
| gaaattcttt  | aagtattttt | aataagaaat  | gaattatcat | ttcttgccag  | aatttgctac | 2340 |
| cttaagggtga | ttgggaaaat | tctgttgcaa  | gaacattaac | atttagtatg  | actccttttt | 2400 |
| actgtattct  | tgcagttaat | aactgcagct  | attatgttaa | taacaagttg  | tttgtatttt | 2460 |
| atttttgttt  | ataccagtct | taaagatcca  | ggttctgaat | aaaaaaatta  | attgatacaa | 2520 |
| aaaaaaaaaa  | aaa        |             |            |             |            | 2533 |

<210> 60  
 <211> 899  
 <212> DNA  
 <213> Homo sapiens

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| <400> 60   |            |            |            |            |            |     |
| ggcagatttc | ccggcacctt | cgtgggcacc | acagagcccg | cctccccacc | cctgagcagc | 60  |
| acctcaccce | ccactgctgc | ggccactatg | cctgtgtgtg | cctctgtggc | cagcctggcc | 120 |
| cctccggggg | aggcctcgct | ctgcctggaa | gagggtggcc | cccttgccag | tgggaccgcg | 180 |
| aaagctcggg | tgctctatga | ctacgaggca | gccgacagca | gtgagctggc | cctgtctggc | 240 |
| gatgaactca | tcactgteta | cagcctgcct | ggcatggacc | ctgactggct | cattggcgag | 300 |
| agaggcaaca | agaagggcaa | ggtccctgtc | acctacttgg | aactgctcag | ctaggcaggt | 360 |
| gcccccatcc | cccccgcat  | ctggcctagg | caggagagga | tgggcgcact | gccacttaac | 420 |
| ttgtttgttg | gtgacacagt | tgttcagagt | ggggagaatt | caccccatc  | tgtccctgcc | 480 |
| cctagtcacc | tagctgtgag | ggtgcctgag | gctgaatggc | tccaccctcc | cccagccctg | 540 |
| cttctgacct | gtggctcttg | agccctgcc  | cctgcctgca | tccccgagca | ccccaccctc | 600 |
| caggctccac | taaggaggga | ggggctgtct | gcagcagctg | cactcagcac | ctaggccagg | 660 |
| gtggggccgc | cgcagatggg | ctcaggaagc | cccaggtgca | ctcagcgaga | gccctgcctt | 720 |
| tcagttgcca | aaagctgcat | caggggaatg | cggcaaggca | cacagggctc | tggcagcccc | 780 |
| tggggactgg | gcgctgcccc | tgggagggga | gagcctggcc | agggctgggt | ttgggcccgg | 840 |
| agcagcatct | tccggtgcta | tccctccctc | ccaccctca  | cagctcaagc | caagtcacg  | 899 |

<210> 61  
 <211> 1079  
 <212> DNA  
 <213> Homo sapiens

|            |            |            |            |             |            |     |
|------------|------------|------------|------------|-------------|------------|-----|
| <400> 61   |            |            |            |             |            |     |
| tgcacccacg | cgtccggggt | tcaccacgtt | ggccaggtcg | gtctcaaaact | cctgacttca | 60  |
| gttggcctcc | caaagtgcgt | ggattaaagg | catgagccac | tgcgcccggc  | ctacctttct | 120 |

36

|            |             |            |            |            |            |      |
|------------|-------------|------------|------------|------------|------------|------|
| aactctactt | ctagcttctt  | gcttctgggc | tgctgctata | ccaaacagga | atgtaatact | 180  |
| ttctgtcagc | ttcaggcctt  | tgcatatgca | gttcaacttt | tctatcttgg | tttttattct | 240  |
| taggatttta | attctcctaa  | gaagctttct | ctgaccagcc | taaaacttac | gtaagccctg | 300  |
| ggttagggtc | tatgcttatg  | tcctcccata | gcatttttgc | tttgcatgtg | ttgtaactct | 360  |
| taatgtacag | catcatgatt  | gcctatttta | actttctctg | ttgttacagt | agactttaat | 420  |
| ctctttaagg | acaggaactg  | tgtcttggtt | agaatcccca | gagcttattt | agtacaatgg | 480  |
| ctatgcttat | aatttaagta  | tttattgaac | aaatgaaatt | ttcctaagcc | ctaaaacctt | 540  |
| gcaagatggt | ttagtgcagg  | aaactggcct | cggtaggagt | gaataactag | cacgaggtca | 600  |
| ctcacctaaa | aagtgggtgag | gagggattaa | aatctaaatc | tgtttagctg | taaagattgg | 660  |
| gcttttttyc | ttgctgctgc  | acatgactgc | ycctctctat | gttgccctga | cacatccctg | 720  |
| tcaagtgttc | aaacagcccg  | tgcttaacaa | ccccatccat | agcttctgag | gaaagtgtg  | 780  |
| tcctctttgg | acagctctga  | gagctgaagc | gagcttttgc | agaataattt | cccatctatt | 840  |
| ggtcttaatt | tatgctttgg  | agaatataac | ttattttcaa | aaaacaaatg | attcagaatt | 900  |
| tgctcatctc | ttaaggtccg  | tttattagtt | tatttcatct | cttcattcac | tgataaccat | 960  |
| ttactgagca | ccagcctggg  | caacatggtg | agaacccatc | tctaccaatt | taaaaaaaaa | 1020 |
| aaaaaagggc | ggccgctcta  | gaggatccaa | gcttacgtac | gcgtgcatgc | gacgtcata  | 1079 |

&lt;210&gt; 62

&lt;211&gt; 1928

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

|            |            |             |             |             |             |      |
|------------|------------|-------------|-------------|-------------|-------------|------|
| ggcacgagag | taggtctgcc | ggcgatggag  | tggtgggcta  | gctcgcgct   | tcggctctgg  | 60   |
| ctgctgttgt | tcctcctgcc | ctcagcgcag  | ggccgccaga  | aggagtcagg  | ttcaaaatgg  | 120  |
| aaagtattta | ttgaccaa   | taacaggtct  | ttggagaatt  | acgaaccatg  | ttcaagtcaa  | 180  |
| aactgcagct | gctaccatgg | tgctatagaa  | gaggatctaa  | ctcctttccg  | aggaggcatc  | 240  |
| tccaggaaga | tgatggcaga | ggtagtcaga  | cggaaagctag | ggaccacta   | tcagatcact  | 300  |
| aagaacagac | tgtaccggga | aaatgactgc  | atgttcccc   | caaggtgtag  | tggtgttgag  | 360  |
| cactttattt | tggaagtgat | cgggcgtctc  | cctgacatgg  | agatgggtgat | caatgtacga  | 420  |
| gattatcctc | aggttcctaa | atggatggag  | cctgccatcc  | cagtcttctc  | cttcagttaag | 480  |
| acatcagagt | accatgatat | catgtatcct  | gcttggacat  | tttgggaagg  | gggacctgtg  | 540  |
| gtttggccaa | tttatcctac | aggtccttga  | cggtagggacc | tcttcagaga  | agatctgtga  | 600  |
| aggtcagcag | cacagtggcc | atggaaaaag  | aaaaactcta  | cagcatattt  | ccgaggatca  | 660  |
| aggacaagtc | cagaacgaga | tcctctcatt  | cttctgtctc  | ggaaaaaccc  | aaaactgtgt  | 720  |
| gatgcagaat | acaacaaaaa | ccaggcctgg  | aaatctatga  | aagatacctt  | aggaaagcca  | 780  |
| gctgctaagg | atgtccatct | tgtggatcac  | tgcaaataca  | agtatctgtt  | taattttcga  | 840  |
| ggcgtagctg | caagtttccg | gtttaaacac  | ctcttccgtg  | gtggctcact  | tgttttccat  | 900  |
| gttggtgatg | agtggctaga | attcttctat  | ccacagctga  | agccatgggt  | tcactatata  | 960  |
| ccagtcaaaa | cagatctctc | caatgtccaa  | gagctgttac  | aatttgtaaa  | agcaaatgat  | 1020 |
| gatgtagctc | aagagattgc | tgaaagggga  | agccagttta  | ttaggaacca  | tttgcagatg  | 1080 |
| gatgacatca | cctgttaact | ggagaacctc  | ttgagtgaat  | actctaaatt  | cctgtcttat  | 1140 |
| aatgtaacga | gaaggaaagg | ttatgatcaa  | attattccca  | aaatgttgaa  | aactgaacta  | 1200 |
| tagtagtcat | cataggacca | tagtctcttt  | tgtggcaaca  | gatctcagat  | atcctacggt  | 1260 |
| gagaagctta | ccataagctt | ggcacctata  | ccttgaatat  | ctgctatcaa  | gccaaatacc  | 1320 |
| tggttttctt | tatcatgctg | cacccagagc  | aactcttgag  | aaagatttaa  | aatgtgtcta  | 1380 |
| atacactgat | atgaagcagt | tcaacttttt  | ggatgaataa  | ggaccagaaa  | tcgtgagatg  | 1440 |
| tggtttttga | acccaactct | accttttcatt | ttcttaagac  | caatcacagc  | ttgtgcctca  | 1500 |
| gatcatccac | ctgtgtgagt | ccatcactgt  | gaaattgact  | gtgtccatgt  | gatgatgccc  | 1560 |
| tttgtcccat | tatttggagc | agaaaattcg  | tcatttggaa  | gtagtacaac  | tcattgtctg  | 1620 |
| aatttgtgaa | ttattcaagg | cgtgatctct  | gtcactttat  | tttaatgtag  | gaaaccttat  | 1680 |
| ggggttttat | aaaaatactt | ggggatcatt  | ctctgaatgg  | tctaaggaag  | cggtagccat  | 1740 |
| gccatgcaat | gatgtaggag | ttctcttttg  | taaaaccata  | aactctgtta  | ctcaggaggt  | 1800 |
| ttctataatg | ccacatagaa | agaggccaat  | tgcatgagta  | attattgcaa  | ttggatttca  | 1860 |
| ggttcccttt | ttgtgccttc | atgccctact  | tcttaatgcc  | tctctaaagc  | caaaaaaaaa  | 1920 |
| aaaaaaaa   |            |             |             |             |             | 1928 |

<210> 63  
 <211> 781  
 <212> DNA  
 <213> Homo sapiens

<400> 63  
 ggcacgagat tttcagcctt tttggactgg tttctccaca tcttcgtgga tttatctaac 60  
 tttggtcttt gatgttgggtg accttcagat tgggtctctg agtgaacatc ctttttgttg 120  
 atgttgatac tattcctttc tgtttgtttg tttgttttcc ttctaacagt cagggccctc 180  
 tgctgcaggt ctgctggagt ttgggtgagg tccactccag accctgtttg tctgggtttt 240  
 gccagaggag gctgcagaat agcaatgatt gctgcctgtt tttcctctgg aagctttgtc 300  
 ccagaggggc acccaccaga tgcagccag agctctcctg tatgagggtg ctgttgccc 360  
 atacttggag gtgccttcca gtcaggatac acaggtgtca ggtaccact tgaggaggca 420  
 ctctgtcccc tatcagagct cgaacactgt gctgggagat ccactgttct cttcagagct 480  
 gtcagacagg gacgtttaag tctgctgaag ctatgcccac agctgcccct tccccagat 540  
 gctctgtccc agggagaagg gaggttttatc tataagtctc tgactggggc tgctgccttt 600  
 tcttcagaga tgcctgtccc caagacgggg actctagaga ggcagtctgg ctgcagtggc 660  
 cttgctgaac tgtggtgggc ttcacccagt tggaccttcc ctgagccttt ttttttacc 720  
 tgtgagggta aaaatgccta atcaagcctc agcaatgggt gatgcccttc cccccacaa 780  
 g 781

<210> 64  
 <211> 1194  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1172)  
 <223> n equals a,t,g, or c

<400> 64  
 ggcacgagaa gacatggagt cttaagtgtg atcagtggga gggggctgga atcatttaga 60  
 ggcacatctca ttcacaaaac caggagctga tactggctgt cagccaggac ttcaactgac 120  
 ctatgtagaa cctgtccatg tggccccctc ttgcagtctc cccatttggg ctgggtttggg 180  
 cttcatcaca gtccggcagc ttacttctaa gggcaagcat tccacgacaa cacagcagaa 240  
 gggcatggca tttttacagt gaagtttggc aatctcatag cgtcgttct gtcctacttt 300  
 atttattggt cagggcaatc acaaagatgt gcataggctc aaagaaaaga gacataacct 360  
 cgaccacgcy atggaagaag tgacacggtc atgttatgag aggagtgtgt gggatgggag 420  
 atagggtgtt ggccacctgc agaaaacagc atctgtctata ggctgtcatg gaagcgcagg 480  
 atggggattt agcctacctg aggggtcagt cagcaaaggc ctctgggagg aagttagatc 540  
 ttcggctgag gatgtgaagg gctaaaagg gaatgaggaa gaggtttcagg gagaggaaatc 600  
 aatgaaacga gtccagagac gctggtgagt tggatggttt gcttcagtat gatgacaata 660  
 cagaggggca aggagactgg tgcaggagaa gagagaaggt gccatgtgct ctgggtcgtg 720  
 tcttctatgc cagactccct tagaagagga gcagcctcca gtcagcgggtg tcccaggaac 780  
 acggaggcta gacaggacaa tggcagccaa tccctgctcc caaactgggt acagtgggga 840  
 aaagtgcgat ggtctagatc caccctgtc cctggcccca gtatagaaga tcaaattcaa 900  
 tctgccaat cttatccaga taaagtaaag gaagactgga aaaaagaact aatccacggc 960  
 tccatctgcc catgactttc tctgctgatg ccggaggcag ctatggataa agagacggca 1020  
 cacggcatgt cccgacgctg tggaggtggg gagacccgc aagtccacag gaaaagagtt 1080  
 aagttgctgc cacctgggca tccgctatc tctgctcttc tgccctatcc tcaattcaga 1140  
 ccatgatgga gctgattgtc tcccatttta tnccttggat tgaatggctc cgag 1194

<210> 65  
 <211> 1677

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1012)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 65

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| ggtgcagtgg  | tgccatcaca  | gttcactgca  | gccttgacct  | cccgggctca  | agcaatcctc  | 60   |
| ccacctcagc  | cacttgagta  | gctgagacct  | cagatatgtg  | ccatcacacc  | cagctgattt  | 120  |
| tttaaaatta  | atTTTTTgta  | gagatagggt  | ctcatatgtt  | gcccattgctg | gtctcaaaact | 180  |
| actgggttca  | aatgatcctc  | ctgcctcagc  | cttccaaagt  | actgggatta  | caggcatgag  | 240  |
| ccaccatgcc  | gggctgggag  | gcggaatttt  | gttcagtcta  | aagataagct  | ttttcatagc  | 300  |
| tctggctgta  | gtgggaggga  | gcagaggagt  | gaatgattgt  | cagttgggag  | ggtgcagagt  | 360  |
| gggctcctgc  | cctaggggtgr | aggtraggggt | ggcttaggtg  | asmcamcaca  | gaggccctgt  | 420  |
| tcagcccccac | gtcccccctcc | tgtgctccct  | cctcctctct  | cctcctcctgc | aggcgtggra  | 480  |
| ggtatcatca  | ttcagcagat  | ttcaccagag  | gcagtggagg  | aggcagggtac | ctgagccaga  | 540  |
| attcagaatg  | tcttattctc  | cacttgactc  | tgccactaac  | ttgttgtgca  | actttgggcc  | 600  |
| tttccccagg  | ccttcatttt  | cttttctttt  | cttttctttt  | yttttttttt  | gaggcggagt  | 660  |
| ctcgctatgt  | tgcccaggct  | ggagtgcagt  | ggcgagcat   | catctcggct  | cactgcaagc  | 720  |
| tocaccttct  | gagttcacgc  | cattctactg  | cctcagcctc  | ccgagtagcc  | gggactgcag  | 780  |
| gcrccccacca | ccacgcccgg  | cttatttttt  | gtatttttag  | tagagacagg  | gtttcaccac  | 840  |
| gttagccaag  | atggtctcga  | tctcctgacc  | tcgtgatcca  | ccgcctggg   | cttcccaaag  | 900  |
| tgctgggatt  | acaggcgtga  | gccactgcgc  | ccggccattt  | tcttaaatat  | ctaataaaaa  | 960  |
| atatatagca  | aatgcagttt  | ttaaactacg  | acaatatgac  | cacgcaaaag  | antattatct  | 1020 |
| tccaagactg  | ctgggtccaa  | gaaaagtcag  | taataaagtg  | gaagcattgt  | agcttatgga  | 1080 |
| atgactgggt  | asatttgga   | gaagccttag  | caataatcta  | gaatctgcat  | agataataca  | 1140 |
| tctgaggatt  | gggctttgtg  | gtttacaaaag | catttttttt  | tcctcttttg  | atcccagccg  | 1200 |
| tttgtctgga  | ctgatacaaa  | gcatttttat  | tagtttgtct  | tattcaatcc  | tcacaccacc  | 1260 |
| tcaaatttac  | agaggatatg  | gatctgggtta | atttgtatga  | ctatgtaacc  | tcagtgcagt  | 1320 |
| ccacagcact  | gcctggagggt | gggtagagggt | ggctcctgggc | tggaatccca  | gccccagtgg  | 1380 |
| gaccttgagc  | aagttacttt  | agctgtctgc  | acctaaattt  | cctcactggc  | aaaacaggaa  | 1440 |
| tactgtgtgt  | tcacacctgc  | aattccagca  | ctttgggagg  | ctgagggtggg | aggattgctt  | 1500 |
| gagtcagaaa  | gttcaaaaacc | agactgggca  | acatagcaag  | accatctcta  | caaaaattaa  | 1560 |
| ataaaataaaa | cattttacaag | ggttgtgtgtg | aagattaaat  | gagatcactc  | acgaaaaaagc | 1620 |
| tcagcagacc  | ctgatgtgca  | gtaggtgctc  | aataaatgtt  | agccagcaaa  | aaaaaag     | 1677 |

&lt;210&gt; 66

&lt;211&gt; 1237

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 66

|             |             |             |             |             |            |     |
|-------------|-------------|-------------|-------------|-------------|------------|-----|
| agcaaaccca  | ggaagggtgtg | gcgtccccgc  | ttcgcgccaa  | gatgggtgctg | gtgctgcgcc | 60  |
| atcctttgtg  | tgccccggaa  | agggcggttc  | gggagccggg  | tcgggggctc  | ctgactcgca | 120 |
| ctgggcagca  | tgacgggtcg  | ccggctgtca  | ctgctgtgcc  | gggacctctg  | ggcgctgtgg | 180 |
| ctgctgtctga | aggccggcgc  | agtgcgtggg  | gcgcggggcg  | gtcctcgcct  | ccccggaagg | 240 |
| tgttgtgggg  | cgacatgcgg  | ggacgcggg   | cgggggtgga  | cgttctgggc  | ccagccctgt | 300 |
| cctcagaagc  | tgtctggggca | gaagcccggg  | gctgggggat  | gccggggatg  | ggtgttgggg | 360 |
| tgggtgcctc  | cgagaccaga  | ggagccctgt  | tccttggcag  | ggaagggtgtg | cacgggcctt | 420 |
| gcccgtgga   | tggtttaggg  | ccatggccct  | gggtccctg   | gtgagcagtg  | gggcccctc  | 480 |
| tgcccttggc  | ctgtgagggga | ctgtctgtgc  | tgggtcccaga | aggctgggat  | cacctttcca | 540 |
| ctggctcctt  | tgttcgaggt  | ttttcataga  | caggctatgt  | ggacaaatga  | gggcagcgcc | 600 |
| cacgtctggc  | tgggtggagg  | gctgcggctc  | ctccttgagg  | gggacgcctg  | gccactgctg | 660 |
| tcccacaat   | ggggccacc   | gtgggtgcaag | gcgtgacaag  | ctgcctctc   | taggtaagca | 720 |
| ggacttggga  | ggcccctggc  | caagcctgtg  | gaccgcgctg  | ggcgccctct  | gtggtctcag | 780 |

39

|             |             |             |            |            |             |      |
|-------------|-------------|-------------|------------|------------|-------------|------|
| gtttgggtgt  | gtttgggtctg | gtcagggtctc | aggggctgct | ggccacact  | ggccccatcc  | 840  |
| tgacaattgg  | agctttgggg  | caagggtccct | ggagaagggg | tcacgtcggg | aggaaacagc  | 900  |
| ctgggttttg  | ttgatgcttt  | tctaagaatg  | gagtactcgt | tttcaagaga | tttgtcctaa  | 960  |
| ttatatatttc | cagcggttac  | ttatgccaa   | tattgatgaa | taattcataa | aataagcatc  | 1020 |
| tttgtgaatt  | ttagtgaatc  | agaccttaac  | tatcaacggc | aatgaatgaa | catctaaagt  | 1080 |
| ttccaatttt  | aaagtaaaga  | actggctggg  | tacagcagtt | cacgcctgta | atccagcac   | 1140 |
| tttgggaggg  | caaggctaga  | ggatcgcttg  | agcccaggag | tttgagatca | gcctggggcaa | 1200 |
| cataccaaga  | cctcatctgt  | taaaaaaaaa  | aaaaaaa    |            |             | 1237 |

&lt;210&gt; 67

&lt;211&gt; 1934

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 67

|             |             |             |             |             |            |      |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| ccacgcgtcc  | ggggcggtcc  | tggtcgtgag  | aggggagccc  | caggggagct  | ggggcagcat | 60   |
| gactgggggtg | ataaatggcc  | ggaaatttgg  | cgtggccaca  | ctcaacacca  | gcgtgatgca | 120  |
| ggaggcacac  | tccgggttca  | gcagcatcca  | cagcagcatc  | cgccatgtcc  | cagcaaactg | 180  |
| ggggcctctg  | atgcgggtgc  | tcgtgggtcac | catcgcccc   | atctactggg  | ccctggccag | 240  |
| agagagtggtg | gaagccctga  | atggccactc  | tctgactggg  | ggcaagtcc   | ggcaggagtc | 300  |
| acacgtggag  | tttgcctacag | gggagctgct  | cacgatgacc  | cagtggcccc  | gggtctggat | 360  |
| cccgatggcc  | tcctgctcct  | cgacgtggtg  | gtcaatggcg  | ttgtccccgg  | acagcctggc | 420  |
| tgacgcagat  | cttcaagtgc  | aggactttga  | ggagcactac  | gtgcaaacag  | ggcctggcca | 480  |
| gctgttctgtg | ggctccacac  | agcgcttctt  | ccaggggcgg  | ctccccctgt  | tcctacgctg | 540  |
| caaccacagc  | atccagtaca  | acgcggcccc  | ggggccccag  | ccccagctgg  | tgcagcacct | 600  |
| gcgggcctca  | gctatcagct  | cggcctttga  | tccagaggcc  | gaggccctgc  | gcttccagct | 660  |
| cgctacagcc  | ctgcaggcgg  | aggagaacga  | ggtcggctgc  | ccccagggct  | ttgagctgga | 720  |
| ctcccaggga  | gcgttttgtg  | tgatgttgga  | cgagtgtgcg  | tgggatgtc   | acctctgccg | 780  |
| agagggacag  | cgctgtgtga  | acctgtctcg  | gtcctaccgc  | tgcctccccg  | actgtgggcc | 840  |
| tggcttccgg  | gtggctgatg  | gggcccggctg | tgaagatgtg  | gacgaatgcc  | tggagggggt | 900  |
| ggacgactgt  | cactacaacc  | agctctgcga  | gaacacccca  | ggcggtcacc  | gctgcagctg | 960  |
| ccccaggggt  | taccggatgc  | agggccccag  | cctgccctgc  | ctagatgtca  | atgagtgcct | 1020 |
| gcagctgccc  | aaggcctgcg  | cctaccagtg  | ccacaacctc  | cagggcagct  | accgctgcct | 1080 |
| gtgcccccca  | ggccagaccc  | tccttcgcga  | cggaaggcc   | tgcacctcac  | tggagcggaa | 1140 |
| tggacaaaat  | gtgaccacgg  | tcagccaccg  | aggccctcta  | ttgccctggc  | tgcggccctg | 1200 |
| ggcctcgatc  | cccggtaacct | cctaccacgc  | ctgggtctct  | ctccgtccgg  | gtcccatggc | 1260 |
| cctgagcagt  | gtgggcccgg  | cctggtgccc  | tcctgggttc  | atcaggcaga  | acggagtctg | 1320 |
| cacagacctt  | gacgagtgcc  | gcgtgaggaa  | cctgtgtcag  | cacgcctgcc  | gcaacactga | 1380 |
| gggcagctac  | cagtgcctgt  | gccccgccgg  | ctaccgtctg  | ctccccagcg  | ggaagaactg | 1440 |
| ccaggacatc  | aacgagtgcg  | aggaggagag  | catcgagtgt  | ggaccgggcc  | agatgtgctt | 1500 |
| caacacccgt  | ggcagctacc  | agtgtgtgga  | cacaccctgt  | cctgccacct  | accggcaggg | 1560 |
| ccccagccct  | gggacgtgct  | tccggcgctg  | ctcgaggac   | tgcggcacgg  | gcccgccttc | 1620 |
| tacgctgcag  | taccggctgc  | tgcgctgccc  | cctggggcgtg | cgcgccacc   | acgacgtggc | 1680 |
| ccgcctcacc  | gccttctccg  | aggctggcgt  | ccccgccaac  | cgccaccgagc | tcagcatgct | 1740 |
| ggagcccagc  | ccccgcagcc  | ccttcgcgct  | gcgtccgctg  | cgcgggggcc  | ttggcgcggt | 1800 |
| ctacacccgt  | cgcgcgctca  | cccgcgcggg  | cctctaccgg  | ctcaccgtgc  | gtgctgcggc | 1860 |
| accgcgccac  | caaagcgtct  | tcgtcttgct  | catcgccgtg  | tccccctacc  | cctactaaac | 1920 |
| gggagagggc  | attg        |             |             |             |            | 1934 |

&lt;210&gt; 68

&lt;211&gt; 3300

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

<222> (1)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (15)  
 <223> n equals a,t,g, or c

<400> 68

|             |             |            |             |             |            |      |
|-------------|-------------|------------|-------------|-------------|------------|------|
| ncngcagccg  | gacgnccgag  | cgagcgaggt | cagtgagcga  | ggaagcggaa  | gagcgcccaa | 60   |
| tacgcaaacc  | gcctctcccc  | gcgcgttggc | cgattcatta  | atgcagctgg  | cacgacaggt | 120  |
| ttcccgaactg | gaaagcgggc  | agtgcgcga  | acgcaattaa  | tgtgagttag  | ctcactcatt | 180  |
| aggcacccca  | ggcttttacac | tttatgcttc | cggtcgtat   | gttggtgga   | attgtgagcg | 240  |
| gataacaatt  | tcacacagga  | aacagctatg | accatgatta  | cgccaagctc  | gaaattaacc | 300  |
| ctcactaaaag | ggaacaaaag  | ctggagctcc | accgcggtgg  | cgcccgctct  | agaactagt  | 360  |
| gatcccccg   | gctgcaggaa  | ttcggcacga | gaacacatct  | taagggaacc  | aagtctcaag | 420  |
| agaaatcaag  | taattatgaa  | tgaacagctc | taaaaaagag  | agagagaata  | ttttcttaaa | 480  |
| tcaacttagt  | tgtgtttatg  | accaaagaac | agtgtttgtg  | gtgttcaccc  | cagagaagca | 540  |
| agagattttc  | ccttaaacct  | cagcttataa | tgaatggaag  | tgaatgacag  | ggagagagtt | 600  |
| tttctctcgt  | ttcccagaac  | tctatccttt | tcttctcaaa  | cagttggaaa  | ctgtagccaa | 660  |
| tacagtagac  | agtgatatgg  | gagaaccaa  | tcgtcatcca  | agcatgtttc  | tcttactttt | 720  |
| ggtgttggag  | agactctacg  | cttccccgat | ggatgggtact | tcttctgctc  | tcagcatggg | 780  |
| accttttgtt  | cccttcatta  | tgaggtgtgg | tcactcacct  | gtctaccact  | cccgtgaaat | 840  |
| ggcagctcgt  | gccttggtcc  | catttggtat | gatagatcac  | attcctaata  | ccattcgaac | 900  |
| tctgtgtgct  | acactcccca  | gctgcactga | ccagtgtttc  | cgccaaaacc  | acattcatgg | 960  |
| gacacttctc  | cagggtttttc | atttggtgca | agcctactca  | gactccaaac  | acggaacgaa | 1020 |
| ttcagacttc  | cagcacgagc  | tgactgacat | cactgtttgt  | accaaagcca  | aactctggct | 1080 |
| ggccaagagg  | caaaatccat  | gtttggtgac | cagagctgta  | tatatgtata  | ttctcttctt | 1140 |
| attgacttgc  | tgccctcaaca | gatctgcaaa | ggacaaccag  | ccagtctctg  | agagtcttgg | 1200 |
| cttctgggag  | gaagtcagag  | ggattatctc | aggatcagag  | ctgataacgg  | gattcccttg | 1260 |
| ggccttcaag  | gtgccaggcc  | tgccccagta | ctccacagagc | ctcaccagac  | tagccattgc | 1320 |
| tgagtggtgg  | gccgcggcag  | ccaagagtgg | agagcgggag  | acgaatgtcc  | ccatctcttt | 1380 |
| ctctcagctg  | ttagaatctg  | ccttccctga | agtgcgctca  | ctaaccactg  | aagccctctt | 1440 |
| ggaaaagttc  | ttagcagcag  | cctctggact | tggagagaag  | ggcgtgccac  | ccttgctgtg | 1500 |
| caacatggga  | gagaagttct  | tattgttggc | catgaaggaa  | aatcaccacg  | aatgcttctg | 1560 |
| caagatactg  | aaaattctcc  | actgcatgga | ccttggtgag  | tggcttcccc  | agacggagca | 1620 |
| ctgtgtccat  | ctgaccccaa  | aggagttctt | gatctggacg  | atggatattg  | cttccaatga | 1680 |
| aagatctgaa  | attcagagtg  | tagctctgag | acttgcttcc  | aaagtcattt  | cccaccacat | 1740 |
| gcagacatgt  | gtggagaaca  | gggaattgat | agctgctgag  | ctgaagcagt  | gggttcagct | 1800 |
| ggtcatcttg  | tcatgtgaag  | accatcttcc | tacagagtct  | aggctggccg  | tcgttgaggt | 1860 |
| cctcaccagt  | actacaccac  | ttttcctcac | caacccccat  | cctattcttg  | agttgcagga | 1920 |
| tacacttgct  | ctctgggaagt | gtgtccttac | ccttctgcag  | agtgaggagc  | aagctgttag | 1980 |
| agatgcagcc  | acggaaaaccg | tgacaactgc | catgtcacaa  | gaaaataacct | gccagtcaac | 2040 |
| agagtttgcc  | ttctgccagg  | tggatgcttc | categtctctg | gccctggccc  | tggccgctct | 2100 |
| gtgtgatctg  | ctccagcagt  | gggaccagtt | ggccctgga   | ctgcccattc  | tgctgggatg | 2160 |
| gctgttggga  | gagagtgatg  | acctcgtggc | ctgtgtggag  | agcatgcata  | aggtggaaga | 2220 |
| agactacctg  | tttgaaaaag  | cagaagtcaa | cttttgggcc  | gagaccctga  | tctttgtgaa | 2280 |
| atacctctgc  | aagcacctct  | tctgtctcct | ctcaaaagtc  | ggetggcgctc | ccccaaagcc | 2340 |
| tgagatgctc  | tgtcaccttc  | aaaggatggt | gtcagagcag  | tgccacctcc  | tgtctcagtt | 2400 |
| cttcagagag  | cttccaccag  | ctgctgagtt | tgtgaagaca  | gtggagttca  | caagactacg | 2460 |
| cattcaagag  | gaaaggactt  | tggcttgctt | gaggetgctg  | gccttttttg  | aaggaaagga | 2520 |
| aggggaagac  | accctagttc  | tcagtgtttg | ggactcttat  | gcagaatcga  | ggcagttaac | 2580 |
| tcttccaaga  | acagaagcgg  | catgttgaag | aaaatctggg  | ggattgggat  | gggggtatgt | 2640 |

41

|            |            |            |            |             |            |      |
|------------|------------|------------|------------|-------------|------------|------|
| gtggattttt | cctccactaa | atctgcagga | aacatgttga | acataaatc   | aaaaatttta | 2700 |
| tcccaaaaa  | aaaaaaaaa  | aaactcgagg | gggggcccgg | tacccaattc  | gccctatagt | 2760 |
| gagtcgtatt | acaattcact | ggccgtcggt | ttacaacgtc | gtgactggga  | aaaccctggc | 2820 |
| gttacccaac | ttaatgcct  | tgcagcacat | ccccctttcg | ccagctggcg  | taatagcgaa | 2880 |
| gaggccccga | ccgatcgccc | ttcccaacag | ttgcgagccc | tgaatggcga  | atggcaaatt | 2940 |
| gtaagcgtaa | atattttggt | aaaattcgcg | ttaaattttt | gttaaatacag | ctcatttttt | 3000 |
| aaccaatagg | ccgaaatcgg | caaaatccct | tataaatcaa | aagaatagac  | cgagataggg | 3060 |
| ttgagtgttg | ttccagtttg | gaacaagagt | ccactattaa | agaacgtgga  | ctccaacgtc | 3120 |
| aaagggcgaa | aaaccgtcta | tcaggggcgt | ggcccactac | gtgaaccatc  | accctaatac | 3180 |
| agtttttttg | ggtcgaggtg | ccgtaaagca | ctaaatcgga | accctaaagg  | gagccccga  | 3240 |
| tttagagctt | gacggggaaa | gccggcgaa  | gtggcgagaa | aggaaggga   | gctgtctctt | 3300 |

<210> 69  
 <211> 1797  
 <212> DNA  
 <213> Homo sapiens

|             |             |
|-------------|-------------|
| <400> 69    |             |
| ggtcgacggt  | atcgataagc  |
| gagagggcca  | cgctccatt   |
| catgagctcg  | gggactgaac  |
| ggcagccagt  | ctgtgtgtgc  |
| ccagcagaga  | agtcctgcgtg |
| ggtcggggcag | gcatggccag  |
| gttgcaattc  | taccccagcc  |
| aggaagcaga  | cacgggtcgg  |
| ctggggggcg  | ttctcgaagc  |
| catttgcaag  | cagaaaacca  |
| cagaggggac  | ctcagcctgt  |
| ctctgcctcc  | ccggaagaag  |
| ccattcagtg  | gcgcgagtc   |
| tggcccgggtg | ggaagcccag  |
| ggcagccaca  | gaagcctagg  |
| tgtgctcatg  | gacccatcgc  |
| agcccctgcc  | atggttgctc  |
| gcgtgcacag  | cctgggaaaa  |
| ctctcccgc   | ccaggctttg  |
| tatggacgga  | tgcgcaggat  |
| gtccaacact  | ggtatctgtg  |
| tgggttgctgg | ggttttaaat  |
| atatttaaca  | ttctggattt  |
| atgtagttta  | tttcagcatc  |
| acctcccctt  | tccttgggct  |
| tgtgcttcca  | gtggaaatgt  |
| agtgaccaga  | acagggcaga  |
| ggctggcctc  | tgagagctg   |
| ccagagggga  | ccttgagtca  |
| ctcaataaaa  | ccatttttagt |
| ttgatatoga  | attcctgcaa  |
| caccaggcca  | cgcatcacia  |
| tgctgtggcc  | eggagcagcg  |
| gctgctcacg  | cccagggtgca |
| aggaccaaca  | gagctttacg  |
| gacctgtggc  | ggacatggca  |
| agcatcttcc  | aggtaccaga  |
| catagacccc  | attgccatgg  |
| tgatgatgcc  | aattcctacg  |
| tgcccagcag  | gagggcatag  |
| gaagactggc  | cccacttctg  |
| ctgaggatta  | tcagaacttc  |
| tggggcaact  | ccagagaaga  |
| cggggaaccg  | gattacgtga  |
| aagaaaggag  | ccaaggcaaa  |
| ggaccatttc  | ccagagctac  |
| aaccagccac  | cctgaggacc  |
| cacgggagct  | gcaggccccg  |
| acctggtacc  | aagggttaacc |
| ctgtcaccca  | gtccccataa  |
| ctatgaattt  | ggattcctaa  |
| cttgtagagt  | taacttatag  |
| atttctgtgt  | tgtctcctag  |
| ggggccctgg  | ctctcttccc  |
| caggaagaaa  | tgaggctgtc  |
| agacaatagt  | gcatgagagt  |
| tccatggccc  | tgaatcctcc  |
| gttgtgactg  | tctcatggga  |
| cagaaaaagt  | atctcctcca  |
| aaaaaaa     | aaaaaaa     |

<210> 70  
 <211> 1373  
 <212> DNA  
 <213> Homo sapiens

|            |            |
|------------|------------|
| <400> 70   |            |
| ggcacgaggg | ctgacggcgc |
| ttttgtctcc | ggtgagtttt |
| gtggcgggaa | gcttctgcgc |



|             |            |            |            |            |            |      |
|-------------|------------|------------|------------|------------|------------|------|
| tggtgcttag  | taaccgactt | tctccggac  | tctgcacga  | cctgctccta | cagccggcga | 120  |
| tccactcccc  | gctgttcccc | cggaggtcca | gaggccttcc | agaaggagaa | ggcagctctg | 180  |
| tttctctgca  | gaggagtagg | gtcctttcag | ccatgaagca | tgtgttgaa  | ctctacctgt | 240  |
| taggtgtggt  | actgacccta | ctctccatct | tcgttagagt | gatggagtcc | ctagagggtc | 300  |
| tactagagag  | cccctgcct  | gggacctcct | ggaccaccag | aagccaacta | gccaacacag | 360  |
| agccacccaa  | gggccttcca | gaccatccat | ccagaagcat | gtgataagac | ctccttccat | 420  |
| actggccata  | ttttggaaca | ctgacctaga | catgtccaga | tgggagtccc | attcctagca | 480  |
| gacaagctga  | gcaccgttgt | aaccagagaa | ctattactag | gccttgaaaa | acctgtctaa | 540  |
| ctggatgctc  | attgcctggg | caaggcctgt | ttaggccggg | tgccgtgggt | catgcctgta | 600  |
| atcctagcac  | tttgggaggg | tgatgtgggt | ggatcacctg | aggtcaggag | ttcagaccag | 660  |
| cctcgccaac  | atggcgaaac | cccatctcta | ctaaaaatac | aaaagttagc | tgggtgtggt | 720  |
| ggcagaggcc  | tgtaatccca | gctccttggg | aggctgaggc | gggagaattg | cttgaacccg | 780  |
| gggacggagg  | ttgcagttag | ccgagatcgc | actgctgtac | ccagcctggg | ccacagtgca | 840  |
| agactccatc  | tcaaaaaaaa | aagaaaagaa | aaagcctgtt | taatgcacag | gtgtgagtgg | 900  |
| attgcttatg  | gctatgagat | aggttgatct | cgcccttacc | ccggggtctg | gtgtatgctg | 960  |
| tgctttcctc  | agcagtatgg | ctctgacatc | tcttagatgt | cccaacttca | gctgttggga | 1020 |
| gatggtgata  | ttttcaaccc | tacttcttaa | acatctgtct | ggggttcctt | tagtcttgaa | 1080 |
| tgtcttatgc  | tcaattatct | ggtgttgagc | ctctcttcca | caagagctcc | tccatggttg | 1140 |
| gatagcagtt  | gaagagtgtg | tgggtggggt | gttgggatga | gatggagtgt | tcagtgcaca | 1200 |
| tttctcattt  | tacattttaa | agtcgttctc | ccaacatagt | gtgtattggt | ctgaaggggg | 1260 |
| tgggtgggatg | ccaaagcctg | ctcaagttat | ggacattgtg | gccaccatgt | ggcttaaatg | 1320 |
| attttttcta  | actaataaag | tgggatatat | atttaaaaaa | aaaaaaaaaa | aaa        | 1373 |

&lt;210&gt; 71

&lt;211&gt; 1579

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 71

|             |             |             |             |             |            |      |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| ggcacgagga  | tttggagggg  | acaaacatcc  | aaaccattta  | agtcacagca  | ctttactccg | 60   |
| cagtgtgaat  | aacacaggca  | ttctcctaca  | taatcacagt  | acagttatca  | tactctggaa | 120  |
| attgaatata  | atctaataata | ctttccatac  | ccagattttc  | ttagattttc  | caatgatatt | 180  |
| tcttactgtc  | ctccctttag  | cccttctctt  | tctccattca  | ggattctacc  | attacatttc | 240  |
| attttcatgt  | ctcttcagtc  | tctctttagc  | cttgtttttc  | tttcttgatg  | ttgccacttt | 300  |
| taggaggcca  | ggccagttgt  | tttgtgaaag  | atctgttctc  | tttgatatgt  | ttcatttttg | 360  |
| atttgtttca  | ttgtttttgc  | atgaatggat  | tcaggctaaa  | cattttttgg  | caggactggt | 420  |
| tattgtatta  | cctagtgtatg | tgttcttttc  | agtcacatcat | ctggaggcac  | ctgatggcag | 480  |
| ttttcccaat  | attgcgaaat  | taagtttgat  | tattttgtta  | aggtagtgtc  | caccagatct | 540  |
| ctccatttta  | aagacatcct  | tttctctaat  | tactcagtgg  | actgtagagt  | gatgctttga | 600  |
| aactgaataa  | ctaactctcc  | ctaactcagt  | gatttagcac  | ccgttgattt  | tttttttttg | 660  |
| cctgaatcaa  | atattattat  | agtagtttta  | aatgggtgatt | ttccattttc  | attcttttgt | 720  |
| tagctgccat  | tcttctataa  | ttttgtcttt  | atattttact  | gggtgttaag  | attgctattc | 780  |
| cagctttcct  | ttgtctttta  | caccttttcc  | cattctttta  | tttttttcca  | tccctttttg | 840  |
| tctgtttttc  | caatagatgg  | atagaatttt  | ctttctctgg  | tttaaagggt  | atacatttgt | 900  |
| gtgtgtgtgt  | gtattctaaa  | ccattttgcc  | ttaaaacata  | gagatgggtta | ttcctgttga | 960  |
| ttaaaaaaa   | ctcagtaaatg | ttactatctt  | ctctttaata  | agatagggtac | tttatttcat | 1020 |
| tctgtgttct  | tgggtgaggt  | ctccctccac  | ccagtcaggt  | tgatgttaat  | ctagaatttt | 1080 |
| tagtttttta  | aattatcgat  | atactttctg  | tcttttctct  | tttttttcac  | tctctctgta | 1140 |
| tttgtgtctt  | ccccctttac  | tctctttccc  | ttcattcctt  | ctttctcact  | ttcttcttct | 1200 |
| atttttctact | cttgggtaga  | ttatctttta  | gaaaacagca  | agatattata  | taatttactt | 1260 |
| tatatctctc  | ttccaaatga  | ttaaagtaat  | aattaaaaat  | ttttgatatg  | tgtgtatgca | 1320 |
| aggataggaa  | tcctcttgta  | agtggaaagaa | ctctaccaca  | tgcatgagtc  | attagtgtgt | 1380 |
| taaacactgg  | gaagtggcct  | taggtccagc  | tgggtgctct  | gaagaaggta  | ggtttcttca | 1440 |
| gttctttatg  | ttaactgtct  | ccttacctta  | aaaaaggagt  | gaagaatact  | gactgcagag | 1500 |
| gttttgtgag  | gattccggta  | acacagaagc  | atagaactgg  | aaaagaatat  | taatatgtgc | 1560 |
| caaaaaaaaa  | aaaaaaaaa   |             |             |             |            | 1579 |

<210> 72  
 <211> 1028  
 <212> DNA  
 <213> Homo sapiens

<400> 72  
 gcacgacaat tgaactgaac cctaaaaatg ctacttcaat tcaccttatg ggtatttgggt 60  
 gctatacatt tcccgaatg ccttgggtatc aaagaagaat tgctaaaatg ctgtttgcaa 120  
 ctgctccta gttccaccta tgagaaggta gtatgatgtc ctttggttaag ttagtacgga 180  
 tttcttgaac cacagcgccc attctacat gtgttccaca cattgtggag ctctggattc 240  
 agtgaagggg acttgaggca atttccttaa cgatccaatt caactgtggt atcacaaggc 300  
 ttaacactta ttatccttga ctgggtgagtg gttttctttt tccccgttag gtgagtggct 360  
 ggtaattctg gaatactgtc atctaaaatg gctcgtggct aaaatctacc ttcattttct 420  
 gtttgaaatc taaactatat tgaagtcata aaatagaaca agaaatacag catctgttac 480  
 ccagcatggt ttagctgtat tacacacaat aacagaaaag taaagcagat gcttaagttg 540  
 ataaaagaag aacactcatt ataacttcta ttttaaaaag catatgaaag gttcatattc 600  
 tctcatattt tcaaggcctt ttgcttttct tgttaaaaat aagatttgag aggaatttct 660  
 ggttaactt tgggtttact catcacaagc ttttcagagt aagaaaacag gcaatcgaaa 720  
 aagctgtact tgtattatct acattataac aaggagcctt tttttcttct tgggaagcta 780  
 tagtgtagaa attgatgtaa aaaatactta gttgtattct ttacacacag ttgagaaata 840  
 ttattaaaaat aatgcaccaa tattttataa tggattattt aaaataatgc ccatttgctg 900  
 gacacggttg ctcatgcctg taatgccagc attttggag gccaaggttg gtggatcagt 960  
 tgagcctggg agtttgagac cagcctgggc aacgtggcaa aacccttgca aaaaaaaaaa 1020  
 aaaaaaaaaa 1028

<210> 73  
 <211> 3674  
 <212> DNA  
 <213> Homo sapiens

<400> 73  
 ggcacgagct caaaagaaat aggggtgattt ttaaaggatt aataaaattc tgaaatgtta 60  
 agtagaagat tacattgtct agtcttgtat ttctctcttc tgttgccttc tttcattcac 120  
 acactctcag tttctcatat ttgtagctca tttatttgggt tatttcoctaa gaattattgaa 180  
 agtgaagcaa ctatgtgact gtattcttca ggtaaacact gactgcgctt gttggatttt 240  
 ccctattttt gtgacttcaa gaataatatg ccctgctgaa tacatgccat ttcacattct 300  
 gaaactgggt agagtgggtg ggtgttctgc caacaattgc tagtgggtgtg aattcattca 360  
 tatttgccag tattgtctac ttcaaagaaa ctcttctatc aagcagcca gagctaggcc 420  
 agatcaatgc tacaatcatg aagttctcat tgcattgcaat tgtgtaggat tgacaaggaa 480  
 ctacagataaa aatttccagg gtgcacttcc agaaccagct tcaacatatg tctacattgc 540  
 ccccaagtta ataaagtgc aaccctttac tctctcatat agccagaaat gttagaatc 600  
 caaaatcttg gtgcattatt ttttcataaa cgctaaaaca tttgaagaaa caatttaatt 660  
 atttaaaatt caagtatttt attcacatta tttgcaatat ccaaatgttt aaaaattccc 720  
 agataattaa ctagctatta cagatctcac cttaggggtt gatgttatga agactccagt 780  
 ggactgtact cacaatttga ctggacacc tatgaaagtg ggtagacctc tcagcgga 840  
 ataagaaggg cttttaccta cagggcagga caggggtccca tgagagcagt tctgtggaga 900  
 tataaaaaga atggaagaag gaatgcctta tagtgatatt gtgacattat atctatatat 960  
 ctacatatat ctatctatct atatctacat ctatataatc ttacatttaa aattgtattc 1020  
 ctacacatat tagaaactct tctaataaat gaagtaaaaa aattaaaaag aatacaata 1080  
 ttccagcccc aaatgagaaa tcaaacatat taaaattgtt caagaaaatt tctttgaaca 1140  
 cttctgaaag tttttggaaa cttagaaaag agggaaaaaa atccagtgtt actagtaatt 1200  
 tccatggtaa tacagataaa atacattctt ttaattctgg gaaattagaa aaagtgggt 1260  
 gatctttcca ggaaaaacat gtgtaacatc tgcttatcac tccagctccc tctctctct 1320  
 cctctccacg ttcccttgag taaatgtctg ggaaagcatg aagcttgatg caagaacctt 1380  
 gttgtactgg cgttttctct ccctgtgaaa acgtaactac tgttgggagt gaattgagga 1440  
 tgtagaaagg tgggtggaacc aaattgttgt caatggaaat aggagaatat ggttctcact 1500

```

cttgagaaaa aaacctaaga ttagccagg tagttgcctg taacttcagt ttttctgcct 1560
gggtttgata tagtttaggg ttggggttag attaagatct aaattacatc aggacaaaga 1620
gacagactat taactccaca gttaattaag gacgtatgtt ccatgtttat ttgttaaagc 1680
agtgtgaata gccttcaagc atgtgaataa tcttccatct tccccgccac acatacacac 1740
acacactttt tgtttctttc aggtagacac cttttaaaat gcagaactaa ctgaggcatt 1800
tcagtaactt tgctttcaaa tcaataaagt caaatgtatg gaaacatttt gtgccctact 1860
ctccataccc cgtgtactca aattctctac tgtatgaatt atgctttaag tagaattcag 1920
tgccaaggag aacttgggtga aataaattat ttttaatttt tttttatcct ttacaaagcc 1980
atggatttta tttggttgat gtgtgctctg tacacaagcc atttcaatag gatggagctg 2040
ttaattattt tccaaagagt aatagacatg caaaagtctt aataaaaact gggccattaa 2100
caagtaaat aataaactaa taagcattcc ctctaggtt tttgccaaac tgcctatcca 2160
ataacaaatt tgagaatcgt tgtaaaagct agttatattt cagagaaatg attttcat 2220
ttgaaactgt tctccctagc aggccatttt ccctttttcc tgggagttta gcaagtttag 2280
gagagatatg tcatgaaaag aaagggaaga aaggggagaa ggaagagggt taaaaagtaa 2340
gtgctcagac ctatgaacgt aatccctttg ctacaaatat ttaagagcag ctgagcttgg 2400
ttgaaactga gttttgtcat cttccatatt tgcaggaggg tattttctga cttgcaatgc 2460
agctagatgt aaaaattttat tttatcatcc tagaaagcct tgactagaaa aatgaataaa 2520
tattgagggt ttctgtcca tatctggctt gcatgtgcca gaaagcagag aatagaaaat 2580
gtaatctcca acatccaagc atcgaaaccc aaggggtagg caattctatg taggttttgg 2640
acatgaagtt tgggtcatct tgggttatgc tggctcaact gctattaaac ctctctggct 2700
tatagtctct tcattctatt agacaagcac gtatcgaaac cttgcttcgc acaaggctct 2760
ttagtttaaca atttagcagc tactgtttgt gttaaacaca cttttcacca aataggttct 2820
gaggcaaacg agagcaatga ctatttaaag aaaggctttc ccagcatcac ttacacatcc 2880
caaaactaaa aagatcaact cttccaactg agaaaagact cctggctttg aatggaaact 2940
tacagcagag agtcacaggc cacggcaaca acaacgacaa caacaaacat ttggaatatt 3000
attctcaact cacgttttaa taatacatct tattattttt ctagtagaga aactacaaat 3060
cagcctcttc aacatttata tacagttaa taagcctctt gcaagttact tgttctctca 3120
cctgagggtat ttttttctc cccaccttgc cctgttctc ccttctctct tctcccttgc 3180
caagaggaaa tatttaacat atttgggtcc aacttcaata atgtaataat taatacatta 3240
aaagcattta acttcctttc tagaaaaatg cacaggctaa ggcatagaca aaacaaagag 3300
aaatgctgag aaatttgcca ctggagacaa gcaatctgaa taaatatttg ccaaaagttc 3360
tttttatgtc atatagtgtc aggtattgaa ggagctattt ttttttaatg ttgcaactag 3420
caactcatct tcggaagaca cagccaggag aatgaagtag aagtgaaggg ttataaaatc 3480
cattttgtaag catttatccc atatatatta aattcaagaa aaattgtgtt tatctttaga 3540
attttgtatt caatacttta tgtactatgt gactcatgct tctggataaa taaagcacca 3600
aatatgtatc tgtaaccaca atcacacata ttatattaaa tatatatcta tataacaaaa 3660
aaaaaaaaaa aaaa 3674

```

&lt;210&gt; 74

&lt;211&gt; 2797

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (853)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 74

```

ggcacgagag agcagacaga attatatgta gaggacacag gagatattta cattgtggat 60
ggagatggag gattgaataa cagattgac aaactgtccc aagatttcat gatcctttgg 120
ctgcatggag aaaatgggac agggcctgct aagttcaaca tacctcacag tgttacactt 180
gattcagctg gtcgggtgtg ggttgctgac cgaggaaata aaagaatcca agtatttgat 240
aaagacactg gggagtgtt agggagcatgg aataattgtt tcacagaaga ggaccttctt 300
cagtcagttt actcctgatg ggaagtactt gattgtggcc cagctgaatc ttagcaggct 360
ctcagtcgta gcagcacccc cagtggaag cattggggag tgtctgtga tcagcacaat 420
ccaactagca gatcaagttt tgccacatct cctagaagtc gacagaaaag actggagcag 480

```

45

|            |            |            |            |            |             |      |
|------------|------------|------------|------------|------------|-------------|------|
| tctatgtagc | agaaattgga | gcaaaacaag | tacaaaaata | tgtccctttg | aatagctatg  | 540  |
| ttccttcatt | tgggtcataa | tgtttctttc | cogggaaat  | ttcaagtggc | agttcagatt  | 600  |
| ctcaattcac | taagtgttta | aaaatgatgt | tcaagcaca  | gaatttat   | ttctagtata  | 660  |
| aaagatctag | tatcagaaa  | atgtgttttt | gtatcattaa | gaatcttata | ttttgttgcc  | 720  |
| ctcttgggac | ttagttttat | ttgtaagtgc | ataaggatat | tttaatgaaa | ggaaaagtaac | 780  |
| taaaaaatgg | ggttgggaag | agggactaag | gtggtaacct | cattattttg | cctggtagac  | 840  |
| tgattctccc | tgngtaaaaa | aaatgggaat | aaaaatgagc | ttgcatgata | atttattaaa  | 900  |
| tttcatgtga | agaactccag | acctccagat | tgtgcaacta | acataaagt  | agctgcttga  | 960  |
| gagattgtaa | ataagatgaa | ctattgatta | atgtgagtac | ccacagagt  | ctgtgtcttg  | 1020 |
| acgacttaaa | aatgaaaaag | catgattgcc | ttttgagtag | cttgcagtct | agtggggaga  | 1080 |
| caagcaggca | aacagtcaca | acacagcaaa | agcgaccttg | gagcatagt  | ggacttttgg  | 1140 |
| agtaggagtg | ctgcatttga | ctgagggaat | catggatact | tcgcaggaga | agtgaatttg  | 1200 |
| agctcagact | tgaaaactga | ggaggagctt | accaaggagc | aaggaggaga | aaacaataat  | 1260 |
| ttccaagtaa | agaaggtata | aaaagttaga | agtgtactgt | aaactttgat | aggcttttag  | 1320 |
| gcctttttta | aagcccaact | tggcttctgt | ccattaccta | taagatat   | aatgtcagtc  | 1380 |
| agccttttaa | tgtaggaata | aaatggctgg | catctaagca | ctttagtaaa | agaggttttt  | 1440 |
| acaaataact | aaggattgta | gagcttcctt | ctcttttttt | ttctttttct | ttctttttgt  | 1500 |
| ttacatgaac | tcaacttatt | cctaacattt | gtctacctca | aagaaatttc | aagattattt  | 1560 |
| agataacatg | gatattgtgc | aaatcctttg | agctgttaag | atgataattt | cctgctttcc  | 1620 |
| tctacatct  | tctcctccca | ctccctcctt | tgggtggaat | attggcttcc | caattaagac  | 1680 |
| cttttttttt | tccagtttgt | tttagcttat | tataggtttt | ggagggaact | tgccattttg  | 1740 |
| taatctttca | aatcattctt | caccttctct | cacatcagct | tctgcttttt | cccagtgttt  | 1800 |
| tactgtaaat | tgtgtagcat | atgacaaatc | ttgagctgac | tttccctctt | acctgttatg  | 1860 |
| gctggagtat | tttccagacc | tgaagggact | cacacttggt | ttgatacttg | gatcacatct  | 1920 |
| ccgtgaggtt | aggaaggtaa | atctaccaac | aggaagccct | gtactctgta | ttccaaggcc  | 1980 |
| attggtaaat | gtgttggtgc | cactgatcgg | actgtatgac | cttaaacaa  | tcaccttagt  | 2040 |
| tttcagtgaa | atgggaatat | cattgtctcc | tctttcatga | atgctgtgag | aatcagatgt  | 2100 |
| gcaacaggta | catacttgcc | ctttggaaat | ctaatacctc | tgggatacca | tttaagggca  | 2160 |
| ttttaattaa | acaaaagggc | ccttctaata | gtgctattta | tttgacaata | actatcagat  | 2220 |
| ttgccttaat | tttgtgttta | tagcatttat | caaaacgtat | cctcatagac | tttatgcaga  | 2280 |
| ttaatatggt | caattgattt | ggataaaaga | aagtaatttc | agggtttgtt | tttaagccag  | 2340 |
| gacaagaagt | gcaaatgcct | ctttgaaaga | athtaggtta | aactgatttt | gaaatttcaa  | 2400 |
| aatgttttat | tttactttgt | tttattaagc | caggacaaga | agtgcaaatg | cctctttgaa  | 2460 |
| gcaattcagg | ctaggtaaac | cgattttgcc | atttcaaaac | gttttatttt | actttgwttt  | 2520 |
| rrrtcagagt | yttawaarvc | ctgctgcaaa | tatttctgaa | tgtctttgta | aaagtgtttg  | 2580 |
| ttagtgtacc | tgtgattata | gtacttcact | tttttccctt | ggattaattg | gttaaatgaa  | 2640 |
| tgagaaatgt | gttatgtttt | ttactaaaaa | gtataaatta | aaattttgga | aagaaaaggc  | 2700 |
| aatattatct | ggctccccaa | ttaaagtttg | attttattgt | cacaaaaaaa | aaaaaaaaaa  | 2760 |
| aaaaaaaaaa | aaaaaaaaaa | aaaaaaaaaa | aaaaaaa    |            |             | 2797 |

&lt;210&gt; 75

&lt;211&gt; 2703

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

|            |            |             |             |            |            |     |
|------------|------------|-------------|-------------|------------|------------|-----|
| ggcacgagat | ttcctacagg | tgaaacgcca  | tcattaggat  | tactgtaac  | gttagtgcta | 60  |
| ttaaactcac | tagcattttt | attaatggcc  | gttatctaca  | ctaagctata | ctgcaacttg | 120 |
| gaaaaagagg | acctctcaga | aaactcaca   | tctagcatga  | ttaagcatgt | cgcttggcta | 180 |
| atcttcacca | attgcatctt | tttctgcctt  | gtggcgtttt  | tttcatttgc | accattgatc | 240 |
| actgcaatct | ctatcagccc | cgaaataatg  | aagtctgtta  | ctctgatatt | ttttccattg | 300 |
| cctgcttgcc | tgaatccagt | cctgtatggt  | ttcttcaacc  | caaagtttaa | agaagactgg | 360 |
| aagttactga | agcgacgtgt | taccaagaaa  | agtggtatcag | tttcagtttc | catcagtagc | 420 |
| caagggtggt | gtctggaaca | ggattttctac | tacgactgtg  | gcatgtactc | acatttgcag | 480 |
| ggcaacctga | ctgtttgcga | ctgctgcgaa  | tcgtttcttt  | taacaaagcc | agtatcatgc | 540 |
| aaacacttga | taaaatcaca | cagctgtcct  | gcattggcag  | tggcttcttg | ccaaagacct | 600 |
| gagggctact | ggtccgactg | tggcacacag  | tcggcccact  | ctgattatgc | agatgaagaa | 660 |

|             |            |            |             |             |            |      |
|-------------|------------|------------|-------------|-------------|------------|------|
| gattcccttg  | tctcagacag | ttctgaccag | gtgcaggcct  | gtggacgagc  | ctgcttctac | 720  |
| cagagtagag  | gattcccttt | ggtgcgctat | gcttacaatc  | taccaagagt  | taaagactga | 780  |
| actactgtgt  | gtgtaaccgt | ttcccccgtc | aaccaaaatc  | agtgtttata  | gagtgaaccc | 840  |
| tattctcatc  | tttcatctgg | gaagcacttc | tgtaatcact  | gcctgggtgc  | acttagaaga | 900  |
| aggagaggtg  | gcagtttatt | tctcaaacca | gtcattttca  | aagaacaggt  | gcctaaatta | 960  |
| taaatttggtg | aaaaatgcaa | tgtccaagca | atgtatgac   | tggttgaaac  | aaatatatga | 1020 |
| cttgaaaagg  | atcttaggtg | tagtagagca | atataatggt  | agttttttct  | gatccataag | 1080 |
| aagcaaattt  | atacctattt | gtgtattaag | cacaagataa  | agaacagctg  | ttaatatttt | 1140 |
| ttaaaaatct  | attttaaaat | gtgattttct | ataactgaag  | aaaatatctt  | gctaatttta | 1200 |
| cctaattgtt  | catccttaat | ctcaggacaa | cttactgcag  | ggccaaaaaa  | gggactgtcc | 1260 |
| cagctagaac  | tgtgagagta | tacataggca | ttactttatt  | atgttttcac  | ttgccatcct | 1320 |
| tgacataaga  | gaactataaa | ttttgtttta | gcaattttata | aatctaaaac  | ctgaagatgt | 1380 |
| tttttaaaaca | atattaacag | ctgttaggtt | aaaaaaatag  | ctggacattt  | gttttcagtc | 1440 |
| attatacatt  | gctttggtcc | aatcagtaat | tttttcttaa  | gtgttttggtg | attacactac | 1500 |
| tagaaaaaaa  | gtaaaaggct | aattgctgtg | tggttttagt  | cgatttggct  | aaactactaa | 1560 |
| ctaattgtggg | ggtttaatag | tatctgaggg | atgttggtggc | ttcatgtaat  | gttctcatta | 1620 |
| atgaatactt  | cctaatatcg | ttggctctac | taatattttc  | caatttgctg  | ggatgtcacc | 1680 |
| tagcaatagc  | ttggattata | tagaaagtaa | actgtgggtc  | atacttgcac  | ttaattagac | 1740 |
| gaaacgggga  | gtaattatga | cacgaagtac | ttatgtttat  | ttcttagtga  | gctggattat | 1800 |
| cttgaacctg  | tgctattaaa | tggaaatttc | catacatctt  | ccccatacta  | ttttttataa | 1860 |
| aagagcctat  | tcaatagctc | agagggtgaa | ctctgggttaa | acaagataat  | atgttattaa | 1920 |
| taaaaataga  | agaagaaaga | ataaagctta | gtcctgtgtc  | tttaaaaaat  | aaaaatttta | 1980 |
| cttgattccc  | atctatgggc | tttagacctt | ttactgggtg  | gagtcttaaa  | gttataattg | 2040 |
| ttcaatatgt  | tttttgaaca | gtgtgctaaa | tcaatagcaa  | accactgcc   | atattagtta | 2100 |
| ttctgaatat  | actaaaaaaa | tccagctaga | ttgcagttta  | ataattaaac  | tgtacatact | 2160 |
| gtgcatataa  | tgaattttta | tcttatgtaa | attattttta  | gaacacaagt  | tgggaaatgt | 2220 |
| ggcttctgtt  | catttcgttt | aattaaagct | acctcctaaa  | ctatagtggc  | tgccagtagc | 2280 |
| agactgttaa  | attgtggttt | atatactttt | tgcattgtaa  | atagtctttg  | ttgtacattg | 2340 |
| tcagtgtaat  | aaaaacagaa | tctttgtata | tcaaaatcat  | gtagtttgta  | taaaatgtgg | 2400 |
| gaaggattta  | tttacagtgt | gttgtaattt | tgtaaggcca  | actattttaca | agttttaaaa | 2460 |
| attgctatca  | tgtatattta | cacatctgat | aaatattaaa  | tcataacttg  | gtaagaaact | 2520 |
| cctaattaaa  | aggttttttc | caaaattcag | gttattgaaa  | attttttcatt | ttattcattt | 2580 |
| aaaaactaga  | ataacagata | tataaaagtg | ttaatctttg  | tgctatatgg  | tatgaaatac | 2640 |
| aatattgtac  | tcagtgtttt | gaattattaa | agtttctaga  | aagcaaaaaa  | aaaaaaaaaa | 2700 |
| aaa         |            |            |             |             |            | 2703 |

&lt;210&gt; 76

&lt;211&gt; 742

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (707)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (724)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (726)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 76

47

|             |             |            |            |            |            |     |
|-------------|-------------|------------|------------|------------|------------|-----|
| gcgctcgaga  | atagtggggtc | ccccggrctg | caggattcgg | cacgagctca | cttcaatyc  | 60  |
| tcttttgagaa | gtttttcctt  | tctccgcaac | cagatgtaca | tatttgaact | ctctttgtac | 120 |
| ttggagggca  | cttctttcgt  | ggtagttctt | ttatttttat | taatctctgt | atccttagat | 180 |
| agtcctccaa  | caaccaaagg  | ttgggactct | gtcttacata | tctgggtgcc | cctcatagtg | 240 |
| cagtaataag  | taagttgatt  | atatacgagc | tatgtaactt | atatttttta | atgggtggat | 300 |
| atcactgagt  | tttttttttt  | aagaattttt | ttattgaggt | aaacttcaca | taacataaaa | 360 |
| ttactatttt  | taaagtgaga  | agttcagtgc | cacttagtat | tgtaacaat  | gttgcataac | 420 |
| caccaccttt  | atttaaagtt  | ccaaaaaaa  | tgttctctc  | taaaaggaaa | ccccatccca | 480 |
| ttaaagcagat | actctccatt  | ccttccttcc | tccagccccc | agcaaccacc | aatctgcttt | 540 |
| ctgtctctat  | ggatttatct  | attcttgcta | ttttatataa | atcgaattgt | atgagacctt | 600 |
| ttgtgtctgg  | cttctttcac  | ttagtacaag | tttttgagat | ttatttacat | agtagcatgt | 660 |
| atcaacacctt | catttttatg  | gccaaaataa | attgtattat | gtgtttntag | cacaaaaaaa | 720 |
| aaananaaaa  | atgacctctg  | ag         |            |            |            | 742 |

&lt;210&gt; 77

&lt;211&gt; 1825

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 77

|             |             |             |             |            |             |      |
|-------------|-------------|-------------|-------------|------------|-------------|------|
| ggcacgagca  | tgtcacatgt  | atacctatgt  | aacacacctg  | cacattctgc | acatgtatcc  | 60   |
| cagaacttaa  | attataataa  | taaaaaaaga  | ataattgggt  | gatggcacat | ccagggttgc  | 120  |
| caaagacagt  | cccagtttat  | gctgttggtcc | tggcattatt  | aataatgaca | ctgcctttaa  | 180  |
| ctctcacat   | taatttggat  | gataacttat  | atggtaactc  | tgctaaataa | aaaaaataaa  | 240  |
| aattaccata  | gtaacaggaa  | cctacttgaa  | atgatgcctc  | tgtttctatt | ctggcttgaa  | 300  |
| ttctgcattc  | tttgaggatt  | tgtagcctca  | tgacagaatc  | ctatctacag | gtgatgtatt  | 360  |
| tcatatgatt  | tttggctatt  | tttttaacaa  | tctcaagccc  | aataatagcc | agtgatataa  | 420  |
| ggaaatgtagt | tactttctcc  | ccactttctg  | gcaagttaag  | tttagccacc | tgattacaag  | 480  |
| aagggacatt  | cagaggtagg  | atggcacaaa  | gacacagggt  | ccactggaga | tcactggaag  | 540  |
| cagctgcagc  | agggttaaga  | gaagggagtc  | ccagcgagtc  | ttcagtcacc | acacactaac  | 600  |
| atcatcagtg  | aaaagttcct  | gggcctgaag  | atccagctat  | gttgtttcta | gttgactatt  | 660  |
| ttaaagtgaca | gaacttggcc  | caagcattga  | coattttggg  | tcctcaataa | gcctgattca  | 720  |
| accaggggtca | cctttgaatc  | tgctctccac  | ctttccaata  | aacctatttt | atgcatcatt  | 780  |
| cagtgaagta  | tttatttatt  | tacttttttg  | ctgagaaaca  | tgactagatt | taggaaaaat  | 840  |
| gtagaattttt | actttttttt  | caatattttc  | tgggttttcc  | agagttttca | cgtgtttcac  | 900  |
| accttccctt  | gcttccacc   | attccccctt  | ctatttggaa  | ctagagagac | atgagtttga  | 960  |
| attctagctg  | tgtaacctga  | gtcagttatt  | taacctcttt  | ttgtttctgt | ttctttgtct  | 1020 |
| gtaaatagca  | aaaactacaa  | ttacttttag  | tcctgtctgt  | acaccaaagt | ttatcttgaa  | 1080 |
| atattataca  | tatttatatg  | aattactact  | gaaatgctct  | aagatgccta | tgtgtgaatg  | 1140 |
| gcattgttgt  | aaagattaaa  | taataataagg | gaagtgtctg  | cttcagtgtc | tggcatataa  | 1200 |
| taaaagctat  | tattttttacg | attatttttc  | atcttataga  | agaattatcg | ttcttccctt  | 1260 |
| ccaaagctaa  | taaatggaca  | tgtgtttatc  | agacagaacg  | taagagctgc | caaataaata  | 1320 |
| gggaataggt  | gctttcggga  | gtctagggaa  | ataaagggtca | gggaattggt | cataaaattt  | 1380 |
| agtacccata  | aatagcctat  | aagtagattc  | cctagtttat  | tctatgcagg | aaaataaagt  | 1440 |
| tctacggagc  | acagattcca  | aaactaattg  | gtcataaata  | tcacctgaaa | gtttagaaaa  | 1500 |
| tgtagcatca  | tggacctctt  | ttcataggtt  | ctaaatctta  | atatctgtgg | gatgggtgcag | 1560 |
| gaatctagct  | ttgctaagtg  | ccctcagatg  | actcttgctg  | ttctaggcta | aaatacatgt  | 1620 |
| ggttttggctt | caatggacat  | gttcttgaag  | aatgtttgga  | tgtcacacat | tcataatttag | 1680 |
| tatgagagat  | gaggtcctcc  | tctcatcatt  | ttcttaggtt  | ctcttctctc | cactccttac  | 1740 |
| cctcccatca  | cttacaataa  | atcttttaga  | aaattagcta  | tacatttgtt | tcattataaa  | 1800 |
| aaagaaagaa  | gataaaaaaa  | aaaaa       |             |            |             | 1825 |

&lt;210&gt; 78

&lt;211&gt; 1674

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 78

|             |             |            |             |            |             |      |
|-------------|-------------|------------|-------------|------------|-------------|------|
| ggccacgaga  | gtatctgagg  | cagctgcagg | tcctggattt  | atttctcgat | tcgctgtcgg  | 60   |
| aggagaatga  | gaccttggtg  | gagtttgcta | ttggaggcct  | gtgcaacctg | tgcccagaca  | 120  |
| gggccaacaa  | ggagcacatc  | ctgcacgcag | gaggtgtccc  | actcatcatc | aactgcctat  | 180  |
| ccagccccaa  | tgaggagacg  | gtgctgtctg | ccatcaccac  | gctcatgcac | ctgagcccg   | 240  |
| cgggcgcgag  | ctttctccca  | gagctgaccg | ccacgcccgt  | ggtgcagtgc | atgcttcgct  | 300  |
| tctccctctc  | ggccagcgcc  | aggttccgga | acctggcaca  | gatcttcctg | gaggacttct  | 360  |
| gctccccccg  | ccaagtggcc  | gaggcccgca | gccggcaggc  | gcaattttgc | cctgggtatc  | 420  |
| ccactgccga  | ggagcgtggc  | cccacggcag | cgctgatcca  | tgagactgc  | gagaccgtgg  | 480  |
| cacctctact  | gctgggggacc | acagtcctga | tgtggacgca  | gggaacgggg | agcacatact  | 540  |
| gccccatttg  | tgctttttca  | gccatctgaa | aggcgggttc  | tttcagcagg | acaggcattt  | 600  |
| acactgatga  | aacgccactg  | ggagtggaga | agccagactc  | cagagacacg | gagaagatca  | 660  |
| aactggagct  | gcgttcatag  | gctggcactc | tcaatcctac  | atcaggtgcc | accaccacca  | 720  |
| gactcaggcc  | ctggtgtaag  | aagcggccaa | gtcctggac   | ccagaggctt | tgaggagacg  | 780  |
| tgctctcagg  | agctgggcct  | gaggcctagg | agagctgcct  | tcgctgcagg | aaatcaggga  | 840  |
| ttatccctta  | acagaagtgt  | ctggagtagt | tttcaggtag  | aggaatgaga | tgctctcgtg  | 900  |
| tgaaaggatc  | tcacctgggg  | aagatgtggt | gccccctcca  | gggctctgga | ggatggatgc  | 960  |
| ctccccccag  | ggctctccaa  | gctgggcatt | tgggcctggt  | ggatgccaac | ctggataacc  | 1020 |
| tgtggccccag | cattgactgt  | ccaccagccc | ttgctgttag  | gcaccatgac | tccaaagatg  | 1080 |
| aagatgtggt  | ccctgccctt  | gagtgacagc | cccagggact  | taatgtggcc | atcgggcac   | 1140 |
| aagcacaagg  | ccatgcaggt  | gatgatacgt | cggaaatagag | gcaccagccc | tggttaactgc | 1200 |
| atcttctccc  | cttgccaccc  | catggccccc | gctgaaagct  | tcggccctcc | tctgtgtgca  | 1260 |
| ctcaatgatg  | gggagcccta  | ccccagaagt | gtatcccacg  | agggcatcag | ggacgcagtg  | 1320 |
| agtggtgctc  | aagggagtc   | ggaagagacg | gcaacgtaaa  | ggatgtggct | ccatgtccat  | 1380 |
| ggtgccccct  | ggtcaacata  | aggagcgtgg | gatccgatgg  | aaaggtggag | ctcagggaaa  | 1440 |
| atgggggtcc  | ttgcctctcg  | tgtacccctt | caaggctgac  | cccttagatg | gcccagggaat | 1500 |
| ggcaggtgct  | acaaaaatgg  | taccacgtg  | ggcatggaaa  | tggggcagat | taggggacca  | 1560 |
| ctggactcag  | aggggagggg  | agggctcatc | agcaccgct   | cagggagcct | gtccctttat  | 1620 |
| gttcccaaat  | aaaggtcctt  | agaagactaa | aaaaaaaaaa  | aaaaaaaaaa | aaaa        | 1674 |

&lt;210&gt; 79

&lt;211&gt; 2191

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1327)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1334)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 79

|             |            |             |             |            |            |     |
|-------------|------------|-------------|-------------|------------|------------|-----|
| ccttctctaa  | aaaagcaaac | aggcaaaaact | tcattgagaat | cttgatcatg | ttaaaatttt | 60  |
| atgtccttctg | atttctccct | acacacacac  | acacacacac  | acacacacac | acacacacac | 120 |
| tcaacatttc  | ctccacccat | atcatcactc  | cttagcatct  | ttattccatc | aaaactttct | 180 |
| acccttgtag  | attctctgtg | cagttttgaa  | aattaccctc  | tcagcattct | ctgttcaccc | 240 |
| ccacacctag  | accctgacct | ctagtcaatt  | ctactacca   | ggggtgtcca | cggttccagc | 300 |
| ctcctccatg  | aagcccagtt | ctatgggctc  | actcctctgg  | gtaagtggga | gccccagct  | 360 |
| atcatcctca  | ttgtatagaa | aaccaactct  | gtgatgctac  | ctgcccctct | tccccttctc | 420 |
| tcctgaaaga  | gggctggggg | agaggtggga  | ggactgggta  | tgccctggc  | cgggtctgta | 480 |
| ttcgtactgg  | gaggagtatt | ggtactctgt  | gtagaaagaa  | atggggaggg | ggaaatgggg | 540 |
| tggcctcagc  | atctccctaa | gtcccagcct  | ttaagtccct  | ctgttgcagt | tcgtcgtcgc | 600 |

|             |             |            |            |             |             |      |
|-------------|-------------|------------|------------|-------------|-------------|------|
| agcttcgaga  | ggagttggat  | cgatcttctt | gtggaaacgt | cctcttcaat  | ggttacctgc  | 660  |
| cgccaacagg  | taggcactcc  | caatggaatg | gaggggcgcg | gaggtgggccc | aaagactaca  | 720  |
| tttcccataa  | ggctgcagct  | ctcgggtgcc | tgtgctgtgc | gtcctgagat  | acagtgggaa  | 780  |
| gtgtagttcc  | ctatcagatg  | cttgggctga | tgcttgaaaa | ggaagttgga  | cacagcattt  | 840  |
| cccatgaaac  | aatggggcaa  | ctaactcttg | aagctcaaaa | agatgtcctt  | ggaaccccat  | 900  |
| ggggaatttg  | ttatcccggg  | tttgggtttc | ttttgttagg | gggggctttg  | ggaaaaactg  | 960  |
| gggattcctc  | cgtatggaag  | gggaaaaaat | attaaatagg | aagttattga  | cattaatgcc  | 1020 |
| catgatagcc  | acccactggt  | gccatggaag | gtatgcccc  | gtgggtattg  | gaactaggct  | 1080 |
| tttctgattg  | gtagaagtaa  | cagagtaggg | aaatttcata | tacagcttta  | tttccctaac  | 1140 |
| tgcagtcagc  | acctgtacct  | tcatgaaagt | tgccagatat | aaagatctgt  | agtagtactt  | 1200 |
| ttccaactta  | gttttatcct  | gttttccgga | aaaacaatca | tttatttatt  | tattttattta | 1260 |
| tttaatttta  | tgagacaggg  | tctggctttg | tcaccagggc | tggagtgcag  | tgggtgcgac  | 1320 |
| ttggctncac  | tgcnacctct  | gcctctcaga | ttcaagccat | ccttccacct  | cagctctgcc  | 1380 |
| actgagtagc  | tgagactaca  | agcactcgcc | accatgcccc | gctaattaaa  | aaaataataa  | 1440 |
| tcatttttaa  | tgcaagcttt  | atattataaa | tacaaagtaa | acatgaaaat  | aaaacccaaa  | 1500 |
| catagcagtg  | ttattaaact  | ctggcctgta | gcagtggttc | acacctgtaa  | tcctagcagt  | 1560 |
| ttggaggccg  | agacagggtg  | attacttgag | acctggagtt | tgagaccagc  | ccagggtgaca | 1620 |
| cagcaagacc  | tcctctctac  | taaaaataaa | aaaaaattag | ccagggtgtg  | tggtagtcac  | 1680 |
| ctgtgggtccc | agctacttag  | gatgtctggg | tgcgaggatc | gcttgagccc  | aggagggtcaa | 1740 |
| ggctgcagtg  | aactatgata  | actcattaca | ccccagcctg | ggtgacagag  | cagatgtctg  | 1800 |
| tctcaaaaaca | aaacaaaacg  | aaaaacaact | ctggctagat | gctattgctt  | gccaaagggtg | 1860 |
| cagtcttcca  | tttattaaaa  | gtgaaaatta | gggccaggca | cattgggtca  | tgctgtgaat  | 1920 |
| cccagcactt  | tgggagggtg  | aggtgggtgg | atcacctgag | gtcaggagtt  | cgagaccagc  | 1980 |
| ctggccaaca  | tggtgaaacc  | ttatctctgc | caaaaatata | aaagattagc  | catgtgtcgt  | 2040 |
| ggtgggtgct  | tgtaatctca  | gctacttggg | aggctgaggg | aggagaatca  | cttgaaccca  | 2100 |
| ggaggcagag  | gttgacagtga | gccaagattg | tgccattgca | ctccagcctg  | tgcaacgagc  | 2160 |
| gaaactccaa  | ctcaaaaaaa  | aaaaaaaaaa | a          |             |             | 2191 |

&lt;210&gt; 80

&lt;211&gt; 1335

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1287)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 80

|             |            |            |             |            |             |      |
|-------------|------------|------------|-------------|------------|-------------|------|
| ggatatatcc  | agggtgcgg  | attttcccc  | cttcaggttt  | aaatgttctt | gtttttctac  | 60   |
| ctttccctcg  | cagtatacgc | tcaacggcaa | gawagtggaa  | gttgccgtca | aacagatcat  | 120  |
| cgctggaaaa  | gccgtggagc | aaggagggtg | tttctcgaa   | cccagagacc | tggatctgta  | 180  |
| ccgggacatc  | cctgagctgc | agggtctctg | agtcagactg  | gctggcgtgt | cactcagccg  | 240  |
| caccogtgtg  | cactgtaact | tttgtgtgct | caagaaatta  | tacagaaacc | tacagctgtt  | 300  |
| gtaaaaggat  | gctcgacca  | agtgttctgt | aggcttgggg  | agggatcggt | tctctgtttt  | 360  |
| gttaaactctg | gtgggtacct | ggatcttcca | cacgagtggg  | attctggcct | tcagagacca  | 420  |
| ggagggagtg  | tctgggccc  | agtgtggcac | tgtggtgaga  | gtgtgtgtct | ttgcacacac  | 480  |
| agtgcagcgg  | gaacgggtgg | gctggctggg | gctgaagaca  | gacacactcc | tgagccaagg  | 540  |
| tcttgtcttc  | aacctcccc  | tccogttgtc | ccattttgct  | ctgtgaagg  | gcaaatccct  | 600  |
| ttcttccctt  | cccatctcag | gctctcctgt | tttccctcag  | ggtccagtat | gcctttgagc  | 660  |
| tttagctgtt  | agaaaggaac | ccccgtgact | tgacacagct  | ttcacagctg | gctgctagga  | 720  |
| ccggcgggct  | gggtgttcac | gtgtgtctgt | gtcatggatg  | caatgcaggc | cctggaggac  | 780  |
| tgtgcgtcac  | ccgtcaacca | gagcgtgcct | ccggggccagc | ttccctccaa | ggaatgagtg  | 840  |
| gatttcatac  | aggatctctt | tattgcacag | actgaatggc  | tttcatgttt | tctaattgtga | 900  |
| attaggcatg  | tgaagcagtg | ggtgtccacc | cgtgtccctc  | atgggtgagc | cctccagctg  | 960  |
| tgagcccagg  | cagtgtgggt | accgagtgag | gacctctctc  | accaggaacc | gcataccctgt | 1020 |
| gctgcctcca  | cctgagagtt | gctagggggt | tcttgtcgag  | atcatgtcat | cagcacccct  | 1080 |



50

|            |             |            |             |            |            |      |
|------------|-------------|------------|-------------|------------|------------|------|
| aagtcaagtc | acgggtttcc  | atagccaggc | agttgggtatg | tacaattcag | ttcagcgtat | 1140 |
| gaacttgat  | ctctaattctg | atgtccattt | ttatatattt  | tgaaactgag | cacaatgaaa | 1200 |
| tcctttcttg | aatcattttc  | cttttggtt  | ataaaaaat   | gggggaaagt | gctatgatga | 1260 |
| attttatgca | ataaatgtat  | acatgtntgc | acatgcaccc  | atgctgaaaa | aaaaaaaaaa | 1320 |
| aaaaaaaaaa | aaaaa       |            |             |            |            | 1335 |

<210> 81  
 <211> 1867  
 <212> DNA  
 <213> Homo sapiens

|             |             |            |            |             |            |      |  |
|-------------|-------------|------------|------------|-------------|------------|------|--|
| <400> 81    |             |            |            |             |            |      |  |
| cccacgcgtc  | cgggccacag  | cagagacagt | ggagggcagt | ggagaggacc  | gcgctgtcct | 60   |  |
| gctgtcacca  | agagctggag  | acaccatctc | ccaccgagag | tcattggcccc | attggccctg | 120  |  |
| cacctcctcg  | tcctcgtccc  | catacctctc | agcctgggtg | cctcccagga  | ctggaaggct | 180  |  |
| gaacgcagcc  | aagaccctt   | cgagaaatgc | atgcaggatc | ctgactatga  | gcagctgctc | 240  |  |
| aagggtggtga | cctgggggct  | caatcggacc | ctgaagcccc | agaggggtgat | tgtgggtggc | 300  |  |
| gctggtgtgg  | ccgggctggg  | ggccgccaag | gtgctcagcg | atgctggaca  | caaggtcacc | 360  |  |
| atcctggagg  | cagataaacag | gacgggggc  | cgcattctca | cctaccggga  | ccagaacacg | 420  |  |
| ggctggattg  | gggagctggg  | agccatgcgc | atgcccagct | ctcacaggat  | cctccacaag | 480  |  |
| ctctgccagg  | gcctggggct  | caacctgacc | aagttcacc  | agtacgacaa  | gaacacgtgg | 540  |  |
| acggaggtgc  | acgaagtga   | gctgcgcaac | tatgtggtg  | agaaggtgcc  | cgagaagctg | 600  |  |
| ggctacgcct  | tgctccccca  | ggaaaagggc | cactcgcccc | aagacatcta  | ccagatggct | 660  |  |
| ctcaaccagg  | ccctcaaaga  | cctcaaggca | ctgggctgca | gaaaggcgat  | gaagaagttt | 720  |  |
| gaaaggcaca  | cgctcttgg   | atatcttctc | ggggaggggg | acctgagccg  | gccggccgtg | 780  |  |
| cagcttctgg  | gagacgtgat  | gtccgaggat | ggcttcttct | atctcagctt  | cgccgaggcc | 840  |  |
| ctccggggcc  | acagctgcct  | cagcgacaga | ctccagtaca | gccgcacgt   | gggtggctgg | 900  |  |
| gacctgctgc  | cgcgcgcgct  | gctgagctcg | ctgtccgggc | ttgtgctgtt  | gaacgcgccc | 960  |  |
| gtggtggcga  | tgaccacagg  | accgcacgat | gtgcacgtgc | agatcgagac  | ctctcccccg | 1020 |  |
| gcgcggaatc  | tgaaggtgct  | gaaggccgac | gtggtgctgc | tgacggcgag  | cggaccggcg | 1080 |  |
| gtgaagcgca  | tcaccttctc  | gccgcccgtg | ccccgccaca | tgaggaggcc  | gctgcggagg | 1140 |  |
| ctgcactacg  | tgccggccac  | caaggtgttc | ctaagcttcc | gcaggccctt  | ctggcgcgag | 1200 |  |
| gagcacattg  | aaggcggcca  | ctcaaacacc | gacgcgccgt | cgcgcatgat  | tttctacccg | 1260 |  |
| ccgcgcgcg   | agggcgcgct  | gctgctggcc | tcgtacacgt | ggtcggacgc  | ggcggcagcg | 1320 |  |
| ttcgccggct  | tgagccggga  | agaggcggtg | cgcttgggcg | tcgacgacgt  | ggcggcattg | 1380 |  |
| cacgggcctg  | tcgtgcgcca  | gctctgggac | ggcaccggcg | tcgtcaagcg  | ttggcgggag | 1440 |  |
| gaccagcaca  | gccagggtgg  | ctttgtggta | cagccgcccg | cgctctggca  | aaccgaaaag | 1500 |  |
| gatgactgga  | cggtccttta  | tggccgcata | tactttgccc | gcgagcacac  | cgcctaccgg | 1560 |  |
| cacggctggg  | tggagacggc  | ggtcaagtgc | ctgcgcgcgg | ccatcaagat  | caacagccgg | 1620 |  |
| aaggggcctg  | catcgacac   | ggccagcccc | gaggggcacg | catctgacat  | ggaggggcag | 1680 |  |
| gggcatgtgc  | atgggtggc   | cagcagcccc | tcgcatgacc | tggcaaagga  | agaaggcagc | 1740 |  |
| caccctccag  | tccaaggcca  | gttatctctc | caaaacacga | cccacacgag  | gacctcgcat | 1800 |  |
| taaagtattt  | tcggaaaaaa  | aaaaaaaaaa | aaaaaaaaaa | aaaaaaaaaa  | aaaaaaaaaa | 1860 |  |
| aaaaaaa     |             |            |            |             |            | 1867 |  |

<210> 82  
 <211> 984  
 <212> DNA  
 <213> Homo sapiens

|            |            |            |            |            |            |     |  |
|------------|------------|------------|------------|------------|------------|-----|--|
| <400> 82   |            |            |            |            |            |     |  |
| gaattcggca | cgagcccagc | ggaagccaag | ccaccaggcc | ccccagcgtc | cacgcggagc | 60  |  |
| atgaacattg | aggatggcgc | gtgcccgcgg | ctcccctgtc | cccccgctgc | cgcccggtag | 120 |  |
| gatgtcctgg | ccccacgggg | cattgtctct | cctctggctc | ttctccccac | ccctgggggc | 180 |  |
| cggtggaggt | ggagtggcgc | tgacgtctgc | cgccggaggg | ggctccccgc | cggccacctc | 240 |  |
| ctgccccgtg | gcctgctcct | gcagcaacca | ggccagccgg | gtgatctgca | cacggagaga | 300 |  |

51

|            |             |            |            |             |            |     |
|------------|-------------|------------|------------|-------------|------------|-----|
| mctggccgag | gtcccagcca  | gcatcccggt | caacacgagg | tacctgaacc  | tgcaagagaa | 360 |
| cggcatccag | gtgatccgga  | cggacacgtt | caagcacctg | cggcacctgg  | agattctgca | 420 |
| gctgagcaag | aacctgggtg  | gcaagatcga | ggtgggagcc | ttcaacgggc  | tgcccagcct | 480 |
| caacacgctg | gagctttttg  | acaaccggct | gaccacgggt | cccacgcagg  | ccttcgagta | 540 |
| cctgtccaag | ctggcgggag  | tctggctgag | gaacaacccc | atcgagagca  | tcccctccta | 600 |
| cgccttcaac | cgcgtgccct  | cgtgcggcgg | cctggacctg | ggcgagctca  | agcggctgga | 660 |
| atacatctcg | gaggcggcct  | tcgargggct | ggtcaacctg | cgtacactca  | acctgggcat | 720 |
| gtgcaacctc | aaggacatcc  | ccaactgacg | gccctggtgc | gcttgaggga  | gctggagctg | 780 |
| tcgggcaacc | ggctggacct  | gatccgcccc | ggctccttcc | agggctctcac | cagcctgcgc | 840 |
| aagctgtggc | tcattgcacgc | ccaggtagcc | accatcgagc | gcaacgcctt  | cgacgacctc | 900 |
| aagtcgctgg | aggagctcaa  | cctgtccccc | aacaacctga | tgtcgctgcc  | ccacgacctc | 960 |
| ttcacgcccc | tgcacgcctc  | cgta       |            |             |            | 984 |

&lt;210&gt; 83

&lt;211&gt; 2664

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 83

|             |            |             |             |             |             |      |
|-------------|------------|-------------|-------------|-------------|-------------|------|
| ggttgctggc  | ccaggtgagc | gggcgcgctg  | gtccaggtga  | gcggggcgcg  | ccccgcgacg  | 60   |
| gcgctgccctg | cccagggcgg | ttcacgtaaa  | gacagcgaga  | tcctgagggc  | cagccgggaa  | 120  |
| ggaggcgtgg  | atatggagct | ggctgctgcc  | aagtcggggg  | cccgcgcgcg  | tgccctagcgc | 180  |
| gtccctgggga | ctctgtgggg | acgcgccccg  | cgccgcgggt  | cggggaccgg  | tagagcccg   | 240  |
| cgtctgcgcg  | atggccctgc | tctcgcgcgc  | cgcgctcacc  | ctcctgctcc  | tcctcatggc  | 300  |
| cgtctgtgtc  | aggtgccagg | agcaggccca  | gaccaccgac  | tgagagagcca | ccctgaagac  | 360  |
| catccgggaac | ggcgttcata | agatagacac  | gtacctgaac  | gcgcgccttg  | acctcctggg  | 420  |
| aggcgaggac  | ggtctctgcc | agtataaatg  | catgacggat  | ctaagccttt  | cccacgttat  | 480  |
| ggttataaac  | cctccccacc | gaatggatgt  | ggctctccac  | tggttggtgt  | tcattctaac  | 540  |
| attggtatcc  | cttccctgac | aaagtgttgc  | aaccaacacg  | acaggtgcta  | tgaracctgt  | 600  |
| ggcaaaagca  | agaatgactg | tgatgaagaa  | ttccagtatt  | gcctctccaa  | gatctgcgca  | 660  |
| gatgtacaga  | aaacactagg | actaactcag  | catgttcagg  | catgtgaaac  | aacagtggag  | 720  |
| ctcttggttg  | acagtggtat | acatttaggt  | tgtaaaccat  | atctggacag  | ccaacgagcc  | 780  |
| gcatgcaggt  | gtcattatga | agaaaaaact  | gatctttaaa  | ggagatgccg  | acagctagtg  | 840  |
| acagatgaag  | atggaagaac | ataacctttg  | acaaataact  | aatgttttta  | caacataaaa  | 900  |
| ctgtcttatt  | tttgtgaaag | gattattttg  | agaccttaaa  | ataatttata  | tcttgatgtt  | 960  |
| aaaacctcaa  | agcaaaaaaa | gtgagggaga  | tagtgagggg  | agggcacgct  | tgtcttctca  | 1020 |
| ggatcttccc  | ccagcattgc | tcccttactt  | agtatgccaa  | atgtcttgac  | caatatcaaa  | 1080 |
| aacaagtgtc  | tggttagcgg | agaattttga  | aaagagggaat | atataactca  | attttcacaa  | 1140 |
| ccacatttac  | caaaaaaaga | gatcaaatat  | aaaattcatc  | ataatgtctg  | ttcaacatta  | 1200 |
| tcttatttgg  | aaaatgggga | aattatcact  | tacaagtatt  | tggttactat  | gaaattttta  | 1260 |
| atacacattt  | atgcctagaa | ggaacggact  | ttttttttct  | attttaatta  | cacataatat  | 1320 |
| gtaattaaag  | tacaacataa | tatgttggtt  | ctctgtagcc  | cgttgagcat  | atgagtaagt  | 1380 |
| cacattttcta | ttaggactac | ttmcaaggac  | aagggtttcca | tttttccagt  | tgtaaaattg  | 1440 |
| gaaccatcag  | ctgataacct | cgtagggagc  | aaccccagga  | tagctaagtg  | ttatgtaata  | 1500 |
| tgccatagaag | gtgatgtgaa | tgcgattcag  | aagcatagcc  | actcccatct  | tatgagctac  | 1560 |
| tcacatgaca  | aatgtcatct | tttgctataa  | cctttgcca   | gttagagaaa  | agatggattt  | 1620 |
| aatgagataa  | atgaaaagat | atttamccta  | atatatcaag  | gcactatttg  | ctgttatgct  | 1680 |
| ttgttattta  | tttcccagca | cttggttcctt | attgtagatt  | ttttaaagac  | tgtaaccttt  | 1740 |
| tactaactgt  | ggtcttacta | aaatttgtgc  | ttgatactgc  | ttttcaaaaa  | gcctttaatt  | 1800 |
| agagccaaaa  | ggatggaaaa | ggcaagatat  | aatgccttt   | tatagatctc  | ttattttacat | 1860 |
| tgaaaattat  | taccatatgt | ttagagcaaa  | tccaagaaaa  | cttcaacagc  | ttctgaagat  | 1920 |
| gtctatgaat  | gttgaaaact | tttcaatctc  | ttggaatgct  | cagttatggt  | cctagaccgg  | 1980 |
| tctttgctga  | ctactggttg | ttaacctttc  | cctagcctgg  | gacctcaagc  | catatatatc  | 2040 |
| ctttgggtga  | cccatggcca | aagttattaa  | gatgaactga  | ctttcaaaagt | cagagaagga  | 2100 |
| cagcataggg  | agaggcgggt | atttgtaagt  | cattacaggt  | agaacagggc  | agaaggaaaa  | 2160 |
| gtatgttctg  | gagaaagggc | catgttccta  | actttggaga  | tatgtcattg  | ccgggaacct  | 2220 |
| agtatcttcc  | aacttgaatt | ggtggcagct  | gttccagtga  | gacaaggcac  | atgtatgcct  | 2280 |

52

|            |            |             |            |            |            |      |
|------------|------------|-------------|------------|------------|------------|------|
| tgtggctaag | tgagcaaact | gggtttccac  | ttaaatgttt | gggacctca  | attgattctt | 2340 |
| tatttcaaac | ctttataaaa | ggtacagttt  | tgtaagccat | tattaataat | taatgcttat | 2400 |
| cggtgggca  | cagtggctca | cacctataat  | cccagcactt | gggaggctga | ggcgggttga | 2460 |
| tcacttgagg | tcaggagttt | gagaccagct  | ggccaacatg | gtgaaacagc | gtctctacta | 2520 |
| aaaatacaaa | aatttgccgg | gcgtgggtggc | gcatgcttat | agtctcagct | actcaggaag | 2580 |
| ctgaggtagc | agaatcactt | gaaccagga   | ggtggagggt | gcagtgaagc | gagattgtgc | 2640 |
| cactgcactg | cagcctggct | cgag        |            |            |            | 2664 |

&lt;210&gt; 84

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 84

|            |            |             |             |             |             |      |
|------------|------------|-------------|-------------|-------------|-------------|------|
| ccacgcgtc  | cgggccagt  | gaggtccgca  | gagtttgggc  | gccaggcgag  | acggcagggc  | 60   |
| ttaaagtcc  | gggaatcaaa | gatcaactcc  | cactgaggac  | aaatggacct  | gtaattccgg  | 120  |
| gtgtgacgag | agaacgagat | ttaccttcc   | gaattaaaaa  | wcwgactccc  | tcgacaagg   | 180  |
| actgtgtact | gcatgaatga | ggctgagata  | gttgatgttg  | ctctgggaat  | cctgattgag  | 240  |
| agccgcaaac | aggaaaaggc | ctgcgagcag  | ccggccctgg  | cgggggctga  | taaccagar   | 300  |
| cactccctc  | cctgctccgt | gtcgctcac   | acaagtctg   | ggagcagcag  | tgaggaagag  | 360  |
| gacagtggga | aacaggcact | grctccaggc  | ctcagccctt  | cccagaggcc  | ggggggttcc  | 420  |
| agctctgct  | gtagcaggag | ccctgaggag  | gaggagggaag | aggatgtgct  | gaaatacgtc  | 480  |
| cgggagatct | tttccagcta | gggcataaac  | tgtgactga   | actgtctgcc  | gagagcagct  | 540  |
| ggaggacagc | tgagcttcca | ctggtgctgc  | tgggccgcc   | gcctgtggga  | atggggctct  | 600  |
| ctgtgctcct | acctttgtgc | cttcttgggc  | ctggcagatt  | cacctcaggc  | cagaagcccc  | 660  |
| tggacactcc | gggccttggg | gctgcgcttc  | tgagtgtgcg  | gaaggcagga  | ctcaaaatga  | 720  |
| gatcccat   | gactccctct | gtatgtactg  | tgccctctcc  | tggtctctga  | ggctctggag  | 780  |
| tcccaattgt | ctgtgttagt | cagtgaccag  | gttccaggga  | aaatgatgtc  | atgtggtggt  | 840  |
| ccaacttact | ggaaccaaag | agacagtact  | ttgcaaagaa  | aaggatcact  | gccagggtgca | 900  |
| ctggaattgc | tacagttag  | tccgcatgat  | ctctcctgaa  | ggagggaagcc | tgtttcaaaa  | 960  |
| atagtttcca | tcattgagct | atcaatgagc  | tcccacctct  | ccagccagcc  | tagaaagcaa  | 1020 |
| acgagctgcc | cacagtcttc | tgccctgtct  | gggaggttga  | ggccacagt   | tatagactgg  | 1080 |
| taagccagac | aggcctcctc | ccgcaagctg  | ctaccttgct  | ttcacctgta  | ccttgggtccc | 1140 |
| cgggcagcta | gctataaagc | aagagggaca  | ggagcccaga  | agagacactg  | aggacaagag  | 1200 |
| atcacaccag | agtacatgtc | tctgctctctg | ttttcagtg   | ggctttggac  | aggaatatat  | 1260 |
| gaataaatca | ctgccatata | ggttttccaa  | tacacaagtg  | ctagaaaata  | cacacaattc  | 1320 |
| cccaatga   |            |             |             |             |             | 1328 |

&lt;210&gt; 85

&lt;211&gt; 1342

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 85

|            |            |            |            |            |            |     |
|------------|------------|------------|------------|------------|------------|-----|
| ggcccgccca | ggaggatttc | tgcctttgac | tgcaactctt | gtcgtcttat | gtgggtgttg | 60  |
| aattgatctg | tctctgcagc | cagatccagg | ctcctggaag | aacctgttcc | ggcagctact | 120 |
| ggtcatgcca | ggcacacact | gctgcccagg | aggagctgct | gtttgaatta | tctgtgaatg | 180 |
| ttgggaagag | gaatgccaga | gctgcccggc | gaaaattacc | caaccaagag | aaatctgcag | 240 |
| gatggacttt | ctggctcctc | tcttgttcta | cctggcttcg | gtgctgatgg | gtcttgttct | 300 |
| tatctgcgtc | tgctcgaaaa | cccatagctt | gaaaggcctg | gccaggggag | gagcacagat | 360 |
| attttctctg | ataattccag | aatgtcttca | gagagccrtg | catggattgc | ttcattacct | 420 |
| tttccatacg | agaaaccaca | ccttcattgt | cctgcacctg | gtcttgcaag | ggatgggtta | 480 |
| tactgagtac | acctggggaa | gtatttggct | actgtcagga | gctggagtgt | tccttgcatt | 540 |
| accttcttct | gccctatctg | ctgctagggt | taaacctgtt | ttttttcacc | ctgacttgtg | 600 |
| gaaccaatcc | tggcattata | acaaaagcaa | atgaattatt | atttcttcat | gtttatgaat | 660 |
| ttgatgaagt | gatgtttcca | aagaacgtga | ggtgctctac | ttgtgattta | aggaaaccag | 720 |

53

|             |             |             |            |            |             |      |
|-------------|-------------|-------------|------------|------------|-------------|------|
| ctcgatccaa  | gcactgcagt  | gtgtgtaact  | ggtgtgtgca | ccgtttcgac | catcactgtg  | 780  |
| tttgggtgaa  | caactgcatc  | ggggcctgga  | acatcaggta | cttcctcatc | tacgtcttga  | 840  |
| ccttgacggc  | ctcggctgcc  | accgtcgcca  | ttgtgagcac | cacttttctg | gtccacttgg  | 900  |
| tggtgatgtc  | agattttatac | caggagactt  | acatcgatga | ccttggacac | ctccatgtta  | 960  |
| tggaacagg   | ctttcttatt  | cagtacctgt  | tcctgacttt | tccacggatt | gtcttcatgc  | 1020 |
| tgggctttgt  | cgtgggttctg | agcttccctcc | tgggtggcta | cctgttggtt | gtcctgtatc  | 1080 |
| tggcggccac  | caaccagact  | actaacgagt  | ggtacagagg | tgactgggcc | tggtgccagc  | 1140 |
| gtttgtcccct | tgtggcctgg  | cctccgtcag  | cagagcccca | agtcacacgg | aacattcact  | 1200 |
| cccattgggct | tgggagcaac  | cttcaagaga  | tctttctacc | tgcccttcca | tgatcatgaga | 1260 |
| ggaagaaaca  | agaatgacaa  | gtgtatgact  | gcctttgagc | tgtagtcccc | gtttatttac  | 1320 |
| acatgtggat  | cctcgtttcc  | ca          |            |            |             | 1342 |

&lt;210&gt; 86

&lt;211&gt; 1154

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 86

|             |             |            |             |             |             |      |
|-------------|-------------|------------|-------------|-------------|-------------|------|
| aagacaggaa  | aagctccagg  | ccgtgggtct | caaagtgtgg  | tccctggaca  | gcagcaacat  | 60   |
| cacctaggag  | cctgttaggg  | aaggcacagc | ctcaggccct  | gccccagacc  | tgacagaatca | 120  |
| gaaactcttg  | ggtgaggcct  | ggttatctgc | tgtaacagac  | cttcacagtgg | gttctgatgc  | 180  |
| cctctagagc  | aggagaacca  | ctagcttaga | ggttgacagta | tggttggcat  | cttgccattt  | 240  |
| gtgttagttc  | agagggaatgg | ctgaccccca | tgctcattt   | ctaagcttca  | ggcagctttt  | 300  |
| ctcctgggca  | gctgtcatte  | tggtgagggg | aatcctgggg  | actgtggctc  | ctcctccctg  | 360  |
| tccgtgtgtc  | cttgatctgg  | cagtctaccc | ccttcatctc  | cccgtggagg  | ctccatgcct  | 420  |
| agagggtggc  | ttcaaacaga  | agaatggcaa | agataattgt  | ctcgtgtttt  | accctgaccc  | 480  |
| cattccctta  | agagggtcac  | ttcttggccc | attcatttaa  | aaaccaatgt  | catagtctctg | 540  |
| tgattccacc  | tatcagacag  | tgccacgtcc | aaaggcgggg  | ctctyacctc  | cctgggraaga | 600  |
| gagactgttg  | ctgtctgtgc  | ttcctgtgtt | ctccagtcct  | acgctccac   | ggacccacgc  | 660  |
| ccttgagagc  | tccctcrgtg  | tcccagggt  | tctggtgtgt  | tcagagacct  | ccacactcaa  | 720  |
| cgaccactgg  | tgctgcagaa  | gggcccgtgc | ttacattcca  | attaacagac  | gcttttccca  | 780  |
| tctaattgct  | cttgcccttct | cctaacacca | cctcgggagt  | gtttatgtct  | attctaagtg  | 840  |
| aatttcactg  | tgtgaaaaaa  | ttcacacctg | ttgtcccagc  | gatttgggag  | gccggggcgg  | 900  |
| gtgtatcatt  | tgagcccagg  | agtttgaggc | tagcctgggc  | aggatgggtga | aaccccgctct | 960  |
| ctataaagaa  | attttaaaaa  | ttagctgggc | atagtggcac  | gtgcctgtag  | ttccatctac  | 1020 |
| tggggagggt  | gggggtgggag | gatcgcatga | gcccgggagt  | ttgaggctgc  | agtgagctgt  | 1080 |
| gatcgacaga  | ctgcactcca  | gtctgggcaa | cagagcaaga  | ccctgtctct  | taaaaaaaaa  | 1140 |
| aaaaaaaaact | cgag        |            |             |             |             | 1154 |

&lt;210&gt; 87

&lt;211&gt; 1197

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (573)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1177)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1185)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 87

|             |             |             |             |            |             |      |
|-------------|-------------|-------------|-------------|------------|-------------|------|
| aagacaggaa  | aagctccagg  | ccgtggttct  | caaagtgtgg  | tccttgga   | gcagcaacat  | 60   |
| cacctaggag  | cctgttaggg  | aaggcacagc  | ctcaggccct  | gcccagacc  | tgacagaatca | 120  |
| gaaactctgg  | ggtgaggcct  | ggttatctgc  | tgtaacagac  | cttccagtgg | gttctgatgc  | 180  |
| cctctagagc  | aggagaacca  | ctagcttaga  | ggttgacagta | tgtttgcat  | cttgccattt  | 240  |
| gtgttagttc  | agagggaatgg | ctgaccccca  | tgtctcattt  | ctaagcttca | ggcagctttt  | 300  |
| ctcctgggca  | gctgtcattc  | tggtgagggg  | aatcctgggg  | actgtggctc | ctcctccctg  | 360  |
| tcctgtgtgc  | cttgatctgg  | cagtctaccc  | ccttcatctc  | ccgtggagg  | ctccatgccw  | 420  |
| agagggtgtc  | ttcaaacaga  | agaatggcaa  | arataattgt  | ctcgtgtttt | accctgaccc  | 480  |
| cattccttta  | agagggtcac  | ttcttggccc  | attcatttaa  | aaaccaatgt | catagtctctg | 540  |
| tgattccacc  | tatcagacag  | tgccacgtcc  | aangcggggc  | tctcacctcc | ctgggaagag  | 600  |
| agactgttgc  | tgtctgtgct  | tcctgtgttc  | tccagtccca  | cgctcccacg | gacccacgcc  | 660  |
| cttgaggact  | ccctcagtgt  | cccagggtct  | ctgggtgtgt  | cagagacctc | cacactcaac  | 720  |
| gacctgtgtg  | gctgcagaag  | ggccggtgct  | tacattccaa  | ttacagacg  | ctttcccat   | 780  |
| ctaattgcctc | ttgccttctc  | ctaaccaccac | ctcgggagtg  | tttatgtcta | ttctaagtga  | 840  |
| atttctactgt | gtgaaaaaat  | tcacacctgt  | tatccagca   | atttgggagg | ccgaggcggg  | 900  |
| tgtatcattt  | gggcccagga  | gtttgagact  | agcctgggca  | agatggtgaa | acccgtctc   | 960  |
| tataaagaaa  | ttttaaaaat  | tggctgggca  | tagtggcgcg  | tgctgtagt  | tccatctgct  | 1020 |
| ggggaggctg  | gggtgggagg  | atcgcatgag  | cccgggagtt  | tgaggctgca | gtgagctgtg  | 1080 |
| atcgcgccac  | tgactccag   | tctgggcaac  | agagcaaac   | cctgtctctt | aaaaaaaaaa  | 1140 |
| aaaactcgag  | ggggggcccg  | gtaccaatt   | cgccctnats  | agtnagtcg  | tattaca     | 1197 |

&lt;210&gt; 88

&lt;211&gt; 910

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 88

|            |            |            |             |             |            |     |
|------------|------------|------------|-------------|-------------|------------|-----|
| ggcagagctg | gccttcgact | cgctatgtcc | actaacaata  | tgctggacc   | acggaggccg | 60  |
| aacaaagtgc | tgaggtgagg | acccacagct | cgtagggcacg | ggttcgggtt  | gtgggtgtgg | 120 |
| atcgggggcc | tggaagcg   | ctgtctatcc | cgggggcagg  | acctgagcgc  | ccctgaccct | 180 |
| cgagcctgtc | gcaggtacaa | gccccgcgcg | agcgaatgta  | acccggcctt  | ggacgacccg | 240 |
| acgccggact | acatgaacct | gctgggcatg | atcttcagca  | tgtagggcct  | catgcttaag | 300 |
| ctgaagtgtg | gtgcttgggt | cgctgtctac | tgctccttca  | tcagctttgc  | caactctcgg | 360 |
| agctcggagg | acacgaagca | aatgatgagt | agcttcatgt  | gagacttgcc  | ctacagaaca | 420 |
| agtgactctt | gagtaagggg | tggggggacc | ccagcctggc  | catcctagac  | tgacacctct | 480 |
| ctcctgtctt | catgctgtcc | atctctgccg | tggtgatgtc  | ctatctgcag  | aatcctcagc | 540 |
| ccatgacgcc | cccatggtga | taccagccta | gaagggtcac  | attttggacc  | ctgtctatcc | 600 |
| actaggcctg | ggctttggct | gctaaacctg | ctgccttcag  | ctgccatcct  | ggacttccct | 660 |
| gaatgaggcc | gtctcggtgc | ccccagctgg | atagagggaa  | cctggccctt  | tcttagggaa | 720 |
| caccttaggc | ttacctctcc | tgctcctctt | cccctgcctg  | ctgctggggg  | agatgctgtc | 780 |
| catgtttcta | gggttattca | tttgctttct | cgttgaaacc  | tggtgttaat  | aaagtttttc | 840 |
| actctgaaaa | aaaaaaaaaa | aaaaaaaaac | tygrgggggg  | gcccgggaacc | caattccscg | 900 |
| gatatgtagt |            |            |             |             |            | 910 |

&lt;210&gt; 89

&lt;211&gt; 1076

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1029)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1037)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1040)

<223> n equals a,t,g, or c

<400> 89

|             |             |             |             |             |            |      |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| ggcagcagg   | gaaagccatg  | ctcccaggac  | tccttccttg  | cagccttaaa  | tcggtctgta | 60   |
| cggaaaattc  | cgcgcccttag | aaaccacgc   | ttgggtgtaa  | cttattattg  | ttcttcctga | 120  |
| cctacttcct  | gtttatcact  | tcgggttca   | tcattttggc  | atttcggtga  | tcgggttgga | 180  |
| actattgaag  | cccgttttca  | ggttcttttc  | cccattttcc  | ctttgaaagg  | aagacttctg | 240  |
| gctttctcta  | aatctccggt  | ctctgggtaa  | ggggagtcca  | agcctctgtc  | atgaggaacg | 300  |
| gaaatgcgag  | ggcctcgggt  | gttactctaa  | aatccgccct  | cagcttgac   | gccggaagct | 360  |
| gcgattccctg | cagcggaaga  | ggcgtgatct  | ggccttcgac  | tcgctatgtc  | cactaacaat | 420  |
| atgtcggacc  | cacggaggcc  | gaacaaagt   | ctgagggtaca | agccccgcc   | gagcgaatgt | 480  |
| aaccgcgcct  | tggacgaccc  | gacgcggac   | tacatgaacc  | tgctgggcat  | gatcttcagc | 540  |
| atgtgcggcc  | tcatgcttaa  | gctgaagtgg  | tgtgcttggg  | tcgctgtcta  | ctgctccttc | 600  |
| atcagctttg  | ccaactctcg  | gagctcggag  | gacacgaagc  | aatgatgag   | tagcttcag  | 660  |
| ctgtccatct  | ctgccgtggt  | gatgtcctat  | ctgcagaatc  | ctcagcccat  | gacgccccca | 720  |
| tggtgatacc  | agcctagaag  | ggtcacattt  | tggaccctgt  | ctatccacta  | ggcctgggct | 780  |
| ttggctgcta  | aacctgctgc  | cttcagctgc  | catcctggac  | ttccctgaat  | gaggccgtct | 840  |
| cggtgcccc   | agctggatag  | agggaaacctg | gccctttcct  | agggaacacc  | ctaggcttac | 900  |
| ccctcctgcc  | tcctttcccc  | tgccctgctgc | tgggggagat  | gctgtccatg  | tttctagggg | 960  |
| tattcatttg  | ctttctcggt  | gaaacctgtt  | gttaataaag  | tttttctactc | tgaaaaaaaa | 1020 |
| aaaaaaaaana | raaaacncgn  | ggggggggccc | ggaacccaat  | tcscgggata  | gtgagt     | 1076 |

<210> 90

<211> 1842

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (67)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (98)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (212)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1838)

<223> n equals a,t,g, or c

&lt;400&gt; 90

|             |            |            |            |             |             |      |
|-------------|------------|------------|------------|-------------|-------------|------|
| gcgaccgccc  | ccttcagcta | gctcgctcgc | tcgctctgct | tccctgctgc  | cggtcgcgca  | 60   |
| tggcttnggc  | gttggcgggc | ctggcgggcg | ctcgagcngc | ctgcsagcc   | ggtaccagca  | 120  |
| gttcgagaat  | gaagaagagt | ctggagaacc | tgaacaggct | gcagggtgat  | ctcctccacc  | 180  |
| ttacagcagc  | atttctgcag | agagcgacac | tnattttgac | tacaaggatg  | agtctgggtt  | 240  |
| tccaaagccc  | ccatcttaca | atgtagctac | aacactgccc | agttatgatg  | aagcggagag  | 300  |
| gaccaaggct  | gaagctacta | tccctttggt | tcctgggaga | gatgaggatt  | ttgtgggtcg  | 360  |
| ggatgatttt  | gatgatgctg | accagctgag | gataggaaat | gatgggattt  | tcatgttaac  | 420  |
| ttttttcatg  | gcattcctct | ttaactggat | tgggtttttc | ctgtcttttt  | gcctgaccac  | 480  |
| ttcagctgca  | ggaaggtagt | gggccatttc | aggatttggt | ctctctctaa  | ttaaattggat | 540  |
| cctgattgtc  | agggtttcca | cctatttccc | tggatatttt | gatggtcagt  | actggctctg  | 600  |
| gtgggtgttc  | cttgttttag | gctttctcct | gtttctcaga | ggatttatca  | attatgcaaa  | 660  |
| agttcggaag  | atgccagaaa | ctttctcaaa | tctccccagg | accagagttc  | tctttattta  | 720  |
| ttaaagatgt  | tttctggcaa | aggccttcct | gcatttatga | attctctctc  | aagaagcaag  | 780  |
| agaacacctg  | caggaagtga | atcaagatgc | agaacacaga | ggaataatca  | cctgctttta  | 840  |
| aaaaataaag  | tactgttgaa | aagatcattt | ctctctattt | gttcctaggt  | gtaaaatttt  | 900  |
| aatagttaat  | gcagaattct | gtaatcattg | aatcattagt | ggttaatggt  | tgaaaaagct  | 960  |
| cttgcaatca  | agtctgtgat | gtattaataa | tgcttatata | attgtttgta  | gtcattttta  | 1020 |
| gtagcatgag  | ccatgtccct | gtagtcggta | gggggcagtc | ttgctttatt  | catcctccat  | 1080 |
| ctcaaaaatga | acttggaatt | aaatattgta | agatatgtat | aatgctggcc  | attttaaagg  | 1140 |
| ggttttctca  | aaagttaaac | ttttgttatg | actgtgtttt | tgacacataat | ccatatttgc  | 1200 |
| tgttcaagtt  | aatctagaaa | tttattcaat | tctgtatgaa | cacctggaag  | caaaatcata  | 1260 |
| gtgcaaaaat  | acatttaagg | tgtggtcaaa | aataagtctt | taattggtaa  | ataataagca  | 1320 |
| ttaatTTTTT  | atagcctgta | ttcacaaatt | tgcggtacct | tattgtacct  | aagggttctt  | 1380 |
| aaaggtgttg  | tactgtata  | aaacagaaag | cactaggata | caaatagaag  | ttaattacta  | 1440 |
| aaatgtaatt  | cttgacactc | tttctataat | tagcgttctt | cacccccacc  | cccccccca   | 1500 |
| cccccttat   | tttcttttg  | tctcctggg  | attaggccaa | agtctgggag  | taaggagagg  | 1560 |
| attagggtact | taggagcaaa | gaaagaagta | gcttggaact | tttgagatga  | tccctaacat  | 1620 |
| actgtactac  | ttgcttttac | aatgtgttag | cagaaaccag | tgggttataa  | tgtagaatga  | 1680 |
| tgtgctttct  | gccaagtgg  | taattcatct | tggtttgcta | tgttaaaact  | gtaaatacaa  | 1740 |
| cagaacatta  | ataaatatct | cttgtgtagc | accttttaaa | aaaaaaaaaa  | aaaaaaaaaa  | 1800 |
| aaaaaaaaaa  | aaaaaaaaaa | aaaaaaaaaa | aaaaaaaaaa | aa          |             | 1842 |

&lt;210&gt; 91

&lt;211&gt; 1963

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (335)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1959)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 91

|            |            |            |            |             |            |     |
|------------|------------|------------|------------|-------------|------------|-----|
| ggatcctcgc | ggcgggggcg | gtgcttacag | cctgagaaga | gcgtctcgcc  | cgggagcgcc | 60  |
| ggcggccatc | gagacccacc | caaggcgcg  | ccccctcgcc | ctcccagcgc  | tcccaagccg | 120 |
| cagcgggcgc | gccccttcag | ctagctcgct | cgctcgctct | gcttccctgc  | tgccggctgc | 180 |
| gcatggcktt | ggcggtggcg | gcgctggcgg | cggtcgagcc | gcctgcgcag  | ccggtaccag | 240 |
| cagttgcaga | atgaagaaga | gtctggagaa | cctgaacagg | ctgcagggtga | tgctcctcca | 300 |
| ccttacagca | gcatttctgc | agagagcgca | gcatnatttt | gactacaagg  | atgagctctg | 360 |
| gtttccaaag | cccccatctt | acaatgtagc | tacaacactg | cccagttatg  | atgaagcgga | 420 |
| gaggaccaag | gctgaagcta | ctatcccttt | ggttcctggg | agagatgagg  | attttgtggg | 480 |

57

|             |            |            |            |             |             |      |
|-------------|------------|------------|------------|-------------|-------------|------|
| tcgggatgat  | tttgatgatg | ctgaccagct | gaggatagga | aatgatggga  | ttttcatgtt  | 540  |
| aacttttttc  | atggcattcc | tctttaactg | gattgggttt | ttcctgtctt  | tttgccctgac | 600  |
| cacttcagct  | gcaggaaggt | atggggccat | ttcaggattt | ggtctctctc  | taattaaatg  | 660  |
| gacctcgatt  | gtcagggttt | ccacctattt | ccctggatat | tttgatggtc  | agtactggct  | 720  |
| ctgggtgggtg | ttccttggtt | taggctttct | cctgtttctc | agaggattta  | tcaattatgc  | 780  |
| aaaagtctcg  | aagatgccag | aaactttctc | aaatctcccc | aggaccagag  | ttctctttat  | 840  |
| ttattaaaga  | tgttttctgg | caaaggcctt | cctgcattta | tgaattctct  | ctcaagaagc  | 900  |
| aagagaacac  | ctgcaggaag | tgaatcaaga | tgcagaacac | agaggaataa  | tcacctgctt  | 960  |
| taaaaaaata  | aagtactggt | gaaaagatca | tttctctcta | tttggtcccta | ggtgtaaaat  | 1020 |
| tttaaatagtt | aatgcagaat | tctgtaatca | ttgaatcatt | agtggttaat  | gtttgaaaaa  | 1080 |
| gctcttgcaa  | tcaagtctgt | gatgtattaa | taatgcctta | tatattgttt  | gtagtcattt  | 1140 |
| taagtagcat  | gagccatgtc | cctgtagtcg | gtagggggca | gtcttgcttt  | attcatcctc  | 1200 |
| catctcaaaa  | tgaacttgga | attaaatatt | gtaagatatg | tataatgctg  | gccattttaa  | 1260 |
| aggggttttc  | tcaaaagtta | aacttttggt | atgactgtgt | ttttgcacat  | aatccatatt  | 1320 |
| tgctgttcaa  | gttaatctag | aaatttattc | aattctgtat | gaacacctgg  | aagcaaaatc  | 1380 |
| atagtgcaaa  | aatacattta | aggtgtggtc | aaaaataagt | ctttaattgg  | taaataataa  | 1440 |
| gcattaattt  | tttatagcct | gtattcacia | ttctgcggta | ccttattgta  | cctaagggat  | 1500 |
| tctaaagggtg | ttgtcactgt | ataaaacaga | aagcactagg | atacaaatga  | agcttaatta  | 1560 |
| ctaaaatgta  | attcttgaca | ctctttctat | aattagcggt | cttcaccccc  | acccccaccc  | 1620 |
| ccacccccct  | tattttcctt | ttgtctcctg | gtgattaggc | caaagtctgg  | gagtaaggag  | 1680 |
| aggattagggt | acttaggagc | aaagaaagaa | gtagcttgga | acttttgaga  | tgatccctaa  | 1740 |
| catactgtac  | tacttgcttt | tacaatgtgt | tagcagaaac | cagtgggtta  | taatgtagaa  | 1800 |
| tgatgtgctt  | tctgcccagg | tggtaatcca | tcttggtttg | ctatgttaaa  | actgtaaata  | 1860 |
| caacagaaca  | ttaataaata | tctcttggtg | agcaccttta | aaaaaaaaaa  | aaaaaaaaaa  | 1920 |
| aaaaaaaaaa  | aaaaaaaaaa | aaaaaaaaaa | aaaaaaaaaa | aaa         |             | 1963 |

<210> 92  
 <211> 1487  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1470)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1487)  
 <223> n equals a,t,g, or c

|            |             |            |            |             |            |     |
|------------|-------------|------------|------------|-------------|------------|-----|
| <400> 92   |             |            |            |             |            |     |
| gcgaccgcgc | ccctttcagc  | tagctcgctc | gctcgctctg | cttccctgct  | gccggctgcg | 60  |
| catggckwtg | gcgttggcgg  | cgctggcggc | ggtcgagccg | gcctgcgcag  | ccggtaccag | 120 |
| cagttgcaga | atgaagaaga  | gtctggagaa | cctgaacagg | ctgcagggtga | tgctcctcca | 180 |
| ccttacagca | gcatttctgc  | agagagcgca | gttttccacc | tatttccctg  | gatattttga | 240 |
| tggtcagtag | tggtctgggt  | gggtgttcct | tgttttaggc | tttctcctgt  | ttctcagagg | 300 |
| atztatcaat | tatgcaaaag  | ttcggaagat | gccagaaact | ttctcaaatc  | tccccaggac | 360 |
| cagagtctct | tttatattatt | aaagatgttt | tctggcaaag | gccttctctg  | atztatgaat | 420 |
| tctctctcaa | gaagcaagag  | aacacctgca | ggaagtgaat | caagatgcag  | aacacagagg | 480 |
| aataatcacc | tgcttttaaaa | aaataaagta | ctgttgaaaa | gatcattttct | ctctatttgt | 540 |
| tcctagggtg | aaaatttttaa | tagttaatgc | agaattctgt | aatcattgaa  | tcatttagtg | 600 |
| ttaatgtttg | aaaaagctct  | tgcaatcaag | tctgtgatgt | attaataatg  | ccttatatat | 660 |
| tgtttgtagt | catttttaagt | agcatgagcc | atgtccctgt | agtcggtagg  | gggcagtcct | 720 |
| gctttattca | tcctccatct  | caaaatgaac | ttggaattaa | atattgttaag | atatgtataa | 780 |
| tgctggccat | tttaaaagggg | ttttctcaaa | agttaaactt | ttgttatgac  | tggtgttttg | 840 |
| cacataatcc | atatttgctg  | ttcaagttaa | tctagaaatt | tattcaattc  | tgtatgaaca | 900 |



58

|            |            |            |             |             |            |      |
|------------|------------|------------|-------------|-------------|------------|------|
| cctggaagca | aaatcatagt | gcaaaaatac | atttaagggtg | tggtcaaaaa  | taagtcttta | 960  |
| atttgtaaat | aataagcatt | aattttttat | agcctgtatt  | cacaattctg  | cggtacctta | 1020 |
| ttgtacctaa | gggattctaa | agggtgtgtc | actgtataaa  | acagaaagca  | ctaggatata | 1080 |
| aatgaagctt | aattactaaa | atgtaattct | tgacactctt  | tctataatta  | gcgttcttca | 1140 |
| ccccacccc  | caccccacc  | ccccttattt | tccttttgtc  | tcctgggtgat | taggccaaag | 1200 |
| tctgggagta | aggagaggat | taggtactta | ggagcaaaga  | aagaagtagc  | ttggaacttt | 1260 |
| tgagatgata | cctaacatac | tgtactactt | gcttttataa  | tgtgttagca  | gaaaccagt  | 1320 |
| ggttataaat | tagaatgatg | tgctttctgc | ccaagtggta  | attcatcttg  | gtttgctatg | 1380 |
| ttaaaactgt | aaatacaaca | gaacattaat | aaatatctct  | tgtgtagcac  | ctttaaaaaa | 1440 |
| aaaaaaaaa  | aaaaaaaaa  | aaaaaaaaa  | cccggggggg  | ggcccn      |            | 1487 |

&lt;210&gt; 93

&lt;211&gt; 1653

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (67)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (212)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1636)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1653)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 93

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gcgaccgcgc  | ccttcagcta  | gctcgcgcgc  | tcgctctgct  | tcctctgctgc | cggtcgcgca  | 60   |
| tggtctnngc  | gttggcggcg  | ctggcggcgc  | ctcgagccgc  | ctgcgsagcc  | ggtaccagca  | 120  |
| gttgacgaat  | gaagaagagt  | ctggagaaac  | tgaacaggct  | gcagggtgatg | ctcctccacc  | 180  |
| ttacagcagc  | atttctgcag  | agagcgcaca  | tnattttgac  | tacaaggatg  | agtctggggtt | 240  |
| tcctaaagccc | ccatcttaca  | atgtagctac  | aacactgccc  | agttatgatg  | aagcggagag  | 300  |
| gaccaaggct  | gaagctacta  | tccttttggt  | tcctgggaga  | gatgaggatt  | ttgtgggtcg  | 360  |
| ggatgatttt  | gatgatgctg  | accagctgag  | gataggaaat  | gatgggattt  | tcattgttaac | 420  |
| ttttttcatg  | gcattcctct  | ttaactggat  | tgggtttttc  | ctgtcttttt  | gcctgaccac  | 480  |
| ttcagctgca  | ggaaggatg   | gggccatttc  | aggatttggt  | ctctctctaa  | ttaaatggat  | 540  |
| cctgattgtc  | aggttttcca  | cctatttccc  | tgcatattatg | aattctctct  | caagaagcaa  | 600  |
| gagaacacct  | gcaggaagtg  | aatcaagatg  | cagaacacag  | aggaataatc  | acctgcttta  | 660  |
| aaaaaataaa  | gtactgttga  | aaagatcatt  | tctctctatt  | tggttctagg  | tgtaaaattt  | 720  |
| taatagttaa  | tgcagaattc  | tgtaatcatt  | gaatcattag  | tggttaattgt | ttgaaaaagc  | 780  |
| tcttgcaatc  | aagtctgtga  | tgtattaata  | atgccttata  | tattgtttgt  | agtcatttta  | 840  |
| agttagcatga | gccatgtccc  | tgtagtcggt  | agggggcagt  | cttgctttat  | tcacctcca   | 900  |
| tctcaaaatg  | aacttggaat  | taaaatttgt  | aagatatgta  | taatgctggc  | cattttaaag  | 960  |
| gggtttttctc | aaaagttaaa  | cttttgttat  | gactgtgttt  | ttgcacataa  | tccatatttg  | 1020 |
| ctgttcaagt  | taatctagaa  | atttattcaa  | ttctgtatga  | acacctggaa  | gcaaaatcat  | 1080 |
| agtgcaaaaa  | tacattttaag | gtgtgggtcaa | aaataagtct  | ttaattggta  | aataataagc  | 1140 |
| attaattttt  | tatagcctgt  | attcacaatt  | ctgcggtacc  | ttattgtacc  | taagggattc  | 1200 |

59

|             |            |            |            |            |            |      |
|-------------|------------|------------|------------|------------|------------|------|
| taaagggtgtt | gtcactgtat | aaaacagaaa | gcactaggat | acaaatgaag | cttaattact | 1260 |
| aaaaatgta   | tcttgacact | ctttctataa | ttagcgttct | tcacccccac | ccccaccccc | 1320 |
| acccccctta  | ttttcctttt | gtctcctggt | gattaggcca | aagtctggga | gtaaggagag | 1380 |
| gattaggtac  | ttaggagcaa | agaaagaagt | agcttgggaa | ttttgagatg | atccctaaca | 1440 |
| tactgtacta  | cttgctttta | caatgtgtta | gcagaaacca | gtgggttata | atgtagaatg | 1500 |
| atgtgctttc  | tgcccaagt  | gtaattcatc | ttggtttgct | atgttaaaac | tgtaaatata | 1560 |
| acagaacatt  | aataaatatc | tcttgtgtag | caccttttaw | aaaaaaaaaa | aaaaaaaaaa | 1620 |
| aaaaaaaaaa  | aaaaancccg | ggggggggcc | ccn        |            |            | 1653 |

&lt;210&gt; 94

&lt;211&gt; 1830

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (67)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (97)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (211)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1813)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1830)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 94

|            |            |             |            |             |             |      |
|------------|------------|-------------|------------|-------------|-------------|------|
| gcgaccgcgc | ccttcagcta | gctcgtcgc   | tcgctctgct | tccttgcctgc | cggtcgcgca  | 60   |
| tggcttnggc | gttggcggcg | ctggcggcg   | tcgagcngcc | tgcsagccg   | gtaccagcag  | 120  |
| ttgcagaatg | aagaagagtc | tggagaacct  | gaacaggctg | caggatgatgc | tcctccacct  | 180  |
| tacagcagca | tttctgcaga | gagcgacat   | nattttgact | acaaggatga  | gtctgggttt  | 240  |
| ccaaagcccc | catcttacaa | tgtagctaca  | acactgcccc | gttatgatga  | agcggagagg  | 300  |
| accaaggctg | aagctactat | ccctttgggt  | cctgggagag | atgaggattt  | tgtgggtcgg  | 360  |
| gatgattttg | atgatgctga | ccagctgagg  | ataggaaatg | atgggatttt  | catgttaact  | 420  |
| tttttcatgg | cattcctctt | taactggatt  | gggtttttcc | tgtctttttg  | cctgaccact  | 480  |
| tcagctgcag | gaaggatatg | ggccatttca  | ggatttggtc | tctctcta    | taaatggatc  | 540  |
| ctgattgtca | ggttttccac | ctatttccct  | ggatattttg | atgggtcagta | ctggtctctg  | 600  |
| tgggtgttcc | ttgttttagg | ctttctcctg  | tttctcagag | gatttatcaa  | ttatgcaaaa  | 660  |
| gttcggaaga | tgccagaaac | tttctcaaat  | ctccccagga | ccagagttct  | ctttatttat  | 720  |
| taaagatgtt | ttctggcaaa | ggccttctctg | catttatgaa | ttctctctca  | agaagcaaga  | 780  |
| gaacacctgc | aggaagtga  | tcaagatgca  | gaacacagag | gaataatcac  | ctgcttttaa  | 840  |
| aaaataaagt | actgttgaaa | agatcatttc  | tctctatttg | ttcctagggtg | taaaatttta  | 900  |
| atagttaatg | cagaattctg | taatcattga  | atcatttagt | gttaatgttt  | gaaaaagctc  | 960  |
| ttgcaatcaa | gtctgtgatg | tattaataat  | gccttatata | ttgtttgtag  | tcatttttaag | 1020 |

60

|            |            |            |             |             |            |      |
|------------|------------|------------|-------------|-------------|------------|------|
| tagcatgagc | catgtccctg | tagtcggtag | ggggcagtcct | tgctttatcc  | atcctccatc | 1080 |
| tcaaaatgaa | cttggaatta | aatatgttaa | gatatgtata  | atgctggcca  | ttttaaaggg | 1140 |
| gttttctcaa | aagttaaact | tttgttatga | ctgtgttttt  | gcacataatc  | catatttgct | 1200 |
| gttcaagtta | atctagaaat | ttattcaatt | ctgtatgaac  | acctggaagc  | aaaatcatag | 1260 |
| tgcaaaaata | catttaaggt | gtggtcaaaa | ataagtcctt  | aattggtaaa  | taataagcat | 1320 |
| taatttttta | tagcctgtat | tcacaattct | gcggtacott  | attgtacctt  | agggattcta | 1380 |
| aaggtgttgt | cactgtataa | aacagaaagc | actaggatac  | aaatgaagct  | taattactaa | 1440 |
| aatgtaattc | ttgacactct | ttctataatt | agcgttcttc  | acccccaccc  | ccacccccac | 1500 |
| cccccttatt | ttccttttgt | ctcctgggtg | ttaggccaaa  | gtctggggagt | aaggagagga | 1560 |
| ttaggtaact | aggagcaaa  | aaagaagtag | cttggaaact  | ttgagatgat  | ccctaacata | 1620 |
| ctgtactact | tgcttttaca | atgtgttagc | agaaaccagt  | gggttataat  | gtagaatgat | 1680 |
| gtgctttctg | cccaagtggg | aattcatctt | ggtttgctat  | gttaaaactg  | taaatacaac | 1740 |
| agaacattaa | taaatatctc | ttgtgtagca | ccttttaaaa  | aaaaaaaaaa  | aaaaaaaaaa | 1800 |
| aaaaaaaaaa | aancccgggg | gggggccccn |             |             |            | 1830 |

&lt;210&gt; 95

&lt;211&gt; 1134

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 95

|             |            |            |             |             |            |      |
|-------------|------------|------------|-------------|-------------|------------|------|
| tccatctaca  | gtcctcacac | aggtattcag | gaataaccagg | atggcgtgcc  | caagattcca | 60   |
| acagcctgta  | ttacgggtga | agatgcagaa | atgatgtcaa  | gaatggcttc  | tcatgggatc | 120  |
| aaaattgtca  | ttcagctaaa | gatgggggca | aagacctacc  | cagatactga  | ttccttcaac | 180  |
| actgtagcag  | agatcactgg | gagcaaatat | ccagaacagg  | ttgtactggg  | cagtggacat | 240  |
| ctggacagct  | gggatgttgg | gcagggtgcc | atggatgatg  | gcggtggagc  | ctttatatca | 300  |
| tggaagcac   | tctcacttat | taaagatctt | gggctgcgtc  | caaagaggac  | tctgcggtcg | 360  |
| gtgctctgga  | ctgcagaaga | acaagggtga | gttgggtgct  | tccagtatta  | tcagttacac | 420  |
| aaggtaaata  | tttccaaact | cagtctgggt | atggagtctg  | acgcaggaac  | cttcttcccc | 480  |
| actgggctgc  | aattcactgg | cagtgaaga  | gccagggcat  | catggaggag  | gttatgagcc | 540  |
| tgctgcagcc  | cctcaatatc | actcagggtc | tgagccatgg  | agaaggagca  | gacatcaact | 600  |
| tttggatcca  | agctggagtg | cctggagcca | gtctacttga  | tgacttatac  | aagtatttct | 660  |
| tcttccatca  | ctcccacgga | gacaccatga | ctgtcatgga  | tccaaagcag  | atgaattgtg | 720  |
| ctgctgctgt  | ttgggctgtt | gtttcttatg | ttgttgacga  | catggaagaa  | atgctgccta | 780  |
| ggctcctagaa | acagtaagaa | agaaacgttt | tcatgcttct  | ggccagggaat | cctgggtctg | 840  |
| caactttgga  | aaactcctct | tcacataaca | atttcatcca  | attcatcttc  | aaagcacaac | 900  |
| tctatttcat  | gctttctgtt | attatctttc | ttgatacttt  | ccaaattctc  | tgcatcttag | 960  |
| aaaaagggaat | cattctcccc | tcctccccc  | cacatagaat  | caacatatgg  | tagggattac | 1020 |
| agtgggggca  | tttctttata | tcacctctta | aaaacattgt  | ttccacttta  | aaagtaaaca | 1080 |
| cttaataaat  | ttttggaaga | tctctgaaaa | aaaaaaaaaa  | aaaaaaaaaa  | aaaa       | 1134 |

&lt;210&gt; 96

&lt;211&gt; 1772

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 96

|             |            |            |            |            |             |     |
|-------------|------------|------------|------------|------------|-------------|-----|
| tcgacccacg  | cgtccgggag | gatccccagc | cgggtcccaa | gcctgtgcct | gagcctgagc  | 60  |
| ctgagcctga  | gccgagccgg | gagccgggtc | cgggggctcc | gggctgtggg | accgctgggc  | 120 |
| ccccagcgat  | ggcgaccctg | tggggaggcc | ttcttcgggt | tggtcctctg | ctcagcctgt  | 180 |
| cgtgcctggc  | gctttccgtg | ctgctgctgg | cgcactgtca | gacgcgcgca | agaatttcga  | 240 |
| ggatgtcaga  | tgtaaatgta | tctgccctcc | ctataaagaa | aaattctggg | catattttata | 300 |
| ataagaacat  | atctcagaaa | gattgtgatt | gccttcatgt | tgtggagccc | atgcctgtgc  | 360 |
| gggggcctga  | tgtagaagca | tactgtctac | gctgtgaatg | caaatatgaa | gaaagaagct  | 420 |
| ctgtcacaat  | caaggttacc | attataattt | atctctccat | tttgggcctt | ctacttctgt  | 480 |
| acatgggtata | tcttactctg | gttgagccca | tactgaagag | gcgcctcttt | ggacatgcac  | 540 |

61

|            |             |             |             |             |             |      |
|------------|-------------|-------------|-------------|-------------|-------------|------|
| agttgataca | gagtgatgat  | gatattgggg  | atcaccagcc  | ttttgcaaat  | gcacacgatg  | 600  |
| tgctagcccg | ctcccgagc   | cgagccaacg  | tgctgaacaa  | ggtagaatat  | ggcacagcag  | 660  |
| cgctggaagc | ttcaagtcca  | agagcagcga  | aaagtctgtc  | tttgaccggc  | atgttgtcct  | 720  |
| cagctaattg | gggaattgaa  | ttcaagggtga | ctagaaagaa  | acaggcagac  | aactggaaag  | 780  |
| gaactgactg | ggttttgctg  | ggtttcattt  | taataccttg  | ttgatttcac  | caactgttgc  | 840  |
| tggaagattc | aaaactggaa  | gkaaaaaactt | gcttgatttt  | tttttcttgt  | taacgtaata  | 900  |
| atagagacat | ttttaaaagc  | acacagctca  | aagtcagcca  | ataagtcttt  | tcctattttgt | 960  |
| gacttttact | aataaaaaata | aatctgcctg  | taaaaataaat | taaaaaatcc  | tttacctggga | 1020 |
| acaagcactc | tcitttttcac | cacatagttt  | taacttgact  | ttccaagata  | atttttcaggg | 1080 |
| tttttgttgt | tgttgttttt  | tgttgttttg  | ttttgggtgg  | agagggggagg | gatgcctggg  | 1140 |
| aagtggtaa  | caactttttt  | caagtcactt  | tactaaacaa  | actttttgtaa | atagacctta  | 1200 |
| ccttctattt | tcgagtttca  | tttatatttt  | gcagtgtagc  | cagcctcatc  | aaagagctga  | 1260 |
| cttactcatt | tgactttttg  | actgactgta  | ttatctgggt  | atctgctgtg  | tctgcacttc  | 1320 |
| atggtaaacg | ggatctaaaa  | tgctgtgtgg  | cttttcacaa  | aaagcagatt  | ttcttcattgt | 1380 |
| actgtgatgt | ctgatgcaat  | gcctcctaga  | acaaactggc  | catttgctag  | tttactctaa  | 1440 |
| agactaaaca | tagtcttggt  | gtgtgtgtgc  | ttactcatct  | tctagtacct  | ttaaggacaa  | 1500 |
| atcctaagga | cttggaact   | tgcaataaag  | aaattttatt  | ttaaacccaa  | gcctccctgg  | 1560 |
| attgataata | tatacacatt  | tgtcagcatt  | tcgggtcgtg  | gtgagaggca  | gctgtttgag  | 1620 |
| ctccaatgtg | tgcaagcttg  | aactagggtc  | ggggtgtgtg  | gtgcctcttc  | tgaaaggctc  | 1680 |
| aaccattatt | ggataactgg  | ctttttttct  | tcctcttttg  | aatgtaacaa  | taaaaataat  | 1740 |
| ttttgaaaca | tcaaaaaaaaa | aaaaaaaaaa  | aa          |             |             | 1772 |

&lt;210&gt; 97

&lt;211&gt; 2381

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 97

|             |             |             |            |            |             |      |
|-------------|-------------|-------------|------------|------------|-------------|------|
| ccacgcgtcc  | cgcaaggcca  | gttctagtgt  | agagagaaaa | aggagccggc | agcggtcttt  | 60   |
| acgcgtcccg  | gggctgcgcg  | ccactctctc  | ggccggtaac | gcggtgcttt | gcggtctgctg | 120  |
| tcaagcgcg   | cgttgggccc  | gcgggcgggg  | gctgaggggc | tgccatggcg | gcggcggggcc | 180  |
| ggctcccag   | ctcctgggcc  | ctctctcgc   | cgctcctgc  | agggtctgca | ctactgggag  | 240  |
| tcgggccggt  | cccagcgccg  | gcgctgcaca  | acgtcacggc | cgagctcttt | ggggcccgagg | 300  |
| cctggggcac  | ccttgcggct  | ttcggggacc  | tcaactccga | caagcagacg | gatctcttcg  | 360  |
| tgctgcggga  | aagaaatgac  | ttaatcgtct  | ttttggcaga | ccagaatgca | ccctatttta  | 420  |
| aacccaaagt  | aaaggtatct  | ttcaagaatc  | acagtgcatt | gataacaagt | gtagtccctg  | 480  |
| gggattatga  | tggagattct  | caaatggatg  | tccttctgac | atatcttccc | aaaaattatg  | 540  |
| ccaagagtga  | attaggagct  | gttatctctt  | ggggacaaaa | tcaaacatta | gatcctaaca  | 600  |
| atatgaccat  | actcaatagg  | acttttcaag  | atgagccact | aattatggat | ttcaatgggtg | 660  |
| atctaattcc  | tgatatTTTT  | ggtatcacaa  | atgaatccaa | ccagccacag | atactattag  | 720  |
| gaggggaattt | atcatggcat  | ccagcattga  | ccactacaag | taaaatgcga | attccacatt  | 780  |
| ctcatgcatt  | tattgatctg  | actgaagatt  | ttacagcaga | tttattcctg | acgacattga  | 840  |
| atgccaccac  | tagtaacctc  | cagtttgaaa  | tatgggaaaa | tttggatgga | aacttctctg  | 900  |
| tcagtactat  | attggaaaaa  | cctcaaaata  | tgatgggtgt | tggacagtca | gcatttgcag  | 960  |
| actttgatgg  | agatggacac  | atggatcatt  | tactgccagg | ctgtgaagat | aaaaattggc  | 1020 |
| aaaagagtac  | catctactta  | gtgagatctg  | ggatgaagca | gtgggttcca | gtcctacaag  | 1080 |
| atttcagcaa  | taagggcaca  | ctctggggct  | ttgtgccatt | tgtggatgaa | cagcaaccaa  | 1140 |
| ctgaaatacc  | aattccaatt  | acccttcata  | ttggagacta | caatatggat | ggctatccag  | 1200 |
| acgctctggt  | catactaaag  | aacacatctg  | gaagcaacca | gcaggccctt | ttactgggaga | 1260 |
| acgtcccttg  | taataatgca  | agctgtgaag  | aggcgcgctc | aatgtttaaa | gtctactggg  | 1320 |
| agctgacaga  | cctaaatcaa  | attaaggatg  | ccatggttgc | caacttcttt | gacatttacg  | 1380 |
| aagatggaat  | cttggacatt  | gtagtgtctaa | gtaaaggata | tacaaagaat | gattttgccca | 1440 |
| ttcatacact  | aaaaaataac  | tttgaagcag  | atgcttattt | tgttaaagtt | attgttctta  | 1500 |
| gtggtctgtg  | ttctaattgac | tgctcctgta  | gataacaccc | tttggagtga | atcaacctgg  | 1560 |
| accttatatc  | atgtatacaa  | ctgtagatgc  | aaatgggtat | ctgaaaaatg | gatcagctgg  | 1620 |
| ccaactcagc  | caatccgcac  | atttagctct  | ccaactacca | tacaacgtgc | ttggtttagg  | 1680 |
| tcggagcgca  | aattttcttg  | accatctcta  | cgttggtatt | ccccgtccat | ctggagaaaa  | 1740 |

|             |             |            |            |            |            |      |
|-------------|-------------|------------|------------|------------|------------|------|
| atctatacga  | aaacaagagt  | ggactgcaat | cattccaaat | tcccagctaa | ttgtcattcc | 1800 |
| ataccctcac  | aatgtccctc  | gaagttggag | tgccaaactg | tatcttacac | caagtaatat | 1860 |
| tggtctgctt  | actgctatag  | ctctcatcgg | tgtctgtgtt | ttcatcttgg | caataattgg | 1920 |
| cattttacat  | tggcaggaaa  | agaaagcaga | tgatagagaa | aaacgacaag | aagcccaccg | 1980 |
| gtttcatttt  | gatgctatgt  | gacttgccct | taatattaca | taatggaatg | gctgttcact | 2040 |
| tgattagtgt  | aaacacaaat  | tctggcttga | aaaaataggg | gagattaaat | attatttata | 2100 |
| aatgatgtat  | cccatggtaa  | ttattggaaa | gtattcaaat | aaatatgggt | tgaatatgtc | 2160 |
| acaagggtctt | tttttttaaa  | gcactttgta | tataaaaatt | tgggttctct | attctgtagt | 2220 |
| gctgtacatt  | tttgttcctt  | tgtggaatgt | gttgcattgt | ctccagtggt | tgtgtattta | 2280 |
| taatcttatt  | tgcattcatga | tgatggaaaa | agttgtgtaa | ataaaaaata | ttaaatgagc | 2340 |
| aggaaaaaaa  | aaaaaaaaaa  | aaaaaaaaaa | aaaaaaaaaa | a          |            | 2381 |

&lt;210&gt; 98

&lt;211&gt; 1955

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 98

|             |             |             |            |             |             |      |
|-------------|-------------|-------------|------------|-------------|-------------|------|
| ggcacgagtg  | ccatccctgt  | atttgctgcc  | atgctcttcc | ttttctccat  | ggctacactg  | 60   |
| ttgaggacca  | gcttcagtga  | ccctggagtg  | attcctcggg | cgctaccaga  | tgaagcagct  | 120  |
| ttcatagaaa  | tggagataga  | agctaccaat  | ggtgcggtgc | cccagggcca  | gcgaccaccg  | 180  |
| cctcgtatca  | agaatttcca  | gataaacaac  | cagattgtga | aactgaaata  | ctgttacaca  | 240  |
| tgcaagatct  | tccggcctcc  | ccgggcctcc  | cattgcagca | tctgtgacaa  | ctgtgtggag  | 300  |
| cgcttcgacc  | atcactgccc  | ctgggtgggg  | aattgtgttg | gaaagaggaa  | ctaccgctac  | 360  |
| ttctacctct  | tcactccttc  | tctctccctc  | ctcacaatct | atgtcttcgc  | cttcaacatc  | 420  |
| gtctatgttg  | ccctcaaata  | tttgaaaatt  | ggcttcttgg | agacattgaa  | aggaaactcc  | 480  |
| tggaaactgtt | ctagaagtcc  | tcatttgctt  | ctttacactc | tgggtccgtcg | tgggactgac  | 540  |
| tggaatttcac | actttcctcg  | tggctctcaa  | ccagacaacc | aatgaaagac  | atcaaaggat  | 600  |
| catggacagg  | gaagaatcgc  | gtccagaatc  | cctacagcca | tggcaatatt  | gtgaagaact  | 660  |
| gctgtgaagt  | gctgtgtggc  | cccttgcccc  | ccagtgtgct | ggatcgaagg  | ggtattttgc  | 720  |
| cactggagga  | aagtgggaagt | cgacctccca  | gtactcaaga | gaccagtagc  | agcctcttgc  | 780  |
| ccagagagccc | agccccccaca | gaacacctga  | actcaaatga | gatgccggag  | gacagcagca  | 840  |
| ctcccgaaga  | gatgccacct  | ccagagcccc  | cagagccacc | acaggaggca  | gctgaagctg  | 900  |
| agaagtagcc  | tatctatgga  | agagactttt  | gtttgtgttt | aattagggct  | atgagagatt  | 960  |
| tcagggtgaga | agttaaacct  | gagacagaga  | gcaagtaagc | tgtccctttt  | aactgttttt  | 1020 |
| cttttggtctt | tagtcaccca  | gttgccacct  | ggcattttct | tgtgtcaagc  | ttttttaaat  | 1080 |
| ttctgaactc  | aaggcagtg   | cagaagatgt  | cagtcacctc | tgataactgg  | aaaaatgggt  | 1140 |
| ctcttggggc  | ctggcactgg  | ttctccatgg  | cctcagccac | agggtccctt  | tggacccctt  | 1200 |
| ctcttccctc  | cagatcccag  | ccctcctgct  | tggggtcact | gggtctcattc | tggggctaaa  | 1260 |
| agttttcgag  | actggctcaa  | atcctcccaa  | gctgctgcac | gtgctgagtc  | cagaggcagt  | 1320 |
| cacagagacc  | tctggccagg  | ggatcctaac  | tgggttcttg | gggtcttcag  | gactgaagag  | 1380 |
| gagggagagt  | ggggtcagaa  | gatttctctg  | gccaccaagt | gccagcattg  | cccacaaatc  | 1440 |
| cttttaggaa  | tgggacaggt  | accttccact  | agttgtatct | attagtgtag  | cttctccttt  | 1500 |
| gtctcccatc  | cactctgaca  | ccttaagccc  | cactcttttc | ccattagata  | tatgtaaagta | 1560 |
| gttgtagtag  | agataataat  | tgacatttct  | cgtagactac | ccagaaactt  | ttttaatacc  | 1620 |
| tgtgccattc  | tcaataagaa  | tttatgagat  | gccagcggca | tagcccttca  | cactctctgt  | 1680 |
| ctcatctctc  | ctcctttctc  | attagccctt  | tttaatttgt | ttttcctttt  | gactcctgct  | 1740 |
| cccattagga  | gcaggaatgg  | cagtaataaa  | agtctgcact | ttgggtcattt | cttttctctca | 1800 |
| gaggaagcct  | gagtgtctac  | ttaaactacta | tcccctcaga | ctccctgtgt  | gaggcctgca  | 1860 |
| gaggccctga  | atgcacaaat  | gggaaaccaa  | ggcacagaga | ggctctcctc  | tcctctcctc  | 1920 |
| tcccccgatg  | taccctcaaa  | aaaaaaaaaa  | aaaaa      |             |             | 1955 |

&lt;210&gt; 99

&lt;211&gt; 1958

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 99

|             |             |             |             |             |            |      |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| ccacgcgtcc  | ggggcggtcc  | tggtcgtgag  | aggggagccc  | caggggagct  | ggggcagcat | 60   |
| gactgggggtg | ataaatggcc  | ggaaatttgg  | cgtggccaca  | ctcaacacca  | gcgtgatgca | 120  |
| ggaggcacac  | tccgggggtca | gcagcatcca  | cagcagcatc  | cgccatgtcc  | cagcaaacgt | 180  |
| ggggcctctg  | atgcgggtgc  | tcgtgggtcac | catcgccccc  | atctactggg  | ccctggccag | 240  |
| agagagtggg  | gaagccctga  | atggccactc  | tctgactggg  | ggcaagtctc  | ggcagagtca | 300  |
| caagtggagt  | ttgctacagg  | gagctgctca  | cgatgaccca  | gtggcccggg  | gtctggatcc | 360  |
| cgatggcctc  | ctgctcctcg  | acgtggtggt  | caatggcggt  | gtccccggac  | gagcctggct | 420  |
| gacgcagatc  | ttcaagtga   | ggactttgaa  | gaagcactac  | gtgcaaacaa  | gggcctggcc | 480  |
| agctgttcgt  | gggctccaca  | cagcgcttct  | tccagggcgg  | cctccccctg  | ttcctacgct | 540  |
| gcaaccacag  | catccagtac  | aacgcggccc  | ggggccccc   | gccccagctg  | gtgcagcacc | 600  |
| tgccggcctc  | agctatcagc  | tcggcctttg  | atccagaggc  | cgaggccctg  | cgcttccagc | 660  |
| tcgtctacagc | cctgcaggcg  | gaggagaacg  | aggtcggctg  | ccccgagggc  | tttgagctgg | 720  |
| actcccaggg  | agcgttttgt  | gtggatgtgg  | acgagtgtgc  | gtgggatgct  | cacctctgcc | 780  |
| gagagggaca  | gcgctgtgtg  | aacctgtctg  | ggtcctaccg  | ctgcctcccc  | gactgtgggc | 840  |
| ctggcttccg  | ggtggctgat  | ggggccggct  | gtgaaaatgt  | ggacgaatgc  | ctggaagggg | 900  |
| ttggacgact  | gtcactacaa  | ccagctctgc  | gagaacaccc  | caggcgggtca | ccgctgcagc | 960  |
| tgccccaggg  | gttaccggat  | gcaggggccc  | agcctgcctt  | gcctagatgt  | caatgagtgc | 1020 |
| ctgcagctgc  | ccaaggcctg  | cgctaccag   | tgcacacaacc | tccagggcag  | ctaccgctgc | 1080 |
| ctgtgcccc   | caggccagac  | cctccttcgc  | gacggcaagg  | cctgcacctc  | actggagcgg | 1140 |
| aatggacaaa  | atgtgaccac  | cgtcagccac  | cgaggccctc  | tattgccctg  | gctgcggccc | 1200 |
| tgggcctcga  | tccccggtac  | ctcctaccac  | gcctgggtct  | ctctccgtcc  | gggtcccatg | 1260 |
| gccctgagca  | gtgtgggccc  | ggcctgggtg  | cctcctgggt  | tcatcaggca  | gaacggagtc | 1320 |
| tgacacagac  | ttgacgagtg  | ccgcgtgagg  | aaactgtgtc  | agcacgcctg  | ccgcaacact | 1380 |
| gagggcagct  | accagtgcct  | gtgccccgcc  | ggctaccgtc  | tgctccccag  | cgggaagaac | 1440 |
| tgccaggaca  | tcaacgagtg  | cgaggaggag  | agcatcgagt  | gtggaccctg  | ccagatgtgc | 1500 |
| ttcaacaccc  | gtggcagcta  | ccagtgtgtg  | gacacaccct  | gtcctgccac  | ctaccggcag | 1560 |
| ggccccagcc  | ctgggacgtg  | cttccggcgc  | tgctcgcagg  | actgcggcac  | gggcggcctt | 1620 |
| tctacgctgc  | agtaccggct  | gctgcgcgtg  | ccccctggcg  | tgcgcgccca  | ccacgacgtg | 1680 |
| gccccgctca  | ccgccttctc  | cgaggctcgg  | gtccccgcca  | accgcaccga  | gctcagcatg | 1740 |
| ctggagcccc  | acccccgcag  | cccccttcgc  | ctgcgtccgc  | tgcgcgcggg  | ccttggcggc | 1800 |
| gtctacaccc  | gtcgcgcgct  | cacccgcgcc  | ggcctctacc  | ggctcaccgt  | gcgtgctgcg | 1860 |
| gcacgcgcgc  | accaaagcgt  | cttcgtcttg  | ctcactgcgc  | tgcccccccta | cccctactaa | 1920 |
| acgggagagg  | gcattggcgg  | ccgctctaga  | ggatccct    |             |            | 1958 |

&lt;210&gt; 100

&lt;211&gt; 2444

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 100

|             |             |            |             |             |            |     |
|-------------|-------------|------------|-------------|-------------|------------|-----|
| ttacgccaaag | ctggcacgag  | caatgaaaga | gttaatctct  | ttggctgggc  | ctacagatga | 60  |
| catacagagt  | acagtccccc  | aggttcatgc | tttaaatatc  | cttagagcat  | tggtcagaga | 120 |
| tacgcgcctg  | ggagaaaata  | ttattcctta | tggttgctgat | ggagctaagg  | ctgcaattct | 180 |
| gggtttttaca | tcaccgggtct | gggcagtgcg | aaattcatcc  | acacttctct  | ttagtgcctt | 240 |
| gatcacaaga  | atttttggag  | ttaaaagggc | aaaggatgaa  | cattccaaaa  | caaatagaat | 300 |
| gacagggaga  | gagtttttct  | ctcggttccc | agaactctat  | ccttttcttc  | tcaaacagtt | 360 |
| ggaaactgta  | gccaatacag  | tagacagtga | tatgggagaa  | ccaaatcgtc  | atccaagcat | 420 |
| gtttctctta  | cttttgggtg  | tggagagact | ctacgcttcc  | ccgatggatg  | gtacttcttc | 480 |
| tgctctcagc  | atgggaacct  | ttgttccctt | cattatgagg  | tgtgggtcact | cacctgtcta | 540 |
| ccactcccgt  | gaaatggcag  | ctcgtgcctt | ggtcccatct  | gttatgatag  | atcacattcc | 600 |
| taataccatt  | cgaactctgt  | tgtccacact | ccccagctgc  | actgaccagt  | gtttccgggc | 660 |
| aaaaccacat  | tcatggggac  | acttctccag | gtttttccat  | ttgttgcaag  | cctactcaga | 720 |
| ctccaaaaca  | cggaaacgaat | tcagacttcc | agcacgagct  | gactgacatc  | actgtttgta | 780 |
| ccaaagccaa  | actctggctg  | gccaaagggc | aaaatccatg  | tttggtgacc  | agagctgtat | 840 |
| atattgatat  | tctcttcccta | ttgacttgct | gcctcaacag  | atctgcaaa   | gacaaccagc | 900 |

|             |            |            |            |             |             |      |
|-------------|------------|------------|------------|-------------|-------------|------|
| cagttctgga  | gagttctggc | ttctgggaag | aaattcaaag | ggaattatct  | caggatcaga  | 960  |
| agctgataac  | gggattccct | tgggccttca | aggtgccagg | cctgcccag   | tacctccaga  | 1020 |
| gcctcaccag  | actagccatt | gctgcagtgt | gggccgcggc | agccaagagt  | ggagagcggg  | 1080 |
| agacgaatgt  | ccccatctct | ttctctcagc | tgttagaatc | tgcttccct   | gaagtgcgct  | 1140 |
| cactaacact  | ggaagccctc | ttggaaaagt | tcttagcagc | agactctgga  | cttggagaga  | 1200 |
| agggcggtgcc | acccttgctg | tgcaacatgg | gagagaagtt | cttattgttg  | gccatgaagg  | 1260 |
| aaaatcacc   | agaatgcttc | tgcaagatac | tgaaaattct | acactgcatg  | gaccctgggtg | 1320 |
| agtggtctcc  | ccagacggag | cactgtgtcc | atctgacccc | aaaggagtcc  | ttgatctgga  | 1380 |
| cgatggatat  | tgcttccaat | gaaagatctg | aaattcagag | tgtagctctg  | agacttgctt  | 1440 |
| ccaaagtcat  | ttcccaccac | atgcagacat | gtgtggagaa | cagggaaattg | atagctgctg  | 1500 |
| agctgaagca  | gtgggttcag | ctggtcatct | tgtcatgtga | agaccatctt  | cctacagagt  | 1560 |
| ctaggctggc  | cgtcgttgaa | gtcctcacca | gtactacacc | acttttccctc | accaaccccc  | 1620 |
| atcctattct  | tgagttgcag | gatacacttg | ctctctggaa | gtgtgtccct  | acccttctgc  | 1680 |
| agagtgaaga  | gcaagctgtt | agagatgcag | ccacggaaac | cgtgacaact  | gccatgtcac  | 1740 |
| aagaaaatac  | ctgccagtca | acagagtttg | ccttctgcca | ggtggatgcc  | tccatcgctc  | 1800 |
| tggccctggc  | cctggccgtc | ctgtgtgac  | tgctccagca | gtgggaccag  | ttggcccttg  | 1860 |
| gactgcccat  | cctgctggga | tggctgttgg | gagagagtga | tgacctcggtg | gcctgtgttg  | 1920 |
| agagcatgca  | tcagggtgga | gaagactacc | tgtttgaaaa | agcagaagtc  | aacttttggg  | 1980 |
| ccgagaccct  | gatctttgtg | aaatacctct | gcaagcacct | cttctgtctc  | ctctcaaagt  | 2040 |
| ccggctggcg  | tcccccaagc | cctgagatgc | tctgtcacct | tcaaaggatg  | gtgtcagagc  | 2100 |
| agtgccacct  | cctgtctcag | ttcttcagag | agcttccacc | agctgctgag  | tttgtgaaga  | 2160 |
| cagtggagtt  | cacaagacta | cgcattcaag | aggaaaggac | tttggcttgc  | ttgaggctgc  | 2220 |
| tggccttttt  | ggaaggaaag | gaaggggaag | acaccctagt | tctcagtgtt  | tgggactctt  | 2280 |
| atgcagaatc  | gaggcagtta | actcttccaa | gaacagaagc | ggcatgttga  | agaaaaatctg | 2340 |
| ggggattggg  | atgggggtat | gtgtggattt | ttctccact  | aaatctgcag  | gaaacatggt  | 2400 |
| gaacataaat  | tcaaaaattt | tatcccaaaa | aaaaaaaaaa | aaaa        |             | 2444 |

&lt;210&gt; 101

&lt;211&gt; 2709

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 101

|            |            |            |            |             |            |      |
|------------|------------|------------|------------|-------------|------------|------|
| ggcacgagat | ttcctacagg | tgaaacgcca | tcattaggat | tcaactgtaac | gttagtgcta | 60   |
| ttaaactcac | tagcattttt | attaatggcc | gttatctaca | ctaagctata  | ctgcaacttg | 120  |
| gaaaaagagg | acctctcaga | aaactcacaa | tctagcatga | ttaagcatgt  | cgcttggcta | 180  |
| atcttcacca | attgcatctt | tttctgccct | gtggcggttt | tttcatttgc  | accattgatc | 240  |
| actgcaatct | ctatcagccc | cgaataatg  | aagtctgtta | ctctgatatt  | ttttccatgc | 300  |
| ctgcttgcc  | gaatccagtc | ctgtatgttt | tcttcaaccc | aaagttaaa   | gaagactgga | 360  |
| agttactgaa | gcgacgtgtt | accaagaaaa | gtggatcagt | ttcagtttcc  | atcagtagcc | 420  |
| aagggtggtg | tctggaacag | gatttctact | acgactgtgg | catgtactca  | catttgcagg | 480  |
| gcaacctgac | tgtttgcgac | tgctgcgaat | cgtttctttt | aacaaagcca  | gtatcatgca | 540  |
| aacacttgat | aaaatcacac | agctgtcctg | cattggcagt | ggcttcttgc  | caaagacctg | 600  |
| agggctactg | gtccgactgt | ggcacacatt | cggcccactc | tgattatgca  | gatgaagaag | 660  |
| attcctttgt | ctcagacagt | tctgaccagg | tgcaggcctg | tggacgagcc  | tgcttctacc | 720  |
| agagtagagg | attccctttg | gtgcgctatg | cttacaatct | accaagagtt  | aaagactgaa | 780  |
| ctactgtgtg | tgtaaccgtt | tcccccgta  | accaaaatca | gtgtttatag  | agtgaacctt | 840  |
| attctcatct | ttcatctggg | aagcacttct | gtaatcactg | cctgggtgtca | cttagaagaa | 900  |
| ggagagggtg | cagttttatt | ctcaaacagg | tcattttcaa | agaacagggtg | cctaaattat | 960  |
| aaattgggtg | aaaatgcaat | gtccaagcaa | tgtatgatct | gtttgaaaca  | aatatatgac | 1020 |
| ttgaaaagga | tcttagtgtg | agtagagcaa | tataatgtta | gttttttctg  | atccataaga | 1080 |
| agcaaattta | tacctatttg | tgtattaagc | acaagataaa | gaacagctgt  | taatattttt | 1140 |
| taaaaattct | atttttaaaa | tgtgattttc | tataactgaa | gaaaaatata  | ttgctaattt | 1200 |
| tacctaatgt | ttcatccttt | aatctcagga | caacttactg | cagggccaaa  | aaagggactg | 1260 |
| tcccagctag | acctgtgaga | gtatacatag | gcattacttt | attatgtttt  | cacttgccat | 1320 |
| ccttgacata | agagaactat | aaattttgtt | taagcaattt | ataaatctaa  | aacctgaaga | 1380 |
| tgtttttaaa | acaatattaa | cagctgttag | gttaaaaaaa | tagctggaca  | tttgttttca | 1440 |

65

|            |             |             |            |             |            |      |
|------------|-------------|-------------|------------|-------------|------------|------|
| gtcattatac | attgcttttg  | tccaatcagt  | aattttttct | taagtgtttt  | gtgattacac | 1500 |
| tactagaaaa | aaagtaaaag  | gctaattgct  | gtgtgggttt | agtcgatttg  | gctaaactac | 1560 |
| taactaatgt | gggggtttta  | tagtatctga  | gggattttgt | ggcttcattg  | aatgttctca | 1620 |
| ttaatgaata | cttcctaata  | tcgttggtct  | tactaatatt | ttccaatttg  | ctgggatgtc | 1680 |
| acctagcaat | agcttggatt  | atatagaaag  | taaactgtgg | tcaatacttg  | catttaatta | 1740 |
| gacgaaacgg | ggagtaatta  | tgacacgaag  | tacttaattg | ttattttctta | gtgagctgga | 1800 |
| ttatcttgaa | cctgtgctat  | taaatggaaa  | tttccataca | tcttcccat   | actatttttt | 1860 |
| ataaaagagc | ctattcaata  | gctcagaggt  | tgaactctgg | ttaaacaaga  | taatatgtta | 1920 |
| ttaataaaaa | tagaagaaga  | aagaataaag  | cttagtcctg | tgtcttttaa  | aaattaaaaa | 1980 |
| ttttacttga | ttcccatctt  | atgggcttta  | gacctattac | tgggtggagt  | cttaaagtta | 2040 |
| taattgttca | atatgttttt  | tgaacagtgt  | gctaaatcaa | tagcaaaccc  | actgccatat | 2100 |
| tagttattct | gaatatacta  | aaaaaatcca  | gctagattgc | agtttaataa  | ttaaactgta | 2160 |
| catactgtgc | atataatgaa  | tttttatctt  | atgtaaatta | tttttagaac  | acaagtgtgg | 2220 |
| aaatgtggct | tctgttcatt  | tcgttttaatt | aaagctacct | cctaaactat  | agtggctgcc | 2280 |
| agtagcagac | tgtaaatttg  | tgggtttatat | actttttgca | ttgtaaatag  | tctttgttgt | 2340 |
| acattgtcag | tgtaataaaa  | acagaatctt  | tgtatatcaa | aatcatgtag  | tttgtataaa | 2400 |
| atgtgggaag | gattttattta | cagtgtgttg  | taattttgta | aggccaacta  | tttacaagtt | 2460 |
| ttaaaaattg | ctatcatgta  | tatttacaca  | tctgataaat | attaaatcat  | aacttggtta | 2520 |
| gaaactccta | attaaaaggt  | tttttccaaa  | attcaggtta | ttgaaaactt  | ttcattttat | 2580 |
| tcatttaaaa | actagaataa  | cagatatata  | aaagtgttaa | tctttgtgct  | atatggtatg | 2640 |
| aaatacaata | ttgtactcag  | tgttttgaat  | tattaaagtt | tctagaaagc  | aaaaaaaaaa | 2700 |
| aaaaaaaaaa |             |             |            |             |            | 2709 |

&lt;210&gt; 102

&lt;211&gt; 1722

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (401)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (695)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 102

|            |            |            |             |            |             |      |
|------------|------------|------------|-------------|------------|-------------|------|
| gggaccgcgc | tgtcctgctg | tcaccaagag | ctggagacac  | catctccac  | cgagagtcac  | 60   |
| ggccccattg | gocctgcacc | tectcgctct | cgtccccatc  | ctcctcagcc | tgggtggcctc | 120  |
| ccaggactgg | aaggctgaac | gcagccaaga | ccccttcgag  | aaatgcatgc | aggatcctga  | 180  |
| ctatgagcag | ctgctcaagg | tcaccatcct | ggaggcagat  | aacaggatcg | ggggccgcac  | 240  |
| cttcacctac | cgggaccaga | wyacgggctg | gattggggag  | ctgggagcca | tgcgcatgcc  | 300  |
| cagctctcac | aggatcctcc | acaagctctg | ccaggggcctg | gggctcaacc | tgaccaagtt  | 360  |
| cacccagtag | gacaagaaca | cgtggacgga | ggtgcacgaa  | ntgaagctgc | gcaactatgt  | 420  |
| ggtggagaag | gtgcccagag | agctgggcta | cgccttgctg  | ccccaggaaa | agggccactc  | 480  |
| gcccgaagac | atctaccaga | tggctctcaa | ccaggccctc  | aaagacctca | aggcactggg  | 540  |
| ctgcagaaa  | gcgatgaaga | agtttgaaag | gcacacgctc  | ttggaatatc | ttctcgggga  | 600  |
| ggggaacctg | agccggccgg | ccgtgcagct | tctgggagac  | gtgatgtccg | aggatggctt  | 660  |
| cttctatctc | agcttcgccc | aggccctccg | ggccnacagc  | tgcttcagcg | acagactcca  | 720  |
| gtacagccgc | atcgtgggtg | gctgggacct | gctgccgcgc  | gcgctgctga | gctcgtgtgc  | 780  |
| cgggctttgt | ctgttgaacg | cgcccgtggt | ggcgatgacc  | cagggaccgc | acgatgtgca  | 840  |
| cgtgcagatc | gagacctctc | ccccggcgcg | gaatctgaag  | gtgctgaagg | ccgacgtggg  | 900  |
| gctgctgacg | gcgagcggac | cggcggtgaa | gcgcatacc   | ttctcgccgc | gctgccccgc  | 960  |
| cacatgcagg | aggcgctgcg | gaggctgcac | tacgtgccgg  | ccaccaaggt | gttccctaagc | 1020 |
| ttccgcaggc | ccttctggcg | cgaggagcac | attgaaggcg  | gccactcaaa | caccgatcgc  | 1080 |



66

```

ccgtcgcgca tgattttcta cccgccgcgc cgcgaggcgc cgtgctgctt ggcctcgtag 1140
acgtgggtcgg acgcggcgcc agcgttcgcc ggcttgagcc gggaagaggc gttgcgcttg 1200
gcgctcgacg acgtggcgcc attgcacggg cctgtcgtgc gccagctctg ggacggcacc 1260
ggcgctcgta agcgttgggc ggaggaccag cacagccagg gtgggtttgt ggtacagmcg 1320
ccggcgctct ggcaaaccga aaaggatgac tggacgggct cttatggccg catctacttt 1380
gcggcgagc acaccgccta cccgcacggc tgggtggaga cggcgggtcaa gtcggcgctg 1440
cgcgcgcgca tcaagatcaa cagccggaag gggcctgcat cggacacggc cagccccgag 1500
gggcacgcat ctgacatgga ggggcagggg catgtgcatg ggtggccag cagccctcgc 1560
catgacctgg caaaggaaga aggcagccac cctccagtcc aaggccagtt atctctccaa 1620
aacacgaccc acacgaggac ctcgcattaa agtattttcg gaaaaaaaaa aaaaaaaaaa 1680
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaggcgcg cc 1722

```

&lt;210&gt; 103

&lt;211&gt; 106

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (14)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 103

```

Met Gly Ser Leu Ser Gly Cys Ala Leu Pro Phe Cys Leu Xaa Val Phe
  1             5             10             15

```

```

Phe Leu Thr Val Ser Pro Ser Ala Val Gly Leu Leu Xaa Phe Ala Gly
      20             25             30

```

```

Gly Pro Leu Gln Thr Leu Phe Ala Trp Val Ser Pro Val Glu Ala Ala
  35             40             45

```

```

Glu Gln Gln Arg Leu Leu Pro Val Leu Ser Ser Gly Ser Phe Val Ser
  50             55             60

```

```

Glu Gly Thr Cys Gln Met Pro Ala Arg Ala Leu Leu Tyr Glu Val Ser
  65             70             75             80

```

```

Val Gly Pro Tyr Trp Glu Ile Pro Pro Ser Gln Asp Thr Arg Arg Ser
      85             90             95

```

```

Gly Thr Tyr Leu Arg Arg Gln Ser Asp Pro
      100             105

```

&lt;210&gt; 104

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 104

Met Thr Leu Pro Ser Arg Ala Leu Ala Ser Leu Gly Val Gly Val Trp

1 5 10 15 67  
 Gly Met Leu Arg Leu Asn Gln Val Thr Val Ser Cys Gly Gly Ser Arg  
 20 25 30  
 Trp Ser Ser Arg Val Ala Leu Gly Ala Phe Ser Trp Val Cys Gly Val  
 35 40 45  
 Ala Leu Val Leu Gln Pro Ser Gly Gly Gly Leu Gly Leu Thr Ser Pro  
 50 55 60  
 Ser Glu Gly Cys Trp Glu Gly Glu Leu Ala Leu Ala Val Leu Arg Ala  
 65 70 75 80  
 Pro Gly Gly Ser Pro Ser  
 85  
 <210> 105  
 <211> 302  
 <212> PRT  
 <213> Homo sapiens  
 <400> 105  
 Met Ala Arg Ala Arg Gly Ser Pro Cys Pro Pro Leu Pro Pro Gly Arg  
 1 5 10 15  
 Met Ser Trp Pro His Gly Ala Leu Leu Phe Leu Trp Leu Phe Ser Pro  
 20 25 30  
 Pro Leu Gly Ala Gly Gly Gly Gly Val Ala Val Thr Ser Ala Ala Gly  
 35 40 45  
 Gly Gly Ser Pro Pro Ala Thr Ser Cys Pro Val Ala Cys Ser Cys Ser  
 50 55 60  
 Asn Gln Ala Ser Arg Val Ile Cys Thr Arg Arg Asp Leu Ala Glu Val  
 65 70 75 80  
 Pro Ala Ser Ile Pro Val Asn Thr Arg Tyr Leu Asn Leu Gln Glu Asn  
 85 90 95  
 Gly Ile Gln Val Ile Arg Thr Asp Thr Phe Lys His Leu Arg His Leu  
 100 105 110  
 Glu Ile Leu Gln Leu Ser Lys Asn Leu Val Arg Lys Ile Glu Val Gly  
 115 120 125  
 Ala Phe Asn Gly Leu Pro Ser Leu Asn Thr Leu Glu Leu Phe Asp Asn  
 130 135 140  
 Arg Leu Thr Thr Val Pro Thr Gln Ala Phe Glu Tyr Leu Ser Lys Leu  
 145 150 155 160  
 Arg Glu Leu Trp Leu Arg Asn Asn Pro Ile Glu Ser Ile Pro Ser Tyr  
 165 170 175  
 Ala Phe Asn Arg Val Pro Ser Leu Arg Arg Leu Asp Leu Gly Glu Leu

68

|   |     |     |     |     |     |     |
|---|-----|-----|-----|-----|-----|-----|
|   | 180 |     | 185 |     | 190 |     |
| Lys Arg Leu Glu Tyr Ile Ser Glu Ala Ala Phe Glu Gly Leu Val Asn |     |     |     |     |     |     |
|   | 195 |     | 200 |     | 205 |     |
| Leu Arg Tyr Leu Asn Leu Gly Met Cys Asn Leu Lys Asp Ile Pro Asn |     |     |     |     |     |     |
|   | 210 |     | 215 |     | 220 |     |
| Leu Thr Ala Leu Val Arg Leu Glu Glu Leu Glu Leu Ser Gly Asn Arg |     |     |     |     |     |     |
|   | 225 |     | 230 |     | 235 | 240 |
| Leu Asp Leu Ile Arg Pro Gly Ser Phe Gln Gly Leu Thr Ser Leu Arg |     |     |     |     |     |     |
|   |     | 245 |     | 250 |     | 255 |
| Lys Leu Trp Leu Met His Ala Gln Val Ala Thr Ile Glu Arg Asn Ala |     |     |     |     |     |     |
|   | 260 |     | 265 |     |     | 270 |
| Phe Asp Asp Leu Lys Ser Leu Glu Glu Leu Asn Leu Ser His Asn Asn |     |     |     |     |     |     |
|   | 275 |     | 280 |     | 285 |     |
| Leu Met Ser Leu Pro His Asp Leu Phe Thr Pro Leu His Arg         |     |     |     |     |     |     |
|   | 290 |     | 295 |     | 300 |     |

&lt;210&gt; 106

&lt;211&gt; 56

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (56)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 106

|   |
|---|
| Met Pro Ser Ser Trp Leu Pro Gly Cys Phe Val Leu Leu Cys Leu Val |
| 1 5 10 15   |

|   |
|---|
| Ala Val Gly Cys Gln Leu Arg Glu Trp Gly Val Gly Gly Val Ser Ala |
| 20 25 30  |

|   |
|---|
| Val Gly Leu Leu Ala Leu Pro His Leu Gln Val Leu Gly Met Arg Gly |
| 35 40 45  |

|                                 |
|---------------------------------|
| Arg Gly Leu Ile Ser Gly Gly Xaa |
| 50 55                           |

&lt;210&gt; 107

&lt;211&gt; 189

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (94)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

69

&lt;400&gt; 107

```

Met Ala Leu Leu Ser Arg Pro Ala Leu Thr Leu Leu Leu Leu Met
 1           5           10           15

Ala Ala Val Val Arg Cys Gln Glu Gln Ala Gln Thr Thr Asp Trp Arg
 20           25           30

Ala Thr Leu Lys Thr Ile Arg Asn Gly Val His Lys Ile Asp Thr Tyr
 35           40           45

Leu Asn Ala Ala Leu Asp Leu Leu Gly Gly Glu Asp Gly Leu Cys Gln
 50           55           60

Tyr Lys Cys Ser Asp Gly Ser Lys Pro Phe Pro Arg Tyr Gly Tyr Lys
 65           70           75           80

Pro Ser Pro Pro Asn Gly Cys Gly Ser Pro Leu Phe Gly Xaa His Leu
           85           90           95

Asn Ile Gly Ile Pro Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg
          100          105          110

Cys Tyr Glu Thr Cys Gly Lys Ser Lys Asn Asp Cys Asp Glu Glu Phe
          115          120          125

Gln Tyr Cys Leu Ser Lys Ile Cys Arg Asp Val Gln Lys Thr Leu Gly
          130          135          140

Leu Thr Gln His Val Gln Ala Cys Glu Thr Thr Val Glu Leu Leu Phe
          145          150          155          160

Asp Ser Val Ile His Leu Gly Cys Lys Pro Tyr Leu Asp Ser Gln Arg
          165          170          175

Ala Ala Cys Arg Cys His Tyr Glu Glu Lys Thr Asp Leu
          180          185

```

&lt;210&gt; 108

&lt;211&gt; 61

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (61)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 108

```

Met Gly Asn Cys Gln Ala Gly His Asn Leu His Leu Cys Leu Ala His
 1           5           10           15

His Pro Pro Leu Val Cys Ala Thr Leu Ile Leu Leu Leu Gly Leu
          20           25           30

Ser Gly Leu Gly Leu Gly Ser Phe Leu Leu Thr His Arg Thr Gly Leu
          35           40           45

```

70

Arg Thr Leu Thr Ser Pro Arg Thr Gly Ser Leu Phe Xaa  
           50                          55                          60

&lt;210&gt; 109

&lt;211&gt; 128

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (90)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 109

Met Arg Leu Glu Ser Leu Cys His Leu Cys Leu Ala Cys Leu Phe Phe  
   1                          5                          10                          15

Arg Leu Pro Ala Thr Arg Thr Val Tyr Cys Met Asn Glu Ala Glu Ile  
                           20                          25                          30

Val Asp Val Ala Leu Gly Ile Leu Ile Glu Ser Arg Lys Gln Xaa Lys  
           35                          40                          45

Ala Cys Glu Gln Pro Ala Leu Ala Gly Ala Asp Asn Pro Glu His Ser  
           50                          55                          60

Pro Pro Cys Ser Val Ser Pro His Thr Ser Ser Gly Ser Ser Ser Glu  
   65                          70                          75                          80

Glu Glu Asp Ser Gly Lys Gln Ala Leu Xaa Pro Gly Leu Ser Pro Ser  
                           85                          90                          95

Gln Arg Pro Gly Gly Ser Ser Ser Ala Cys Ser Arg Ser Pro Glu Glu  
                           100                          105                          110

Glu Glu Glu Glu Asp Val Leu Lys Tyr Val Arg Glu Ile Phe Phe Ser  
           115                          120                          125

&lt;210&gt; 110

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (50)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

71

<220>  
<221> SITE  
<222> (69)  
<223> Xaa equals stop translation  
  
<400> 110  
Met Pro His Phe Leu Asp Trp Phe Val Pro Val Tyr Leu Val Ile Ser  
1 5 10 15  
Val Leu Ile Leu Val Gly Phe Gly Ala Cys Ile Tyr Tyr Phe Glu Pro  
20 25 30  
Gly Leu Gln Glu Ala His Lys Trp Arg Met Gln Arg Pro Leu Val Asp  
35 40 45  
Arg Xaa Leu Arg Lys Thr Leu Met Val Arg Asp Asn Leu Ala Phe Gly  
50 55 60  
Gly Pro Glu Val Xaa  
65

<210> 111  
<211> 123  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (123)  
<223> Xaa equals stop translation  
  
<400> 111  
Met Ile Gly Gly Ile Thr Cys Ile Leu Ser Leu Ile Cys Ala Leu Ala  
1 5 10 15  
Leu Ala Tyr Leu Asp Gln Arg Ala Glu Arg Ile Leu His Lys Glu Gln  
20 25 30  
Gly Lys Thr Gly Glu Val Ile Lys Leu Thr Asp Val Lys Asp Phe Ser  
35 40 45  
Leu Pro Leu Trp Leu Ile Phe Ile Ile Cys Val Cys Tyr Tyr Val Ala  
50 55 60  
Val Phe Pro Phe Ile Gly Leu Gly Lys Val Phe Phe Thr Glu Lys Phe  
65 70 75 80  
Gly Phe Ser Ser Gln Ala Ala Ser Ala Ile Asn Ser Val Val Tyr Val  
85 90 95  
Ile Ser Ala Pro Met Ser Pro Val Phe Gly Leu Leu Val Asp Lys Thr  
100 105 110  
Gly Lys Asn Ile Ile Trp Val Leu Cys Ala Xaa  
115 120

72

<210> 112  
 <211> 83  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (83)  
 <223> Xaa equals stop translation

<400> 112  
 Met Glu Lys Gln Cys Cys Ser His Pro Val Ile Cys Ser Leu Ser Thr  
           1                  5                  10                  15  
 Met Tyr Thr Phe Leu Leu Gly Ala Ile Phe Ile Ala Leu Ser Ser Ser  
                   20                  25                  30  
 Arg Ile Leu Leu Val Lys Tyr Ser Ala Asn Glu Gly Lys Leu Arg Leu  
           35                  40                  45  
 Gly Ile Cys Met Glu His Phe His Leu Ile Thr His Leu Ser Leu Ala  
           50                  55                  60  
 Phe Gly Ser Val Ile Tyr Asn Met Glu Ile Ile Met Pro Phe Ala Ser  
           65                  70                  75                  80  
 Cys Glu Xaa

<210> 113  
 <211> 345  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (53)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (345)  
 <223> Xaa equals stop translation

<400> 113  
 Met Asp Phe Leu Val Leu Phe Leu Phe Tyr Leu Ala Ser Val Leu Met  
           1                  5                  10                  15  
 Gly Leu Val Leu Ile Cys Val Cys Ser Lys Thr His Ser Leu Lys Gly  
                   20                  25                  30  
 Leu Ala Arg Gly Gly Ala Gln Ile Phe Ser Cys Ile Ile Pro Glu Cys  
           35                  40                  45  
 Leu Gln Arg Ala Xaa His Gly Leu Leu His Tyr Leu Phe His Thr Arg  
           50                  55                  60

73

Asn His Thr Phe Ile Val Leu His Leu Val Leu Gln Gly Met Val Tyr  
 65 70 75 80  
 Thr Glu Tyr Thr Trp Glu Val Phe Gly Tyr Cys Gln Glu Leu Glu Leu  
 85 90 95  
 Ser Leu His Tyr Leu Leu Leu Pro Tyr Leu Leu Leu Gly Val Asn Leu  
 100 105 110  
 Phe Phe Phe Thr Leu Thr Cys Gly Thr Asn Pro Gly Ile Ile Thr Lys  
 115 120 125  
 Ala Asn Glu Leu Leu Phe Leu His Val Tyr Glu Phe Asp Glu Val Met  
 130 135 140  
 Phe Pro Lys Asn Val Arg Cys Ser Thr Cys Asp Leu Arg Lys Pro Ala  
 145 150 155 160  
 Arg Ser Lys His Cys Ser Val Cys Asn Trp Cys Val His Arg Phe Asp  
 165 170 175  
 His His Cys Val Trp Val Asn Asn Cys Ile Gly Ala Trp Asn Ile Arg  
 180 185 190  
 Tyr Phe Leu Ile Tyr Val Leu Thr Leu Thr Ala Ser Ala Ala Thr Val  
 195 200 205  
 Ala Ile Val Ser Thr Thr Phe Leu Val His Leu Val Val Met Ser Asp  
 210 215 220  
 Leu Tyr Gln Glu Thr Tyr Ile Asp Asp Leu Gly His Leu His Val Met  
 225 230 235 240  
 Asp Thr Val Phe Leu Ile Gln Tyr Leu Phe Leu Thr Phe Pro Arg Ile  
 245 250 255  
 Val Phe Met Leu Gly Phe Val Val Val Leu Ser Phe Leu Leu Gly Gly  
 260 265 270  
 Tyr Leu Leu Phe Val Leu Tyr Leu Ala Ala Thr Asn Gln Thr Thr Asn  
 275 280 285  
 Glu Trp Tyr Arg Gly Asp Trp Ala Trp Cys Gln Arg Cys Pro Leu Val  
 290 295 300  
 Ala Trp Pro Pro Ser Ala Glu Pro Gln Val His Arg Asn Ile His Ser  
 305 310 315 320  
 His Gly Leu Arg Ser Asn Leu Gln Glu Ile Phe Leu Pro Ala Phe Pro  
 325 330 335  
 Cys His Glu Arg Lys Lys Gln Glu Xaa  
 340 345

&lt;210&gt; 114

&lt;211&gt; 181

&lt;212&gt; PRT



74

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (110)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 114

```

Met Ala Asp Pro His Val Ser Phe Leu Ser Phe Arg Gln Leu Phe Ser
 1              5              10              15

Trp Ala Ala Val Ile Leu Leu Arg Gly Ile Leu Gly Thr Val Ala Pro
      20              25              30

Pro Pro Cys Pro Cys Val Leu Asp Leu Ala Val Tyr Pro Leu His Leu
      35              40              45

Pro Val Glu Ala Pro Cys Leu Glu Val Val Phe Lys Gln Lys Asn Gly
      50              55              60

Lys Asp Asn Cys Leu Val Phe Tyr Pro Asp Pro Ile Pro Leu Arg Gly
      65              70              75              80

Ser Leu Leu Gly Pro Phe Ile Lys Asn Gln Cys His Ser Ser Val Ile
      85              90              95

Pro Leu Ser Asp Ser Ala Thr Ser Lys Ala Arg Ala Leu Xaa Leu Pro
      100              105              110

Gly Arg Glu Thr Val Leu Ser Val Leu Pro Val Phe Ser Ser Pro Thr
      115              120              125

Leu Pro Arg Thr His Ala Leu Gly Asp Ser Leu Gly Val Pro Gly Leu
      130              135              140

Leu Val Cys Ser Glu Thr Ser Thr Leu Asn Asp His Trp Cys Cys Arg
      145              150              155              160

Arg Ala Gly Ala Tyr Ile Pro Ile Asn Arg Arg Phe Ser His Leu Met
      165              170              175

Pro Leu Ala Phe Ser
      180

```

&lt;210&gt; 115

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (116)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 115

```

Met Pro Ser Ser Ser Ser Gly Leu Gly Ser Pro Ser Arg Pro Pro Ser
 1              5              10              15

```

75

Ser Phe Leu Cys Leu Leu Leu Leu Leu Leu Pro Pro Ala Ala Leu Ala  
20 25 30  
Leu Leu Leu Phe Phe Leu Asp Phe Phe Pro Pro Arg Ala Ala Val Ser  
35 40 45  
Pro Phe Leu Pro Asp His Cys Ser Ala Arg Gln Pro Arg Val Trp Arg  
50 55 60  
Arg Glu Thr Leu Asn Arg Ser Ala Ser Gly Leu Gly Cys Trp Ala Arg  
65 70 75 80  
Ser Thr Glu Gln Gly Ala Val Gly Val Ala Thr Gly Thr Val Leu Asp  
85 90 95  
Ile Ser Leu Pro Ala Ser Cys Leu Ser Leu Trp Pro Pro Gly Pro Ser  
100 105 110  
Gly Gly Ile Xaa  
115

<210> 116  
<211> 71  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (71)  
<223> Xaa equals stop translation

<400> 116  
Met Asn Leu Leu Gly Met Ile Phe Ser Met Cys Gly Leu Met Leu Lys  
1 5 10 15  
Leu Lys Trp Cys Ala Trp Val Ala Val Tyr Cys Ser Phe Ile Ser Phe  
20 25 30  
Ala Asn Ser Arg Ser Ser Glu Asp Thr Lys Gln Met Met Ser Ser Phe  
35 40 45  
Met Leu Ser Ile Ser Ala Val Val Met Ser Tyr Leu Gln Asn Pro Gln  
50 55 60  
Pro Met Thr Pro Pro Trp Xaa  
65 70

<210> 117  
<211> 64  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (64)

76

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 117

Met Arg Asp Leu Ser Phe Leu Tyr Thr Leu Leu Trp Leu Pro Glu Ile  
1 5 10 15  
Trp Gln Ala Leu Ala Gly Gly Ile Arg Leu Asp Glu Val Glu Leu Leu  
20 25 30  
Glu Asn Glu Ala Val Leu Gly Glu Glu Met Arg Leu Tyr Arg Lys Ile  
35 40 45  
Asn Glu Val Val Leu Ser Gly Asn Glu Val Val Leu Gly Gly Lys Xaa  
50 55 60

&lt;210&gt; 118

&lt;211&gt; 335

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (335)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 118

Met Gly Ile Phe Pro Gly Ile Ile Leu Ile Phe Leu Arg Val Lys Phe  
1 5 10 15  
Ala Thr Ala Ala Val Ile Val Ser Gly Val Ser Lys His Leu His Cys  
20 25 30  
Ile Ser His Gln Lys Ser Thr Thr Val Ser His Glu Met Ser Gly Leu  
35 40 45  
Asn Trp Lys Pro Phe Val Tyr Gly Gly Leu Ala Ser Ile Val Ala Glu  
50 55 60  
Phe Gly Thr Phe Pro Val Asp Leu Thr Lys Thr Arg Leu Gln Val Gln  
65 70 75 80  
Gly Gln Ser Ile Asp Ala Arg Phe Lys Glu Ile Lys Tyr Arg Gly Met  
85 90 95  
Phe His Ala Leu Phe Arg Ile Cys Lys Glu Glu Gly Val Leu Ala Leu  
100 105 110  
Tyr Ser Gly Ile Ala Pro Ala Leu Leu Arg Gln Ala Ser Tyr Gly Thr  
115 120 125  
Ile Lys Ile Gly Ile Tyr Gln Ser Leu Lys Arg Leu Phe Val Glu Arg  
130 135 140  
Leu Glu Asp Glu Thr Leu Leu Ile Asn Met Ile Cys Gly Val Val Ser

77

145                      150                      155                      160  
 Gly Val Ile Ser Ser Thr Ile Ala Asn Pro Thr Asp Val Leu Lys Ile  
                                  165                      170                      175  
 Arg Met Gln Ala Gln Gly Ser Leu Phe Gln Gly Ser Met Ile Gly Ser  
                                  180                      185                      190  
 Phe Ile Asp Ile Tyr Gln Gln Glu Gly Thr Arg Gly Leu Trp Arg Gly  
                                  195                      200                      205  
 Val Val Pro Thr Ala Gln Arg Ala Ala Ile Val Val Gly Val Glu Leu  
                                  210                      215                      220  
 Pro Val Tyr Asp Ile Thr Lys Lys His Leu Ile Leu Ser Gly Met Met  
                                  225                      230                      235                      240  
 Gly Asp Thr Ile Leu Thr His Phe Val Ser Ser Phe Thr Cys Gly Leu  
                                  245                      250                      255  
 Ala Gly Ala Leu Ala Ser Asn Pro Val Asp Val Val Arg Thr Arg Met  
                                  260                      265                      270  
 Met Asn Gln Arg Ala Ile Val Gly His Val Asp Leu Tyr Lys Gly Thr  
                                  275                      280                      285  
 Val Asp Gly Ile Leu Lys Met Trp Lys His Glu Gly Phe Phe Ala Leu  
                                  290                      295                      300  
 Tyr Lys Gly Phe Trp Pro Asn Trp Leu Arg Leu Gly Pro Trp Asn Ile  
                                  305                      310                      315                      320  
 Ile Phe Phe Ile Thr Tyr Glu Gln Leu Lys Arg Leu Gln Ile Xaa  
                                  325                      330                      335

&lt;210&gt; 119

&lt;211&gt; 221

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 119

Met Ala Leu Ala Leu Ala Ala Leu Ala Ala Val Glu Pro Ala Cys Gly  
   1                                  5                                  10                                  15

Ser Arg Tyr Gln Gln Leu Gln Asn Glu Glu Ser Gly Glu Pro Glu  
                                   20                                  25                                  30

Gln Ala Ala Gly Asp Ala Pro Pro Pro Tyr Ser Ser Ile Ser Ala Glu  
                                   35                                  40                                  45

Ser Ala Xaa Tyr Phe Asp Tyr Lys Asp Glu Ser Gly Phe Pro Lys Pro  
   50                                  55                                  60

78

Pro Ser Tyr Asn Val Ala Thr Thr Leu Pro Ser Tyr Asp Glu Ala Glu  
 65 70 75 80  
 Arg Thr Lys Ala Glu Ala Thr Ile Pro Leu Val Pro Gly Arg Asp Glu  
 85 90 95  
 Asp Phe Val Gly Arg Asp Asp Phe Asp Asp Ala Asp Gln Leu Arg Ile  
 100 105 110  
 Gly Asn Asp Gly Ile Phe Met Leu Thr Phe Phe Met Ala Phe Leu Phe  
 115 120 125  
 Asn Trp Ile Gly Phe Phe Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala  
 130 135 140  
 Gly Arg Tyr Gly Ala Ile Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp  
 145 150 155 160  
 Ile Leu Ile Val Arg Phe Ser Thr Tyr Phe Pro Gly Tyr Phe Asp Gly  
 165 170 175  
 Gln Tyr Trp Leu Trp Trp Val Phe Leu Val Leu Gly Phe Leu Leu Phe  
 180 185 190  
 Leu Arg Gly Phe Ile Asn Tyr Ala Lys Val Arg Lys Met Pro Glu Thr  
 195 200 205  
 Phe Ser Asn Leu Pro Arg Thr Arg Val Leu Phe Ile Tyr  
 210 215 220  
  
 <210> 120  
 <211> 473  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (473)  
 <223> Xaa equals stop translation  
  
 <400> 120  
 Met Lys Phe Leu Ile Phe Ala Phe Phe Gly Gly Val His Leu Leu Ser  
 1 5 10 15  
 Leu Cys Ser Gly Lys Ala Ile Cys Lys Asn Gly Ile Ser Lys Arg Thr  
 20 25 30  
 Phe Glu Glu Ile Lys Glu Glu Ile Ala Ser Cys Gly Asp Val Ala Lys  
 35 40 45  
 Ala Ile Ile Asn Leu Ala Val Tyr Gly Lys Ala Gln Asn Arg Ser Tyr  
 50 55 60  
 Glu Arg Leu Ala Leu Leu Val Asp Thr Val Gly Pro Arg Leu Ser Gly  
 65 70 75 80

79

Ser Lys Asn Leu Glu Lys Ala Ile Gln Ile Met Tyr Gln Asn Leu Gln  
 85 90 95

Gln Asp Gly Leu Glu Lys Val His Leu Glu Pro Val Arg Ile Pro His  
 100 105 110

Trp Glu Arg Gly Glu Glu Ser Ala Val Met Leu Glu Pro Arg Ile His  
 115 120 125

Lys Ile Ala Ile Leu Gly Leu Gly Ser Ser Ile Gly Thr Pro Pro Glu  
 130 135 140

Gly Ile Thr Ala Glu Val Leu Val Val Thr Ser Phe Asp Glu Leu Gln  
 145 150 155 160

Arg Arg Ala Ser Glu Ala Arg Gly Lys Ile Val Val Tyr Asn Gln Pro  
 165 170 175

Tyr Ile Asn Tyr Ser Arg Thr Val Gln Tyr Arg Thr Gln Gly Ala Val  
 180 185 190

Glu Ala Ala Lys Val Gly Ala Leu Ala Ser Leu Ile Arg Ser Val Ala  
 195 200 205

Ser Phe Ser Ile Tyr Ser Pro His Thr Gly Ile Gln Glu Tyr Gln Asp  
 210 215 220

Gly Val Pro Lys Ile Pro Thr Ala Cys Ile Thr Val Glu Asp Ala Glu  
 225 230 235 240

Met Met Ser Arg Met Ala Ser His Gly Ile Lys Ile Val Ile Gln Leu  
 245 250 255

Lys Met Gly Ala Lys Thr Tyr Pro Asp Thr Asp Ser Phe Asn Thr Val  
 260 265 270

Ala Glu Ile Thr Gly Ser Lys Tyr Pro Glu Gln Val Val Leu Val Ser  
 275 280 285

Gly His Leu Asp Ser Trp Asp Val Gly Gln Gly Ala Met Asp Asp Gly  
 290 295 300

Gly Gly Ala Phe Ile Ser Trp Glu Ala Leu Ser Leu Ile Lys Asp Leu  
 305 310 315 320

Gly Leu Arg Pro Lys Arg Thr Leu Arg Leu Val Leu Trp Thr Ala Glu  
 325 330 335

Glu Gln Gly Gly Val Gly Ala Phe Gln Tyr Tyr Gln Leu His Lys Val  
 340 345 350

Asn Ile Ser Asn Tyr Ser Leu Val Met Glu Ser Asp Ala Gly Thr Phe  
 355 360 365

Leu Pro Thr Gly Leu Gln Phe Thr Gly Ser Glu Lys Ala Arg Ala Ile  
 370 375 380

Met Glu Glu Val Met Ser Leu Leu Gln Pro Leu Asn Ile Thr Gln Val

80

385                      390                      395                      400  
 Leu Ser His Gly Glu Gly Thr Asp Ile Asn Phe Trp Ile Gln Ala Gly  
                                  405                      410                      415  
 Val Pro Gly Ala Ser Leu Leu Asp Asp Leu Tyr Lys Tyr Phe Phe Phe  
                                  420                      425                      430  
 His His Ser His Gly Asp Thr Met Thr Val Met Asp Pro Lys Gln Met  
                                  435                      440                      445  
 Asn Val Ala Ala Ala Val Trp Ala Val Val Ser Tyr Val Val Ala Asp  
                                  450                      455                      460  
 Met Glu Glu Met Leu Pro Arg Ser Xaa  
 465                      470

&lt;210&gt; 121

&lt;211&gt; 168

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (168)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 121

Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser  
   1                                  5                                  10                                  15  
 Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Cys Gln Thr  
                                   20                                  25                                  30  
 Pro Pro Ser Asp Cys Leu His Val Val Glu Pro Met Pro Val Arg Gly  
                                   35                                  40                                  45  
 Pro Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu Cys Lys Tyr Glu Glu  
                                   50                                  55                                  60  
 Arg Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile  
   65                                  70                                  75                                  80  
 Leu Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro  
                                   85                                  90                                  95  
 Ile Leu Lys Arg Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp  
                                   100                                  105                                  110  
 Asp Asp Ile Gly Asp His Gln Pro Phe Ala Asn Ala His Asp Val Leu  
                                   115                                  120                                  125  
 Ala Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Ala  
                                   130                                  135                                  140  
 Gln Gln Arg Trp Lys Leu Gln Val Gln Glu Gln Arg Lys Ser Val Phe  
   145                                  150                                  155                                  160

Asp Arg His Val Val Leu Ser Xaa  
165

<210> 122  
<211> 47  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (47)  
<223> Xaa equals stop translation

<400> 122  
Met Lys Phe Ile Leu Trp Arg Arg Phe Arg Trp Ala Ile Ile Leu Phe  
1 5 10 15  
Ile Ile Leu Phe Ile Leu Leu Leu Phe Leu Ala Ile Phe Ile Tyr Ala  
20 25 30  
Phe Pro Asn Tyr Ala Ala Met Lys Leu Val Lys Pro Phe Ser Xaa  
35 40 45

<210> 123  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 123  
Met His Gln Asp Trp Leu Cys Asn Leu Gly Trp Pro Leu Leu Ser Leu  
1 5 10 15  
Trp Ala Ala Glu Ser Ala Pro His Val Ala Met Ala Ser Ala Thr Ala  
20 25 30  
Gln Leu Trp Ser Arg Pro Cys Gly Arg Thr His Met Val Ser Leu Ala  
35 40 45  
Leu Gly His Gln Glu Thr Gly Leu Trp Leu Cys Ser Ala Phe Gly Cys  
50 55 60  
Val Val Asp Ser Pro Trp Ala Ser Val Cys Pro Ser Val Lys Gly Gln  
65 70 75 80  
Leu Thr Val Cys Gly Ile Leu Pro Arg Val Pro Val Cys Val Tyr Val  
85 90 95  
Cys Ala Cys Val Arg Val Ser Met Cys Val His Ile  
100 105

<210> 124  
<211> 60  
<212> PRT  
<213> Homo sapiens



82

&lt;400&gt; 124

Met Arg Gly Cys Val Pro Ala Phe Leu Leu His Val Leu Ser Leu Arg  
 1 5 10 15  
 Arg Ala Cys Cys Thr Gln Ala Ala Gln Val Phe Thr Ala Gln Leu Pro  
 20 25 30  
 Gly Arg Gln Val Ala Arg Arg Arg Gly Gly Trp His Glu Gln Gln Gly  
 35 40 45  
 Gly Pro Met Leu Cys Ser Ser His His Ser Arg Thr  
 50 55 60

&lt;210&gt; 125

&lt;211&gt; 248

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

Met Ala Met Leu Pro Leu Val Leu His Trp Phe Phe Ile Glu Trp Tyr  
 1 5 10 15  
 Ser Gly Lys Lys Ser Ser Ser Ala Leu Phe Gln His Ile Thr Ala Leu  
 20 25 30  
 Phe Glu Cys Ser Met Ala Ala Ile Ile Thr Leu Leu Val Ser Asp Pro  
 35 40 45  
 Val Gly Val Leu Tyr Ile Arg Ser Cys Arg Val Leu Met Leu Ser Asp  
 50 55 60  
 Trp Tyr Thr Met Leu Tyr Asn Pro Ser Pro Asp Tyr Val Thr Thr Val  
 65 70 75 80  
 His Cys Thr His Glu Ala Val Tyr Pro Leu Tyr Thr Ile Val Phe Ile  
 85 90 95  
 Tyr Tyr Ala Phe Cys Leu Val Leu Met Met Leu Leu Arg Pro Leu Leu  
 100 105 110  
 Val Lys Lys Ile Ala Cys Gly Leu Gly Lys Ser Asp Arg Phe Lys Ser  
 115 120 125  
 Ile Tyr Ala Ala Leu Tyr Phe Phe Pro Ile Leu Thr Val Leu Gln Ala  
 130 135 140  
 Val Gly Gly Gly Leu Leu Tyr Tyr Ala Phe Pro Tyr Ile Ile Leu Val  
 145 150 155 160  
 Leu Ser Leu Val Thr Leu Ala Val Tyr Met Ser Ala Ser Glu Ile Glu  
 165 170 175  
 Asn Cys Tyr Asp Leu Leu Val Arg Lys Lys Arg Leu Ile Val Leu Phe  
 180 185 190  
 Ser His Trp Leu Leu His Ala Tyr Gly Ile Ile Ser Ile Ser Arg Val

83

195 200 205

Asp Lys Leu Glu Gln Asp Leu Pro Pro Leu Ala Leu Val Pro Thr Pro  
 210 215 220

Ala Leu Phe Tyr Leu Phe Thr Ala Lys Phe Thr Glu Pro Ser Arg Ile  
 225 230 235 240

Leu Ser Glu Gly Ala Asn Gly His  
 245

<210> 126  
 <211> 248  
 <212> PRT  
 <213> Homo sapiens

<400> 126

Met Glu Lys Ile Pro Glu Ile Gly Lys Phe Gly Glu Lys Ala Pro Pro  
 1 5 10 15

Ala Pro Ser His Val Trp Arg Pro Ala Ala Leu Phe Leu Thr Leu Leu  
 20 25 30

Cys Leu Leu Leu Leu Ile Gly Leu Gly Val Leu Ala Ser Met Phe His  
 35 40 45

Val Thr Leu Lys Ile Glu Met Lys Lys Met Asn Lys Leu Gln Asn Ile  
 50 55 60

Ser Glu Glu Leu Gln Arg Asn Ile Ser Leu Gln Leu Met Ser Asn Met  
 65 70 75 80

Asn Ile Ser Asn Lys Ile Arg Asn Leu Ser Thr Thr Leu Gln Thr Ile  
 85 90 95

Ala Thr Lys Leu Cys Arg Glu Leu Tyr Ser Lys Glu Gln Glu His Lys  
 100 105 110

Cys Lys Pro Cys Pro Arg Arg Trp Ile Trp His Lys Asp Ser Cys Tyr  
 115 120 125

Phe Leu Ser Asp Asp Val Gln Thr Trp Gln Glu Ser Lys Met Ala Cys  
 130 135 140

Ala Ala Gln Asn Ala Ser Leu Leu Lys Ile Asn Asn Lys Asn Ala Leu  
 145 150 155 160

Glu Phe Ile Lys Ser Gln Ser Arg Ser Tyr Asp Tyr Trp Leu Gly Leu  
 165 170 175

Ser Pro Glu Glu Asp Ser Thr Arg Gly Met Arg Val Asp Asn Ile Ile  
 180 185 190

Asn Ser Ser Ala Trp Val Ile Arg Asn Ala Pro Asp Leu Asn Asn Met  
 195 200 205

Tyr Cys Gly Tyr Ile Asn Arg Leu Tyr Val Gln Tyr Tyr His Cys Thr

84

210 215 220

Tyr Lys Gln Arg Met Ile Cys Glu Lys Met Ala Asn Pro Val Gln Leu  
 225 230 235 240

Gly Ser Thr Tyr Phe Arg Glu Ala  
 245

<210> 127  
 <211> 612  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (245)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (246)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (249)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 127  
 Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro  
 1 5 10 15

Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg  
 20 25 30

Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly  
 35 40 45

Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu  
 50 55 60

Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln  
 65 70 75 80

Asn Ala Pro Tyr Phe Lys Pro Lys Val Lys Val Ser Phe Lys Asn His  
 85 90 95

Ser Ala Leu Ile Thr Ser Val Val Pro Gly Asp Tyr Asp Gly Asp Ser  
 100 105 110

Gln Met Asp Val Leu Leu Thr Tyr Leu Pro Lys Asn Tyr Ala Lys Ser  
 115 120 125

Glu Leu Gly Ala Val Ile Phe Trp Gly Gln Asn Gln Thr Leu Asp Pro  
 130 135 140

Asn Asn Met Thr Ile Leu Asn Arg Thr Phe Gln Asp Glu Pro Leu Ile

85

|   |     |     |     |     |     |     |
|---|-----|-----|-----|-----|-----|-----|
| 145   |     | 150 |     | 155 |     | 160 |
| Met Asp Phe Asn Gly Asp Leu Ile Pro Asp Ile Phe Gly Ile Thr Asn |     |     |     |     |     |     |
|   | 165 |     |     | 170 |     | 175 |
| Glu Ser Asn Gln Pro Gln Ile Leu Leu Gly Gly Asn Leu Ser Trp His |     |     |     |     |     |     |
|   | 180 |     | 185 |     |     | 190 |
| Pro Ala Leu Thr Thr Thr Ser Lys Met Arg Ile Pro His Ser His Ala |     |     |     |     |     |     |
|   | 195 |     | 200 |     |     | 205 |
| Phe Ile Asp Leu Thr Glu Asp Phe Thr Ala Asp Leu Phe Leu Thr Thr |     |     |     |     |     |     |
|   | 210 |     | 215 |     |     | 220 |
| Leu Asn Ala Thr Thr Ser Thr Phe Gln Phe Glu Ile Trp Glu Asn Leu |     |     |     |     |     |     |
|   | 225 |     | 230 |     | 235 | 240 |
| Asp Gly Asn Phe Xaa Xaa Ser Thr Xaa Leu Glu Lys Pro Gln Asn Met |     |     |     |     |     |     |
|   |     | 245 |     | 250 |     | 255 |
| Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His |     |     |     |     |     |     |
|   | 260 |     | 265 |     |     | 270 |
| Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser |     |     |     |     |     |     |
|   | 275 |     | 280 |     |     | 285 |
| Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu |     |     |     |     |     |     |
|   | 290 |     | 295 |     |     | 300 |
| Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val |     |     |     |     |     |     |
|   | 305 |     | 310 |     | 315 | 320 |
| Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile |     |     |     |     |     |     |
|   |     | 325 |     | 330 |     | 335 |
| Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys |     |     |     |     |     |     |
|   | 340 |     | 345 |     |     | 350 |
| Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro |     |     |     |     |     |     |
|   | 355 |     | 360 |     |     | 365 |
| Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr |     |     |     |     |     |     |
|   | 370 |     | 375 |     |     | 380 |
| Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr |     |     |     |     |     |     |
|   | 385 |     | 390 |     | 395 | 400 |
| Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser |     |     |     |     |     |     |
|   |     | 405 |     | 410 |     | 415 |
| Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn |     |     |     |     |     |     |
|   | 420 |     | 425 |     |     | 430 |
| Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu |     |     |     |     |     |     |
|   | 435 |     | 440 |     |     | 445 |
| Cys Ser Asn Asp Cys Pro Arg Lys Ile Thr Pro Phe Gly Val Asn Gln |     |     |     |     |     |     |
|   | 450 |     | 455 |     |     | 460 |

Pro Gly Pro Tyr Ile Met Tyr Thr Thr Val Asp Ala Asn Gly Tyr Leu  
 465 470 475 480  
 Lys Asn Gly Ser Ala Gly Gln Leu Ser Gln Ser Ala His Leu Ala Leu  
 485 490 495  
 Gln Leu Pro Tyr Asn Val Leu Gly Leu Gly Arg Ser Ala Asn Phe Leu  
 500 505 510  
 Asp His Leu Tyr Val Gly Ile Pro Arg Pro Ser Gly Glu Lys Ser Ile  
 515 520 525  
 Arg Lys Gln Glu Trp Thr Ala Ile Ile Pro Asn Ser Gln Leu Ile Val  
 530 535 540  
 Ile Pro Tyr Pro His Asn Val Pro Arg Ser Trp Ser Ala Lys Leu Tyr  
 545 550 555 560  
 Leu Thr Pro Ser Asn Ile Val Leu Leu Thr Ala Ile Ala Leu Ile Gly  
 565 570 575  
 Val Cys Val Phe Ile Leu Ala Ile Ile Gly Ile Leu His Trp Gln Glu  
 580 585 590  
 Lys Lys Ala Asp Asp Arg Glu Lys Arg Gln Glu Ala His Arg Phe His  
 595 600 605  
 Phe Asp Ala Met  
 610

<210> 128  
 <211> 447  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (8)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (309)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (333)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 128

87

Met Glu Leu Ser Gln Met Ser Xaa Leu Met Gly Leu Ser Val Leu Leu  
1 5 10 15

Gly Leu Leu Ala Leu Met Ala Thr Ala Ala Val Xaa Arg Gly Trp Leu  
20 25 30

Arg Ala Gly Glu Glu Arg Ser Gly Arg Pro Ala Cys Gln Lys Ala Asn  
35 40 45

Gly Phe Pro Pro Asp Lys Ser Ser Gly Ser Lys Lys Gln Lys Gln Tyr  
50 55 60

Gln Arg Ile Arg Lys Glu Lys Pro Gln Gln His Asn Phe Thr His Arg  
65 70 75 80

Leu Leu Ala Ala Ala Leu Lys Ser His Ser Gly Asn Ile Ser Cys Met  
85 90 95

Asp Phe Ser Ser Asn Gly Lys Tyr Leu Ala Thr Cys Ala Asp Asp Arg  
100 105 110

Thr Ile Arg Ile Trp Ser Thr Lys Asp Phe Leu Gln Arg Glu His Arg  
115 120 125

Ser Met Arg Ala Asn Val Glu Leu Asp His Ala Thr Leu Val Arg Phe  
130 135 140

Ser Pro Asp Cys Arg Ala Phe Ile Val Trp Leu Ala Asn Gly Asp Thr  
145 150 155 160

Leu Arg Val Phe Lys Met Thr Lys Arg Glu Asp Gly Gly Tyr Thr Phe  
165 170 175

Thr Ala Thr Pro Glu Asp Phe Pro Lys Lys His Lys Ala Pro Val Ile  
180 185 190

Asp Ile Gly Ile Ala Asn Thr Gly Lys Phe Ile Met Thr Ala Ser Ser  
195 200 205

Asp Thr Thr Val Leu Ile Trp Ser Leu Lys Gly Gln Val Leu Ser Thr  
210 215 220

Ile Asn Thr Asn Gln Met Asn Asn Thr His Ala Ala Val Ser Pro Cys  
225 230 235 240

Gly Arg Phe Val Ala Ser Cys Gly Phe Thr Pro Asp Val Lys Val Trp  
245 250 255

Glu Val Cys Phe Gly Lys Lys Gly Glu Phe Gln Glu Val Val Arg Ala  
260 265 270

Phe Glu Leu Lys Gly His Ser Ala Ala Val His Ser Phe Ala Phe Ser  
275 280 285

Asn Asp Ser Arg Arg Met Ala Ser Val Ser Lys Asp Gly Thr Trp Lys  
290 295 300

Leu Trp Asp Thr Xaa Val Glu Tyr Lys Lys Lys Gln Asp Pro Tyr Leu

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |  |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |  |  |  |  |
| Leu | Lys | Thr | Gly | Arg | Phe | Glu | Glu | Ala | Ala | Gly | Ala | Xaa | Pro | Cys | Arg |  |  |  |  |
|     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |  |  |  |  |
| Leu | Ala | Leu | Ser | Pro | Asn | Ala | Gln | Val | Leu | Ala | Leu | Ala | Ser | Gly | Ser |  |  |  |  |
|     |     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |  |  |  |  |
| Ser | Ile | His | Leu | Tyr | Asn | Thr | Arg | Arg | Gly | Glu | Lys | Glu | Glu | Cys | Phe |  |  |  |  |
|     |     |     |     | 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |  |  |  |  |
| Glu | Arg | Val | His | Gly | Glu | Cys | Ile | Ala | Asn | Leu | Ser | Phe | Asp | Ile | Thr |  |  |  |  |
|     |     |     |     | 370 |     |     |     |     | 375 |     |     |     |     | 380 |     |  |  |  |  |
| Gly | Arg | Phe | Leu | Ala | Ser | Cys | Gly | Asp | Arg | Ala | Val | Arg | Leu | Phe | His |  |  |  |  |
|     |     |     |     | 385 |     |     |     |     | 390 |     |     |     |     | 395 |     |  |  |  |  |
| Asn | Thr | Pro | Gly | His | Arg | Ala | Met | Val | Glu | Glu | Met | Gln | Gly | His | Leu |  |  |  |  |
|     |     |     |     | 405 |     |     |     |     | 410 |     |     |     |     | 415 |     |  |  |  |  |
| Lys | Arg | Ala | Ser | Asn | Glu | Ser | Thr | Arg | Gln | Arg | Leu | Gln | Gln | Gln | Leu |  |  |  |  |
|     |     |     |     | 420 |     |     |     |     | 425 |     |     |     |     | 430 |     |  |  |  |  |
| Thr | Gln | Ala | Gln | Glu | Thr | Leu | Lys | Ser | Leu | Gly | Ala | Leu | Lys | Lys |     |  |  |  |  |
|     |     |     |     | 435 |     |     |     |     | 440 |     |     |     |     | 445 |     |  |  |  |  |

```
<210> 129
<211> 291
<212> PRT
<213> Homo sapiens
```

|           |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| <400> 129 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Met       | Leu | Phe | Leu | Phe | Ser | Met | Ala | Thr | Leu | Leu | Arg | Thr | Ser | Phe | Ser |  |
| 1         |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |  |
| Asp       | Pro | Gly | Val | Ile | Pro | Arg | Ala | Leu | Pro | Asp | Glu | Ala | Ala | Phe | Ile |  |
|           |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |  |
| Glu       | Met | Glu | Ile | Glu | Ala | Thr | Asn | Gly | Ala | Val | Pro | Gln | Gly | Gln | Arg |  |
|           |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |  |
| Pro       | Pro | Pro | Arg | Ile | Lys | Asn | Phe | Gln | Ile | Asn | Asn | Gln | Ile | Val | Lys |  |
|           | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |
| Leu       | Lys | Tyr | Cys | Tyr | Thr | Cys | Lys | Ile | Phe | Arg | Pro | Pro | Arg | Ala | Ser |  |
| 65        |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |  |
| His       | Cys | Ser | Ile | Cys | Asp | Asn | Cys | Val | Glu | Arg | Phe | Asp | His | His | Cys |  |
|           |     |     | 85  |     |     |     |     |     | 90  |     |     |     |     | 95  |     |  |
| Pro       | Trp | Val | Gly | Asn | Cys | Val | Gly | Lys | Arg | Asn | Tyr | Arg | Tyr | Phe | Tyr |  |
|           |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |
| Leu       | Phe | Ile | Leu | Ser | Leu | Ser | Leu | Leu | Thr | Ile | Tyr | Val | Phe | Ala | Phe |  |
|           |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |
| Asn       | Ile | Val | Tyr | Val | Ala | Leu | Lys | Ser | Leu | Lys | Ile | Gly | Phe | Leu | Glu |  |

89

130                      135                      140  
 Thr Leu Lys Glu Thr Pro Gly Thr Val Leu Glu Val Leu Ile Cys Phe  
 145                      150                      155                      160  
 Phe Thr Leu Trp Ser Val Val Gly Leu Thr Gly Phe His Thr Phe Leu  
 165                      170                      175  
 Val Ala Leu Asn Gln Thr Thr Asn Glu Asp Ile Lys Gly Ser Trp Thr  
 180                      185                      190  
 Gly Lys Asn Arg Val Gln Asn Pro Tyr Ser His Gly Asn Ile Val Lys  
 195                      200                      205  
 Asn Cys Cys Glu Val Leu Cys Gly Pro Leu Pro Pro Ser Val Leu Asp  
 210                      215                      220  
 Arg Arg Gly Ile Leu Pro Leu Glu Glu Ser Gly Ser Arg Pro Pro Ser  
 225                      230                      235                      240  
 Thr Gln Glu Thr Ser Ser Ser Leu Leu Pro Gln Ser Pro Ala Pro Thr  
 245                      250                      255  
 Glu His Leu Asn Ser Asn Glu Met Pro Glu Asp Ser Ser Thr Pro Glu  
 260                      265                      270  
 Glu Met Pro Pro Pro Glu Pro Pro Glu Pro Pro Gln Glu Ala Ala Glu  
 275                      280                      285  
 Ala Glu Lys  
 290

<210> 130  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens

<400> 130  
 Met Val Arg Lys Trp Leu Thr Phe Val Glu His Leu Leu Cys Ala Trp  
 1                      5                      10                      15  
 Pro Arg Leu Gly Ala Phe Val Pro Arg Val Thr Pro Ser Glu Cys Ser  
 20                      25                      30  
 Ser Leu Pro His Ser Asn Trp Gly Val Gly Gly Arg Ala Ala Gln Leu  
 35                      40                      45  
 Thr Gly Ala Glu Leu Lys Thr His Ser Trp Val Cys Leu Gly Trp Ala  
 50                      55                      60  
 Val Leu Val Ala Pro Val Ala Asn Thr Arg Ala Pro Phe Thr  
 65                      70                      75

<210> 131  
 <211> 333  
 <212> PRT



90

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (97)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 131

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Leu | Met | Phe | Ala | Val | Ile | Val | Ala | Ser | Ser | Gly | Leu | Leu | Leu | Met |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ile | Glu | Arg | Gly | Ile | Leu | Ala | Glu | Met | Lys | Pro | Leu | Pro | Leu | His | Pro |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Pro | Gly | Arg | Glu | Gly | Thr | Ala | Trp | Arg | Gly | Lys | Ala | Pro | Lys | Pro | Gly |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Gly | Leu | Ser | Leu | Arg | Ala | Gly | Asp | Ala | Asp | Leu | Gln | Val | Arg | Gln | Asp |
|     | 50  |     |     |     |     | 55  |     |     |     | 60  |     |     |     |     |     |
| Val | Arg | Asn | Arg | Thr | Leu | Arg | Ala | Val | Cys | Gly | Gln | Pro | Gly | Met | Pro |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Arg | Asp | Pro | Trp | Asp | Leu | Pro | Val | Gly | Gln | Arg | Arg | Thr | Leu | Leu | Arg |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Xaa | Ile | Leu | Val | Ser | Asp | Arg | Tyr | Arg | Phe | Leu | Tyr | Cys | Tyr | Val | Pro |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Lys | Val | Ala | Cys | Ser | Asn | Trp | Lys | Arg | Val | Met | Lys | Val | Leu | Ala | Gly |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Val | Leu | Asp | Ser | Val | Asp | Val | Arg | Leu | Lys | Met | Asp | His | Arg | Ser | Asp |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Leu | Val | Phe | Leu | Ala | Asp | Leu | Arg | Pro | Glu | Glu | Ile | Arg | Tyr | Arg | Leu |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Gln | His | Tyr | Phe | Lys | Phe | Leu | Phe | Val | Arg | Glu | Pro | Leu | Glu | Arg | Leu |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Leu | Ser | Ala | Tyr | Arg | Asn | Lys | Phe | Gly | Glu | Ile | Arg | Glu | Tyr | Gln | Gln |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Arg | Tyr | Gly | Ala | Glu | Ile | Val | Arg | Arg | Tyr | Arg | Ala | Gly | Ala | Gly | Pro |
|     |     | 195 |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     |
| Ser | Pro | Ala | Gly | Asp | Asp | Val | Thr | Phe | Pro | Glu | Phe | Leu | Arg | Tyr | Leu |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Val | Asp | Glu | Asp | Pro | Glu | Arg | Met | Asn | Glu | His | Trp | Met | Pro | Val | Tyr |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| His | Leu | Cys | Gln | Pro | Cys | Ala | Val | His | Tyr | Asp | Phe | Val | Gly | Ser | Tyr |
|     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |     |
| Glu | Arg | Leu | Glu | Ala | Asp | Ala | Asn | Gln | Val | Leu | Glu | Trp | Val | Arg | Ala |
|     |     |     | 260 |     |     |     | 265 |     |     |     |     |     | 270 |     |     |

Pro Pro His Val Arg Phe Pro Ala Arg Gln Ala Trp Tyr Arg Pro Ala  
275 280 285

Ser Pro Glu Ser Leu His Tyr His Leu Cys Ser Ala Pro Arg Ala Leu  
290 295 300

Leu Gln Asp Val Leu Pro Lys Tyr Ile Leu Asp Phe Ser Leu Phe Ala  
305 310 315 320

Tyr Pro Leu Pro Asn Val Thr Lys Glu Ala Cys Gln Gln  
325 330

<210> 132

<211> 164

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (126)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 132

Met Leu Pro Leu Leu Ile Ile Cys Leu Leu Pro Ala Ile Glu Gly Lys  
1 5 10 15

Asn Cys Leu Arg Cys Trp Pro Glu Leu Ser Ala Leu Ile Asp Tyr Asp  
20 25 30

Leu Gln Ile Leu Trp Val Thr Pro Gly Pro Pro Thr Glu Leu Ser Gln  
35 40 45

Ser Ile His Ser Leu Phe Leu Glu Asp Asn Asn Phe Leu Lys Pro Trp  
50 55 60

Tyr Leu Asp Arg Asp His Leu Glu Glu Glu Thr Ala Lys Phe Phe Thr  
65 70 75 80

Gln Val His Gln Ala Ile Lys Thr Leu Arg Asp Asp Lys Thr Val Leu  
85 90 95

Leu Glu Glu Ile Tyr Thr His Lys Asn Leu Phe Thr Glu Arg Leu Asn  
100 105 110

Lys Ile Ser Asp Gly Leu Lys Glu Lys Gly Ala Pro Pro Xaa Ser Met  
115 120 125

Asn Ala Phe Pro Ala Pro Ser Pro Thr Cys Thr Pro Glu Pro Leu Gly  
130 135 140

Ser Val Cys Leu Pro Ser Thr Ser Val Ser Leu Pro Ser His Leu Pro  
145 150 155 160

Gly Ser Leu Gln

<210> 133  
 <211> 245  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (245)  
 <223> Xaa equals stop translation

<400> 133  
 Met Val Ala Val Gly Val Tyr Ala Arg Leu Met Lys His Ala Glu Ala  
 1 5 10 15  
 Ala Leu Ala Cys Leu Ala Val Asp Pro Ala Ile Leu Leu Ile Val Val  
 20 25 30  
 Gly Val Leu Met Phe Leu Leu Thr Phe Cys Gly Cys Ile Gly Ser Leu  
 35 40 45  
 Arg Glu Asn Ile Cys Leu Leu Gln Thr Phe Ser Leu Cys Leu Thr Ala  
 50 55 60  
 Val Phe Leu Leu Gln Leu Ala Ala Gly Ile Leu Gly Phe Val Phe Ser  
 65 70 75 80  
 Asp Lys Ala Arg Gly Lys Val Ser Glu Ile Ile Asn Asn Ala Ile Val  
 85 90 95  
 His Tyr Arg Asp Asp Leu Asp Leu Gln Asn Leu Ile Asp Phe Gly Gln  
 100 105 110  
 Lys Lys Phe Ser Cys Cys Gly Gly Ile Ser Tyr Lys Asp Trp Ser Gln  
 115 120 125  
 Asn Met Tyr Phe Asn Cys Ser Glu Asp Asn Pro Ser Arg Glu Arg Cys  
 130 135 140  
 Ser Val Pro Tyr Ser Cys Cys Leu Pro Thr Pro Asp Gln Ala Val Ile  
 145 150 155 160  
 Asn Thr Met Cys Gly Gln Gly Met Gln Ala Phe Asp Tyr Leu Glu Ala  
 165 170 175  
 Ser Lys Val Ile Tyr Thr Asn Gly Cys Ile Asp Lys Leu Val Asn Trp  
 180 185 190  
 Ile His Ser Asn Leu Phe Leu Leu Gly Gly Val Ala Leu Gly Leu Ala  
 195 200 205  
 Ile Pro Gln Leu Val Gly Ile Leu Leu Ser Gln Ile Leu Val Asn Gln  
 210 215 220  
 Ile Lys Asp Gln Ile Lys Leu Gln Leu Tyr Asn Gln Gln His Arg Ala  
 225 230 235 240  
 Asp Pro Trp Tyr Xaa

245

<210> 134  
<211> 56  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (56)  
<223> Xaa equals stop translation

<400> 134  
Met Gly Thr Val Gly Leu Trp Pro Ser Trp Leu Trp Leu Pro Ala Ser  
1 5 10 15  
Trp Pro Leu Thr Ser Cys Gly Val Thr Arg Arg Arg Leu Arg Gly Pro  
20 25 30  
Gly Leu Arg Arg Thr Ser Gln Thr Gly Arg His Thr Ser Pro Cys Pro  
35 40 45  
Thr Ala Thr Trp Ala Glu Ser Xaa  
50 55

<210> 135  
<211> 55  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (47)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (51)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (55)  
<223> Xaa equals stop translation

<400> 135  
Met Ser Ile Val Met Ser Pro Leu Leu Leu Pro Ile Cys Tyr Leu Asn  
1 5 10 15  
Leu Leu Leu Phe Phe Val Asn Leu Ala Lys Asn Leu Ser Ile Leu Phe  
20 25 30  
Val Ser Ser Lys Lys Tyr Thr Phe Val Phe Met Ile Ser Leu Xaa Phe  
35 40 45  
Phe His Xaa Tyr Phe Ile Xaa

50

55

<210> 136  
<211> 89  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (89)  
<223> Xaa equals stop translation

<400> 136  
Met Ala Ile Ile Ser Phe Glu Leu Leu Phe Leu Met Asn Leu Pro Thr  
1 5 10 15  
Val Asn Ser Ser Asn Phe Lys Leu Ile Ile Pro Glu Asp Val Thr Leu  
20 25 30  
Ser Phe Val Ser His Leu Asp Ile Thr Val Asn His Phe Val Phe Leu  
35 40 45  
Ser Thr Phe Glu Leu Ala Gly Val Ile Glu Gly Lys Pro Leu Pro Asp  
50 55 60  
Ser Lys Ser Asp Leu Cys Pro Ile Leu Gly Gln Leu Trp Phe His Ile  
65 70 75 80  
Leu Leu Phe Phe Ile Phe Trp Val Xaa  
85

<210> 137  
<211> 62  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (62)  
<223> Xaa equals stop translation

<400> 137  
Met Arg Leu Pro Ile Ala Pro His Leu Gln Tyr Phe Met Trp Ser Val  
1 5 10 15  
Leu Leu Phe Leu Val Ile Leu Val Asp Met Lys Trp His Leu Ser Val  
20 25 30  
Ala Phe His Tyr Ile Ser Leu Met Thr Asn Gly Ile Leu Ser Pro Phe  
35 40 45  
Gln Cys Leu Leu Ala Ile His Val Ser Leu Phe Phe Val Xaa  
50 55 60

<210> 138

95

<211> 106  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (106)  
<223> Xaa equals stop translation

&lt;400&gt; 138

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Cys | Leu | Leu | Pro | Gly | Gly | Val | Leu | Leu | Ile | Trp | Ser | Cys | Ala | Ser |
| 1   |     |     |     | 5   |     |     |     |     |     | 10  |     |     |     | 15  |     |
| Gly | Thr | Pro | Ala | Ser | His | Thr | Lys | Asp | Trp | Gly | Arg | Cys | Lys | Phe | Ser |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Ala | Ala | Thr | Lys | Arg | Thr | Ala | Glu | Ser | Asn | Leu | Glu | Ser | Thr | Gln | Leu |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Met | Leu | Ala | Ser | Gln | Ile | Asp | Pro | Leu | Leu | Ala | Glu | Cys | Trp | His | Leu |
|     | 50  |     |     |     |     | 55  |     |     |     |     |     | 60  |     |     |     |
| Cys | Ala | Ser | Val | Ser | Ser | Ser | Val | Asn | Gly | Gly | Asp | Lys | Lys | Cys | Val |
|     | 65  |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| His | Thr | Ser | Arg | Ala | Val | Gly | Arg | Ile | Lys | Leu | Cys | Ser | Asp | Thr | Ile |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Arg | Ala | Cys | Ser | Gly | Trp | Tyr | Leu | Gln | Xaa |     |     |     |     |     |     |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     |     |     |     |

<210> 139  
<211> 52  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (52)  
<223> Xaa equals stop translation

&lt;400&gt; 139

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | His | Ser | Val | Phe | Ala | His | Tyr | Ile | Phe | Asn | Ile | Leu | Leu | Leu |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Leu | Leu | Leu | Leu | Leu | Leu | Ile | Gly | Phe | Leu | Tyr | Ser | Met | Pro | Phe | Ile |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Tyr | Lys | Asp | Thr | Lys | Lys | Thr | His | Val | Cys | Asn | Phe | Asn | Asn | Ile | Phe |
|     | 35  |     |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Pro | Ile | Leu | Xaa |     |     |     |     |     |     |     |     |     |     |     |     |
|     |     | 50  |     |     |     |     |     |     |     |     |     |     |     |     |     |

<210> 140  
<211> 119

96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 140

Met Lys Trp Arg Arg Lys Ser Ala Tyr Trp Lys Ala Leu Lys Val Phe  
1 5 10 15

Lys Leu Pro Val Glu Phe Leu Leu Leu Leu Thr Val Pro Val Val Asp  
20 25 30

Pro Asp Lys Asp Asp Gln Asn Trp Lys Arg Pro Leu Asn Cys Leu His  
35 40 45

Leu Val Ile Ser Pro Leu Val Val Val Leu Thr Leu Gln Ser Gly Thr  
50 55 60

Tyr Gly Val Tyr Glu Ile Gly Gly Leu Val Pro Val Trp Val Val Val  
65 70 75 80

Val Ile Ala Gly Thr Ala Leu Ala Ser Val Thr Phe Phe Ala Thr Ser  
85 90 95

Asp Ser Gln Pro Pro Arg Leu His Trp Leu Phe Ala Phe Leu Gly Phe  
100 105 110

Leu Thr Ser Ala Leu Trp Ile  
115

&lt;210&gt; 141

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (59)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 141

Met Cys Ser Gly Ser Phe Lys Glu Leu Tyr Leu Val Pro Ile Ser Leu  
1 5 10 15

Phe Ser Thr Cys Val Leu Gly Phe Tyr Phe His Asn Phe Leu Leu Leu  
20 25 30

Ile Ile Leu Phe Ser Ile Leu Leu Arg Lys Ile Thr Gly Lys Leu Phe  
35 40 45

Phe Thr Tyr Tyr His Phe Ser Cys Gly Val Xaa  
50 55

&lt;210&gt; 142

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

97

<220>  
<221> SITE  
<222> (100)  
<223> Xaa equals stop translation  
  
<400> 142  
Met Leu Phe Phe Leu Ser Leu Phe Leu Ser Leu Leu Leu Thr Leu Ser  
1 5 10 15  
Leu Pro Ser Phe Leu Pro Phe Ser Phe Phe Phe Phe Ser Leu Phe Pro  
20 25 30  
His Leu Ser Ala Cys Leu Leu Pro Ser Leu Pro Ser Pro Pro Phe Pro  
35 40 45  
Leu Pro Pro Ser Leu Pro Ser Phe Leu Pro Ser Phe Leu Pro Ser Phe  
50 55 60  
Leu Pro Ser Leu Leu Ser Pro Ser Phe Pro Ala Phe Phe Pro Ser Phe  
65 70 75 80  
Cys Gln Leu Ala Arg Arg Ser Pro Arg Lys Ser Thr Gln Met Leu Gln  
85 90 95  
Ser Thr Ser Xaa  
100

<210> 143  
<211> 65  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (61)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (65)  
<223> Xaa equals stop translation

<400> 143  
Met Ala Val Leu Leu Ile Thr Ile Leu Leu Phe Leu Cys Leu Gly Tyr  
1 5 10 15  
Tyr Arg Val Ile Thr Glu Ile Ser Arg Lys Thr Pro Ala Cys Arg Met  
20 25 30  
Phe Thr Ser Ser Leu Ser Ser Trp Tyr Ile Met Arg Lys Leu Tyr Asp  
35 40 45  
Thr Pro Gly Glu Val Phe Leu Ser His Ala Ile Val Xaa Phe Leu Lys  
50 55 60  
Xaa  
65



<210> 144  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (67)  
 <223> Xaa equals stop translation

<400> 144  
 Met Leu Asn Gln Pro Cys Ile Leu Gly Met Lys Pro Thr Trp Leu Trp  
           1                  5                  10                  15  
 Trp Ile Ser Phe Leu Met Cys Cys Trp Val Trp Leu Ala Ser Val Leu  
                   20                  25                  30  
 Leu Gly Ile Phe Ala Ser Ile Phe Ile Arg Asp Ile Gly Leu Glu Phe  
                   35                  40                  45  
 Ser Phe Phe Val Met Cys Leu Pro Gly Phe Gly Ile Arg Val Met Leu  
           50                  55                  60  
 Ala Ser Xaa  
       65

<210> 145  
 <211> 59  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (59)  
 <223> Xaa equals stop translation

<400> 145  
 Met Thr Ala Met Ser Ile His Leu Phe Cys Thr Ala Leu Ser Cys Gly  
           1                  5                  10                  15  
 Ser Ser Gly Gln Cys Asn Lys Ala Ile Lys Arg Asn Lys Ile Ser Asn  
                   20                  25                  30  
 Asp Trp Lys Asp Val Asn Val Ser Ser Phe Ile Glu Asn Met Ile His  
           35                  40                  45  
 Arg Tyr Thr Tyr Thr Asn Ala Leu Asn Ser Xaa  
           50                  55

<210> 146  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

99

<220>  
<221> SITE  
<222> (56)  
<223> Xaa equals stop translation

<400> 146  
Met Ser His Cys Thr Trp Pro Val Cys Leu Phe Cys Leu Val Pro Pro  
1 5 10 15  
Pro Met Gly Asp Leu Lys Glu Val Cys Leu Pro His Arg Cys Pro Gly  
20 25 30  
Arg Thr Ala Cys Cys Ser Tyr Ser Glu Pro His Leu Gln Thr Glu Glu  
35 40 45  
Asp Arg Arg Thr Leu Ile Cys Xaa  
50 55

<210> 147  
<211> 66  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (66)  
<223> Xaa equals stop translation

<400> 147  
Met Thr Asn Gly His Gln Val Leu Leu Leu Leu Leu Thr Ser Ala  
1 5 10 15  
Val Ala Ala Gly Pro Trp Pro Gln Val His Ala Gly Gln Trp Gly Trp  
20 25 30  
Met Cys Leu Pro Pro Gly Leu Pro Ser Val Gln Ala Arg Ser Gly Leu  
35 40 45  
Gly Gly Leu Pro Gly Gly Pro Gln Trp Val Pro Gly Gly Ala Arg Gly  
50 55 60  
Tyr Xaa  
65

<210> 148  
<211> 328  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (328)  
<223> Xaa equals stop translation

<400> 148  
Met Ala Cys Arg Lys Leu Ala Val Ala His Pro Leu Leu Leu Arg

**PCT/US99/15849**

| 100 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |  |  |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|
| 1   |     |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |  |  |  |
| His | Leu | Pro | Met | Ile | Ala | Ala | Leu | Leu | His | Gly | Arg | Thr | His | Leu | Asn |  |  |  |  |
| 20  |     |     |     |     |     |     |     |     | 25  |     |     |     | 30  |     |     |  |  |  |  |
| Phe | Gln | Glu | Phe | Arg | Gln | Gln | Asn | His | Leu | Ser | Cys | Phe | Leu | His | Val |  |  |  |  |
| 35  |     |     |     |     | 40  |     |     |     |     |     |     |     | 45  |     |     |  |  |  |  |
| Leu | Gly | Leu | Leu | Glu | Leu | Leu | Gln | Pro | His | Val | Phe | Arg | Ser | Glu | His |  |  |  |  |
| 50  |     |     |     |     | 55  |     |     |     | 60  |     |     |     |     |     |     |  |  |  |  |
| Gln | Gly | Ala | Leu | Trp | Asp | Cys | Leu | Leu | Ser | Phe | Ile | Arg | Leu | Leu | Leu |  |  |  |  |
| 65  |     |     |     |     | 70  |     |     |     | 75  |     |     |     | 80  |     |     |  |  |  |  |
| Asn | Tyr | Arg | Lys | Ser | Ser | Arg | His | Leu | Ala | Ala | Phe | Ile | Asn | Lys | Phe |  |  |  |  |
|     |     |     |     | 85  |     |     |     | 90  |     |     |     | 95  |     |     |     |  |  |  |  |
| Val | Gln | Phe | Ile | His | Lys | Tyr | Ile | Thr | Tyr | Asn | Ala | Pro | Ala | Ala | Ile |  |  |  |  |
|     |     |     |     | 100 |     |     |     | 105 |     |     |     | 110 |     |     |     |  |  |  |  |
| Ser | Phe | Leu | Gln | Lys | His | Ala | Asp | Pro | Leu | His | Asp | Leu | Ser | Phe | Asp |  |  |  |  |
| 115 |     |     |     |     | 120 |     |     |     | 125 |     |     |     |     |     |     |  |  |  |  |
| Asn | Ser | Asp | Leu | Val | Met | Leu | Lys | Ser | Leu | Leu | Ala | Gly | Leu | Ser | Leu |  |  |  |  |
| 130 |     |     |     |     | 135 |     |     |     | 140 |     |     |     |     |     |     |  |  |  |  |
| Pro | Ser | Arg | Asp | Asp | Arg | Thr | Asp | Arg | Gly | Leu | Asp | Glu | Glu | Gly | Glu |  |  |  |  |
| 145 |     |     |     |     | 150 |     |     |     | 155 |     |     |     | 160 |     |     |  |  |  |  |
| Glu | Glu | Ser | Ser | Ala | Gly | Ser | Leu | Pro | Leu | Val | Ser | Val | Ser | Leu | Phe |  |  |  |  |
|     |     |     |     | 165 |     |     |     | 170 |     |     |     | 175 |     |     |     |  |  |  |  |
| Thr | Pro | Leu | Thr | Ala | Ala | Glu | Met | Ala | Pro | Tyr | Met | Lys | Arg | Leu | Ser |  |  |  |  |
|     |     |     |     | 180 |     |     |     | 185 |     |     |     | 190 |     |     |     |  |  |  |  |
| Arg | Gly | Gln | Thr | Val | Glu | Asp | Leu | Leu | Glu | Val | Leu | Ser | Asp | Ile | Asp |  |  |  |  |
| 195 |     |     |     |     | 200 |     |     |     | 205 |     |     |     |     |     |     |  |  |  |  |
| Glu | Met | Ser | Arg | Arg | Arg | Pro | Glu | Ile | Leu | Ser | Phe | Phe | Ser | Thr | Asn |  |  |  |  |
| 210 |     |     |     |     | 215 |     |     |     | 220 |     |     |     |     |     |     |  |  |  |  |
| Leu | Gln | Arg | Leu | Met | Ser | Ser | Ala | Glu | Glu | Cys | Cys | Arg | Asn | Leu | Ala |  |  |  |  |
| 225 |     |     |     |     | 230 |     |     |     | 235 |     |     |     | 240 |     |     |  |  |  |  |
| Phe | Ser | Leu | Ala | Leu | Arg | Ser | Met | Gln | Asn | Ser | Pro | Ser | Ile | Ala | Ala |  |  |  |  |
|     |     |     |     | 245 |     |     |     | 250 |     |     |     | 255 |     |     |     |  |  |  |  |
| Ala | Phe | Leu | Pro | Thr | Phe | Met | Tyr | Cys | Leu | Gly | Ser | Gln | Asp | Phe | Glu |  |  |  |  |
| 260 |     |     |     |     | 265 |     |     |     | 270 |     |     |     |     |     |     |  |  |  |  |
| Val | Val | Gln | Thr | Ala | Leu | Arg | Asn | Leu | Pro | Glu | Tyr | Ala | Leu | Leu | Cys |  |  |  |  |
| 275 |     |     |     |     | 280 |     |     |     | 285 |     |     |     |     |     |     |  |  |  |  |
| Gln | Glu | His | Ala | Ala | Val | Leu | Leu | His | Arg | Ala | Phe | Leu | Val | Gly | Met |  |  |  |  |
| 290 |     |     |     |     | 295 |     |     |     | 300 |     |     |     |     |     |     |  |  |  |  |
| Tyr | Gly | Gln | Met | Asp | Pro | Ser | Ala | Gln | Ile | Ser | Glu | Ala | Leu | Arg | Ile |  |  |  |  |
| 305 |     |     |     |     | 310 |     |     |     | 315 |     |     |     | 320 |     |     |  |  |  |  |

101

Leu His Met Glu Ala Val Met Xaa  
325

&lt;210&gt; 149

&lt;211&gt; 90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (10)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (90)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 149

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Phe | Leu | Gln | Leu | Leu | Val | Val | Xaa | Val | Leu | Xaa | Ser | Glu | His |
| 1   |     |     |     |     | 5   |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Val | Ala | Gly | Ala | Ala | Glu | Val | Phe | Gly | Asn | Ser | Ser | Glu | Gly | Leu |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Glu | Phe | Ser | Val | Gly | Lys | Phe | Arg | Tyr | Phe | Glu | Leu | Asn | Arg | Pro |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Pro | Glu | Glu | Ala | Ile | Leu | His | Asp | Ile | Ser | Ser | Asn | Val | Thr | Phe |
|     | 50  |     |     |     |     | 55  |     |     |     |     |     | 60  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ile | Phe | Gln | Ile | His | Ser | Gln | Tyr | Gln | Asn | Thr | Thr | Val | Ser | Phe |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Pro | Arg | Arg | Arg | Ser | Pro | Thr | Met | Xaa |
|     |     |     | 85  |     |     |     |     | 90  |     |

&lt;210&gt; 150

&lt;211&gt; 149

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (149)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 150

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Gly | Ser | Pro | Leu | Leu | Trp | Gly | Pro | Arg | Ala | Gly | Gly | Val | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

102

Leu Leu Val Leu Leu Leu Leu Gly Leu Phe Arg Pro Pro Pro Ala Leu  
                     20                    25                    30  
 Cys Ala Arg Pro Val Lys Glu Pro Arg Gly Leu Ser Ala Ala Ser Pro  
                     35                    40                    45  
 Pro Leu Ala Arg Leu Ala Leu Leu Ala Ala Ser Gly Gly Gln Cys Pro  
                     50                    55                    60  
 Glu Val Arg Arg Arg Gly Arg Cys Arg Pro Gly Ala Gly Ala Gly Ala  
                     65                    70                    75                    80  
 Ser Ala Gly Ala Glu Arg Gln Glu Arg Ala Arg Ala Glu Ala Gln Arg  
                     85                    90                    95  
 Leu Arg Ile Ser Arg Arg Ala Ser Trp Arg Ser Cys Cys Ala Ser Gly  
                     100                    105                    110  
 Ala Pro Pro Ala Thr Leu Ile Arg Leu Trp Ala Trp Thr Thr Thr Pro  
                     115                    120                    125  
 Thr Arg Leu Gln Arg Ser Ser Leu Ala Leu Cys Ser Ala Pro Ala Leu  
                     130                    135                    140  
 Thr Leu Pro Pro Xaa  
 145

&lt;210&gt; 151

&lt;211&gt; 391

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (391)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 151

Met Leu Pro Thr Trp Trp Ile Val Ser Ser Trp Leu Val Trp Gly Val  
                     1                    5                    10                    15  
 Ile Leu Phe Val Tyr Leu Val Ile Arg Ala Leu Arg Leu Trp Arg Thr  
                     20                    25                    30  
 Ala Lys Leu Gln Val Thr Leu Lys Lys Tyr Ser Val His Leu Glu Asp  
                     35                    40                    45  
 Met Ala Thr Asn Ser Arg Ala Phe Thr Asn Leu Val Arg Lys Ala Leu  
                     50                    55                    60  
 Arg Leu Ile Gln Glu Thr Glu Val Ile Ser Arg Gly Phe Thr Leu Val  
                     65                    70                    75                    80  
 Ser Ala Ala Cys Pro Phe Asn Lys Ala Gly Gln His Pro Ser Gln His  
                     85                    90                    95

103

Leu Ile Gly Leu Arg Lys Ala Val Tyr Arg Thr Leu Arg Ala Asn Phe  
 100 105 110  
 Gln Ala Ala Arg Leu Ala Thr Leu Tyr Met Leu Lys Asn Tyr Pro Leu  
 115 120 125  
 Asn Ser Glu Ser Asp Asn Val Thr Asn Tyr Ile Cys Val Val Pro Phe  
 130 135 140  
 Lys Glu Leu Gly Leu Gly Leu Ser Glu Glu Gln Ile Ser Glu Glu Glu  
 145 150 155 160  
 Ala His Asn Phe Thr Asp Gly Phe Ser Leu Pro Ala Leu Lys Val Leu  
 165 170 175  
 Phe Gln Leu Trp Val Ala Gln Ser Ser Glu Phe Phe Arg Arg Leu Ala  
 180 185 190  
 Leu Leu Leu Ser Thr Ala Asn Ser Pro Pro Gly Pro Leu Leu Thr Pro  
 195 200 205  
 Ala Leu Leu Pro His Arg Ile Leu Ser Asp Val Thr Gln Gly Leu Pro  
 210 215 220  
 His Ala His Ser Ala Cys Leu Glu Glu Leu Lys Arg Ser Tyr Glu Phe  
 225 230 235 240  
 Tyr Arg Tyr Phe Glu Thr Gln His Gln Ser Val Pro Gln Cys Leu Ser  
 245 250 255  
 Lys Thr Gln Gln Lys Ser Arg Glu Leu Asn Asn Val His Thr Ala Val  
 260 265 270  
 Arg Ser Leu Gln Leu His Leu Lys Ala Leu Leu Asn Glu Val Ile Ile  
 275 280 285  
 Leu Glu Asp Glu Leu Glu Lys Leu Val Cys Thr Lys Glu Thr Gln Glu  
 290 295 300  
 Leu Val Ser Glu Ala Tyr Pro Ile Leu Glu Gln Lys Leu Lys Leu Ile  
 305 310 315 320  
 Gln Pro His Val Gln Ala Ser Asn Asn Cys Trp Glu Glu Ala Ile Ser  
 325 330 335  
 Gln Val Asp Lys Leu Leu Arg Arg Asn Thr Asp Lys Lys Gly Lys Pro  
 340 345 350  
 Glu Ile Ala Cys Glu Asn Pro His Cys Thr Val Ser Thr Phe Glu Ala  
 355 360 365  
 Ala Tyr Ser Thr His Cys Arg Gln Arg Ser Asn Pro Arg Gly Ala Gly  
 370 375 380  
 Ile Arg Ser Leu Cys Arg Xaa  
 385 390

104

<210> 152  
<211> 99  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (99)  
<223> Xaa equals stop translation

<400> 152  
Met Thr Thr Arg Gln Pro Thr Ala Val Ser Trp Pro Cys Trp Leu Met  
1 5 10 15  
Ser Ser Ser Leu Ser Thr Ala Cys Leu Ala Trp Thr Leu Thr Gly Ser  
20 25 30  
Leu Ala Arg Glu Ala Thr Arg Arg Ala Arg Ser Leu Ser Pro Thr Trp  
35 40 45  
Asn Cys Ser Ala Arg Gln Val Pro Pro Ser Pro Pro His Ser Gly Leu  
50 55 60  
Gly Arg Arg Gly Trp Ala His Cys His Leu Thr Cys Leu Leu Val Thr  
65 70 75 80  
Gln Leu Phe Arg Val Gly Arg Ile His Pro Ile Leu Ser Leu Pro Leu  
85 90 95  
Val Thr Xaa

<210> 153  
<211> 61  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (61)  
<223> Xaa equals stop translation

<400> 153  
Met Ser His Cys Ala Arg Pro Thr Phe Leu Thr Leu Leu Ala Ser  
1 5 10 15  
Cys Phe Trp Ala Ala Ala Ile Pro Asn Arg Asn Val Ile Leu Ser Val  
20 25 30  
Ser Phe Arg Pro Leu His Met Gln Phe Thr Leu Ser Ile Leu Val Phe  
35 40 45  
Ile Leu Arg Ile Leu Ile Leu Leu Arg Ser Phe Leu Xaa  
50 55 60

<210> 154

105

&lt;211&gt; 393

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (393)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 154

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Trp | Trp | Ala | Ser | Ser | Pro | Leu | Arg | Leu | Trp | Leu | Leu | Leu | Phe |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Leu | Pro | Ser | Ala | Gln | Gly | Arg | Gln | Lys | Glu | Ser | Gly | Ser | Lys | Trp |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Val | Phe | Ile | Asp | Gln | Ile | Asn | Arg | Ser | Leu | Glu | Asn | Tyr | Glu | Pro |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Ser | Ser | Gln | Asn | Cys | Ser | Cys | Tyr | His | Gly | Val | Ile | Glu | Glu | Asp |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Thr | Pro | Phe | Arg | Gly | Gly | Ile | Ser | Arg | Lys | Met | Met | Ala | Glu | Val |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     | 80  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Arg | Arg | Lys | Leu | Gly | Thr | His | Tyr | Gln | Ile | Thr | Lys | Asn | Arg | Leu |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Arg | Glu | Asn | Asp | Cys | Met | Phe | Pro | Ser | Arg | Cys | Ser | Gly | Val | Glu |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Phe | Ile | Leu | Glu | Val | Ile | Gly | Arg | Leu | Pro | Asp | Met | Glu | Met | Val |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Asn | Val | Arg | Asp | Tyr | Pro | Gln | Val | Pro | Lys | Trp | Met | Glu | Pro | Ala |
|     | 130 |     |     |     |     |     | 135 |     |     |     | 140 |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Pro | Val | Phe | Ser | Phe | Ser | Lys | Thr | Ser | Glu | Tyr | His | Asp | Ile | Met |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     | 160 |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Pro | Ala | Trp | Thr | Phe | Trp | Glu | Gly | Gly | Pro | Ala | Val | Trp | Pro | Ile |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Pro | Thr | Gly | Leu | Gly | Arg | Trp | Asp | Leu | Phe | Arg | Glu | Asp | Leu | Val |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ser | Ala | Ala | Gln | Trp | Pro | Trp | Lys | Lys | Lys | Asn | Ser | Thr | Ala | Tyr |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Arg | Gly | Ser | Arg | Thr | Ser | Pro | Glu | Arg | Asp | Pro | Leu | Ile | Leu | Leu |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Arg | Lys | Asn | Pro | Lys | Leu | Val | Asp | Ala | Glu | Tyr | Thr | Lys | Asn | Gln |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     | 240 |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Trp | Lys | Ser | Met | Lys | Asp | Thr | Leu | Gly | Lys | Pro | Ala | Ala | Lys | Asp |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |



106

Val His Leu Val Asp His Cys Lys Tyr Lys Tyr Leu Phe Asn Phe Arg  
260 265 270

Gly Val Ala Ala Ser Phe Arg Phe Lys His Leu Phe Leu Cys Gly Ser  
275 280 285

Leu Val Phe His Val Gly Asp Glu Trp Leu Glu Phe Phe Tyr Pro Gln  
290 295 300

Leu Lys Pro Trp Val His Tyr Ile Pro Val Lys Thr Asp Leu Ser Asn  
305 310 315 320

Val Gln Glu Leu Leu Gln Phe Val Lys Ala Asn Asp Asp Val Ala Gln  
325 330 335

Glu Ile Ala Glu Arg Gly Ser Gln Phe Ile Arg Asn His Leu Gln Met  
340 345 350

Asp Asp Ile Thr Cys Tyr Trp Glu Asn Leu Leu Ser Glu Tyr Ser Lys  
355 360 365

Phe Leu Ser Tyr Asn Val Thr Arg Arg Lys Gly Tyr Asp Gln Ile Ile  
370 375 380

Pro Lys Met Leu Lys Thr Glu Leu Xaa  
385 390

&lt;210&gt; 155

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (75)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 155

Met Leu Ile Leu Phe Leu Ser Val Cys Leu Phe Val Phe Leu Leu Thr  
1 5 10 15

Val Arg Ala Leu Cys Cys Arg Ser Ala Gly Val Trp Leu Arg Ser Thr  
20 25 30

Pro Asp Pro Val Cys Leu Gly Phe Ala Arg Gly Gly Cys Arg Ile Ala  
35 40 45

Met Ile Ala Ala Cys Phe Ser Ser Gly Ser Phe Val Pro Glu Gly His  
50 55 60

Pro Pro Asp Ala Ser Gln Ser Ser Pro Val Xaa  
65 70 75

&lt;210&gt; 156

&lt;211&gt; 82

&lt;212&gt; PRT

107

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (82)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 156

Met Trp Pro Leu Leu Ala Val Ser Pro Phe Gly Leu Val Trp Ala Ser  
1 5 10 15  
Ser Gln Ser Gly Ser Leu Leu Leu Arg Ala Ser Ile Pro Arg Gln His  
20 25 30  
Ser Arg Arg Ala Trp His Phe Tyr Ser Glu Val Trp Gln Ser His Ser  
35 40 45  
Val Ala Ser Val Leu Leu Tyr Leu Leu Val Arg Ala Ile Thr Lys Met  
50 55 60  
Cys Ile Gly Ser Lys Lys Arg Asp Ile Thr Pro Thr Thr Arg Trp Lys  
65 70 75 80  
Lys Xaa

&lt;210&gt; 157

&lt;211&gt; 54

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (49)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (54)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 157

Met Ser His His Ala Gly Leu Gly Gly Gly Ile Leu Phe Ser Leu Lys  
1 5 10 15  
Ile Ser Phe Phe Ile Ala Leu Ala Val Val Gly Gly Ser Arg Gly Val  
20 25 30  
Asn Asp Cys Gln Leu Gly Gly Cys Arg Val Gly Ser Cys Pro Arg Val  
35 40 45  
Xaa Val Arg Val Ala Xaa  
50

&lt;210&gt; 158

&lt;211&gt; 103

108

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (103)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 158

```

Met Thr Val Arg Arg Leu Ser Leu Leu Cys Arg Asp Leu Trp Ala Leu
 1             5             10             15

Trp Leu Leu Leu Lys Ala Gly Ala Val Arg Gly Ala Arg Ala Gly Pro
          20             25             30

Arg Leu Pro Gly Arg Cys Cys Gly Ala Thr Cys Gly Asp Ala Gly Arg
          35             40             45

Gly Trp Thr Phe Trp Ala Gln Pro Cys Pro Gln Lys Leu Leu Gly Gln
          50             55             60

Lys Pro Gly Ala Gly Gly Cys Arg Gly Trp Val Leu Gly Trp Val Pro
          65             70             75             80

Pro Arg Pro Glu Glu Pro Cys Ser Leu Ala Gly Lys Val Cys Thr Gly
          85             90             95

Leu Ala Arg Trp Met Val Xaa
          100

```

&lt;210&gt; 159

&lt;211&gt; 575

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 159

```

Met Arg Val Leu Val Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala
 1             5             10             15

Arg Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys
          20             25             30

Phe Arg Gln Glu Ser His Val Glu Phe Ala Thr Gly Glu Leu Leu Thr
          35             40             45

Met Thr Gln Trp Pro Gly Val Trp Ile Pro Met Ala Ser Cys Ser Ser
          50             55             60

Thr Trp Trp Ser Met Ala Leu Ser Pro Asp Ser Leu Ala Asp Ala Asp
          65             70             75             80

Leu Gln Val Gln Asp Phe Glu Glu His Tyr Val Gln Thr Gly Pro Gly
          85             90             95

Gln Leu Phe Val Gly Ser Thr Gln Arg Phe Phe Gln Gly Gly Leu Pro
          100             105             110

```

109

Ser Phe Leu Arg Cys Asn His Ser Ile Gln Tyr Asn Ala Ala Arg Gly  
 115 120 125  
 Pro Gln Pro Gln Leu Val Gln His Leu Arg Ala Ser Ala Ile Ser Ser  
 130 135 140  
 Ala Phe Asp Pro Glu Ala Glu Ala Leu Arg Phe Gln Leu Ala Thr Ala  
 145 150 155 160  
 Leu Gln Ala Glu Glu Asn Glu Val Gly Cys Pro Glu Gly Phe Glu Leu  
 165 170 175  
 Asp Ser Gln Gly Ala Phe Cys Val Asp Val Asp Glu Cys Ala Trp Asp  
 180 185 190  
 Ala His Leu Cys Arg Glu Gly Gln Arg Cys Val Asn Leu Leu Gly Ser  
 195 200 205  
 Tyr Arg Cys Leu Pro Asp Cys Gly Pro Gly Phe Arg Val Ala Asp Gly  
 210 215 220  
 Ala Gly Cys Glu Asp Val Asp Glu Cys Leu Glu Gly Leu Asp Asp Cys  
 225 230 235 240  
 His Tyr Asn Gln Leu Cys Glu Asn Thr Pro Gly Gly His Arg Cys Ser  
 245 250 255  
 Cys Pro Arg Gly Tyr Arg Met Gln Gly Pro Ser Leu Pro Cys Leu Asp  
 260 265 270  
 Val Asn Glu Cys Leu Gln Leu Pro Lys Ala Cys Ala Tyr Gln Cys His  
 275 280 285  
 Asn Leu Gln Gly Ser Tyr Arg Cys Leu Cys Pro Pro Gly Gln Thr Leu  
 290 295 300  
 Leu Arg Asp Gly Lys Ala Cys Thr Ser Leu Glu Arg Asn Gly Gln Asn  
 305 310 315 320  
 Val Thr Thr Val Ser His Arg Gly Pro Leu Leu Pro Trp Leu Arg Pro  
 325 330 335  
 Trp Ala Ser Ile Pro Gly Thr Ser Tyr His Ala Trp Val Ser Leu Arg  
 340 345 350  
 Pro Gly Pro Met Ala Leu Ser Ser Val Gly Arg Ala Trp Cys Pro Pro  
 355 360 365  
 Gly Phe Ile Arg Gln Asn Gly Val Cys Thr Asp Leu Asp Glu Cys Arg  
 370 375 380  
 Val Arg Asn Leu Cys Gln His Ala Cys Arg Asn Thr Glu Gly Ser Tyr  
 385 390 395 400  
 Gln Cys Leu Cys Pro Ala Gly Tyr Arg Leu Leu Pro Ser Gly Lys Asn  
 405 410 415  
 Cys Gln Asp Ile Asn Glu Cys Glu Glu Glu Ser Ile Glu Cys Gly Pro

PCT/US99/15849

```

<400> 160
Met Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Leu Val
  1              5              10              15

Leu Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu
      20              25              30

Ser Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro
      35              40              45

Val Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val
      50              55              60

Met Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu
      65              70              75              80

Pro Ser Cys Thr Asp Gln Cys Phe Arg Gln Asn His Ile His Gly Thr
      85              90              95

Leu Leu Gln Val Phe His Leu Leu Gln Ala Tyr Ser Asp Ser Lys His
      100              105              110

Gly Thr Asn Ser Asp Phe Gln His Glu Leu Thr Asp Ile Thr Val Cys

```

111

115 120 125  
Thr Lys Ala Lys Leu Trp Leu Ala Lys Arg Gln Asn Pro Cys Leu Val  
130 135 140  
Thr Arg Ala Val Tyr Ile Asp Ile Leu Phe Leu Leu Thr Cys Cys Leu  
145 150 155 160  
Asn Arg Ser Ala Lys Asp Asn Gln Pro Val Leu Glu Ser Leu Gly Phe  
165 170 175  
Trp Glu Glu Val Arg Gly Ile Ile Ser Gly Ser Glu Leu Ile Thr Gly  
180 185 190  
Phe Pro Trp Ala Phe Lys Val Pro Gly Leu Pro Gln Tyr Leu Gln Ser  
195 200 205  
Leu Thr Arg Leu Ala Ile Ala Ala Val Trp Ala Ala Ala Lys Ser  
210 215 220  
Gly Glu Arg Glu Thr Asn Val Pro Ile Ser Phe Ser Gln Leu Leu Glu  
225 230 235 240  
Ser Ala Phe Pro Glu Val Arg Ser Leu Thr Leu Glu Ala Leu Leu Glu  
245 250 255  
Lys Phe Leu Ala Ala Ala Ser Gly Leu Gly Glu Lys Gly Val Pro Pro  
260 265 270  
Leu Leu Cys Asn Met Gly Glu Lys Phe Leu Leu Leu Ala Met Lys Glu  
275 280 285  
Asn His Pro Glu Cys Phe Cys Lys Ile Leu Lys Ile Leu His Cys Met  
290 295 300  
Asp Pro Gly Glu Trp Leu Pro Gln Thr Glu His Cys Val His Leu Thr  
305 310 315 320  
Pro Lys Glu Phe Leu Ile Trp Thr Met Asp Ile Ala Ser Asn Glu Arg  
325 330 335  
Ser Glu Ile Gln Ser Val Ala Leu Arg Leu Ala Ser Lys Val Ile Ser  
340 345 350  
His His Met Gln Thr Cys Val Glu Asn Arg Glu Leu Ile Ala Ala Glu  
355 360 365  
Leu Lys Gln Trp Val Gln Leu Val Ile Leu Ser Cys Glu Asp His Leu  
370 375 380  
Pro Thr Glu Ser Arg Leu Ala Val Val Glu Val Leu Thr Ser Thr Thr  
385 390 395 400  
Pro Leu Phe Leu Thr Asn Pro His Pro Ile Leu Glu Leu Gln Asp Thr  
405 410 415  
Leu Ala Leu Trp Lys Cys Val Leu Thr Leu Leu Gln Ser Glu Glu Gln  
420 425 430

112

Ala Val Arg Asp Ala Ala Thr Glu Thr Val Thr Thr Ala Met Ser Gln  
 435 440 445

Glu Asn Thr Cys Gln Ser Thr Glu Phe Ala Phe Cys Gln Val Asp Ala  
 450 455 460

Ser Ile Ala Leu Ala Leu Ala Leu Ala Val Leu Cys Asp Leu Leu Gln  
 465 470 475 480

Gln Trp Asp Gln Leu Ala Pro Gly Leu Pro Ile Leu Leu Gly Trp Leu  
 485 490 495

Leu Gly Glu Ser Asp Asp Leu Val Ala Cys Val Glu Ser Met His Gln  
 500 505 510

Val Glu Glu Asp Tyr Leu Phe Glu Lys Ala Glu Val Asn Phe Trp Ala  
 515 520 525

Glu Thr Leu Ile Phe Val Lys Tyr Leu Cys Lys His Leu Phe Cys Leu  
 530 535 540

Leu Ser Lys Ser Gly Trp Arg Pro Pro Ser Pro Glu Met Leu Cys His  
 545 550 555 560

Leu Gln Arg Met Val Ser Glu Gln Cys His Leu Leu Ser Gln Phe Phe  
 565 570 575

Arg Glu Leu Pro Pro Ala Ala Glu Phe Val Lys Thr Val Glu Phe Thr  
 580 585 590

Arg Leu Arg Ile Gln Glu Glu Arg Thr Leu Ala Cys Leu Arg Leu Leu  
 595 600 605

Ala Phe Leu Glu Gly Lys Glu Gly Glu Asp Thr Leu Val Leu Ser Val  
 610 615 620

Trp Asp Ser Tyr Ala Glu Ser Arg Gln Leu Thr Leu Pro Arg Thr Glu  
 625 630 635 640

Ala Ala Cys

&lt;210&gt; 161

&lt;211&gt; 191

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (191)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 161

Met Ser Ser Gly Thr Glu Leu Leu Trp Pro Gly Ala Ala Leu Leu Val  
 1 5 10 15

113

Leu Leu Gly Val Ala Ala Ser Leu Cys Val Arg Cys Ser Arg Pro Gly  
                   20                  25                  30  
 Ala Lys Arg Ser Glu Lys Ile Tyr Gln Gln Arg Ser Leu Arg Glu Asp  
                   35                  40                  45  
 Gln Gln Ser Phe Thr Gly Ser Arg Thr Tyr Ser Leu Val Gly Gln Ala  
                   50                  55                  60  
 Trp Pro Gly Pro Leu Ala Asp Met Ala Pro Thr Arg Lys Asp Lys Leu  
                   65                  70                  75                  80  
 Leu Gln Phe Tyr Pro Ser Leu Glu Asp Pro Ala Ser Ser Arg Tyr Gln  
                   85                  90                  95  
 Asn Phe Ser Lys Gly Ser Arg His Gly Ser Glu Glu Ala Tyr Ile Asp  
                   100                  105                  110  
 Pro Ile Ala Met Glu Tyr Tyr Asn Trp Gly Arg Phe Ser Lys Pro Pro  
                   115                  120                  125  
 Glu Asp Asp Asp Ala Asn Ser Tyr Glu Asn Val Leu Ile Cys Lys Gln  
                   130                  135                  140  
 Lys Thr Thr Glu Thr Gly Ala Gln Gln Glu Gly Ile Gly Gly Leu Cys  
                   145                  150                  155                  160  
 Arg Gly Asp Leu Ser Leu Ser Leu Ala Leu Lys Thr Gly Pro Thr Ser  
                   165                  170                  175  
 Gly Leu Cys Pro Ser Ala Ser Pro Glu Glu Asp Glu Gly Ile Xaa  
                   180                  185                  190

&lt;210&gt; 162

&lt;211&gt; 64

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (64)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 162

Met Lys His Val Leu Asn Leu Tyr Leu Leu Gly Val Val Leu Thr Leu  
           1                  5                  10                  15  
 Leu Ser Ile Phe Val Arg Val Met Glu Ser Leu Glu Gly Leu Leu Glu  
                   20                  25                  30  
 Ser Pro Ser Pro Gly Thr Ser Trp Thr Thr Arg Ser Gln Leu Ala Asn  
                   35                  40                  45  
 Thr Glu Pro Thr Lys Gly Leu Pro Asp His Pro Ser Arg Ser Met Xaa  
           50                  55                  60



114

<210> 163  
<211> 118  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (118)  
<223> Xaa equals stop translation

&lt;400&gt; 163

Met Ile Phe Leu Thr Val Leu Pro Leu Ala Phe Leu Phe Leu His Ser  
1 5 10 15

Gly Phe Tyr His Tyr Ile Ser Phe Ser Cys Leu Phe Ser Leu Ser Leu  
20 25 30

Ala Leu Phe Phe Phe Leu Asp Val Ala Thr Phe Arg Arg Pro Gly Gln  
35 40 45

Leu Phe Cys Glu Arg Ser Val Leu Phe Asp Met Phe His Phe Gly Phe  
50 55 60

Val Ser Leu Phe Leu His Glu Trp Ile Gln Ala Lys His Phe Trp Ala  
65 70 75 80

Gly Leu Phe Ile Val Leu Pro Ser Asp Val Phe Phe Ser Val His His  
85 90 95

Leu Glu Ala Pro Asp Gly Ser Phe Pro Asn Ile Ala Lys Leu Ser Leu  
100 105 110

Ile Ile Leu Leu Arg Xaa  
115

<210> 164  
<211> 43  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (43)  
<223> Xaa equals stop translation

&lt;400&gt; 164

Met Leu Leu Gln Phe Thr Leu Trp Val Phe Gly Ala Ile His Phe Pro  
1 5 10 15

Lys Cys Leu Gly Ile Lys Glu Glu Leu Leu Lys Cys Cys Leu Gln Leu  
20 25 30

Pro Pro Ser Ser Thr Tyr Glu Lys Val Val Xaa  
35 40

115

<210> 165  
<211> 48  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (48)  
<223> Xaa equals stop translation

<400> 165  
Met Leu Ser Arg Arg Leu His Cys Leu Val Leu Tyr Phe Leu Leu Leu  
1 5 10 15  
Leu Leu Ser Phe Ile His Thr Leu Ser Val Ser His Ile Cys Ser Ser  
20 25 30  
Phe Ile Trp Leu Phe Pro Lys Asn Ile Glu Ser Glu Ala Thr Met Xaa  
35 40 45

<210> 166  
<211> 46  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (46)  
<223> Xaa equals stop translation

<400> 166  
Met Glu Lys Met Gly Gln Gly Leu Leu Ser Ser Thr Tyr Leu Thr Val  
1 5 10 15  
Leu His Leu Ile Gln Leu Val Gly Cys Gly Leu Leu Thr Glu Glu Ile  
20 25 30  
Lys Glu Ser Lys Tyr Leu Ile Lys Thr Leu Gly Ser Gly Xaa  
35 40 45

<210> 167  
<211> 207  
<212> PRT  
<213> Homo sapiens

<400> 167  
Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn Cys Ile Phe Phe  
1 5 10 15  
Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile Thr Ala Ile Ser  
20 25 30

116

Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile Phe Phe Pro Leu  
                   35                                  40                                  45  
 Pro Ala Cys Leu Asn Pro Val Leu Tyr Val Phe Phe Asn Pro Lys Phe  
                   50                                  55                                  60  
 Lys Glu Asp Trp Lys Leu Leu Lys Arg Arg Val Thr Lys Lys Ser Gly  
                   65                                  70                                  75                                  80  
 Ser Val Ser Val Ser Ile Ser Ser Gln Gly Gly Cys Leu Glu Gln Asp  
                                   85                                  90                                  95  
 Phe Tyr Tyr Asp Cys Gly Met Tyr Ser His Leu Gln Gly Asn Leu Thr  
                   100                                  105                                  110  
 Val Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr Lys Pro Val Ser Cys  
                   115                                  120                                  125  
 Lys His Leu Ile Lys Ser His Ser Cys Pro Ala Leu Ala Val Ala Ser  
                   130                                  135                                  140  
 Cys Gln Arg Pro Glu Gly Tyr Trp Ser Asp Cys Gly Thr Gln Ser Ala  
                   145                                  150                                  155                                  160  
 His Ser Asp Tyr Ala Asp Glu Glu Asp Ser Phe Val Ser Asp Ser Ser  
                                   165                                  170                                  175  
 Asp Gln Val Gln Ala Cys Gly Arg Ala Cys Phe Tyr Gln Ser Arg Gly  
                   180                                  185                                  190  
 Phe Pro Leu Val Arg Tyr Ala Tyr Asn Leu Pro Arg Val Lys Asp  
                   195                                  200                                  205

&lt;210&gt; 168

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 168

Met Tyr Ile Phe Glu Leu Ser Leu Tyr Leu Glu Gly Thr Ser Phe Val  
                   1                                  5                                  10                                  15  
 Val Val Leu Leu Phe Leu Leu Ile Ser Val Ser Leu Asp Ser Pro Pro  
                   20                                  25                                  30  
 Thr Thr Lys Gly Trp Asp Ser Val Leu His Ile Trp Val Pro Leu Ile  
                   35                                  40                                  45  
 Val Gln Xaa  
                   50

117

<210> 169  
<211> 43  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (43)  
<223> Xaa equals stop translation

<400> 169  
Met Ala His Pro Gly Leu Pro Lys Thr Val Pro Val Tyr Ala Val Val  
1 5 10 15  
Leu Ala Leu Leu Ile Met Thr Leu Pro Leu Thr Leu Thr Ile Asn Leu  
20 25 30  
Asp Asp Asn Leu Tyr Gly Asn Ser Ala Lys Xaa  
35 40

<210> 170  
<211> 56  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (56)  
<223> Xaa equals stop translation

<400> 170  
Met Arg Pro Trp Trp Ser Leu Leu Leu Glu Ala Cys Ala Thr Cys Ala  
1 5 10 15  
Gln Thr Gly Pro Thr Arg Ser Thr Ser Cys Thr Gln Glu Val Ser His  
20 25 30  
Ser Ser Ser Thr Ala Tyr Pro Ala Pro Met Arg Arg Arg Cys Cys Leu  
35 40 45  
Pro Ser Pro Arg Ser Cys Thr Xaa  
50 55

<210> 171  
<211> 109  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (109)  
<223> Xaa equals stop translation

<400> 171  
Met Ala Leu Ala Gly Ser Val Phe Val Leu Gly Gly Val Leu Val Leu

118

|   |     |     |    |
|---|-----|-----|----|
| 1   | 5   | 10  | 15 |
| Cys Val Glu Arg Asn Gly Glu Gly Glu Met Gly Trp Pro Gln His Leu | 20  | 25  | 30 |
| Pro Lys Ser Gln Pro Leu Ser Pro Pro Val Ala Val Arg Arg Cys Ser | 35  | 40  | 45 |
| Phe Glu Arg Ser Trp Ile Asp Leu Leu Val Glu Thr Ser Ser Ser Met | 50  | 55  | 60 |
| Val Thr Cys Arg Gln Gln Val Gly Thr Pro Asn Gly Met Glu Gly Arg | 65  | 70  | 75 |
| Gly Gly Gly Pro Lys Thr Thr Phe Pro Ile Arg Leu Gln Leu Ser Gly | 85  | 90  | 95 |
| Ala Cys Ala Val Arg Pro Glu Ile Gln Trp Glu Val Xaa             | 100 | 105 |    |

&lt;210&gt; 172

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (17)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 172

|   |   |   |    |    |
|---|---|---|----|----|
| Met Phe Leu Phe Phe Tyr Leu Ser Leu Ala Val Tyr Ala Gln Arg Gln | 1 | 5 | 10 | 15 |
|---|---|---|----|----|

|   |    |    |    |
|---|----|----|----|
| Xaa Ser Gly Ser Cys Arg Gln Thr Asp His Arg Trp Lys Ser Arg Gly | 20 | 25 | 30 |
|---|----|----|----|

|   |    |    |    |
|---|----|----|----|
| Ala Arg Arg Cys Phe Leu Glu Pro Arg Asp Pro Gly Ser Val Pro Gly | 35 | 40 | 45 |
|---|----|----|----|

|             |    |
|-------------|----|
| His Pro Xaa | 50 |
|-------------|----|

&lt;210&gt; 173

&lt;211&gt; 566

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 173

|   |   |   |    |    |
|---|---|---|----|----|
| Met Ala Pro Leu Ala Leu His Leu Leu Val Leu Val Pro Ile Leu Leu | 1 | 5 | 10 | 15 |
|---|---|---|----|----|

119

Ser Leu Val Ala Ser Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro  
 20 25 30  
 Phe Glu Lys Cys Met Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val  
 35 40 45  
 Val Thr Trp Gly Leu Asn Arg Thr Leu Lys Pro Gln Arg Val Ile Val  
 50 55 60  
 Val Gly Ala Gly Val Ala Gly Leu Val Ala Ala Lys Val Leu Ser Asp  
 65 70 75 80  
 Ala Gly His Lys Val Thr Ile Leu Glu Ala Asp Asn Arg Ile Gly Gly  
 85 90 95  
 Arg Ile Phe Thr Tyr Arg Asp Gln Asn Thr Gly Trp Ile Gly Glu Leu  
 100 105 110  
 Gly Ala Met Arg Met Pro Ser Ser His Arg Ile Leu His Lys Leu Cys  
 115 120 125  
 Gln Gly Leu Gly Leu Asn Leu Thr Lys Phe Thr Gln Tyr Asp Lys Asn  
 130 135 140  
 Thr Trp Thr Glu Val His Glu Val Lys Leu Arg Asn Tyr Val Val Glu  
 145 150 155 160  
 Lys Val Pro Glu Lys Leu Gly Tyr Ala Leu Arg Pro Gln Glu Lys Gly  
 165 170 175  
 His Ser Pro Glu Asp Ile Tyr Gln Met Ala Leu Asn Gln Ala Leu Lys  
 180 185 190  
 Asp Leu Lys Ala Leu Gly Cys Arg Lys Ala Met Lys Lys Phe Glu Arg  
 195 200 205  
 His Thr Leu Leu Glu Tyr Leu Leu Gly Glu Gly Asn Leu Ser Arg Pro  
 210 215 220  
 Ala Val Gln Leu Leu Gly Asp Val Met Ser Glu Asp Gly Phe Phe Tyr  
 225 230 235 240  
 Leu Ser Phe Ala Glu Ala Leu Arg Ala His Ser Cys Leu Ser Asp Arg  
 245 250 255  
 Leu Gln Tyr Ser Arg Ile Val Gly Gly Trp Asp Leu Leu Pro Arg Ala  
 260 265 270  
 Leu Leu Ser Ser Leu Ser Gly Leu Val Leu Leu Asn Ala Pro Val Val  
 275 280 285  
 Ala Met Thr Gln Gly Pro His Asp Val His Val Gln Ile Glu Thr Ser  
 290 295 300  
 Pro Pro Ala Arg Asn Leu Lys Val Leu Lys Ala Asp Val Val Leu Leu  
 305 310 315 320

120

Thr Ala Ser Gly Pro Ala Val Lys Arg Ile Thr Phe Ser Pro Pro Leu  
 325 330 335  
 Pro Arg His Met Gln Glu Ala Leu Arg Arg Leu His Tyr Val Pro Ala  
 340 345 350  
 Thr Lys Val Phe Leu Ser Phe Arg Arg Pro Phe Trp Arg Glu Glu His  
 355 360 365  
 Ile Glu Gly Gly His Ser Asn Thr Asp Arg Pro Ser Arg Met Ile Phe  
 370 375 380  
 Tyr Pro Pro Pro Arg Glu Gly Ala Leu Leu Leu Ala Ser Tyr Thr Trp  
 385 390 395 400  
 Ser Asp Ala Ala Ala Ala Phe Ala Gly Leu Ser Arg Glu Glu Ala Leu  
 405 410 415  
 Arg Leu Ala Leu Asp Asp Val Ala Ala Leu His Gly Pro Val Val Arg  
 420 425 430  
 Gln Leu Trp Asp Gly Thr Gly Val Val Lys Arg Trp Ala Glu Asp Gln  
 435 440 445  
 His Ser Gln Gly Gly Phe Val Val Gln Pro Pro Ala Leu Trp Gln Thr  
 450 455 460  
 Glu Lys Asp Asp Trp Thr Val Pro Tyr Gly Arg Ile Tyr Phe Ala Gly  
 465 470 475 480  
 Glu His Thr Ala Tyr Pro His Gly Trp Val Glu Thr Ala Val Lys Leu  
 485 490 495  
 Leu Arg Ala Ala Ile Lys Ile Asn Ser Arg Lys Gly Pro Ala Ser Asp  
 500 505 510  
 Thr Ala Ser Pro Glu Gly His Ala Ser Asp Met Glu Gly Gln Gly His  
 515 520 525  
 Val His Gly Val Ala Ser Ser Pro Ser His Asp Leu Ala Lys Glu Glu  
 530 535 540  
 Gly Ser His Pro Pro Val Gln Gly Gln Leu Ser Leu Gln Asn Thr Thr  
 545 550 555 560  
 His Thr Arg Thr Ser His  
 565

&lt;210&gt; 174

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (76)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

121

&lt;400&gt; 174

Met Ala Arg Ala Arg Gly Ser Pro Cys Pro Pro Leu Pro Pro Gly Arg  
 1 5 10 15

Met Ser Trp Pro His Gly Ala Leu Leu Phe Leu Trp Leu Phe Ser Pro  
 20 25 30

Pro Leu Gly Ala Gly Gly Gly Gly Val Ala Val Thr Ser Ala Ala Gly  
 35 40 45

Gly Gly Ser Pro Pro Ala Thr Ser Cys Pro Val Ala Cys Ser Cys Ser  
 50 55 60

Asn Gln Ala Ser Arg Val Ile Cys Thr Arg Arg Xaa Leu Ala Glu Val  
 65 70 75 80

Pro Ala Ser Ile Pro Val Asn Thr Arg Tyr Leu Asn Leu Gln Glu Asn  
 85 90 95

Gly Ile Gln Val Ile Arg Thr Asp Thr Phe Lys His Leu Arg His Leu  
 100 105 110

Glu Ile Leu Gln Leu Ser Lys Asn Leu Val Arg Lys Ile Glu Val Gly  
 115 120 125

Ala Phe Asn Gly Leu Pro Ser Leu Asn Thr Leu Glu Leu Phe Asp Asn  
 130 135 140

Arg Leu Thr Thr Val Pro Thr Gln Ala Phe Glu Tyr Leu Ser Lys Leu  
 145 150 155 160

Arg Glu Leu Trp Leu Arg Asn Asn Pro Ile Glu Ser Ile Pro Ser Tyr  
 165 170 175

Ala Phe Asn Arg Val Pro Ser Leu Arg Arg Leu Asp Leu Gly Glu Leu  
 180 185 190

Lys Arg Leu Glu Tyr Ile Ser Glu Ala Ala Phe Glu Gly Leu Val Asn  
 195 200 205

Leu Arg Tyr Leu Asn Leu Gly Met Cys Asn Leu Lys Asp Ile Pro Asn  
 210 215 220

&lt;210&gt; 175

&lt;211&gt; 123

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 175

Met His Asp Gly Ser Lys Pro Phe Pro Arg Tyr Gly Tyr Lys Pro Ser  
 1 5 10 15

Pro Pro Asn Gly Cys Gly Ser Pro Leu Phe Gly Val His Leu Asn Ile



122

|   |     |     |
|---|-----|-----|
| 20  | 25  | 30  |
| Gly Ile Pro Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg Cys Tyr |     |     |
| 35  | 40  | 45  |
| Glu Thr Cys Gly Lys Ser Lys Asn Asp Cys Asp Glu Glu Phe Gln Tyr |     |     |
| 50  | 55  | 60  |
| Cys Leu Ser Lys Ile Cys Arg Asp Val Gln Lys Thr Leu Gly Leu Thr |     |     |
| 65  | 70  | 75  |
| Gln His Val Gln Ala Cys Glu Thr Thr Val Glu Leu Leu Phe Asp Ser |     |     |
| 85  | 90  | 95  |
| Val Ile His Leu Gly Cys Lys Pro Tyr Leu Asp Ser Gln Arg Ala Ala |     |     |
| 100   | 105 | 110 |
| Cys Arg Cys His Tyr Glu Glu Lys Thr Asp Leu                     |     |     |
| 115   | 120 |     |

<210> 176  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (60)  
 <223> Xaa equals stop translation

<400> 176

|   |    |    |
|---|----|----|
| Met Gly Leu Ser Val Leu Leu Pro Leu Cys Leu Leu Gly Pro Gly Arg |    |    |
| 1   | 5  | 10 |
| 15  |    |    |
| Phe Thr Ser Gly Gln Lys Pro Leu Asp Thr Pro Gly Leu Gly Ala Ala |    |    |
| 20  | 25 | 30 |
| Val Leu Ser Val Arg Lys Ala Gly Leu Lys Met Arg Ser His Leu Thr |    |    |
| 35  | 40 | 45 |
| Pro Ser Val Cys Thr Val Pro Ser Pro Gly Ser Xaa                 |    |    |
| 50  | 55 | 60 |

<210> 177  
 <211> 105  
 <212> PRT  
 <213> Homo sapiens

<400> 177

|   |    |    |
|---|----|----|
| Met Asp Thr Val Phe Leu Ile Gln Tyr Leu Phe Leu Thr Phe Pro Arg |    |    |
| 1   | 5  | 10 |
| 15  |    |    |
| Ile Val Phe Met Leu Gly Phe Val Val Val Leu Ser Phe Leu Leu Gly |    |    |
| 20  | 25 | 30 |
| Gly Tyr Leu Leu Phe Val Leu Tyr Leu Ala Ala Thr Asn Gln Thr Thr |    |    |

123

|   |     |       |
|---|-----|-------|
| 35  | 40  | 45    |
| Asn Glu Trp Tyr Arg Gly Asp Trp Ala Trp Cys Gln Arg Cys Pro Leu |     |       |
| 50  | 55  | 60    |
| Val Ala Trp Pro Pro Ser Ala Glu Pro Gln Val His Arg Asn Ile His |     |       |
| 65  | 70  | 75 80 |
| Ser His Gly Leu Arg Ser Asn Leu Gln Glu Ile Phe Leu Pro Ala Phe |     |       |
| 85  | 90  | 95    |
| Pro Cys His Glu Arg Lys Lys Gln Glu                             |     |       |
| 100   | 105 |       |

<210> 178  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (88)  
 <223> Xaa equals stop translation

<400> 178  
 Met Ala Asp Pro His Val Ser Phe Leu Ser Phe Arg Gln Leu Phe Ser  
           1                  5                  10                  15  
 Trp Ala Ala Val Ile Leu Leu Arg Gly Ile Leu Gly Thr Val Ala Pro  
                   20                  25                  30  
 Pro Pro Cys Pro Cys Val Leu Asp Leu Ala Val Tyr Pro Leu His Leu  
           35                  40                  45  
 Pro Val Glu Ala Pro Cys Leu Glu Val Val Phe Lys Gln Lys Asn Gly  
           50                  55                  60  
 Lys Asp Asn Cys Leu Val Phe Tyr Pro Asp Pro Ile Pro Leu Arg Gly  
           65                  70                  75                  80  
 Ser Leu Leu Gly Pro Phe Ile Xaa  
                   85

<210> 179  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (66)

124

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (88)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 179

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Asp | Pro | His | Val | Ser | Phe | Leu | Ser | Phe | Arg | Gln | Leu | Phe | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Ala | Ala | Val | Ile | Leu | Leu | Arg | Gly | Ile | Leu | Gly | Thr | Val | Ala | Pro |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     |     | 30  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Pro | Cys | Pro | Cys | Val | Leu | Asp | Leu | Ala | Val | Tyr | Pro | Leu | His | Leu |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     |     | 45  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Val | Glu | Ala | Pro | Cys | Xaa | Glu | Val | Val | Phe | Lys | Gln | Lys | Asn | Gly |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Xaa | Asn | Cys | Leu | Val | Phe | Tyr | Pro | Asp | Pro | Ile | Pro | Leu | Arg | Gly |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Leu | Leu | Gly | Pro | Phe | Ile | Xaa |
|     |     |     |     |     |     |     | 85  |

&lt;210&gt; 180

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 180

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Leu | Leu | Gly | Met | Ile | Phe | Ser | Met | Cys | Gly | Leu | Met | Leu | Lys |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Lys | Trp | Cys | Ala | Trp | Val | Ala | Val | Tyr | Cys | Ser | Phe | Ile | Ser | Phe |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asn | Ser | Arg | Ser | Ser | Glu | Asp | Thr | Lys | Gln | Met | Met | Ser | Ser | Phe |
|     |     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

Met

&lt;210&gt; 181

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 181

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Gly | Ser | Leu | Ser | Thr | Ala | Pro | Ser | Ser | Ala | Leu | Pro | Thr | Leu | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|
| Ala | Arg | Arg | Thr | Arg | Ser | Lys |
|     |     |     |     |     |     | 20  |

125

<210> 182  
<211> 104  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (104)  
<223> Xaa equals stop translation

<400> 182  
Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe  
1 5 10 15  
Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
20 25 30  
Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
35 40 45  
Ser Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp  
50 55 60  
Val Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn  
65 70 75 80  
Tyr Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg  
85 90 95  
Thr Arg Val Leu Phe Ile Tyr Xaa  
100

<210> 183  
<211> 198  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (29)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 183  
Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
1 5 10 15  
His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln His Xaa Phe Asp Tyr  
20 25 30  
Lys Asp Glu Ser Gly Phe Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr  
35 40 45  
Thr Leu Pro Ser Tyr Asp Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr  
50 55 60  
Ile Pro Leu Val Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp

PCT/US99/15849

```
<210> 184
<211> 70
<212> PRT
<213> Homo sapiens
```

```
<210> 185
<211> 82
<212> PRT
<213> Homo sapiens
```

```

<400> 185
Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe
  1             5             10            15

```

127

Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
                   20                  25                  30  
 Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
                   35                  40                  45  
 Ser Thr Tyr Phe Pro Ala Phe Met Asn Ser Leu Ser Arg Ser Lys Arg  
                   50                  55                  60  
 Thr Pro Ala Gly Ser Glu Ser Arg Cys Arg Thr Gln Arg Asn Asn His  
                   65                  70                  75                  80  
 Leu Leu

<210> 186  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 186  
 Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
   1                  5                  10                  15  
 His Leu Thr Ala Ala Phe Leu Gln Arg Ala His Xaa Ile Leu Thr Thr  
                   20                  25                  30  
 Arg Met Ser Leu Gly Phe Gln Ser Pro His Leu Thr Met  
                   35                  40                  45

<210> 187  
 <211> 34  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (34)  
 <223> Xaa equals stop translation

<400> 187  
 Met Thr Val Met Asp Pro Lys Gln Met Asn Val Ala Ala Ala Val Trp  
   1                  5                  10                  15  
 Ala Val Val Ser Tyr Val Val Ala Asp Met Glu Glu Met Leu Pro Arg  
                   20                  25                  30  
 Ser Xaa

128

<210> 188  
<211> 232  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (232)  
<223> Xaa equals stop translation

<400> 188  
Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser  
1 5 10 15  
Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Cys Gln Thr  
20 25 30  
Pro Pro Arg Ile Ser Arg Met Ser Asp Val Asn Val Ser Ala Leu Pro  
35 40 45  
Ile Lys Lys Asn Ser Gly His Ile Tyr Asn Lys Asn Ile Ser Gln Lys  
50 55 60  
Asp Cys Asp Cys Leu His Val Val Glu Pro Met Pro Val Arg Gly Pro  
65 70 75 80  
Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu Cys Lys Tyr Glu Glu Arg  
85 90 95  
Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile Leu  
100 105 110  
Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro Ile  
115 120 125  
Leu Lys Arg Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp Asp  
130 135 140  
Asp Ile Gly Asp His Gln Pro Phe Ala Asn Ala His Asp Val Leu Ala  
145 150 155 160  
Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Gly Thr  
165 170 175  
Ala Ala Leu Glu Ala Ser Ser Pro Arg Ala Ala Lys Ser Leu Ser Leu  
180 185 190  
Thr Gly Met Leu Ser Ser Ala Asn Trp Gly Ile Glu Phe Lys Val Thr  
195 200 205  
Arg Lys Lys Gln Ala Asp Asn Trp Lys Gly Thr Asp Trp Val Leu Leu  
210 215 220  
Gly Phe Ile Leu Ile Pro Cys Xaa  
225 230

&lt;210&gt; 189

129

<211> 457  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (457)  
 <223> Xaa equals stop translation

&lt;400&gt; 189

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ala | Ala | Gly | Arg | Leu | Pro | Ser | Ser | Trp | Ala | Leu | Phe | Ser | Pro | 1   | 5   | 10  | 15  |
| Leu | Leu | Ala | Gly | Leu | Ala | Leu | Leu | Gly | Val | Gly | Pro | Val | Pro | Ala | Arg | 20  | 25  | 30  |     |
| Ala | Leu | His | Asn | Val | Thr | Ala | Glu | Leu | Phe | Gly | Ala | Glu | Ala | Trp | Gly | 35  | 40  | 45  |     |
| Thr | Leu | Ala | Ala | Phe | Gly | Asp | Leu | Asn | Ser | Asp | Lys | Gln | Thr | Asp | Leu | 50  | 55  | 60  |     |
| Phe | Val | Leu | Arg | Glu | Arg | Asn | Asp | Leu | Ile | Val | Phe | Leu | Ala | Asp | Gln | 65  | 70  | 75  | 80  |
| Asn | Ala | Pro | Tyr | Phe | Lys | Pro | Lys | Val | Lys | Val | Ser | Phe | Lys | Asn | His | 85  | 90  | 95  |     |
| Ser | Ala | Leu | Ile | Thr | Ser | Val | Val | Pro | Gly | Asp | Tyr | Asp | Gly | Asp | Ser | 100 | 105 | 110 |     |
| Gln | Met | Asp | Val | Leu | Leu | Thr | Tyr | Leu | Pro | Lys | Asn | Tyr | Ala | Lys | Ser | 115 | 120 | 125 |     |
| Glu | Leu | Gly | Ala | Val | Ile | Phe | Trp | Gly | Gln | Asn | Gln | Thr | Leu | Asp | Pro | 130 | 135 | 140 |     |
| Asn | Asn | Met | Thr | Ile | Leu | Asn | Arg | Thr | Phe | Gln | Asp | Glu | Pro | Leu | Ile | 145 | 150 | 155 | 160 |
| Met | Asp | Phe | Asn | Gly | Asp | Leu | Ile | Pro | Asp | Ile | Phe | Gly | Ile | Thr | Asn | 165 | 170 | 175 |     |
| Glu | Ser | Asn | Gln | Pro | Gln | Ile | Leu | Leu | Gly | Gly | Asn | Leu | Ser | Trp | His | 180 | 185 | 190 |     |
| Pro | Ala | Leu | Thr | Thr | Thr | Ser | Lys | Met | Arg | Ile | Pro | His | Ser | His | Ala | 195 | 200 | 205 |     |
| Phe | Ile | Asp | Leu | Thr | Glu | Asp | Phe | Thr | Ala | Asp | Leu | Phe | Leu | Thr | Thr | 210 | 215 | 220 |     |
| Leu | Asn | Ala | Thr | Thr | Ser | Thr | Phe | Gln | Phe | Glu | Ile | Trp | Glu | Asn | Leu | 225 | 230 | 235 | 240 |
| Asp | Gly | Asn | Phe | Ser | Val | Ser | Thr | Ile | Leu | Glu | Lys | Pro | Gln | Asn | Met | 245 | 250 | 255 |     |



130

Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His  
 260 265 270

Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser  
 275 280 285

Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu  
 290 295 300

Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val  
 305 310 315 320

Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile  
 325 330 335

Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys  
 340 345 350

Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro  
 355 360 365

Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr  
 370 375 380

Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr  
 385 390 395 400

Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser  
 405 410 415

Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn  
 420 425 430

Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu  
 435 440 445

Cys Ser Asn Asp Cys Pro Arg Arg Xaa  
 450 455

&lt;210&gt; 190

&lt;211&gt; 185

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (185)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 190

Met Leu Phe Leu Phe Ser Met Ala Thr Leu Leu Arg Thr Ser Phe Ser  
 1 5 10 15

Asp Pro Gly Val Ile Pro Arg Ala Leu Pro Asp Glu Ala Ala Phe Ile  
 20 25 30

Glu Met Glu Ile Glu Ala Thr Asn Gly Ala Val Pro Gln Gly Gln Arg

131

35

40

45

Pro Pro Pro Arg Ile Lys Asn Phe Gln Ile Asn Asn Gln Ile Val Lys  
 50 55 60  
 Leu Lys Tyr Cys Tyr Thr Cys Lys Ile Phe Arg Pro Pro Arg Ala Ser  
 65 70 75 80  
 His Cys Ser Ile Cys Asp Asn Cys Val Glu Arg Phe Asp His His Cys  
 85 90 95  
 Pro Trp Val Gly Asn Cys Val Gly Lys Arg Asn Tyr Arg Tyr Phe Tyr  
 100 105 110  
 Leu Phe Ile Leu Ser Leu Ser Leu Leu Thr Ile Tyr Val Phe Ala Phe  
 115 120 125  
 Asn Ile Val Tyr Val Ala Leu Lys Ser Leu Lys Ile Gly Phe Leu Glu  
 130 135 140  
 Thr Leu Lys Gly Asn Ser Trp Asn Cys Ser Arg Ser Pro His Leu Leu  
 145 150 155 160  
 Leu Tyr Thr Leu Val Arg Arg Gly Thr Asp Trp Ile Ser Tyr Phe Pro  
 165 170 175  
 Arg Gly Ser Gln Pro Asp Asn Gln Xaa  
 180 185

&lt;210&gt; 191

&lt;211&gt; 147

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (147)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 191

Met Arg Val Leu Val Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala  
 1 5 10 15  
 Arg Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys  
 20 25 30  
 Phe Arg Gln Ser His Thr Trp Ser Leu Leu Gln Gly Ala Ala His Asp  
 35 40 45  
 Asp Pro Val Ala Arg Gly Leu Asp Pro Asp Gly Leu Leu Leu Asp  
 50 55 60  
 Val Val Val Asn Gly Val Val Pro Gly Arg Ala Trp Leu Thr Gln Ile  
 65 70 75 80  
 Phe Lys Cys Arg Thr Leu Lys Lys His Tyr Val Gln Thr Arg Ala Trp  
 85 90 95

132

Pro Ala Val Arg Gly Leu His Thr Ala Leu Leu Pro Gly Arg Pro Pro  
                   100                  105                  110

Leu Val Pro Thr Leu Gln Pro Gln His Pro Val Gln Arg Gly Pro Gly  
                   115                  120                  125

Pro Pro Ala Pro Ala Gly Ala Ala Pro Ala Gly Leu Ser Tyr Gln Leu  
                   130                  135                  140

Gly Leu Xaa  
 145

<210> 192  
 <211> 125  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (125)  
 <223> Xaa equals stop translation

<400> 192  
 Met Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Leu Val  
   1                  5                  10                  15

Leu Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu  
                   20                  25                  30

Ser Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro  
                   35                  40                  45

Val Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val  
                   50                  55                  60

Met Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu  
   65                  70                  75                  80

Pro Ser Cys Thr Asp Gln Cys Phe Arg Ala Lys Pro His Ser Trp Gly  
                   85                  90                  95

His Phe Ser Arg Phe Phe His Leu Leu Gln Ala Tyr Ser Asp Ser Lys  
                   100                  105                  110

Thr Arg Asn Glu Phe Arg Leu Pro Ala Arg Ala Asp Xaa  
                   115                  120                  125

<210> 193  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (52)

133

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 193

Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn Cys Ile Phe Phe  
 1 5 10 15

Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile Thr Ala Ile Ser  
 20 25 30

Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile Phe Phe Pro Cys  
 35 40 45

Leu Leu Ala Xaa  
 50

&lt;210&gt; 194

&lt;211&gt; 320

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (68)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (115)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (213)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (320)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 194

Met Ala Pro Leu Ala Leu His Leu Leu Val Leu Val Pro Ile Leu Leu  
 1 5 10 15

Ser Leu Val Ala Ser Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro  
 20 25 30

Phe Glu Lys Cys Met Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val  
 35 40 45

Thr Ile Leu Glu Ala Asp Asn Arg Ile Gly Gly Arg Ile Phe Thr Tyr  
 50 55 60

Arg Asp Gln Xaa Thr Gly Trp Ile Gly Glu Leu Gly Ala Met Arg Met  
 65 70 75 80

Pro Ser Ser His Arg Ile Leu His Lys Leu Cys Gln Gly Leu Gly Leu

134  
 85 90 95  
 Asn Leu Thr Lys Phe Thr Gln Tyr Asp Lys Asn Thr Trp Thr Glu Val  
 100 105 110  
 His Glu Xaa Lys Leu Arg Asn Tyr Val Val Glu Lys Val Pro Glu Lys  
 115 120 125  
 Leu Gly Tyr Ala Leu Arg Pro Gln Glu Lys Gly His Ser Pro Glu Asp  
 130 135 140  
 Ile Tyr Gln Met Ala Leu Asn Gln Ala Leu Lys Asp Leu Lys Ala Leu  
 145 150 155 160  
 Gly Cys Arg Lys Ala Met Lys Lys Phe Glu Arg His Thr Leu Leu Glu  
 165 170 175  
 Tyr Leu Leu Gly Glu Gly Asn Leu Ser Arg Pro Ala Val Gln Leu Leu  
 180 185 190  
 Gly Asp Val Met Ser Glu Asp Gly Phe Phe Tyr Leu Ser Phe Ala Glu  
 195 200 205  
 Ala Leu Arg Ala Xaa Ser Cys Leu Ser Asp Arg Leu Gln Tyr Ser Arg  
 210 215 220  
 Ile Val Gly Gly Trp Asp Leu Leu Pro Arg Ala Leu Leu Ser Ser Leu  
 225 230 235 240  
 Ser Gly Leu Val Leu Leu Asn Ala Pro Val Val Ala Met Thr Gln Gly  
 245 250 255  
 Pro His Asp Val His Val Gln Ile Glu Thr Ser Pro Pro Ala Arg Asn  
 260 265 270  
 Leu Lys Val Leu Lys Ala Asp Val Val Leu Leu Thr Ala Ser Gly Pro  
 275 280 285  
 Ala Val Lys Arg Ile Thr Phe Ser Pro Arg Cys Pro Ala Thr Cys Arg  
 290 295 300  
 Arg Arg Cys Gly Gly Cys Thr Thr Cys Arg Pro Pro Arg Cys Ser Xaa  
 305 310 315 320

&lt;210&gt; 195

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

135

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (53)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 195

Pro Phe Cys Ser Gly Phe Phe Pro Ser Leu Trp Ile Tyr Leu Pro Phe  
 1 5 10 15

Ile Phe Asn Val Ser Asp Leu Trp Met Gly Ser Leu Ser Gly Cys Ala  
 20 25 30

Leu Pro Phe Cys Leu Xaa Val Phe Phe Leu Thr Val Ser Pro Ser Ala  
 35 40 45

Val Gly Leu Leu Xaa Phe Ala Gly Gly Pro Leu Gln Thr Leu Phe Ala  
 50 55 60

Trp Val Ser Pro Val Glu Ala Ala Glu Gln Gln Arg Leu Leu Pro Val  
 65 70 75 80

Leu Ser Ser Gly Ser Phe Val Ser Glu Gly Thr Cys Gln Met Pro Ala  
 85 90 95

Arg Ala Leu Leu Tyr Glu Val Ser Val Gly Pro Tyr Trp Glu Ile Pro  
 100 105 110

Pro Ser Gln Asp Thr Arg Arg Ser Gly Thr Tyr Leu Arg Arg Gln Ser  
 115 120 125

Asp Pro  
 130

&lt;210&gt; 196

&lt;211&gt; 108

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 196

His Glu Gly Ser Cys Arg Ala Pro Gly Phe Ser Ala His Lys Gly Arg  
 1 5 10 15

Gly Cys Pro Ser Pro Arg Met Thr Leu Pro Ser Arg Ala Leu Ala Ser  
 20 25 30

Leu Gly Val Gly Val Trp Gly Met Leu Arg Leu Asn Gln Val Thr Val  
 35 40 45

Ser Cys Gly Gly Ser Arg Trp Ser Ser Arg Val Ala Leu Gly Ala Phe  
 50 55 60

Ser Trp Val Cys Gly Val Ala Leu Val Leu Gln Pro Ser Gly Gly Gly  
 65 70 75 80

Leu Gly Leu Thr Ser Pro Ser Glu Gly Cys Trp Glu Gly Glu Leu Ala  
 85 90 95

136

Leu Ala Val Leu Arg Ala Pro Gly Gly Ser Pro Ser  
 100 105

&lt;210&gt; 197

&lt;211&gt; 104

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 197

Ile Pro Leu Thr Leu Pro Gly Ile Phe Leu Leu Ile Arg Leu Phe Trp  
 1 5 10 15  
 Arg Leu Gly Gln Ser Ile Cys Gly Pro Gly Lys Leu Val Leu Trp Pro  
 20 25 30  
 Gln Phe Cys Cys Gly Cys Ala Val Ile Ser Gly His Cys Val Pro Arg  
 35 40 45  
 Gly Met Pro Ser Ser Trp Leu Pro Gly Cys Phe Val Leu Leu Cys Leu  
 50 55 60  
 Val Ala Val Gly Cys Gln Leu Arg Glu Trp Gly Val Gly Gly Val Ser  
 65 70 75 80  
 Ala Val Gly Leu Leu Ala Leu Pro His Leu Gln Val Leu Gly Met Arg  
 85 90 95  
 Gly Arg Gly Leu Ile Ser Gly Gly  
 100

&lt;210&gt; 198

&lt;211&gt; 237

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (142)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 198

Gly Pro Ala Gly Lys Glu Ala Trp Ile Trp Ser Trp Leu Leu Pro Ser  
 1 5 10 15  
 Pro Gly Pro Ala Pro Leu Pro Ser Ala Ser Trp Gly Leu Cys Gly Asp  
 20 25 30  
 Ala Pro Arg Ala Ala Ala Arg Gly Pro Val Glu Pro Gly Ala Ala Arg  
 35 40 45  
 Met Ala Leu Leu Ser Arg Pro Ala Leu Thr Leu Leu Leu Leu Met  
 50 55 60  
 Ala Ala Val Val Arg Cys Gln Glu Gln Ala Gln Thr Thr Asp Trp Arg  
 65 70 75 80

137

Ala Thr Leu Lys Thr Ile Arg Asn Gly Val His Lys Ile Asp Thr Tyr  
85 90 95

Leu Asn Ala Ala Leu Asp Leu Leu Gly Gly Glu Asp Gly Leu Cys Gln  
100 105 110

Tyr Lys Cys Ser Asp Gly Ser Lys Pro Phe Pro Arg Tyr Gly Tyr Lys  
115 120 125

Pro Ser Pro Pro Asn Gly Cys Gly Ser Pro Leu Phe Gly Xaa His Leu  
130 135 140

Asn Ile Gly Ile Pro Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg  
145 150 155 160

Cys Tyr Glu Thr Cys Gly Lys Ser Lys Asn Asp Cys Asp Glu Glu Phe  
165 170 175

Gln Tyr Cys Leu Ser Lys Ile Cys Arg Asp Val Gln Lys Thr Leu Gly  
180 185 190

Leu Thr Gln His Val Gln Ala Cys Glu Thr Thr Val Glu Leu Leu Phe  
195 200 205

Asp Ser Val Ile His Leu Gly Cys Lys Pro Tyr Leu Asp Ser Gln Arg  
210 215 220

Ala Ala Cys Arg Cys His Tyr Glu Glu Lys Thr Asp Leu  
225 230 235

&lt;210&gt; 199

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 199

Cys Cys Asn Gln His Asp Arg Cys  
1 5

&lt;210&gt; 200

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 200

Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg Cys Tyr Glu Thr  
1 5 10 15

&lt;210&gt; 201

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 201

Leu Thr Lys Cys Cys Asn Gln His Asp Arg Cys Tyr Glu Thr Cys Gly



138

1                      5                      10                      15

<210> 202  
 <211> 260  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 202

Gly Thr Ser Ser Ala Arg Pro Arg Gly Ala Leu Pro Gly Gly Ser Ala  
 1                      5                      10                      15

Pro Ser Ala Pro His Gly Gln Leu Pro Gly Arg Ala Gln Pro Ala Pro  
                     20                      25                      30

Val Ser Gly Pro Pro Pro Thr Ser Gly Leu Cys His Phe Asp Pro Ala  
                     35                      40                      45

Ala Pro Trp Pro Leu Trp Pro Gly Pro Trp Gln Leu Pro Pro His Pro  
                     50                      55                      60

Gln Asp Trp Pro Ala His Pro Asp Ile Pro Gln Asp Trp Val Ser Phe  
                     65                      70                      75                      80

Leu Arg Ser Phe Gly Gln Leu Thr Leu Cys Pro Arg Asn Gly Thr Val  
                     85                      90                      95

Thr Gly Lys Trp Arg Gly Ser His Val Val Gly Leu Leu Thr Thr Leu  
                     100                      105                      110

Asn Phe Gly Asp Gly Pro Asp Arg Asn Lys Thr Arg Thr Phe Gln Ala  
                     115                      120                      125

Thr Val Leu Gly Ser Gln Met Gly Leu Lys Gly Ser Ser Ala Gly Gln  
                     130                      135                      140

Leu Val Leu Ile Thr Ala Arg Val Thr Thr Glu Arg Thr Ala Gly Thr  
                     145                      150                      155                      160

Cys Leu Tyr Phe Ser Ala Val Pro Gly Ile Leu Pro Ser Ser Gln Pro  
                     165                      170                      175

Pro Ile Ser Cys Ser Glu Glu Gly Ala Gly Asn Ala Thr Leu Ser Pro  
                     180                      185                      190

Arg Met Gly Glu Glu Cys Val Ser Val Trp Ser His Glu Gly Leu Val  
                     195                      200                      205

Leu Thr Lys Leu Leu Thr Ser Glu Glu Leu Ala Leu Cys Gly Ser Arg  
                     210                      215                      220

Leu Leu Val Leu Gly Ser Phe Leu Leu Leu Phe Cys Gly Leu Leu Cys  
                     225                      230                      235                      240

Cys Val Thr Ala Met Cys Phe His Pro Arg Arg Glu Ser His Trp Ser

139

245

250

255

Arg Thr Arg Leu  
260

<210> 203  
<211> 80  
<212> PRT  
<213> Homo sapiens

<400> 203  
Ala Arg Ala Pro Pro Gly Pro Glu Gly Leu Ser Pro Glu Ala Gln Pro  
1 5 10 15  
Pro Leu Leu Pro Met Gly Asn Cys Gln Ala Gly His Asn Leu His Leu  
20 25 30  
Cys Leu Ala His His Pro Pro Leu Val Cys Ala Thr Leu Ile Leu Leu  
35 40 45  
Leu Leu Gly Leu Ser Gly Leu Gly Leu Gly Ser Phe Leu Leu Thr His  
50 55 60  
Arg Thr Gly Leu Arg Thr Leu Thr Ser Pro Arg Thr Gly Ser Leu Phe  
65 70 75 80

<210> 204  
<211> 224  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (6)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (9)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (22)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (143)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE

140

&lt;222&gt; (186)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 204

Arg Phe Leu Ser Val Xaa Pro Gln Xaa Glu Val Pro Phe Leu Leu His  
 1 5 10 15  
 Pro Cys Val Cys Phe Xaa Gly Gly His Pro Ser Leu Leu Pro Asp Pro  
 20 25 30  
 Cys Arg Ala Val Gly Gly Gly Trp Glu Ala Pro Arg Cys Cys Leu His  
 35 40 45  
 Glu Ala Leu Cys Gln Ser Leu Gly Cys Lys Ala Glu Glu Ile Val Ser  
 50 55 60  
 Val Ser Glu Ser Ser Ser Ala Gln Arg Cys Trp Tyr Leu Leu Arg Gly  
 65 70 75 80  
 Arg Lys Ala Gly Gly Arg Gly Pro Ala Ser Pro Val Leu Phe Ala Leu  
 85 90 95  
 Met Arg Leu Glu Ser Leu Cys His Leu Cys Leu Ala Cys Leu Phe Phe  
 100 105 110  
 Arg Leu Pro Ala Thr Arg Thr Val Tyr Cys Met Asn Glu Ala Glu Ile  
 115 120 125  
 Val Asp Val Ala Leu Gly Ile Leu Ile Glu Ser Arg Lys Gln Xaa Lys  
 130 135 140  
 Ala Cys Glu Gln Pro Ala Leu Ala Gly Ala Asp Asn Pro Glu His Ser  
 145 150 155 160  
 Pro Pro Cys Ser Val Ser Pro His Thr Ser Ser Gly Ser Ser Ser Glu  
 165 170 175  
 Glu Glu Asp Ser Gly Lys Gln Ala Leu Xaa Pro Gly Leu Ser Pro Ser  
 180 185 190  
 Gln Arg Pro Gly Gly Ser Ser Ser Ala Cys Ser Arg Ser Pro Glu Glu  
 195 200 205  
 Glu Glu Glu Glu Asp Val Leu Lys Tyr Val Arg Glu Ile Phe Phe Ser  
 210 215 220

&lt;210&gt; 205

&lt;211&gt; 199

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

141

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (103)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (191)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 205

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Pro | Gly | Trp | Pro | Arg | Ala | Cys | Ser | Pro | Cys | Gln | Ala | Asp | Ser | Pro |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ala | His | Pro | Pro | Lys | Leu | Arg | Gly | Ile | Leu | Arg | Trp | Ala | Pro | Val |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Leu | Xaa | Cys | Ala | Ala | Leu | Cys | Pro | Pro | Leu | Asp | Ser | Gly | Met | Ser |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ala | Cys | Pro | Glu | Ala | Pro | Glu | Pro | Ser | Phe | Leu | Arg | Glu | Val |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Ser | Ser | Pro | Ala | Ser | Thr | Gln | Trp | His | Arg | Pro | Cys | Asn | Phe | Arg |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Val | Glu | Ala | Asn | Pro | Arg | Lys | Glu | Pro | Lys | Asn | Leu | Val | Trp | Arg |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Val | Ser | Leu | Gly | Gln | Xaa | Ser | Arg | Thr | Pro | Arg | Gly | Ser | Gly | Leu |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Leu | Val | Arg | Val | Cys | Gly | Gly | Gly | Met | Gln | Arg | Asp | Lys | Thr | Val |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Glu | Glu | Arg | Val | Gly | Glu | Glu | Arg | Glu | Arg | Glu | Arg | Glu | Arg | Glu |
|     |     | 130 |     |     |     | 135 |     |     |     | 140 |     |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Leu | Gly | Gly | Ala | Gly | Lys | His | Gly | Glu | Met | Arg | Cys | Val | Tyr | Val |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Glu | Ser | Val | Gly | Ala | Pro | Gly | Arg | Ala | Gly | Gly | Gly | Gly | Asn | Gly |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Asn | Ser | Val | Gly | Cys | Val | Arg | Thr | Val | His | Ser | Gly | Ser | Xaa | Pro |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |

|     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|
| Pro | Pro | Ser | Ala | Gly | Val | Ser |
|     |     |     |     |     |     | 195 |

&lt;210&gt; 206

&lt;211&gt; 174

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

142

&lt;400&gt; 206

Thr Arg Pro Gly Lys Glu Leu Asn Leu Val Phe Gly Leu Gln Leu Ser  
1 5 10 15

Met Ala Arg Ile Gly Ser Thr Val Asn Met Asn Leu Met Gly Trp Leu  
20 25 30

Tyr Ser Lys Ile Glu Ala Leu Leu Gly Ser Ala Gly His Thr Thr Leu  
35 40 45

Gly Ile Thr Leu Met Ile Gly Gly Ile Thr Cys Ile Leu Ser Leu Ile  
50 55 60

Cys Ala Leu Ala Leu Ala Tyr Leu Asp Gln Arg Ala Glu Arg Ile Leu  
65 70 75 80

His Lys Glu Gln Gly Lys Thr Gly Glu Val Ile Lys Leu Thr Asp Val  
85 90 95

Lys Asp Phe Ser Leu Pro Leu Trp Leu Ile Phe Ile Ile Cys Val Cys  
100 105 110

Tyr Tyr Val Ala Val Phe Pro Phe Ile Gly Leu Gly Lys Val Phe Phe  
115 120 125

Thr Glu Lys Phe Gly Phe Ser Ser Gln Ala Ala Ser Ala Ile Asn Ser  
130 135 140

Val Val Tyr Val Ile Ser Ala Pro Met Ser Pro Val Phe Gly Leu Leu  
145 150 155 160

Val Asp Lys Thr Gly Lys Asn Ile Ile Trp Val Leu Cys Ala  
165 170

&lt;210&gt; 207

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 207

Cys Lys Asp Leu Cys Ser Arg Val Tyr Leu Leu Thr Leu Ser Pro Leu  
1 5 10 15

Leu Ser Tyr Asp Pro Ala Thr Ser His Ser Pro Arg Asn Thr Gln  
20 25 30

&lt;210&gt; 208

&lt;211&gt; 369

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (78)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

143

&lt;400&gt; 208

Ile Ile Cys Glu Cys Trp Glu Glu Glu Cys Gln Ser Cys Arg Leu Lys  
 1 5 10 15  
 Ile Thr Gln Pro Arg Glu Ile Cys Arg Met Asp Phe Leu Val Leu Phe  
 20 25 30  
 Leu Phe Tyr Leu Ala Ser Val Leu Met Gly Leu Val Leu Ile Cys Val  
 35 40 45  
 Cys Ser Lys Thr His Ser Leu Lys Gly Leu Ala Arg Gly Gly Ala Gln  
 50 55 60  
 Ile Phe Ser Cys Ile Ile Pro Glu Cys Leu Gln Arg Ala Xaa His Gly  
 65 70 75 80  
 Leu Leu His Tyr Leu Phe His Thr Arg Asn His Thr Phe Ile Val Leu  
 85 90 95  
 His Leu Val Leu Gln Gly Met Val Tyr Thr Glu Tyr Thr Trp Glu Val  
 100 105 110  
 Phe Gly Tyr Cys Gln Glu Leu Glu Leu Ser Leu His Tyr Leu Leu Leu  
 115 120 125  
 Pro Tyr Leu Leu Leu Gly Val Asn Leu Phe Phe Phe Thr Leu Thr Cys  
 130 135 140  
 Gly Thr Asn Pro Gly Ile Ile Thr Lys Ala Asn Glu Leu Leu Phe Leu  
 145 150 155 160  
 His Val Tyr Glu Phe Asp Glu Val Met Phe Pro Lys Asn Val Arg Cys  
 165 170 175  
 Ser Thr Cys Asp Leu Arg Lys Pro Ala Arg Ser Lys His Cys Ser Val  
 180 185 190  
 Cys Asn Trp Cys Val His Arg Phe Asp His His Cys Val Trp Val Asn  
 195 200 205  
 Asn Cys Ile Gly Ala Trp Asn Ile Arg Tyr Phe Leu Ile Tyr Val Leu  
 210 215 220  
 Thr Leu Thr Ala Ser Ala Ala Thr Val Ala Ile Val Ser Thr Thr Phe  
 225 230 235 240  
 Leu Val His Leu Val Val Met Ser Asp Leu Tyr Gln Glu Thr Tyr Ile  
 245 250 255  
 Asp Asp Leu Gly His Leu His Val Met Asp Thr Val Phe Leu Ile Gln  
 260 265 270  
 Tyr Leu Phe Leu Thr Phe Pro Arg Ile Val Phe Met Leu Gly Phe Val  
 275 280 285  
 Val Val Leu Ser Phe Leu Leu Gly Gly Tyr Leu Leu Phe Val Leu Tyr  
 290 295 300

144

Leu Ala Ala Thr Asn Gln Thr Thr Asn Glu Trp Tyr Arg Gly Asp Trp  
 305 310 315 320

Ala Trp Cys Gln Arg Cys Pro Leu Val Ala Trp Pro Pro Ser Ala Glu  
 325 330 335

Pro Gln Val His Arg Asn Ile His Ser His Gly Leu Arg Ser Asn Leu  
 340 345 350

Gln Glu Ile Phe Leu Pro Ala Phe Pro Cys His Glu Arg Lys Lys Gln  
 355 360 365

Glu

<210> 209  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens

<400> 209  
 Leu Leu Ser Phe Lys Ile Arg Gly Leu Arg Thr Glu Asp Ala Gly Trp  
 1 5 10 15

Ala Gln Ser Ser Ser Gly Gly Leu Cys Val Arg Gly Asp Ala Phe Trp  
 20 25 30

Met Pro Ser Ser Ser Ser Gly Leu Gly Ser Pro Ser Arg Pro Pro Ser  
 35 40 45

Ser Phe Leu Cys Leu Leu Leu Leu Leu Pro Pro Ala Ala Leu Ala  
 50 55 60

Leu Leu Leu Phe Phe Leu Asp Phe Phe Pro Pro Arg Ala Ala Val Ser  
 65 70 75 80

Pro Phe Leu Pro Asp His Cys Ser Ala Arg Gln Pro Arg Val Trp Arg  
 85 90 95

Arg Glu Thr Leu Asn Arg Ser Ala Ser Gly Leu Gly Cys Trp Ala Arg  
 100 105 110

Ser Thr Glu Gln Gly Ala Val Gly Val Ala Thr Gly Thr Val Leu Asp  
 115 120 125

Ile Ser Leu Pro Ala Ser Cys Leu Ser Leu Trp Pro Pro Gly Pro Ser  
 130 135 140

Gly Gly Ile  
 145

<210> 210  
 <211> 143  
 <212> PRT  
 <213> Homo sapiens

145

&lt;400&gt; 210

Gln Leu Gly Leu Cys Leu Thr Ser Ala Ser Leu Pro Pro Ala Ser Arg  
 1 5 10 15  
 Cys Gly His Gln Ala Pro Leu Gly Ala Ser Asp Leu Ser Ala His His  
 20 25 30  
 Ser Ala Pro Gly Phe Ser Asp Ser Tyr Phe Thr Met Ser Cys Gln Ser  
 35 40 45  
 Ser Leu Ser Arg Ala Glu Ile Leu Gln Cys Pro Leu Val Pro Ser Val  
 50 55 60  
 Ser Pro Pro Thr His Leu Pro Gln Gly Arg Ala Asn Lys Ser Ser Arg  
 65 70 75 80  
 Ala Ser Leu Pro Leu Leu Pro Gln Thr His Trp Cys Leu Phe Pro Ser  
 85 90 95  
 Ala Arg Gly Trp Arg Arg Gly Ile Gln Ser Gly Leu Pro Pro Gly Gly  
 100 105 110  
 Ser Cys Thr Ser Pro Arg Ser Pro Pro Gln Thr Leu His Gln His Ile  
 115 120 125  
 Thr Leu Val Asn His Asn Thr Ser Tyr Trp Gln Ser Pro Ser Thr  
 130 135 140

&lt;210&gt; 211

&lt;211&gt; 160

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 211

His Gln Pro Pro Cys Leu Leu Pro Leu Ala Val Ala Thr Arg Pro Leu  
 1 5 10 15  
 Trp Gly His Leu Thr Cys Leu Pro Ile Ile Leu His Leu Val Ser Val  
 20 25 30  
 Thr Leu Thr Ser Pro Cys Leu Ala Asn Gln Ala Phe Gln Gly Gln Arg  
 35 40 45  
 Ser Tyr Asn Ala Leu Trp Cys Pro Leu Phe Leu Leu Leu Pro Thr Ser  
 50 55 60  
 Pro Lys Gly Glu Gln Thr Asn His Pro Glu Pro Ala Cys Pro Cys Phe  
 65 70 75 80  
 Pro Lys Leu Thr Gly Val Phe Ser Leu Gln His Val Val Gly Ala Glu  
 85 90 95  
 Glu Phe Ser Gln Val Phe Leu Leu Val Asp Pro Val Pro Val Leu Asp  
 100 105 110  
 His Leu Leu Lys Leu Phe Thr Ser Thr Ser His Leu Leu Ile Ile Ile  
 115 120 125



146

Pro His Ile Gly Lys Ala Pro Ala Pro Asp Ser Leu Leu Glu Glu Leu  
130 135 140  
Ser Leu Ser Leu Ala Thr His Cys Lys Val Ala Val Ala Arg Phe Thr  
145 150 155 160

<210> 212  
<211> 157  
<212> PRT  
<213> Homo sapiens

<400> 212  
Met Ala Ala Glu Gly Ser Arg Phe Ser Ser Gln Ser Pro Gly Leu Val  
1 5 10 15  
Asp Arg Gln Gly Pro Lys Cys Asp Pro Ser Arg Leu Val Ser Pro Trp  
20 25 30  
Gly Arg His Gly Leu Arg Ile Leu Gln Ile Gly His His His Gly Arg  
35 40 45  
Asp Gly Gln His Glu Ala Thr His His Leu Leu Arg Val Leu Arg Ala  
50 55 60  
Pro Arg Val Gly Lys Ala Asp Glu Gly Ala Val Asp Ser Asp Pro Ser  
65 70 75 80  
Thr Pro Leu Gln Leu Lys His Glu Ala Ala His Ala Glu Asp His Ala  
85 90 95  
Gln Gln Val His Val Val Arg Arg Arg Val Val Gln Gly Arg Val Thr  
100 105 110  
Phe Ala Arg Arg Gly Leu Val Pro Gln His Phe Val Arg Pro Pro Trp  
115 120 125  
Val Arg His Ile Val Ser Gly His Ser Glu Ser Lys Ala Arg Ser Arg  
130 135 140  
Leu Phe Arg Cys Arg Asn Arg Ser Phe Arg Arg Ala Ser  
145 150 155

<210> 213  
<211> 38  
<212> PRT  
<213> Homo sapiens

<400> 213  
Arg Leu Val Ser Pro Trp Gly Arg His Gly Leu Arg Ile Leu Gln Ile  
1 5 10 15  
Gly His His His Gly Arg Asp Gly Gln His Glu Ala Thr His His Leu

147

20

25

30

Leu Arg Val Leu Arg Ala  
35

<210> 214  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 214  
Pro Thr Asp Val Leu Lys Ile Arg Met Gln Ala Gln  
1 5 10

<210> 215  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 215  
Thr Tyr Glu Gln Leu Lys Arg  
1 5

<210> 216  
<211> 137  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (22)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (33)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (71)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 216  
Arg Pro Arg Pro Ser Ala Ser Ser Leu Ala Arg Ser Ala Ser Leu Leu  
1 5 10 15

Pro Ala Ala His Gly Xaa Gly Val Gly Gly Ala Gly Gly Gly Ser Ser  
20 25 30

Xaa Leu Arg Ser Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly  
35 40 45

Glu Pro Glu Gln Ala Ala Gly Asp Ala Pro Pro Pro Tyr Ser Ser Ile  
50 55 60

148

Ser Ala Glu Ser Ala His Xaa Phe Asp Tyr Lys Asp Glu Ser Gly Phe  
65 70 75 80  
Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr Thr Leu Pro Ser Tyr Asp  
85 90 95  
Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr Ile Pro Leu Val Pro Gly  
100 105 110  
Arg Asp Glu Asp Phe Val Gly Arg Asp Asp Phe Asp Ala Asp Gln  
115 120 125  
Leu Arg Ile Gly Asn Asp Gly Ile Phe  
130 135

<210> 217  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 217  
Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly Glu Pro Glu Gln  
1 5 10 15

Ala Ala Gly Asp  
20

<210> 218  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 218  
Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp Phe Asp Ala  
1 5 10 15

Asp Gln Leu Arg Ile Gly  
20

<210> 219  
<211> 103  
<212> PRT  
<213> Homo sapiens

<400> 219  
Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe  
1 5 10 15

Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
20 25 30

Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
35 40 45

149

Ser Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp  
 50 55 60

Val Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn  
 65 70 75 80

Tyr Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg  
 85 90 95

Thr Arg Val Leu Phe Ile Tyr  
 100

&lt;210&gt; 220

&lt;211&gt; 198

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 220

Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
 1 5 10 15

His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln His Xaa Phe Asp Tyr  
 20 25 30

Lys Asp Glu Ser Gly Phe Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr  
 35 40 45

Thr Leu Pro Ser Tyr Asp Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr  
 50 55 60

Ile Pro Leu Val Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp  
 65 70 75 80

Phe Asp Asp Ala Asp Gln Leu Arg Ile Gly Asn Asp Gly Ile Phe Met  
 85 90 95

Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe Leu  
 100 105 110

Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile Ser  
 115 120 125

Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe Ser  
 130 135 140

Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp Val  
 145 150 155 160

Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn Tyr  
 165 170 175

Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg Thr

WO 00/04140

PCT/US99/15849

150  
180 185 190  
Arg Val Leu Phe Ile Tyr  
195  
  
<210> 221  
<211> 70  
<212> PRT  
<213> Homo sapiens  
  
<400> 221  
Met Leu Leu His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln Phe Ser  
1 5 10 15  
Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp Val  
20 25 30  
Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn Tyr  
35 40 45  
Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg Thr  
50 55 60  
Arg Val Leu Phe Ile Tyr  
65 70  
  
<210> 222  
<211> 82  
<212> PRT  
<213> Homo sapiens  
  
<400> 222  
Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe  
1 5 10 15  
Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
20 25 30  
Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
35 40 45  
Ser Thr Tyr Phe Pro Ala Phe Met Asn Ser Leu Ser Arg Ser Lys Arg  
50 55 60  
Thr Pro Ala Gly Ser Glu Ser Arg Cys Arg Thr Gln Arg Asn Asn His  
65 70 75 80  
Leu Leu

<210> 223  
<211> 45  
<212> PRT  
<213> Homo sapiens

151

<220>  
<221> SITE  
<222> (28)  
<223> Xaa equals any of the naturally occurring L-amino acids  
  
<400> 223  
Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
1 5 10 15  
His Leu Thr Ala Ala Phe Leu Gln Arg Ala His Xaa Ile Leu Thr Thr  
20 25 30  
Arg Met Ser Leu Gly Phe Gln Ser Pro His Leu Thr Met  
35 40 45  
  
<210> 224  
<211> 33  
<212> PRT  
<213> Homo sapiens  
  
<400> 224  
Met Thr Val Met Asp Pro Lys Gln Met Asn Val Ala Ala Ala Val Trp  
1 5 10 15  
Ala Val Val Ser Tyr Val Val Ala Asp Met Glu Glu Met Leu Pro Arg  
20 25 30  
Ser  
  
<210> 225  
<211> 189  
<212> PRT  
<213> Homo sapiens  
  
<400> 225  
Pro Arg Val Arg Ser Arg Glu Pro Val Ala Gly Ala Pro Gly Cys Gly  
1 5 10 15  
Thr Ala Gly Pro Pro Ala Met Ala Thr Leu Trp Gly Gly Leu Leu Arg  
20 25 30  
Leu Gly Ser Leu Leu Ser Leu Ser Cys Leu Ala Leu Ser Val Leu Leu  
35 40 45  
Leu Ala His Cys Gln Thr Pro Pro Ser Asp Cys Leu His Val Val Glu  
50 55 60  
Pro Met Pro Val Arg Gly Pro Asp Val Glu Ala Tyr Cys Leu Arg Cys  
65 70 75 80  
Glu Cys Lys Tyr Glu Glu Arg Ser Ser Val Thr Ile Lys Val Thr Ile  
85 90 95  
Ile Ile Tyr Leu Ser Ile Leu Gly Leu Leu Leu Tyr Met Val Tyr  
100 105 110

152

Leu Thr Leu Val Glu Pro Ile Leu Lys Arg Arg Leu Phe Gly His Ala  
 115 120 125

Gln Leu Ile Gln Ser Asp Asp Ile Gly Asp His Gln Pro Phe Ala  
 130 135 140

Asn Ala His Asp Val Leu Ala Arg Ser Arg Ser Arg Ala Asn Val Leu  
 145 150 155 160

Asn Lys Val Glu Tyr Ala Gln Gln Arg Trp Lys Leu Gln Val Gln Glu  
 165 170 175

Gln Arg Lys Ser Val Phe Asp Arg His Val Val Leu Ser  
 180 185

<210> 226  
 <211> 231  
 <212> PRT  
 <213> Homo sapiens

<400> 226  
 Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser  
 1 5 10 15

Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Cys Gln Thr  
 20 25 30

Pro Pro Arg Ile Ser Arg Met Ser Asp Val Asn Val Ser Ala Leu Pro  
 35 40 45

Ile Lys Lys Asn Ser Gly His Ile Tyr Asn Lys Asn Ile Ser Gln Lys  
 50 55 60

Asp Cys Asp Cys Leu His Val Val Glu Pro Met Pro Val Arg Gly Pro  
 65 70 75 80

Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu Cys Lys Tyr Glu Glu Arg  
 85 90 95

Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile Leu  
 100 105 110

Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro Ile  
 115 120 125

Leu Lys Arg Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp Asp  
 130 135 140

Asp Ile Gly Asp His Gln Pro Phe Ala Asn Ala His Asp Val Leu Ala  
 145 150 155 160

Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Gly Thr  
 165 170 175

Ala Ala Leu Glu Ala Ser Ser Pro Arg Ala Ala Lys Ser Leu Ser Leu  
 180 185 190

153

Thr Gly Met Leu Ser Ser Ala Asn Trp Gly Ile Glu Phe Lys Val Thr  
 195 200 205  
 Arg Lys Lys Gln Ala Asp Asn Trp Lys Gly Thr Asp Trp Val Leu Leu  
 210 215 220  
 Gly Phe Ile Leu Ile Pro Cys  
 225 230

<210> 227  
 <211> 456  
 <212> PRT  
 <213> Homo sapiens

<400> 227  
 Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro  
 1 5 10 15  
 Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg  
 20 25 30  
 Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly  
 35 40 45  
 Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu  
 50 55 60  
 Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln  
 65 70 75 80  
 Asn Ala Pro Tyr Phe Lys Pro Lys Val Lys Val Ser Phe Lys Asn His  
 85 90 95  
 Ser Ala Leu Ile Thr Ser Val Val Pro Gly Asp Tyr Asp Gly Asp Ser  
 100 105 110  
 Gln Met Asp Val Leu Leu Thr Tyr Leu Pro Lys Asn Tyr Ala Lys Ser  
 115 120 125  
 Glu Leu Gly Ala Val Ile Phe Trp Gly Gln Asn Gln Thr Leu Asp Pro  
 130 135 140  
 Asn Asn Met Thr Ile Leu Asn Arg Thr Phe Gln Asp Glu Pro Leu Ile  
 145 150 155 160  
 Met Asp Phe Asn Gly Asp Leu Ile Pro Asp Ile Phe Gly Ile Thr Asn  
 165 170 175  
 Glu Ser Asn Gln Pro Gln Ile Leu Leu Gly Gly Asn Leu Ser Trp His  
 180 185 190  
 Pro Ala Leu Thr Thr Thr Ser Lys Met Arg Ile Pro His Ser His Ala  
 195 200 205  
 Phe Ile Asp Leu Thr Glu Asp Phe Thr Ala Asp Leu Phe Leu Thr Thr  
 210 215 220



154

Leu Asn Ala Thr Thr Ser Thr Phe Gln Phe Glu Ile Trp Glu Asn Leu  
 225 230 235 240  
 Asp Gly Asn Phe Ser Val Ser Thr Ile Leu Glu Lys Pro Gln Asn Met  
 245 250 255  
 Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His  
 260 265 270  
 Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser  
 275 280 285  
 Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu  
 290 295 300  
 Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val  
 305 310 315 320  
 Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile  
 325 330 335  
 Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys  
 340 345 350  
 Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro  
 355 360 365  
 Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr  
 370 375 380  
 Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr  
 385 390 395 400  
 Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser  
 405 410 415  
 Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn  
 420 425 430  
 Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu  
 435 440 445  
 Cys Ser Asn Asp Cys Pro Arg Arg  
 450 455

&lt;210&gt; 228

&lt;211&gt; 282

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (144)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

155

&lt;221&gt; SITE

&lt;222&gt; (168)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 228

```

Met Thr Lys Arg Glu Asp Gly Gly Tyr Thr Phe Thr Ala Thr Pro Glu
  1              5              10              15

Asp Phe Pro Lys Lys His Lys Ala Pro Val Ile Asp Ile Gly Ile Ala
      20              25              30

Asn Thr Gly Lys Phe Ile Met Thr Ala Ser Ser Asp Thr Thr Val Leu
      35              40              45

Ile Trp Ser Leu Lys Gly Gln Val Leu Ser Thr Ile Asn Thr Asn Gln
      50              55              60

Met Asn Asn Thr His Ala Ala Val Ser Pro Cys Gly Arg Phe Val Ala
      65              70              75              80

Ser Cys Gly Phe Thr Pro Asp Val Lys Val Trp Glu Val Cys Phe Gly
      85              90              95

Lys Lys Gly Glu Phe Gln Glu Val Val Arg Ala Phe Glu Leu Lys Gly
      100              105              110

His Ser Ala Ala Val His Ser Phe Ala Phe Ser Asn Asp Ser Arg Arg
      115              120              125

Met Ala Ser Val Ser Lys Asp Gly Thr Trp Lys Leu Trp Asp Thr Xaa
      130              135              140

Val Glu Tyr Lys Lys Lys Gln Asp Pro Tyr Leu Leu Lys Thr Gly Arg
      145              150              155              160

Phe Glu Glu Ala Ala Gly Ala Xaa Pro Cys Arg Leu Ala Leu Ser Pro
      165              170              175

Asn Ala Gln Val Leu Ala Leu Ala Ser Gly Ser Ser Ile His Leu Tyr
      180              185              190

Asn Thr Arg Arg Gly Glu Lys Glu Glu Cys Phe Glu Arg Val His Gly
      195              200              205

Glu Cys Ile Ala Asn Leu Ser Phe Asp Ile Thr Gly Arg Phe Leu Ala
      210              215              220

Ser Cys Gly Asp Arg Ala Val Arg Leu Phe His Asn Thr Pro Gly His
      225              230              235              240

Arg Ala Met Val Glu Glu Met Gln Gly His Leu Lys Arg Ala Ser Asn
      245              250              255

Glu Ser Thr Arg Gln Arg Leu Gln Gln Gln Leu Thr Gln Ala Gln Glu
      260              265              270

Thr Leu Lys Ser Leu Gly Ala Leu Lys Lys
      275              280

```

<210> 229  
 <211> 456  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (17)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (37)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (318)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (342)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 229  
 Val Ile Arg His Glu Gly Ser Thr Asn Met Glu Leu Ser Gln Met Ser  
           1                  5                  10                  15  
 Xaa Leu Met Gly Leu Ser Val Leu Leu Gly Leu Leu Ala Leu Met Ala  
                   20                  25                  30  
 Thr Ala Ala Val Xaa Arg Gly Trp Leu Arg Ala Gly Glu Glu Arg Ser  
           35                  40                  45  
 Gly Arg Pro Ala Cys Gln Lys Ala Asn Gly Phe Pro Pro Asp Lys Ser  
           50                  55                  60  
 Ser Gly Ser Lys Lys Gln Lys Gln Tyr Gln Arg Ile Arg Lys Glu Lys  
           65                  70                  75                  80  
 Pro Gln Gln His Asn Phe Thr His Arg Leu Leu Ala Ala Ala Leu Lys  
                   85                  90                  95  
 Ser His Ser Gly Asn Ile Ser Cys Met Asp Phe Ser Ser Asn Gly Lys  
                   100                  105                  110  
 Tyr Leu Ala Thr Cys Ala Asp Asp Arg Thr Ile Arg Ile Trp Ser Thr  
           115                  120                  125  
 Lys Asp Phe Leu Gln Arg Glu His Arg Ser Met Arg Ala Asn Val Glu  
           130                  135                  140  
 Leu Asp His Ala Thr Leu Val Arg Phe Ser Pro Asp Cys Arg Ala Phe  
           145                  150                  155                  160

157

Ile Val Trp Leu Ala Asn Gly Asp Thr Leu Arg Val Phe Lys Met Thr  
 165 170 175  
 Lys Arg Glu Asp Gly Gly Tyr Thr Phe Thr Ala Thr Pro Glu Asp Phe  
 180 185 190  
 Pro Lys Lys His Lys Ala Pro Val Ile Asp Ile Gly Ile Ala Asn Thr  
 195 200 205  
 Gly Lys Phe Ile Met Thr Ala Ser Ser Asp Thr Thr Val Leu Ile Trp  
 210 215 220  
 Ser Leu Lys Gly Gln Val Leu Ser Thr Ile Asn Thr Asn Gln Met Asn  
 225 230 235 240  
 Asn Thr His Ala Ala Val Ser Pro Cys Gly Arg Phe Val Ala Ser Cys  
 245 250 255  
 Gly Phe Thr Pro Asp Val Lys Val Trp Glu Val Cys Phe Gly Lys Lys  
 260 265 270  
 Gly Glu Phe Gln Glu Val Val Arg Ala Phe Glu Leu Lys Gly His Ser  
 275 280 285  
 Ala Ala Val His Ser Phe Ala Phe Ser Asn Asp Ser Arg Arg Met Ala  
 290 295 300  
 Ser Val Ser Lys Asp Gly Thr Trp Lys Leu Trp Asp Thr Xaa Val Glu  
 305 310 315 320  
 Tyr Lys Lys Lys Gln Asp Pro Tyr Leu Leu Lys Thr Gly Arg Phe Glu  
 325 330 335  
 Glu Ala Ala Gly Ala Xaa Pro Cys Arg Leu Ala Leu Ser Pro Asn Ala  
 340 345 350  
 Gln Val Leu Ala Leu Ala Ser Gly Ser Ser Ile His Leu Tyr Asn Thr  
 355 360 365  
 Arg Arg Gly Glu Lys Glu Glu Cys Phe Glu Arg Val His Gly Glu Cys  
 370 375 380  
 Ile Ala Asn Leu Ser Phe Asp Ile Thr Gly Arg Phe Leu Ala Ser Cys  
 385 390 395 400  
 Gly Asp Arg Ala Val Arg Leu Phe His Asn Thr Pro Gly His Arg Ala  
 405 410 415  
 Met Val Glu Glu Met Gln Gly His Leu Lys Arg Ala Ser Asn Glu Ser  
 420 425 430  
 Thr Arg Gln Arg Leu Gln Gln Gln Leu Thr Gln Ala Gln Glu Thr Leu  
 435 440 445  
 Lys Ser Leu Gly Ala Leu Lys Lys  
 450 455

158

<210> 230  
 <211> 363  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 230

```

Met Ser Val Met Val Val Arg Lys Lys Val Thr Arg Lys Trp Glu Lys
  1              5              10              15

Leu Pro Gly Arg Asn Thr Phe Cys Cys Asp Gly Arg Val Met Met Ala
      20              25              30

Arg Gln Lys Gly Ile Phe Tyr Leu Thr Leu Phe Leu Ile Leu Gly Thr
      35              40              45

Cys Thr Leu Phe Phe Ala Phe Glu Cys Arg Tyr Leu Ala Val Gln Leu
      50              55              60

Ser Pro Ala Ile Pro Val Phe Ala Ala Met Leu Phe Leu Phe Ser Met
      65              70              75              80

Ala Thr Leu Leu Arg Thr Ser Phe Ser Asp Pro Gly Val Ile Pro Arg
      85              90              95

Ala Leu Pro Asp Glu Ala Ala Phe Ile Glu Met Glu Ile Glu Ala Thr
      100              105              110

Asn Gly Ala Val Pro Gln Gly Gln Arg Pro Pro Pro Arg Ile Lys Asn
      115              120              125

Phe Gln Ile Asn Asn Gln Ile Val Lys Leu Lys Tyr Cys Tyr Thr Cys
      130              135              140

Lys Ile Phe Arg Pro Pro Arg Ala Ser His Cys Ser Ile Cys Asp Asn
      145              150              155              160

Cys Val Glu Arg Phe Asp His His Cys Pro Trp Val Gly Asn Cys Val
      165              170              175

Gly Lys Arg Asn Tyr Arg Tyr Phe Tyr Leu Phe Ile Leu Ser Leu Ser
      180              185              190

Leu Leu Thr Ile Tyr Val Phe Ala Phe Asn Ile Val Tyr Val Ala Leu
      195              200              205

Lys Ser Leu Lys Ile Gly Phe Leu Glu Thr Leu Lys Glu Thr Pro Gly
      210              215              220

Thr Val Leu Glu Val Leu Ile Cys Phe Phe Thr Leu Trp Ser Val Val
      225              230              235              240

Gly Leu Thr Gly Phe His Thr Phe Leu Val Ala Leu Asn Gln Thr Thr
      245              250              255

Asn Glu Asp Ile Lys Gly Ser Trp Thr Gly Lys Asn Arg Val Gln Asn
      260              265              270

Pro Tyr Ser His Gly Asn Ile Val Lys Asn Cys Cys Glu Val Leu Cys

```

159

275                      280                      285  
 Gly Pro Leu Pro Pro Ser Val Leu Asp Arg Arg Gly Ile Leu Pro Leu  
     290                      295                      300  
 Glu Glu Ser Gly Ser Arg Pro Pro Ser Thr Gln Glu Thr Ser Ser Ser  
     305                      310                      315                      320  
 Leu Leu Pro Gln Ser Pro Ala Pro Thr Glu Leu Asn Ser Asn Glu Met  
                     325                      330                      335  
 Pro Glu Asp Ser Ser Thr Pro Glu Glu Met Pro Pro Pro Glu Pro Pro  
                     340                      345                      350  
 Glu Pro Pro Gln Glu Ala Ala Glu Ala Glu Lys  
                     355                      360

<210> 231  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<400> 231  
 Met Leu Phe Leu Phe Ser Met Ala Thr Leu Leu Arg Thr Ser Phe Ser  
     1                      5                      10                      15  
 Asp Pro Gly Val Ile Pro Arg Ala Leu Pro Asp Glu Ala Ala Phe Ile  
                     20                      25                      30  
 Glu Met Glu Ile Glu Ala Thr Asn Gly Ala Val Pro Gln Gly Gln Arg  
                     35                      40                      45  
 Pro Pro Pro Arg Ile Lys Asn Phe Gln Ile Asn Asn Gln Ile Val Lys  
                     50                      55                      60  
 Leu Lys Tyr Cys Tyr Thr Cys Lys Ile Phe Arg Pro Pro Arg Ala Ser  
     65                      70                      75                      80  
 His Cys Ser Ile Cys Asp Asn Cys Val Glu Arg Phe Asp His His Cys  
                     85                      90                      95  
 Pro Trp Val Gly Asn Cys Val Gly Lys Arg Asn Tyr Arg Tyr Phe Tyr  
                     100                      105                      110  
 Leu Phe Ile Leu Ser Leu Ser Leu Leu Thr Ile Tyr Val Phe Ala Phe  
                     115                      120                      125  
 Asn Ile Val Tyr Val Ala Leu Lys Ser Leu Lys Ile Gly Phe Leu Glu  
                     130                      135                      140  
 Thr Leu Lys Gly Asn Ser Trp Asn Cys Ser Arg Ser Pro His Leu Leu  
     145                      150                      155                      160  
 Leu Tyr Thr Leu Val Arg Arg Gly Thr Asp Trp Ile Ser Tyr Phe Pro  
                     165                      170                      175  
 Arg Gly Ser Gln Pro Asp Asn Gln

160

180

<210> 232  
<211> 52  
<212> PRT  
<213> Homo sapiens

<400> 232  
Leu His Glu Cys Leu Pro Gly Ser Ile Ser Tyr Leu His Pro Arg Thr  
1 5 10 15  
Pro Trp Leu Cys Leu Pro Pro Gln His Leu Ser Phe Ser Thr Phe Ser  
20 25 30  
Pro Pro Trp Gln Pro Ala Met Ser Pro Val Pro Gly Thr Gly Gly Pro  
35 40 45  
Pro Cys Gly Leu  
50

<210> 233  
<211> 177  
<212> PRT  
<213> Homo sapiens

<400> 233  
Met Leu Pro Leu Leu Ile Ile Cys Leu Leu Pro Ala Ile Glu Gly Lys  
1 5 10 15  
Asn Cys Leu Arg Cys Trp Pro Glu Leu Ser Ala Leu Ile Asp Tyr Asp  
20 25 30  
Leu Gln Ile Leu Trp Val Thr Pro Gly Pro Pro Thr Glu Leu Ser Gln  
35 40 45  
Ser Ile His Ser Leu Phe Leu Glu Asp Asn Asn Phe Leu Lys Pro Trp  
50 55 60  
Tyr Leu Asp Arg Asp His Leu Glu Glu Glu Thr Ala Lys Phe Phe Thr  
65 70 75 80  
Gln Val His Gln Ala Ile Lys Thr Leu Arg Asp Asp Lys Thr Val Leu  
85 90 95  
Leu Glu Glu Ile Tyr Thr His Lys Asn Leu Phe Thr Glu Arg Leu Asn  
100 105 110  
Lys Ile Ser Asp Gly Leu Lys Glu Lys Gly Ala Pro Pro Leu His Glu  
115 120 125  
Cys Leu Pro Gly Ser Ile Ser Tyr Leu His Pro Arg Thr Pro Trp Leu  
130 135 140  
Cys Leu Pro Pro Gln His Leu Ser Phe Ser Thr Phe Ser Pro Pro Trp  
145 150 155 160

161

Gln Pro Ala Met Ser Pro Val Pro Gly Thr Gly Gly Pro Pro Cys Gly  
 165 170 175

Leu

&lt;210&gt; 234

&lt;211&gt; 95

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 234

Pro Pro Val Pro Pro Trp Ile Ser Leu Pro Leu Thr Gly Ser Pro Pro  
 1 5 10 15

Arg Pro Gly Phe Val Pro Val Ser Pro Phe Cys Phe Ser Pro Met Thr  
 20 25 30

Asn Gly His Gln Val Leu Leu Leu Leu Leu Thr Ser Ala Val Ala  
 35 40 45

Ala Gly Pro Trp Pro Gln Val His Ala Gly Gln Trp Gly Trp Met Cys  
 50 55 60

Leu Pro Pro Gly Leu Pro Ser Val Gln Ala Arg Ser Gly Leu Gly Gly  
 65 70 75 80

Leu Pro Gly Gly Pro Gln Trp Val Pro Gly Gly Ala Arg Gly Tyr  
 85 90 95

&lt;210&gt; 235

&lt;211&gt; 404

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 235

Ile Gln Gln Trp Gly Asp Ser Val Leu Gly Arg Arg Cys Arg Asp Leu  
 1 5 10 15

Leu Leu Gln Leu Tyr Leu Gln Arg Pro Glu Leu Arg Val Pro Val Pro  
 20 25 30

Glu Val Leu Leu His Ser Glu Gly Ala Ala Ser Ser Ser Val Cys Lys  
 35 40 45

Leu Asp Gly Leu Ile His Arg Phe Ile Thr Leu Leu Ala Asp Thr Ser  
 50 55 60

Asp Ser Arg Ala Leu Glu Asn Arg Gly Ala Asp Ala Ser Met Ala Cys  
 65 70 75 80

Arg Lys Leu Ala Val Ala His Pro Leu Leu Leu Leu Arg His Leu Pro  
 85 90 95

Met Ile Ala Ala Leu Leu His Gly Arg Thr His Leu Asn Phe Gln Glu  
 100 105 110



162

Phe Arg Gln Gln Asn His Leu Ser Cys Phe Leu His Val Leu Gly Leu  
 115 120 125  
 Leu Glu Leu Leu Gln Pro His Val Phe Arg Ser Glu His Gln Gly Ala  
 130 135 140  
 Leu Trp Asp Cys Leu Leu Ser Phe Ile Arg Leu Leu Leu Asn Tyr Arg  
 145 150 155 160  
 Lys Ser Ser Arg His Leu Ala Ala Phe Ile Asn Lys Phe Val Gln Phe  
 165 170 175  
 Ile His Lys Tyr Ile Thr Tyr Asn Ala Pro Ala Ala Ile Ser Phe Leu  
 180 185 190  
 Gln Lys His Ala Asp Pro Leu His Asp Leu Ser Phe Asp Asn Ser Asp  
 195 200 205  
 Leu Val Met Leu Lys Ser Leu Leu Ala Gly Leu Ser Leu Pro Ser Arg  
 210 215 220  
 Asp Asp Arg Thr Asp Arg Gly Leu Asp Glu Glu Gly Glu Glu Glu Ser  
 225 230 235 240  
 Ser Ala Gly Ser Leu Pro Leu Val Ser Val Ser Leu Phe Thr Pro Leu  
 245 250 255  
 Thr Ala Ala Glu Met Ala Pro Tyr Met Lys Arg Leu Ser Arg Gly Gln  
 260 265 270  
 Thr Val Glu Asp Leu Leu Glu Val Leu Ser Asp Ile Asp Glu Met Ser  
 275 280 285  
 Arg Arg Arg Pro Glu Ile Leu Ser Phe Phe Ser Thr Asn Leu Gln Arg  
 290 295 300  
 Leu Met Ser Ser Ala Glu Glu Cys Cys Arg Asn Leu Ala Phe Ser Leu  
 305 310 315 320  
 Ala Leu Arg Ser Met Gln Asn Ser Pro Ser Ile Ala Ala Ala Phe Leu  
 325 330 335  
 Pro Thr Phe Met Tyr Cys Leu Gly Ser Gln Asp Phe Glu Val Val Gln  
 340 345 350  
 Thr Ala Leu Arg Asn Leu Pro Glu Tyr Ala Leu Leu Cys Gln Glu His  
 355 360 365  
 Ala Ala Val Leu Leu His Arg Ala Phe Leu Val Gly Met Tyr Gly Gln  
 370 375 380  
 Met Asp Pro Ser Ala Gln Ile Ser Glu Ala Leu Arg Ile Leu His Met  
 385 390 395 400  
 Glu Ala Val Met

163

<210> 236  
 <211> 361  
 <212> PRT  
 <213> Homo sapiens

<400> 236

```

Met Leu Leu Lys His Leu Gln Arg Met Val Ser Val Pro Gln Val Lys
  1              5              10              15

Ala Ser Ala Leu Lys Val Val Thr Leu Thr Ala Asn Asp Lys Thr Ser
          20              25              30

Val Ser Phe Ser Ser Leu Pro Gly Gln Gly Val Ile Tyr Asn Val Ile
      35              40              45

Val Trp Asp Pro Phe Leu Asn Thr Ser Ala Ala Tyr Ile Pro Ala His
      50              55              60

Thr Tyr Ala Cys Ser Phe Glu Ala Gly Glu Gly Ser Cys Ala Ser Leu
      65              70              75              80

Gly Arg Val Ser Ser Lys Val Phe Phe Thr Leu Phe Ala Leu Leu Gly
          85              90              95

Phe Phe Ile Cys Phe Phe Gly His Arg Phe Trp Lys Thr Glu Leu Phe
      100              105              110

Phe Ile Gly Phe Ile Ile Met Gly Phe Phe Phe Tyr Ile Leu Ile Thr
      115              120              125

Arg Leu Thr Pro Ile Lys Tyr Asp Val Asn Leu Ile Leu Thr Ala Val
      130              135              140

Thr Gly Ser Val Gly Gly Met Phe Leu Val Ala Val Trp Trp Arg Phe
      145              150              155              160

Gly Ile Leu Ser Ile Cys Met Leu Cys Val Gly Leu Val Leu Gly Phe
      165              170              175

Leu Ile Ser Ser Val Thr Phe Phe Thr Pro Leu Gly Asn Leu Lys Ile
          180              185              190

Phe His Asp Asp Gly Val Phe Trp Val Thr Phe Ser Cys Ile Ala Ile
      195              200              205

Leu Ile Pro Val Val Phe Met Gly Cys Leu Arg Ile Leu Asn Ile Leu
      210              215              220

Thr Cys Gly Val Ile Gly Ser Tyr Ser Val Val Leu Ala Ile Asp Ser
      225              230              235              240

Tyr Trp Ser Thr Ser Leu Ser Tyr Ile Thr Leu Asn Val Leu Lys Arg
          245              250              255

Ala Leu Asn Lys Asp Phe His Arg Ala Phe Thr Asn Val Pro Phe Gln
      260              265              270

```

164

Thr Asn Asp Phe Ile Ile Leu Ala Val Trp Gly Met Leu Ala Val Ser  
 275 280 285

Gly Ile Thr Leu Gln Ile Arg Arg Glu Arg Gly Arg Pro Phe Phe Pro  
 290 295 300

Pro His Pro Tyr Lys Leu Trp Lys Gln Glu Arg Glu Arg Arg Val Thr  
 305 310 315 320

Asn Ile Leu Asp Pro Ser Tyr His Ile Pro Pro Leu Arg Glu Arg Leu  
 325 330 335

Tyr Gly Arg Leu Thr Gln Ile Lys Gly Leu Phe Gln Lys Glu Gln Pro  
 340 345 350

Ala Gly Glu Arg Thr Pro Leu Leu Leu  
 355 360

&lt;210&gt; 237

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (40)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 237

Trp Ala Arg Leu Arg Gly Pro Gly Ala His Ala Arg Thr Ser Pro Gln  
 1 5 10 15

Pro Trp Arg Gly Pro Ser Pro Ala Gln Ala Ala Met Gly Phe Leu Gln  
 20 25 30

Leu Leu Val Val Xaa Val Leu Xaa Ser Glu His Arg Val Ala Gly Ala  
 35 40 45

Ala Glu Val Phe Gly Asn Ser Ser Glu Gly Leu Ile Glu Phe Ser Val  
 50 55 60

Gly Lys Phe Arg Tyr Phe Glu Leu Asn Arg Pro Phe Pro Glu Glu Ala  
 65 70 75 80

Ile Leu His Asp Ile Ser Ser Asn Val Thr Phe Leu Ile Phe Gln Ile  
 85 90 95

His Ser Gln Tyr Gln Asn Thr Thr Val Ser Phe Ser Pro Arg Arg Arg  
 100 105 110

Ser Pro Thr Met  
 115

165

<210> 238  
 <211> 166  
 <212> PRT  
 <213> Homo sapiens

<400> 238  
 Pro Arg Val Arg Pro Ala Ser Pro Pro Val Arg Ser Pro Ala Arg Trp  
 1 5 10 15  
 Gly Ser Met Ala Gly Ser Pro Leu Leu Trp Gly Pro Arg Ala Gly Gly  
 20 25 30  
 Val Gly Leu Leu Val Leu Leu Leu Gly Leu Phe Arg Pro Pro Pro  
 35 40 45  
 Ala Leu Cys Ala Arg Pro Val Lys Glu Pro Arg Gly Leu Ser Ala Ala  
 50 55 60  
 Ser Pro Pro Leu Ala Arg Leu Ala Leu Leu Ala Ala Ser Gly Gly Gln  
 65 70 75 80  
 Cys Pro Glu Val Arg Arg Arg Gly Arg Cys Arg Pro Gly Ala Gly Ala  
 85 90 95  
 Gly Ala Ser Ala Gly Ala Glu Arg Gln Glu Arg Ala Arg Ala Glu Ala  
 100 105 110  
 Gln Arg Leu Arg Ile Ser Arg Arg Ala Ser Trp Arg Ser Cys Cys Ala  
 115 120 125  
 Ser Gly Ala Pro Pro Ala Thr Leu Ile Arg Leu Trp Ala Trp Thr Thr  
 130 135 140  
 Thr Pro Thr Arg Leu Gln Arg Ser Ser Leu Ala Leu Cys Ser Ala Pro  
 145 150 155 160  
 Ala Leu Thr Leu Pro Pro  
 165

<210> 239  
 <211> 414  
 <212> PRT  
 <213> Homo sapiens

<400> 239  
 Pro Arg Val Arg Leu Ala Thr Pro Asn Ile Trp Asp Leu Ser Met Leu  
 1 5 10 15  
 Phe Ala Phe Ile Ser Leu Leu Val Met Leu Pro Thr Trp Trp Ile Val  
 20 25 30  
 Ser Ser Trp Leu Val Trp Gly Val Ile Leu Phe Val Tyr Leu Val Ile  
 35 40 45  
 Arg Ala Leu Arg Leu Trp Arg Thr Ala Lys Leu Gln Val Thr Leu Lys

166

|   |     |             |
|---|-----|-------------|
| 50  | 55  | 60          |
| Lys Tyr Ser Val His Leu Glu Asp Met Ala Thr Asn Ser Arg Ala Phe |     |             |
| 65  | 70  | 75 80       |
| Thr Asn Leu Val Arg Lys Ala Leu Arg Leu Ile Gln Glu Thr Glu Val |     |             |
|   | 85  | 90 95       |
| Ile Ser Arg Gly Phe Thr Leu Val Ser Ala Ala Cys Pro Phe Asn Lys |     |             |
|   | 100 | 105 110     |
| Ala Gly Gln His Pro Ser Gln His Leu Ile Gly Leu Arg Lys Ala Val |     |             |
|   | 115 | 120 125     |
| Tyr Arg Thr Leu Arg Ala Asn Phe Gln Ala Ala Arg Leu Ala Thr Leu |     |             |
|   | 130 | 135 140     |
| Tyr Met Leu Lys Asn Tyr Pro Leu Asn Ser Glu Ser Asp Asn Val Thr |     |             |
|   | 145 | 150 155 160 |
| Asn Tyr Ile Cys Val Val Pro Phe Lys Glu Leu Gly Leu Gly Leu Ser |     |             |
|   | 165 | 170 175     |
| Glu Glu Gln Ile Ser Glu Glu Glu Ala His Asn Phe Thr Asp Gly Phe |     |             |
|   | 180 | 185 190     |
| Ser Leu Pro Ala Leu Lys Val Leu Phe Gln Leu Trp Val Ala Gln Ser |     |             |
|   | 195 | 200 205     |
| Ser Glu Phe Phe Arg Arg Leu Ala Leu Leu Leu Ser Thr Ala Asn Ser |     |             |
|   | 210 | 215 220     |
| Pro Pro Gly Pro Leu Leu Thr Pro Ala Leu Leu Pro His Arg Ile Leu |     |             |
|   | 225 | 230 235 240 |
| Ser Asp Val Thr Gln Gly Leu Pro His Ala His Ser Ala Cys Leu Glu |     |             |
|   | 245 | 250 255     |
| Glu Leu Lys Arg Ser Tyr Glu Phe Tyr Arg Tyr Phe Glu Thr Gln His |     |             |
|   | 260 | 265 270     |
| Gln Ser Val Pro Gln Cys Leu Ser Lys Thr Gln Gln Lys Ser Arg Glu |     |             |
|   | 275 | 280 285     |
| Leu Asn Asn Val His Thr Ala Val Arg Ser Leu Gln Leu His Leu Lys |     |             |
|   | 290 | 295 300     |
| Ala Leu Leu Asn Glu Val Ile Ile Leu Glu Asp Glu Leu Glu Lys Leu |     |             |
|   | 305 | 310 315 320 |
| Val Cys Thr Lys Glu Thr Gln Glu Leu Val Ser Glu Ala Tyr Pro Ile |     |             |
|   | 325 | 330 335     |
| Leu Glu Gln Lys Leu Lys Leu Ile Gln Pro His Val Gln Ala Ser Asn |     |             |
|   | 340 | 345 350     |
| Asn Cys Trp Glu Glu Ala Ile Ser Gln Val Asp Lys Leu Leu Arg Arg |     |             |
|   | 355 | 360 365     |

167

Asn Thr Asp Lys Lys Gly Lys Pro Glu Ile Ala Cys Glu Asn Pro His  
 370 375 380

Cys Thr Val Ser Thr Phe Glu Ala Ala Tyr Ser Thr His Cys Arg Gln  
 385 390 395 400

Arg Ser Asn Pro Arg Gly Ala Gly Ile Arg Ser Leu Cys Arg  
 405 410

&lt;210&gt; 240

&lt;211&gt; 145

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 240

Ala Ala Pro His Pro Pro Leu Leu Arg Pro Leu Cys Leu Trp Cys Pro  
 1 5 10 15

Leu Trp Pro Ala Trp Pro Leu Arg Gly Arg Pro Arg Ser Ala Trp Lys  
 20 25 30

Arg Trp Pro Pro Leu Pro Val Gly Pro Ala Lys Leu Gly Cys Ser Met  
 35 40 45

Thr Thr Arg Gln Pro Thr Ala Val Ser Trp Pro Cys Trp Leu Met Ser  
 50 55 60

Ser Ser Leu Ser Thr Ala Cys Leu Ala Trp Thr Leu Thr Gly Ser Leu  
 65 70 75 80

Ala Arg Glu Ala Thr Arg Arg Ala Arg Ser Leu Ser Pro Thr Trp Asn  
 85 90 95

Cys Ser Ala Arg Gln Val Pro Pro Ser Pro Pro His Ser Gly Leu Gly  
 100 105 110

Arg Arg Gly Trp Ala His Cys His Leu Thr Cys Leu Leu Val Thr Gln  
 115 120 125

Leu Phe Arg Val Gly Arg Ile His Pro Ile Leu Ser Leu Pro Leu Val  
 130 135 140

Thr

145

&lt;210&gt; 241

&lt;211&gt; 72

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 241

Leu Gln Leu Ala Ser Gln Ser Ala Gly Ile Lys Gly Met Ser His Cys  
 1 5 10 15

Ala Arg Pro Thr Phe Leu Thr Leu Leu Leu Ala Ser Cys Phe Trp Ala

168

20 25 30

Ala Ala Ile Pro Asn Arg Asn Val Ile Leu Ser Val Ser Phe Arg Pro  
35 40 45

Leu His Met Gln Phe Thr Leu Ser Ile Leu Val Phe Ile Leu Arg Ile  
50 55 60

Leu Ile Leu Leu Arg Ser Phe Leu  
65 70

<210> 242  
<211> 140  
<212> PRT  
<213> Homo sapiens

<400> 242

Met Val Leu Val Leu Arg His Pro Leu Cys Ala Arg Glu Arg Ala Phe  
1 5 10 15

Arg Glu Pro Gly Arg Gly Leu Leu Thr Arg Thr Gly Gln His Asp Gly  
20 25 30

Ala Pro Ala Val Thr Ala Val Pro Gly Pro Leu Gly Ala Val Ala Ala  
35 40 45

Ala Glu Gly Arg Arg Ser Ala Trp Gly Ala Gly Gly Ser Ser Pro Pro  
50 55 60

Arg Lys Val Leu Trp Gly Asp Met Arg Gly Arg Arg Ala Gly Val Asp  
65 70 75 80

Val Leu Gly Pro Ala Leu Ser Ser Glu Ala Ala Gly Ala Glu Ala Arg  
85 90 95

Gly Trp Gly Met Pro Gly Met Gly Val Gly Val Gly Ala Ser Glu Thr  
100 105 110

Arg Gly Ala Leu Phe Leu Gly Arg Glu Gly Val His Gly Pro Cys Pro  
115 120 125

Met Asp Gly Leu Gly Pro Trp Pro Trp Gly Pro Trp  
130 135 140

<210> 243  
<211> 353  
<212> PRT  
<213> Homo sapiens

<400> 243

Met Gly Pro Ala Val Lys Met Trp Thr Asn Ala Trp Lys Gly Leu Asp  
1 5 10 15

Asp Cys His Tyr Asn Gln Leu Cys Glu Asn Thr Pro Gly Gly His Arg  
20 25 30

169

Cys Ser Cys Pro Arg Gly Tyr Arg Met Gln Gly Pro Ser Leu Pro Cys  
 35 40 45  
 Leu Asp Val Asn Glu Cys Leu Gln Leu Pro Lys Ala Cys Ala Tyr Gln  
 50 55 60  
 Cys His Asn Leu Gln Gly Ser Tyr Arg Cys Leu Cys Pro Pro Gly Gln  
 65 70 75 80  
 Thr Leu Leu Arg Asp Gly Lys Ala Cys Thr Ser Leu Glu Arg Asn Gly  
 85 90 95  
 Gln Asn Val Thr Thr Val Ser His Arg Gly Pro Leu Leu Pro Trp Leu  
 100 105 110  
 Arg Pro Trp Ala Ser Ile Pro Gly Thr Ser Tyr His Ala Trp Val Ser  
 115 120 125  
 Leu Arg Pro Gly Pro Met Ala Leu Ser Ser Val Gly Arg Ala Trp Cys  
 130 135 140  
 Pro Pro Gly Phe Ile Arg Gln Asn Gly Val Cys Thr Asp Leu Asp Glu  
 145 150 155 160  
 Cys Arg Val Arg Asn Leu Cys Gln His Ala Cys Arg Asn Thr Glu Gly  
 165 170 175  
 Ser Tyr Gln Cys Leu Cys Pro Ala Gly Tyr Arg Leu Leu Pro Ser Gly  
 180 185 190  
 Lys Asn Cys Gln Asp Ile Asn Glu Cys Glu Glu Glu Ser Ile Glu Cys  
 195 200 205  
 Gly Pro Gly Gln Met Cys Phe Asn Thr Arg Gly Ser Tyr Gln Cys Val  
 210 215 220  
 Asp Thr Pro Cys Pro Ala Thr Tyr Arg Gln Gly Pro Ser Pro Gly Thr  
 225 230 235 240  
 Cys Phe Arg Arg Cys Ser Gln Asp Cys Gly Thr Gly Gly Pro Ser Thr  
 245 250 255  
 Leu Gln Tyr Arg Leu Leu Pro Leu Pro Leu Gly Val Arg Ala His His  
 260 265 270  
 Asp Val Ala Arg Leu Thr Ala Phe Ser Glu Val Gly Val Pro Ala Asn  
 275 280 285  
 Arg Thr Glu Leu Ser Met Leu Glu Pro Asp Pro Arg Ser Pro Phe Ala  
 290 295 300  
 Leu Arg Pro Leu Arg Ala Gly Leu Gly Ala Val Tyr Thr Arg Arg Ala  
 305 310 315 320  
 Leu Thr Arg Ala Gly Leu Tyr Arg Leu Thr Val Arg Ala Ala Ala Pro  
 325 330 335  
 Arg His Gln Ser Val Phe Val Leu Leu Ile Ala Val Ser Pro Tyr Pro



170

340

345

350

Tyr

&lt;210&gt; 244

&lt;211&gt; 146

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 244

Met Arg Val Leu Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala  
 1 5 10 15

Arg Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys  
 20 25 30

Phe Arg Gln Ser His Thr Trp Ser Leu Leu Gln Gly Ala Ala His Asp  
 35 40 45

Asp Pro Val Ala Arg Gly Leu Asp Pro Asp Gly Leu Leu Leu Asp  
 50 55 60

Val Val Val Asn Gly Val Val Pro Gly Arg Ala Trp Leu Thr Gln Ile  
 65 70 75 80

Phe Lys Cys Arg Thr Leu Lys Lys His Tyr Val Gln Thr Arg Ala Trp  
 85 90 95

Pro Ala Val Arg Gly Leu His Thr Ala Leu Leu Pro Gly Arg Pro Pro  
 100 105 110

Leu Val Pro Thr Leu Gln Pro Gln His Pro Val Gln Arg Gly Pro Gly  
 115 120 125

Pro Pro Ala Pro Ala Gly Ala Ala Pro Ala Gly Leu Ser Tyr Gln Leu  
 130 135 140

Gly Leu  
 145

&lt;210&gt; 245

&lt;211&gt; 638

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 245

His Ala Ser Gly Ala Phe Leu Val Val Arg Gly Glu Pro Gln Gly Ser  
 1 5 10 15

Trp Gly Ser Met Thr Gly Val Ile Asn Gly Arg Lys Phe Gly Val Ala  
 20 25 30

Thr Leu Asn Thr Ser Val Met Gln Glu Ala His Ser Gly Val Ser Ser  
 35 40 45

171

Ile His Ser Ser Ile Arg His Val Pro Ala Asn Val Gly Pro Leu Met  
 50 55 60

Arg Val Leu Val Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala Arg  
 65 70 75 80

Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys Phe  
 85 90 95

Arg Gln Glu Ser His Val Glu Phe Ala Thr Gly Glu Leu Leu Thr Met  
 100 105 110

Thr Gln Trp Pro Gly Val Trp Ile Pro Met Ala Ser Cys Ser Ser Thr  
 115 120 125

Trp Trp Ser Met Ala Leu Ser Pro Asp Ser Leu Ala Asp Ala Asp Leu  
 130 135 140

Gln Val Gln Asp Phe Glu Glu His Tyr Val Gln Thr Gly Pro Gly Gln  
 145 150 155 160

Leu Phe Val Gly Ser Thr Gln Arg Phe Phe Gln Gly Gly Leu Pro Ser  
 165 170 175

Phe Leu Arg Cys Asn His Ser Ile Gln Tyr Asn Ala Ala Arg Gly Pro  
 180 185 190

Gln Pro Gln Leu Val Gln His Leu Arg Ala Ser Ala Ile Ser Ser Ala  
 195 200 205

Phe Asp Pro Glu Ala Glu Ala Leu Arg Phe Gln Leu Ala Thr Ala Leu  
 210 215 220

Gln Ala Glu Glu Asn Glu Val Gly Cys Pro Glu Gly Phe Glu Leu Asp  
 225 230 235 240

Ser Gln Gly Ala Phe Cys Val Asp Val Asp Glu Cys Ala Trp Asp Ala  
 245 250 255

His Leu Cys Arg Glu Gly Gln Arg Cys Val Asn Leu Leu Gly Ser Tyr  
 260 265 270

Arg Cys Leu Pro Asp Cys Gly Pro Gly Phe Arg Val Ala Asp Gly Ala  
 275 280 285

Gly Cys Glu Asp Val Asp Glu Cys Leu Glu Gly Leu Asp Asp Cys His  
 290 295 300

Tyr Asn Gln Leu Cys Glu Asn Thr Pro Gly Gly His Arg Cys Ser Cys  
 305 310 315 320

Pro Arg Gly Tyr Arg Met Gln Gly Pro Ser Leu Pro Cys Leu Asp Val  
 325 330 335

Asn Glu Cys Leu Gln Leu Pro Lys Ala Cys Ala Tyr Gln Cys His Asn  
 340 345 350

Leu Gln Gly Ser Tyr Arg Cys Leu Cys Pro Pro Gly Gln Thr Leu Leu

172

|   |     |     |
|---|-----|-----|
| 355   | 360 | 365 |
| Arg Asp Gly Lys Ala Cys Thr Ser Leu Glu Arg Asn Gly Gln Asn Val |     |     |
| 370   | 375 | 380 |
| Thr Thr Val Ser His Arg Gly Pro Leu Leu Pro Trp Leu Arg Pro Trp |     |     |
| 385   | 390 | 395 |
| Ala Ser Ile Pro Gly Thr Ser Tyr His Ala Trp Val Ser Leu Arg Pro |     |     |
| 405   | 410 | 415 |
| Gly Pro Met Ala Leu Ser Ser Val Gly Arg Ala Trp Cys Pro Pro Gly |     |     |
| 420   | 425 | 430 |
| Phe Ile Arg Gln Asn Gly Val Cys Thr Asp Leu Asp Glu Cys Arg Val |     |     |
| 435   | 440 | 445 |
| Arg Asn Leu Cys Gln His Ala Cys Arg Asn Thr Glu Gly Ser Tyr Gln |     |     |
| 450   | 455 | 460 |
| Cys Leu Cys Pro Ala Gly Tyr Arg Leu Leu Pro Ser Gly Lys Asn Cys |     |     |
| 465   | 470 | 475 |
| Gln Asp Ile Asn Glu Cys Glu Glu Glu Ser Ile Glu Cys Gly Pro Gly |     |     |
| 485   | 490 | 495 |
| Gln Met Cys Phe Asn Thr Arg Gly Ser Tyr Gln Cys Val Asp Thr Pro |     |     |
| 500   | 505 | 510 |
| Cys Pro Ala Thr Tyr Arg Gln Gly Pro Ser Pro Gly Thr Cys Phe Arg |     |     |
| 515   | 520 | 525 |
| Arg Cys Ser Gln Asp Cys Gly Thr Gly Gly Pro Ser Thr Leu Gln Tyr |     |     |
| 530   | 535 | 540 |
| Arg Leu Leu Pro Leu Pro Leu Gly Val Arg Ala His His Asp Val Ala |     |     |
| 545   | 550 | 555 |
| Arg Leu Thr Ala Phe Ser Glu Val Gly Val Pro Ala Asn Arg Thr Glu |     |     |
| 565   | 570 | 575 |
| Leu Ser Met Leu Glu Pro Asp Pro Arg Ser Pro Phe Ala Leu Arg Pro |     |     |
| 580   | 585 | 590 |
| Leu Arg Ala Gly Leu Gly Ala Val Tyr Thr Arg Arg Ala Leu Thr Arg |     |     |
| 595   | 600 | 605 |
| Ala Gly Leu Tyr Arg Leu Thr Val Arg Ala Ala Ala Pro Arg His Gln |     |     |
| 610   | 615 | 620 |
| Ser Val Phe Val Leu Leu Ile Ala Val Ser Pro Tyr Pro Tyr         |     |     |
| 625   | 630 | 635 |

&lt;210&gt; 246

&lt;211&gt; 367

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

173

&lt;400&gt; 246

```

Met Gly Glu Lys Phe Leu Leu Leu Ala Met Lys Glu Asn His Pro Glu
  1             5             10             15

Cys Phe Cys Lys Ile Leu Lys Ile Leu His Cys Met Asp Pro Gly Glu
      20             25             30

Trp Leu Pro Gln Thr Glu His Cys Val His Leu Thr Pro Lys Glu Phe
      35             40             45

Leu Ile Trp Thr Met Asp Ile Ala Ser Asn Glu Arg Ser Glu Ile Gln
      50             55             60

Ser Val Ala Leu Arg Leu Ala Ser Lys Val Ile Ser His His Met Gln
      65             70             75             80

Thr Cys Val Glu Asn Arg Glu Leu Ile Ala Ala Glu Leu Lys Gln Trp
      85             90             95

Val Gln Leu Val Ile Leu Ser Cys Glu Asp His Leu Pro Thr Glu Ser
      100            105            110

Arg Leu Ala Val Val Glu Val Leu Thr Ser Thr Thr Pro Leu Phe Leu
      115            120            125

Thr Asn Pro His Pro Ile Leu Glu Leu Gln Asp Thr Leu Ala Leu Trp
      130            135            140

Lys Cys Val Leu Thr Leu Leu Gln Ser Glu Glu Gln Ala Val Arg Asp
      145            150            155            160

Ala Ala Thr Glu Thr Val Thr Thr Ala Met Ser Gln Glu Asn Thr Cys
      165            170            175

Gln Ser Thr Glu Phe Ala Phe Cys Gln Val Asp Ala Ser Ile Ala Leu
      180            185            190

Ala Leu Ala Leu Ala Val Leu Cys Asp Leu Leu Gln Gln Trp Asp Gln
      195            200            205

Leu Ala Pro Gly Leu Pro Ile Leu Leu Gly Trp Leu Leu Gly Glu Ser
      210            215            220

Asp Asp Leu Val Ala Cys Val Glu Ser Met His Gln Val Glu Glu Asp
      225            230            235            240

Tyr Leu Phe Glu Lys Ala Glu Val Asn Phe Trp Ala Glu Thr Leu Ile
      245            250            255

Phe Val Lys Tyr Leu Cys Lys His Leu Phe Cys Leu Leu Ser Lys Ser
      260            265            270

Gly Trp Arg Pro Pro Ser Pro Glu Met Leu Cys His Leu Gln Arg Met
      275            280            285

Val Ser Glu Gln Cys His Leu Leu Ser Gln Phe Phe Arg Glu Leu Pro
      290            295            300

```

174

Pro Ala Ala Glu Phe Val Lys Thr Val Glu Phe Thr Arg Leu Arg Ile  
305 310 315 320

Gln Glu Glu Arg Thr Leu Ala Cys Leu Arg Leu Leu Ala Phe Leu Glu  
325 330 335

Gly Lys Glu Gly Glu Asp Thr Leu Val Leu Ser Val Trp Asp Ser Tyr  
340 345 350

Ala Glu Ser Arg Gln Leu Thr Leu Pro Arg Thr Glu Ala Ala Cys  
355 360 365

<210> 247  
<211> 124  
<212> PRT  
<213> Homo sapiens

<400> 247  
Met Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Leu Val  
1 5 10 15

Leu Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu  
20 25 30

Ser Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro  
35 40 45

Val Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val  
50 55 60

Met Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu  
65 70 75 80

Pro Ser Cys Thr Asp Gln Cys Phe Arg Ala Lys Pro His Ser Trp Gly  
85 90 95

His Phe Ser Arg Phe Phe His Leu Leu Gln Ala Tyr Ser Asp Ser Lys  
100 105 110

Thr Arg Asn Glu Phe Arg Leu Pro Ala Arg Ala Asp  
115 120

<210> 248  
<211> 674  
<212> PRT  
<213> Homo sapiens

<400> 248  
Met Thr Gly Arg Glu Phe Phe Ser Arg Phe Pro Glu Leu Tyr Pro Phe  
1 5 10 15

Leu Leu Lys Gln Leu Glu Thr Val Ala Asn Thr Val Asp Ser Asp Met  
20 25 30

Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Leu Val Leu

175

|   |     |     |
|---|-----|-----|
| 35  | 40  | 45  |
| Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu Ser |     |     |
| 50  | 55  | 60  |
| Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro Val |     |     |
| 65  | 70  | 75  |
| Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val Met |     |     |
| 85  | 90  | 95  |
| Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu Pro |     |     |
| 100   | 105 | 110 |
| Ser Cys Thr Asp Gln Cys Phe Arg Gln Asn His Ile His Gly Thr Leu |     |     |
| 115   | 120 | 125 |
| Leu Gln Val Phe His Leu Leu Gln Ala Tyr Ser Asp Ser Lys His Gly |     |     |
| 130   | 135 | 140 |
| Thr Asn Ser Asp Phe Gln His Glu Leu Thr Asp Ile Thr Val Cys Thr |     |     |
| 145   | 150 | 155 |
| Lys Ala Lys Leu Trp Leu Ala Lys Arg Gln Asn Pro Cys Leu Val Thr |     |     |
| 165   | 170 | 175 |
| Arg Ala Val Tyr Ile Asp Ile Leu Phe Leu Leu Thr Cys Cys Leu Asn |     |     |
| 180   | 185 | 190 |
| Arg Ser Ala Lys Asp Asn Gln Pro Val Leu Glu Ser Leu Gly Phe Trp |     |     |
| 195   | 200 | 205 |
| Glu Glu Val Arg Gly Ile Ile Ser Gly Ser Glu Leu Ile Thr Gly Phe |     |     |
| 210   | 215 | 220 |
| Pro Trp Ala Phe Lys Val Pro Gly Leu Pro Gln Tyr Leu Gln Ser Leu |     |     |
| 225   | 230 | 235 |
| Thr Arg Leu Ala Ile Ala Ala Val Trp Ala Ala Ala Ala Lys Ser Gly |     |     |
| 245   | 250 | 255 |
| Glu Arg Glu Thr Asn Val Pro Ile Ser Phe Ser Gln Leu Leu Glu Ser |     |     |
| 260   | 265 | 270 |
| Ala Phe Pro Glu Val Arg Ser Leu Thr Leu Glu Ala Leu Leu Glu Lys |     |     |
| 275   | 280 | 285 |
| Phe Leu Ala Ala Ala Ser Gly Leu Gly Glu Lys Gly Val Pro Pro Leu |     |     |
| 290   | 295 | 300 |
| Leu Cys Asn Met Gly Glu Lys Phe Leu Leu Leu Ala Met Lys Glu Asn |     |     |
| 305   | 310 | 315 |
| His Pro Glu Cys Phe Cys Lys Ile Leu Lys Ile Leu His Cys Met Asp |     |     |
| 325   | 330 | 335 |
| Pro Gly Glu Trp Leu Pro Gln Thr Glu His Cys Val His Leu Thr Pro |     |     |
| 340   | 345 | 350 |

176

Lys Glu Phe Leu Ile Trp Thr Met Asp Ile Ala Ser Asn Glu Arg Ser  
 355 360 365  
 Glu Ile Gln Ser Val Ala Leu Arg Leu Ala Ser Lys Val Ile Ser His  
 370 375 380  
 His Met Gln Thr Cys Val Glu Asn Arg Glu Leu Ile Ala Ala Glu Leu  
 385 390 395 400  
 Lys Gln Trp Val Gln Leu Val Ile Leu Ser Cys Glu Asp His Leu Pro  
 405 410 415  
 Thr Glu Ser Arg Leu Ala Val Val Glu Val Leu Thr Ser Thr Thr Pro  
 420 425 430  
 Leu Phe Leu Thr Asn Pro His Pro Ile Leu Glu Leu Gln Asp Thr Leu  
 435 440 445  
 Ala Leu Trp Lys Cys Val Leu Thr Leu Leu Gln Ser Glu Glu Gln Ala  
 450 455 460  
 Val Arg Asp Ala Ala Thr Glu Thr Val Thr Thr Ala Met Ser Gln Glu  
 465 470 475 480  
 Asn Thr Cys Gln Ser Thr Glu Phe Ala Phe Cys Gln Val Asp Ala Ser  
 485 490 495  
 Ile Ala Leu Ala Leu Ala Leu Ala Val Leu Cys Asp Leu Leu Gln Gln  
 500 505 510  
 Trp Asp Gln Leu Ala Pro Gly Leu Pro Ile Leu Leu Gly Trp Leu Leu  
 515 520 525  
 Gly Glu Ser Asp Asp Leu Val Ala Cys Val Glu Ser Met His Gln Val  
 530 535 540  
 Glu Glu Asp Tyr Leu Phe Glu Lys Ala Glu Val Asn Phe Trp Ala Glu  
 545 550 555 560  
 Thr Leu Ile Phe Val Lys Tyr Leu Cys Lys His Leu Phe Cys Leu Leu  
 565 570 575  
 Ser Lys Ser Gly Trp Arg Pro Pro Ser Pro Glu Met Leu Cys His Leu  
 580 585 590  
 Gln Arg Met Val Ser Glu Gln Cys His Leu Leu Ser Gln Phe Phe Arg  
 595 600 605  
 Glu Leu Pro Pro Ala Ala Glu Phe Val Lys Thr Val Glu Phe Thr Arg  
 610 615 620  
 Leu Arg Ile Gln Glu Glu Arg Thr Leu Ala Cys Leu Arg Leu Leu Ala  
 625 630 635 640  
 Phe Leu Glu Gly Lys Glu Gly Glu Asp Thr Leu Val Leu Ser Val Trp  
 645 650 655

177

Asp Ser Tyr Ala Glu Ser Arg Gln Leu Thr Leu Pro Arg Thr Glu Ala  
 660 665 670

Ala Cys

&lt;210&gt; 249

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 249

Ile Ile Ser Gly Ser Glu Leu Ile Thr Gly  
 1 5 10

&lt;210&gt; 250

&lt;211&gt; 230

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 250

Val Asp Gly Ile Asp Lys Leu Asp Ile Glu Phe Leu Gln Gln Phe Leu  
 1 5 10 15

Glu Thr His Ser Arg Gly Pro Arg Leu His Ser Pro Gly His Ala Ser  
 20 25 30

Gln Glu Ala Thr Pro Gly Ala Asn Met Ser Ser Gly Thr Glu Leu Leu  
 35 40 45

Trp Pro Gly Ala Ala Leu Leu Val Leu Leu Gly Val Ala Ala Ser Leu  
 50 55 60

Cys Val Arg Cys Ser Arg Pro Gly Ala Lys Arg Ser Glu Lys Ile Tyr  
 65 70 75 80

Gln Gln Arg Ser Leu Arg Glu Asp Gln Gln Ser Phe Thr Gly Ser Arg  
 85 90 95

Thr Tyr Ser Leu Val Gly Gln Ala Trp Pro Gly Pro Leu Ala Asp Met  
 100 105 110

Ala Pro Thr Arg Lys Asp Lys Leu Leu Gln Phe Tyr Pro Ser Leu Glu  
 115 120 125

Asp Pro Ala Ser Ser Arg Tyr Gln Asn Phe Ser Lys Gly Ser Arg His  
 130 135 140

Gly Ser Glu Glu Ala Tyr Ile Asp Pro Ile Ala Met Glu Tyr Tyr Asn  
 145 150 155 160

Trp Gly Arg Phe Ser Lys Pro Pro Glu Asp Asp Asp Ala Asn Ser Tyr  
 165 170 175

Glu Asn Val Leu Ile Cys Lys Gln Lys Thr Thr Glu Thr Gly Ala Gln  
 180 185 190



178

Gln Glu Gly Ile Gly Gly Leu Cys Arg Gly Asp Leu Ser Leu Ser Leu  
 195 200 205

Ala Leu Lys Thr Gly Pro Thr Ser Gly Leu Cys Pro Ser Ala Ser Pro  
 210 215 220

Glu Glu Asp Glu Gly Ile  
 225 230

<210> 251  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<400> 251  
 Val Leu Trp Arg Glu Ala Ser Ala Leu Val Leu Ser Asn Arg Leu Ser  
 1 5 10 15

Ser Gly Leu Leu His Asp Leu Leu Leu Gln Pro Ala Ile His Ser Arg  
 20 25 30

Leu Phe Pro Arg Arg Ser Arg Gly Leu Ser Glu Gly Glu Gly Ser Ser  
 35 40 45

Val Ser Leu Gln Arg Ser Arg Val Leu Ser Ala Met Lys His Val Leu  
 50 55 60

Asn Leu Tyr Leu Leu Gly Val Val Leu Thr Leu Leu Ser Ile Phe Val  
 65 70 75 80

Arg Val Met Glu Ser Leu Glu Gly Leu Leu Glu Ser Pro Ser Pro Gly  
 85 90 95

Thr Ser Trp Thr Thr Arg Ser Gln Leu Ala Asn Thr Glu Pro Thr Lys  
 100 105 110

Gly Leu Pro Asp His Pro Ser Arg Ser Met  
 115 120

<210> 252  
 <211> 129  
 <212> PRT  
 <213> Homo sapiens

<400> 252  
 Tyr Thr Phe His Thr Gln Ile Phe Leu Asp Phe Pro Met Ile Phe Leu  
 1 5 10 15

Thr Val Leu Pro Leu Ala Phe Leu Phe Leu His Ser Gly Phe Tyr His  
 20 25 30

Tyr Ile Ser Phe Ser Cys Leu Phe Ser Leu Ser Leu Ala Leu Phe Phe  
 35 40 45

Phe Leu Asp Val Ala Thr Phe Arg Arg Pro Gly Gln Leu Phe Cys Glu

179

50

55

60

Arg Ser Val Leu Phe Asp Met Phe His Phe Gly Phe Val Ser Leu Phe  
 65 70 75 80  
 Leu His Glu Trp Ile Gln Ala Lys His Phe Trp Ala Gly Leu Phe Ile  
 85 90 95  
 Val Leu Pro Ser Asp Val Phe Phe Ser Val His His Leu Glu Ala Pro  
 100 105 110  
 Asp Gly Ser Phe Pro Asn Ile Ala Lys Leu Ser Leu Ile Ile Leu Leu  
 115 120 125

Arg

&lt;210&gt; 253

&lt;211&gt; 99

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 253

Gly Thr Arg Phe Pro Thr Gly Glu Thr Pro Ser Leu Gly Phe Thr Val  
 1 5 10 15  
 Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu Met Ala Val Ile  
 20 25 30  
 Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp Leu Ser Glu Asn  
 35 40 45  
 Ser Gln Ser Ser Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn  
 50 55 60  
 Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile  
 65 70 75 80  
 Thr Ala Ile Ser Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile  
 85 90 95  
 Phe Phe Pro

&lt;210&gt; 254

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 254

Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn Cys Ile Phe Phe  
 1 5 10 15  
 Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile Thr Ala Ile Ser  
 20 25 30

180

Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile Phe Phe Pro Cys  
 35 40 45

Leu Leu Ala  
 50

<210> 255  
 <211> 259  
 <212> PRT  
 <213> Homo sapiens

<400> 255  
 Gly Thr Arg Phe Pro Thr Gly Glu Thr Pro Ser Leu Gly Phe Thr Val  
 1 5 10 15

Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu Met Ala Val Ile  
 20 25 30

Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp Leu Ser Glu Asn  
 35 40 45

Ser Gln Ser Ser Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn  
 50 55 60

Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile  
 65 70 75 80

Thr Ala Ile Ser Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile  
 85 90 95

Phe Phe Pro Leu Pro Ala Cys Leu Asn Pro Val Leu Tyr Val Phe Phe  
 100 105 110

Asn Pro Lys Phe Lys Glu Asp Trp Lys Leu Leu Lys Arg Arg Val Thr  
 115 120 125

Lys Lys Ser Gly Ser Val Ser Val Ser Ile Ser Ser Gln Gly Gly Cys  
 130 135 140

Leu Glu Gln Asp Phe Tyr Tyr Asp Cys Gly Met Tyr Ser His Leu Gln  
 145 150 155 160

Gly Asn Leu Thr Val Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr Lys  
 165 170 175

Pro Val Ser Cys Lys His Leu Ile Lys Ser His Ser Cys Pro Ala Leu  
 180 185 190

Ala Val Ala Ser Cys Gln Arg Pro Glu Gly Tyr Trp Ser Asp Cys Gly  
 195 200 205

Thr Gln Ser Ala His Ser Asp Tyr Ala Asp Glu Glu Asp Ser Phe Val  
 210 215 220

Ser Asp Ser Ser Asp Gln Val Gln Ala Cys Gly Arg Ala Cys Phe Tyr  
 225 230 235 240

181

Gln Ser Arg Gly Phe Pro Leu Val Arg Tyr Ala Tyr Asn Leu Pro Arg  
                   245                  250                  255

Val Lys Asp

<210> 256  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 256  
 Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr Lys Pro Val Ser Cys Lys  
       1                  5                  10                  15

His Leu Ile Lys Ser His  
                   20

<210> 257  
 <211> 81  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (20)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 257  
 Ala Leu Glu Asn Ser Gly Ser Pro Gly Leu Gln Asp Ser Ala Arg Ala  
       1                  5                  10                  15

His Phe Asn Xaa Ser Leu Arg Ser Phe Ser Phe Leu Arg Asn Gln Met  
                   20                  25                  30

Tyr Ile Phe Glu Leu Ser Leu Tyr Leu Glu Gly Thr Ser Phe Val Val  
           35                  40                  45

Val Leu Leu Phe Leu Leu Ile Ser Val Ser Leu Asp Ser Pro Pro Thr  
       50                  55                  60

Thr Lys Gly Trp Asp Ser Val Leu His Ile Trp Val Pro Leu Ile Val  
       65                  70                  75                  80

Gln

<210> 258  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 258  
 Gly His Glu Ser Ile Cys Gly Ser Cys Arg Ser Trp Ile Tyr Phe Ser  
       1                  5                  10                  15

182

Ile Arg Cys Arg Arg Arg Met Arg Pro Trp Trp Ser Leu Leu Leu Glu  
20 25 30  
Ala Cys Ala Thr Cys Ala Gln Thr Gly Pro Thr Arg Ser Thr Ser Cys  
35 40 45  
Thr Gln Glu Val Ser His Ser Ser Ser Thr Ala Tyr Pro Ala Pro Met  
50 55 60  
Arg Arg Arg Cys Cys Leu Pro Ser Pro Arg Ser Cys Thr  
65 70 75

<210> 259  
<211> 119  
<212> PRT  
<213> Homo sapiens

<400> 259  
Lys Arg Ala Gly Val Glu Val Gly Gly Leu Val Met Ala Leu Ala Gly  
1 5 10 15  
Ser Val Phe Val Leu Gly Gly Val Leu Val Leu Cys Val Glu Arg Asn  
20 25 30  
Gly Glu Gly Glu Met Gly Trp Pro Gln His Leu Pro Lys Ser Gln Pro  
35 40 45  
Leu Ser Pro Pro Val Ala Val Arg Arg Cys Ser Phe Glu Arg Ser Trp  
50 55 60  
Ile Asp Leu Leu Val Glu Thr Ser Ser Ser Met Val Thr Cys Arg Gln  
65 70 75 80  
Gln Val Gly Thr Pro Asn Gly Met Glu Gly Arg Gly Gly Gly Pro Lys  
85 90 95  
Thr Thr Phe Pro Ile Arg Leu Gln Leu Ser Gly Ala Cys Ala Val Arg  
100 105 110  
Pro Glu Ile Gln Trp Glu Val  
115

<210> 260  
<211> 275  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (47)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (94)

183

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (192)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 260

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Asp | Trp | Lys | Ala | Glu | Arg | Ser | Gln | Asp | Pro | Phe | Glu | Lys | Cys | Met |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Gln | Asp | Pro | Asp | Tyr | Glu | Gln | Leu | Leu | Lys | Val | Thr | Ile | Leu | Glu | Ala |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Asp | Asn | Arg | Ile | Gly | Gly | Arg | Ile | Phe | Thr | Tyr | Arg | Asp | Gln | Xaa | Thr |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Gly | Trp | Ile | Gly | Glu | Leu | Gly | Ala | Met | Arg | Met | Pro | Ser | Ser | His | Arg |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ile | Leu | His | Lys | Leu | Cys | Gln | Gly | Leu | Gly | Leu | Asn | Leu | Thr | Lys | Phe |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Thr | Gln | Tyr | Asp | Lys | Asn | Thr | Trp | Thr | Glu | Val | His | Glu | Xaa | Lys | Leu |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Arg | Asn | Tyr | Val | Val | Glu | Lys | Val | Pro | Glu | Lys | Leu | Gly | Tyr | Ala | Leu |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Arg | Pro | Gln | Glu | Lys | Gly | His | Ser | Pro | Glu | Asp | Ile | Tyr | Gln | Met | Ala |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Leu | Asn | Gln | Ala | Leu | Lys | Asp | Leu | Lys | Ala | Leu | Gly | Cys | Arg | Lys | Ala |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |
| Met | Lys | Lys | Phe | Glu | Arg | His | Thr | Leu | Leu | Glu | Tyr | Leu | Leu | Gly | Glu |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |
| Gly | Asn | Leu | Ser | Arg | Pro | Ala | Val | Gln | Leu | Leu | Gly | Asp | Val | Met | Ser |
|     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |
| Glu | Asp | Gly | Phe | Phe | Tyr | Leu | Ser | Phe | Ala | Glu | Ala | Leu | Arg | Ala | Xaa |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |
| Ser | Cys | Leu | Ser | Asp | Arg | Leu | Gln | Tyr | Ser | Arg | Ile | Val | Gly | Gly | Trp |
|     | 195 |     |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Asp | Leu | Leu | Pro | Arg | Ala | Leu | Leu | Ser | Ser | Leu | Ser | Gly | Leu | Val | Leu |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Leu | Asn | Ala | Pro | Val | Val | Ala | Met | Thr | Gln | Gly | Pro | His | Asp | Val | His |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| Val | Gln | Ile | Glu | Thr | Ser | Pro | Pro | Ala | Arg | Asn | Leu | Lys | Val | Leu | Lys |
|     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Ala | Asp | Val | Val | Leu | Leu | Thr | Ala | Ser | Gly | Pro | Ala | Val | Lys | Arg | Ile |
|     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |

Thr Phe Ser  
275

<210> 261  
<211> 212  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (123)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 261  
Leu Pro Arg His Met Gln Glu Ala Leu Arg Arg Leu His Tyr Val Pro  
1 5 10 15  
Ala Thr Lys Val Phe Leu Ser Phe Arg Arg Pro Phe Trp Arg Glu Glu  
20 25 30  
His Ile Glu Gly Gly His Ser Asn Thr Asp Arg Pro Ser Arg Met Ile  
35 40 45  
Phe Tyr Pro Pro Pro Arg Glu Gly Ala Leu Leu Leu Ala Ser Tyr Thr  
50 55 60  
Trp Ser Asp Ala Ala Ala Ala Phe Ala Gly Leu Ser Arg Glu Glu Ala  
65 70 75 80  
Leu Arg Leu Ala Leu Asp Asp Val Ala Ala Leu His Gly Pro Val Val  
85 90 95  
Arg Gln Leu Trp Asp Gly Thr Gly Val Val Lys Arg Trp Ala Glu Asp  
100 105 110  
Gln His Ser Gln Gly Gly Phe Val Val Gln Xaa Pro Ala Leu Trp Gln  
115 120 125  
Thr Glu Lys Asp Asp Trp Thr Val Pro Tyr Gly Arg Ile Tyr Phe Ala  
130 135 140  
Gly Glu His Thr Ala Tyr Pro His Gly Trp Val Glu Thr Ala Val Lys  
145 150 155 160  
Ser Ala Leu Arg Ala Ala Ile Lys Ile Asn Ser Arg Lys Gly Pro Ala  
165 170 175  
Ser Asp Thr Ala Ser Pro Glu Gly His Ala Ser Asp Met Glu Gly Gln  
180 185 190  
Gly His Val His Gly Val Ala Ser Ser Pro Ser His Asp Leu Ala Lys  
195 200 205  
Glu Glu Gly Ser  
210

185

<210> 262  
 <211> 319  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (68)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (115)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (213)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 262  
 Met Ala Pro Leu Ala Leu His Leu Leu Val Leu Val Pro Ile Leu Leu  
     1                    5                    10                    15  
 Ser Leu Val Ala Ser Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro  
                     20                    25                    30  
 Phe Glu Lys Cys Met Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val  
             35                    40                    45  
 Thr Ile Leu Glu Ala Asp Asn Arg Ile Gly Gly Arg Ile Phe Thr Tyr  
     50                    55                    60  
 Arg Asp Gln Xaa Thr Gly Trp Ile Gly Glu Leu Gly Ala Met Arg Met  
     65                    70                    75                    80  
 Pro Ser Ser His Arg Ile Leu His Lys Leu Cys Gln Gly Leu Gly Leu  
                     85                    90                    95  
 Asn Leu Thr Lys Phe Thr Gln Tyr Asp Lys Asn Thr Trp Thr Glu Val  
             100                    105                    110  
 His Glu Xaa Lys Leu Arg Asn Tyr Val Val Glu Lys Val Pro Glu Lys  
             115                    120                    125  
 Leu Gly Tyr Ala Leu Arg Pro Gln Glu Lys Gly His Ser Pro Glu Asp  
     130                    135                    140  
 Ile Tyr Gln Met Ala Leu Asn Gln Ala Leu Lys Asp Leu Lys Ala Leu  
     145                    150                    155                    160  
 Gly Cys Arg Lys Ala Met Lys Lys Phe Glu Arg His Thr Leu Leu Glu  
             165                    170                    175  
 Tyr Leu Leu Gly Glu Gly Asn Leu Ser Arg Pro Ala Val Gln Leu Leu  
             180                    185                    190



WO 00/04140

PCT/US99/15849

186

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Asp | Val | Met | Ser | Glu | Asp | Gly | Phe | Phe | Tyr | Leu | Ser | Phe | Ala | Glu |
|     | 195 |     |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Ala | Leu | Arg | Ala | Xaa | Ser | Cys | Leu | Ser | Asp | Arg | Leu | Gln | Tyr | Ser | Arg |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Ile | Val | Gly | Gly | Trp | Asp | Leu | Leu | Pro | Arg | Ala | Leu | Leu | Ser | Ser | Leu |
| 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| Ser | Gly | Leu | Val | Leu | Leu | Asn | Ala | Pro | Val | Val | Ala | Met | Thr | Gln | Gly |
|     |     |     | 245 |     |     |     |     |     | 250 |     |     |     |     | 255 |     |
| Pro | His | Asp | Val | His | Val | Gln | Ile | Glu | Thr | Ser | Pro | Pro | Ala | Arg | Asn |
|     |     | 260 |     |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Leu | Lys | Val | Leu | Lys | Ala | Asp | Val | Val | Leu | Leu | Thr | Ala | Ser | Gly | Pro |
|     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Ala | Val | Lys | Arg | Ile | Thr | Phe | Ser | Pro | Arg | Cys | Pro | Ala | Thr | Cys | Arg |
|     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Arg | Arg | Cys | Gly | Gly | Cys | Thr | Thr | Cys | Arg | Pro | Pro | Arg | Cys | Ser |     |
| 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     |     |

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/15849

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12N 15/11, 15/00, 15/63; C07H 21/02, 21/04

US CL : 536/23.1, 23.4; 435/320.1, 69.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.4; 435/320.1, 69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Sequence searched SEQ ID NO: 11, SEQ ID NO: 103, APS, STN, CAPLUS, terms nucleic acid, express, vector, pancreas islet cell tumors.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A, P      | US 5,849,498 A (BANDMAN et al) 15 December 1998, sequence listing.                 | 1-10, 14-15, and 21   |
| A         | US 5,670,367 A (DORNER et al) 23 September 1997, especially sequence listing.      | 1-10, 14-15, and 21   |

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*B\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\* document member of the same patent family

Date of the actual completion of the international search

30 SEPTEMBER 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LI LEE

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/15849

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10, 14-15, and 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/15849

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-10, 14-15, and 21, drawn to isolated nucleic acid and expression system.

Group II, claim(s) 11-12 and 16, drawn to isolated polypeptide.

Group III, claim(s) 13, drawn to antibody.

Group IV, claim(s) 17, drawn to method for preventing a medical condition.

Group V, claim(s) 18-19, drawn to method of diagnosing a disease.

Group VI, claim(s) 20, 22, drawn to method for identifying a binding partner.

Group VII, claim 23, drawn to product produced by method of claim 20.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is considered to be isolated nucleic acid and expression system.

The special technical feature of Group II is considered to be isolated polypeptide.

The special technical feature of Group III is considered to be antibody.

The special technical feature of Group IV is considered to be a method for preventing a medical condition..

The special technical feature of Group V is considered to be method of diagnosing a disease.

The special technical feature of Group VI is considered to be a method for identifying a binding partner..

The special technical feature of Group VII is considered to be product produced by method of claim 20.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

There are 71 genes, from gene Nos 1-71.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The 71 genes have different nucleic acid sequences and they are from different cell. Therefore they lack same special technical features.